

Belém, 08 de fevereiro de 2021

Ao
Ministério Público Federal
Procuradoria da República de Goiás
3º Ofício do Núcleo da Tutela Coletiva
Excelentíssimo Procurador da República,
Senhor Ailton Benedito de Souza
Avenida Olinda, Edifício Rosângela Pofahl Batista - Qd. G, Lt. 2, Park Lozandes
Goiânia/GO. CEP: 74884-120.

Remetente:

Regis Bruni Andriolo
RG: 24.667.038-1
End.: Rod. Augusto Montenegro, 3975, Bloco 1D – Apto 1203, CEP: 66820-000
Belém/PA-Brasil.
Telefone: (91)98132-4271
Email: regis.andriolo@gmail.com

Assunto: Manifestação sobre o protocolo PR-GO-00052522/2020, que trata da resposta ao Ofício nº 1.18.000.000947/2020-82.

Excelentíssimo Procurador,

Honrado em cumprimentá-lo, venho, por meio deste, prover informações relevantes para a contestação do conteúdo apresentado pela Sociedade Brasileira de Infectologia (SBI), por meio do protocolo PR-GO-00052522/2020, que fora produzido em resposta ao Ofício nº 1.18.000.000947/2020-82.

A motivação para o presente se dá em função de minha qualificação e atuação acadêmicas, naquilo que tem sido denominado atualmente de Medicina Baseada em Evidências, desde 2003. Conclui mestrado e doutorado pelo Programa de Pós-Graduação (PPG) em Medicina Interna e Terapêutica e Saúde Baseada em Evidências e pós-doutorado pelo PPG em Saúde Coletiva – todos pela Universidade Federal de São Paulo. Atualmente, atuo como Professor Adjunto III, na Universidade do Estado do Pará, lotado no Departamento de Saúde Comunitária, no qual sou responsável pelo módulo de Pesquisa Científica IV (Medicina Baseada em Evidências), entre outras atribuições na graduação, pós-graduação, gestão, pesquisa e extensão, conforme disponível em meu currículo Lattes (<http://lattes.cnpq.br/1205071530087205>), com *RG-Score* 33 e Fator-H 23 (https://www.researchgate.net/profile/Regis_Andriolo/scores).

A contestação será norteadada pela demonstração pedagógica da clara negligência de seis princípios elementares que devem ser seguidos (itens 1-6) e seis condutas que devem ser evitadas (itens 7-12), todos dos quais muito bem conhecidos na ciência da boa **Prática Baseada em Evidências**, e no próprio método científico.

Ela será ilustrada especificamente para o caso da hidroxicloroquina, que venho acompanhando paulatinamente, na medida em que os estudos são disponibilizados, mas que deve ser estendida para as demais tecnologias com potencial para uso precoce na COVID-19.

A seguir está disponível um sumário, para melhor localização dos itens discorridos, e, ao final, apêndice com lista de referências de estudos recuperados em diferentes bases de dados eletrônicas.

1. Elementos da pergunta de pesquisa clínica (PICO)

A construção de uma pergunta de pesquisa clara e definida é fundamental para o planejamento e condução da estudos clínicos, tanto primários (ensaios clínicos) como secundários (revisões sistemáticas, diretrizes clínicas e outros). Tal prática se dá por meio de definições igualmente claras e definidas dos elementos que a compõem, cujo instrumental converge para o acrônimo PICO, do inglês: *problem* (problema), *intervention* (intervenção), *control* (controle) e *outcome* (desfecho ou resultado decorrente da intervenção) (Twa 2016).

Em se tratando do potencial benéfico de intervenções farmacológicas em pacientes em estágio precoce da infecção ou até profiláticas, os estudos primários e secundários devem possuir seus critérios de inclusão (“P”, de *problem*) restritos a eles.

Como exemplo, podemos citar um dos estudos utilizados pela SBI para justificar seu posicionamento equivocado, que parecia ter sido o melhor estudo já publicado até o final do mês de julho de 2020 (Cavalcanti et al., 2020). No entanto, os autores procederam com início tardio do tratamento, em até 14 dias após o início dos sintomas, entre outros problemas que tornam o estudo inviável para a tomada de decisão.

Outro elemento negligenciado no âmbito da estratégia PICO é a intervenção (I, de *intervention*). Ele não se restringe à mera oferta da tecnologia, mas ao modo (posologia adequada e co-intervenções propostas, como zinco e azitromicina) e, no caso específico, virtualmente a totalidade de estudos citados usam altas doses, ainda que se conheça a dose limite de 5 gramas diárias, desde a década de 1980, ao menos quanto à cloroquina (Rious et al., 1988).

Assim, aproximadamente 80% dos estudos utilizados pela SBI, no protocolo PR-GO-00052522/2020, para desencorajar o uso da hidroxicloroquina, não atendem a critérios de inclusão aceitáveis para o propósito desejado, exceto Skipper et al. (2020) e Mitjà et al. (2020) que, em verdade, encorajam o prosseguimento nos estudos, não o contrário (!), do mesmo modo que Arshad et al. (2020), que observaram redução de mortalidade, apesar de não ter atendido aos critérios de inclusão para o qual a indicação é proposta (tratamento precoce ou profilático).

De todo o exposto, a maioria dos estudos utilizados pela SBI (e outras sociedades) para justificar a rejeição ao tratamento precoce/profilático com hidroxicloroquina é algo análogo ao desejo de se investigar causas de mortalidade neonatal tardia por meio da análise de registros de óbito fetal.

2. Busca sistemática por evidências científicas, incluindo estudos não publicados em revistas indexadas (conhecido por *gray literature*).

De posse de uma pergunta de pesquisa bem estruturada, conforme citado acima, é necessário proceder com a busca sistemática e reunir todos os estudos que atendam a critérios claros e definidos, independente da forma de suas disseminações (resumos de congressos não publicados,

revistas científicas indexadas em bases de dados eletrônicas, dissertações e teses não publicadas, *preprints* não avaliados por pares de revisores, entre outros) (Paez 2017). No apêndice deste documento, está disponível uma estratégia de busca sistemática, e o resultado obtido apenas em diferentes bases de dados eletrônicas (Medline via Pubmed, The Cochrane Library, BVS, Lilacs, Current Controlled Trials e ClinicalTrials.gov).

Claramente, o conteúdo do protocolo PR-GO-00052522/2020 não explicita tal conduta, mas apenas um número limitado de estudos realmente disponíveis para as possibilidades de aplicação. Assim, estudos relevantes como Abella et al. (2020), Gasperetti et al. (2020), Ladapo et al. (2020), Boulware et al (2020), Mitjà et al. (2020a,b), Rajasingham et al. (2020) e Skipper et al. (2020).

Gasperetti et al. (2020), em um total de 600 pacientes em estágio precoce da infecção, os autores demonstraram a segurança do tratamento, segundo relato de ausência de eventos arrítmicos; enquanto Ladapo et al. (2020), em um estudo controlado e randomizado com adicional meta-análise, que reuniram cinco estudos controlados e randomizados (Mitjà et al., 2020a; Boulware et al., 2020; Mitjà et al., 2020b; Rajasingham et al., 2020; Skipper et al., 2020), totalizando mais de 5.000 pacientes, sugerem uma redução de risco relativo de aproximadamente 25% na incidência de hospitalizações, mortes ou COVID-19 (RR 0,76; IC a 95% de 0,59 – 0,97; $P < 0.05$), sem qualquer evento adverso clinicamente relevante reportado em todos os mais de 2 mil participantes que receberam a hidroxicloroquina, ainda que as dosagens dos estudos tivessem sido potencialmente altas.

3. Avaliação da validade interna dos estudos (riscos de erros sistemáticos) (Higgins 2019).

A exemplo do que ocorreu com Mehra et al. (2020), em um estudo com fraude irremediavelmente reconhecida, tem sido recorrente o desequilíbrio de pacientes com características prognósticas importantes no *baseline* (na entrada do estudo), ainda que alguns deles tivessem sido anunciados como randomizados (Skipper et al., 2020 e Cavalcanti et al., 2020).

Vejamos o estudo de Cavalcanti et al. (2020). Nele, foram encontrados os seguintes percentuais adicionais de chance no grupo HCQ (isolado ou combinado) para características de pior prognóstico na admissão (grupos não comparáveis).

- Homens (pior prognóstico): 30%
- Hipertensão: 15%
- Diabetes : 16%
- Insuficiência cardíaca 21%
- Internados em UTI: 8%
- Uso de enzima conversora de angiotensina (insuficiência cardíaca): 43%

O que chama a atenção, no entanto, não é o desequilíbrio entre os grupos, por si, mas a força da associação e a quantidade de características prognósticas relevantes com que ele ocorreu. O mesmo não foi diferente para Skipper et al. (2020). Nele, foram observadas maiores chances de pacientes, na entrada do estudo, com asma, dor de garganta, dores musculares, febre, fadiga e duração de sintomas prévios, no grupo que recebeu hidroxicloroquina (sem significância estatística, mas clinicamente relevantes – ler item 11). No entanto, no contexto geral, o estudo apresenta direção de

efeito e segurança favoráveis à hidroxicloroquina, constituindo importante fonte encorajadora de estudos adicionais e incentivo à livre escolha de seu uso entre médicos e pacientes; fato que contraria nitidamente a posição da SBI.

4. Níveis de evidência.

Nas avaliações tecnológicas em saúde, especificamente no caso de avaliação da efetividade e segurança de tratamentos, há um instrumental que abrange os níveis de evidências. Eles variam do maior nível (revisões sistemáticas com meta-análises de estudos controlados e randomizados) para os menores, como os estudos observacionais menos rigorosos ou até a simples opinião de especialistas.

Assim, diante da ausência de opções idealmente comprovadas pelo melhor nível de evidência, é parte da boa prática das decisões baseadas em evidências o uso de informações de menor rigor, desde que sejam feitas as ressalvas (Burns et al., 2011). No entanto, o que tem sido visto ao longo destes meses é a veemente e injustificável rejeição institucional de um dos medicamentos mais baratos e seguros da história humana, com base na ausência de revisões sistemáticas com meta-análises de estudos controlados e randomizados, e isso constitui uma perversão da aplicabilidade dos diferentes níveis de evidências.

Por fim, o melhor nível de evidência parece já estar disponível, independente de ser ou não passível de críticas, como ocorre com qualquer estudo científico (Ladapo et al., 2020).

5. Ponderação entre benefícios e potenciais malefícios

É amplamente reconhecido que a adoção de qualquer estratégia deve ser apoiada quando os benefícios superam os malefícios (Arora & McHorney, 2000; Deber et al., 1996). Sendo assim, há de se dispensar delongas sobre a segurança de uma tecnologia utilizada há muitas décadas, sem prescrição médica, de baixo custo (sem patente), e para situações clínicas de etiologias relativamente diversas entre si.

Tais evidências empíricas – tanto informais ou anedóticas, como formais (sistemáticas), ambas de longa data – são corroboradas por dados também empíricos, nas mesmas circunstâncias, assistemáticas (sem o rigor científico) e sistemáticas (estudos científicos), mas, agora, específicos para a COVID-19. Entre as evidências informais (não sistematizadas) temos aquelas geradas nos municípios de Belém/PA e Porto Feliz/SP (Garcia 2020).

No caso das evidências empíricas formais e sistematizadas, as demonstrações de segurança são suficientemente consistentes, tanto em estudos observacionais (Ip et al., 2021; Derwand et al., 2020; Dhibar et al., 2020; Fonseca et al., 2020; Gasperetti et al., 2020) como nos experimentais (Boulware et a., 2020; Mitjà et al., 2020b; Rajasingham et al., 2020; Skipper et al., 2020), ao menos para que não haja interferências incisivas nas liberdades individuais de escolha do medicamento, e prosseguimento de investigações científicas descentralizadas em todos o país.

Por fim, Oscanoa et al. (2020) demonstraram a segurança cardíaca da hidroxicloroquina para COVID-19, em uma meta-análise composta por 28 estudos experimentais e

observacionais, perfazendo um total de mais de 9 mil participantes – ainda que muitos estudos primários tivessem incluído doses acima de 500 mg/dia, pacientes em fase tardia da infecção e médias de idade a partir de 60 anos em mais de 60% dos estudos (17/28).

6. Decisões conforme as preferências e valores do paciente

De acordo com os itens 1 a 5, não há qualquer razão para campanhas institucionais contra a decisão compartilhada entre médicos e pacientes para o uso de hidroxicloroquina/cloroquina (isolada ou combinada com outras opções, como azitromicina e/ou sulfato de zinco). Afinal, as preferências do paciente fazem parte do tripé que define a boa prática baseada em evidências, citando-se, especificamente, as preferências e valores do paciente, a melhor evidência científica e o *expertise* do profissional de saúde (Sackett et al., 2007).

7. Decisões por autoridade, não por evidências empíricas (a falácia da autoridade).

O conteúdo do protocolo PR-GO-00052522/2020 é também composto de justificativas baseadas no posicionamento de autoridades institucionais (ex., Organização mundial da Saúde, Sociedade de Infectologia dos Estados Unidos/IDSA e outras), a falácia da autoridade (LeFevre, 2017).

A história da medicina é igualmente plena de exemplos da chamada “falácia da autoridade”, conforme primorosamente relatada por Dohert (2005), em artigo intitulado *History of evidence-based medicine. Oranges, chloride of lime and leeches: barriers to teaching old dogs new tricks* (História da medicina baseada em evidências. Laranjas, cloreto de cálcio e sanguessugas: barreiras para ensinar novos truques a velhos cães).

Dohert (2005) cita, por exemplo, a solene recusa da Sociedade Médica de Viena em relação aos achados de Semmelweis, que demonstravam a efetividade e a segurança da lavagem das mãos para a redução de mortalidade entre gestantes no Hospital de Viena. Ele também citou o exemplo mais recente dos malefícios da proteína-C-ativada (Xigris®, Eli Lilly) – um medicamento de altíssimo custo para pacientes com sepse grave – mas que foram solene e insistentemente negligenciados (os malefícios e manipulações de cenários de estudos) por certas sociedades médicas, incluindo as brasileiras.

Dentro do princípio das decisões por autoridade, os defensores da hidroxicloroquina poderiam, da mesma forma, assumir como demonstração definitiva e invariável de sua efetividade por meio de uma revisão narrativa do *American Journal of Medicine*, que defende o tratamento precoce com hidroxicloroquina, entre outras opções (McCullough et al., 2021).

8. Fraude em pesquisa médica

Para uma breve e suficiente introdução sobre as modalidades de fraude ou distorções em pesquisa clínica, recomendo os estudos de George (2016) e Mavrogenis et al. (2018).

Aqui, chamo a atenção para o estudo de Mehra et al. (2020), cujos resultados foram amplamente disseminados e aceitos por todas as autoridades acadêmicas e midiáticas, até que tivesse

sido reconhecida a real fraude, após decorridas duas semanas. No entanto, tal suspeita já havia sido detectada por mim e outros pesquisadores, apenas por avaliação das informações disponíveis na publicação, tendo sido publicada em mais de um veículo, por ocasião do trabalho investigativo do jornalista francês Xavier Azalbert, cujo contato fora intermediado pelo cientista brasileiro, Dr. Marcos Eberlin. Uma delas está disponível na Media-Press-Info (<https://www.medias-presse.info/les-graves-defauts-de-letude-de-the-lancet-contre-lhydrochloroquine-une-etude-biasee-doffice/120777/>). No entanto, a fraude foi confirmada apenas duas semanas após a referida avaliação.

Ademais, se há suspeita de fraudes nos vários estudos publicados, cabe aos órgãos jurídicos competentes investigá-las, por iniciativas próprias ou demanda social, dentro da ética e do ordenamento jurídicos que vigem em seus países de origem, restando a mim e a outros colegas cientistas apenas as avaliações críticas das validades internas e externas dos estudos que são disponibilizados.

9. Decisões por contagem de votos (*vote-counting*)

Ainda no contexto da pesquisa clínica, é absolutamente frequente as decisões baseadas na contagem de estudos em que os autores referem sucesso ou insucesso das intervenções em suas conclusões (*vote-counting*), sem o domínio do instrumental apropriado para a avaliação crítica dos estudos individuais e do corpo de toda a evidência empírica disponível (Verbeek et al., 2012).

10. Assunção de evidência de ausência de efeito, quando da ausência de evidência.

Ao longo destes meses de pandemia, muitas autoridades individuais e institucionais têm cometido o erro elementar de conceberem a ausência de evidências consistentes como evidência de ausência de efeitos ou algo ainda mais grave, no sentido de que ausência de evidência corresponderia à evidência de que os malefícios supostamente prevalecem sobre os potenciais benefícios (Altman & Bland, 1995).

A má prática tratada neste item é fortemente evidenciada, inclusive, em um detalhe sutil expresso na legenda da tabela de recomendações da IDSA (folha 07 do protocolo PR-GO-00052522/2020), na qual há clara distorção semântica da expressão “não aplicável”, sendo interpretada pela SBI como algo “que não pode ser aplicado, posto em prática”, o que não corresponde com o conceito de ausência de evidência (perversão institucionalizada de princípios elementares).

11. Assunção de diferenças significativas entre grupos de comparação, apenas baseadas em valores de p (erro falso-positivo ou do Tipo I)


No estudo de Skipper et al. (2020), por exemplo, foi possível observar redução de risco relativo clinicamente relevante de aproximadamente 60% na necessidade de hospitalização no grupo hidroxicloroquina, em comparação com o controle, apesar da ausência de significância estatística ($P = 0.29$). De outro modo, mas ainda com referência à supervalorização do elemento acessório que é o

valor de “P”, na busca pela causalidade, houve diferença estatística significativa na incidência de eventos adversos ($P < 0,001$), mas sem qualquer relevância clínica que pudesse desencorajar seu uso, conforme referido pelos próprios autores.

Já é bem conhecido, mas ao mesmo tempo extremamente negligenciado, que valores de significância estatística são meros acessórios na busca pela causalidade, e não devem prevalecer sobre outros aspectos, como temporalidade, relevância clínica dos achados, consistência, força da associação e outros (Hill 1965).

Um excelente exemplo para se ilustrar o popular equívoco da omissão de potenciais efeitos de uma intervenção é possível de ser visto em uma revisão sistemática realizada por Lewis et al. (2020). Os autores ao reunirem quatro estudos controlados e randomizados de alta qualidade metodológica em uma meta-análise (Abella et al., 2020, Boulware et al. 2020, Mitjà et al., 2020b e Rajasingham et al., 2020). Eles demonstraram que o uso profilático de hidroxicloroquina pode estar associado a uma redução de risco relativo na incidência de COVID-19 de aproximadamente 18%, (RR 0,82), mas ainda sem a significância estatística desejada (equivocadamente) para assumir provável causalidade (IC95% 0,65-1.04; $p = 0.10$), conforme observado na figura abaixo (Figura 1):

Figura 1 – Meta-análise sobre o uso profilático de hidroxicloroquina para a prevenção de COVID-19



Adaptado de Lewis et al. (2020).

Curiosamente, os autores do estudo em questão (Lewis et al., 2020) anunciaram a necessidade de revisões sistemáticas adicionais, mas relataram, em suas conclusões, que não houve diferença entre os grupos de comparação. Contudo, não me pareceu uma atitude cientificamente honesta o fato de não terem assumido que a demonstração de efetividade da tecnologia se mostra muito promissora e, por isso, mais estudos ainda são necessários.


O referido posicionamento de Lewis et al. (2020), nas conclusões, se deve à clara negligência dos autores, no que diz respeito à reprodutibilidade dos estudos em relação às direções de seus efeitos (todos favoráveis à hidroxicloroquina), força da associação de dois estudos individuais e todos combinados na meta-análise.

Conforme observado na **Figura 2**, o *Trial Sequential Analysis*, que quantifica a confiabilidade de dados cumulativos em uma meta-análise, sugere que, baseado na incidência de 9,3%

de COVID-19 no grupo controle e uma redução de risco relativo de 22.37% associada ao uso profilático de hidroxicloroquina, o tamanho amostral total requerido (*required information size*) para conclusões mais firmes seria de 5.499 participantes, exclusivamente para a pergunta clínica sobre o uso PROFILÁTICO da hidroxicloroquina. Portanto, com apenas 3.094 participantes testados até o momento, somente o percentual de 56% do total necessário para a tão desejada demonstração “definitiva” foi atingido. Ademais, é importante ressaltar que o traçado azul (meta-análise cumulativa) se encontra com aspecto ascendente, e seu extremo fora dos limiares de futilidade (traçados horizontais vermelhos).

Assim, por posicionamentos equivocados de sociedades e autores individuais, temos um cenário de impedimento do caminho científico tão necessário.

Figura 2 – *Trial sequential analysis* sobre o uso profilático de hidroxicloroquina para a prevenção de COVID-19.



12. Supressão do exercício do método científico

A ciência médica utiliza o método de inferência por tentativas sucessivas de refutação, de forma que enquanto a hipótese não for refutada, ela permanecerá como uma boa explicação para o nexos causal presumido. Desta feita, não há qualquer elemento que refute a efetividade e a segurança da hidroxicloroquina para pacientes em estágio viral (precoce) da COVID-19, ou até profilaticamente.

Forças institucionais equivocadas e obscuras, tanto as acadêmicas como as midiáticas, parecem apontar para a aniquilação do necessário, coerente e ético prosseguimento na investigação

científica sobre o uso isolado e/ou combinado da hidroxicloroquina, de forma independente, descentralizada, com variações geográficas, clínicas e metodológicas tão fundamentais para a construção adequada de um corpo robusto de evidências, num contexto de efetividade (circunstâncias reais da prática), não de eficácia, conforme referido pela SBI.

Considerações finais

Instituições de saúde e midiáticas, juntamente com atores individuais relacionados cometem grande equívoco ao suprimirem as liberdades individuais de escolha do uso isolado e/ou combinado, profilático ou precoce de hidroxicloroquina para a COVID-19, com reflexos negativos, inclusive no salutar andamento regular e independente de pesquisas científicas sobre a questão, dado à sua segurança e às escassas opções igualmente promissoras e acessíveis.

Reitero que o conteúdo aqui disponibilizado não constitui uma revisão sistemática, tampouco se presta à comprovação definitiva da efetividade da hidroxicloroquina, mas uma síntese pedagógica de princípios claramente negligenciados na busca pelas evidências sobre a sua efetividade e segurança para a COVID-19, em pessoas, combinações, momentos e doses adequadas.

De todo o exposto, considero ético e produtivo que a SBI se manifeste explicitamente junto à imprensa, sobre o fato de que ela se posiciona a favor do tratamento precoce (folhas 2 e 3 do protocolo PR-GO-00052522/2020), mas com a ressalva relativa ao entendimento de que a evidência ainda não existe, pois isso não corresponde com a realidade das melhores evidências disponíveis, ao menos para o caso de fazer prevalecer o equivocado entendimento generalizado de que supostamente os malefícios superam os benefícios, a ponto de interferir na liberdade de escolhas individuais e inibição de estudos científicos descentralizados já referidos acima.

Outro ponto passível de análise judicial seria o aspecto ético das tratativas da SBI para com o Ministério Público Federal, quando referem que existem coisas mais importantes a serem discutidas (folha 3 do protocolo PR-GO-00052522/2020), o que reflete um contrassenso da SBI, no sentido de que a motivação da discussão é a óbvia possibilidade de prevenir o pior prognóstico de pessoas acometidas, internações e dispêndio desnecessário de recursos humanos, físicos e financeiros.

Referências bibliográficas.

Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure sars-cov-2 prophylaxis among health care workers: a randomized clinical trial. *JAMA Intern Med.* 2020; <https://doi.org/10.1001/jamainternmed.2020.6319> PMID: 33001138

Altman DG, Bland JM. Absence of evidence is not evidence of absence. *BMJ.* 1995 Aug 19;311(7003):485. doi: 10.1136/bmj.311.7003.485. PMID: 7647644; PMCID: PMC2550545.

Arora NK, McHorney CA Patient preferences for medical decision making: who really wants to participate? *Medical Care*. 38(3):335-41, 2000.

Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis*. 2020;97:396–403. doi:10.1016/j.ijid.2020.06.099.

Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *JAMA Netw Open*. 2020;3:e208857. doi:10.1001/jamanetworkopen.2020.8857.

Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N Engl J Med* 2020 Aug 6;383(6):517-25. <https://www.nejm.org/doi/full/10.1056/NEJMoa2016638>.

Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg*. 2011 Jul;128(1):305-10. doi: 10.1097/PRS.0b013e318219c171. PMID: 21701348; PMCID: PMC3124652.

Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020;383:2041–52. doi:10.1056/nejmoa2019014.

Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? *Archives of Internal Medicine*. 1996; 156: 1414-1420.

Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. *Int J Antimicrob Agents*. 2020 Dec;56(6):106214. doi: 10.1016/j.ijantimicag.2020.106214. Epub 2020 Oct 26. PMID: 33122096; PMCID: PMC7587171.

Dhibar DP, Arora N, Kakkar A, Singla N, Mohindra R, Suri V, Bhalla A, Sharma N, Singh MP, Prakash A, Pvm L, Medhi B. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. *Int J Antimicrob Agents*. 2020 Dec;56(6):106224. doi: 10.1016/j.ijantimicag.2020.106224. Epub 2020 Nov 6. PMID: 33166694; PMCID: PMC7646370.

Doherty S. History of evidence-based medicine. Oranges, chloride of lime and leeches: barriers to teaching old dogs new tricks. *Emerg Med Australas*. 2005 Aug;17(4):314-21. doi: 10.1111/j.1742-6723.2005.00752.x. PMID: 16091093.

Fonseca SNS, de Queiroz Sousa A, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, Rebouças E, Vasconcellos Abdon AP, Nascimento ALA, Risch HA. Risk of hospitalization for

Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. *Travel Med Infect Dis.* 2020 Nov-Dec;38:101906. doi: 10.1016/j.tmaid.2020.101906. Epub 2020 Oct 31. PMID: 33137493; PMCID: PMC7604153.

Garcia. Há provas de que podemos derrotar o vírus. *Correio Braziliense*. Publicado em 01 de julho de 2020. Acessado em 04 de janeiro de 2021. Disponível em https://www.correio braziliense.com.br/app/noticia/politica/2020/07/01/interna_politica,868305/alexandre-garcia-ha-provas-de-que-podemos-derrotar-o-virus.shtml

Gasperetti A, Biffi M, Duru F, Schiavone M, Ziacchi M, Mitacchione G, Lavallo C, Saguner A, Lanfranchi A, Casalini G, Tocci M, Fabbriatore D, Salghetti F, Mariani MV, Busana M, Bellia A, Cogliati CB, Viale P, Antinori S, Galli M, Galiè N, Tondo C, Forleo GB. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. *Europace.* 2020 Dec 23;22(12):1855-1863. doi: 10.1093/europace/euaa216. PMID: 32971536; PMCID: PMC7543547.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* 2020;382:2411–8. doi:10.1056/nejmoa2012410.

George SL. Research misconduct and data fraud in clinical trials: prevalence and causal factors. *Int J Clin Oncol.* 2016 Feb;21(1):15-21. doi: 10.1007/s10147-015-0887-3. Epub 2015 Aug 20. PMID: 26289019.

Hill AB. The environment and disease: association or causation? 1965. *J R Soc Med.* 2015 Jan;108(1):32-7. doi: 10.1177/0141076814562718. PMID: 25572993; PMCID: PMC4291332.

Ip A, Ahn J, Zhou Y, Goy AH, Hansen E, Pecora AL, Sinclair BA, Bednarz U, Marafelias M, Sawczuk IS, Underwood JP 3rd, Walker DM, Prasad R, Sweeney RL, Ponce MG, La Capra S, Cunningham FJ, Calise AG, Pulver BL, Ruocco D, Mojares GE, Eagan MP, Ziontz KL, Mastrokyriakos P, Goldberg SL. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. *BMC Infect Dis.* 2021 Jan 14;21(1):72. doi: 10.1186/s12879-021-05773-w. PMID: 33446136; PMCID: PMC7807228.

Lewis K, Chaudhuri D, Alshamsi F, Carayannopoulos L, Dearness K, Chagla Z, Alhazzani W; GUIDE Group. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. *PLoS One.* 2021 Jan 6;16(1):e0244778. doi: 10.1371/journal.pone.0244778. PMID: 33406138; PMCID: PMC7787432.

Ladapo JA, McKinnon JE, McCullough PA, Risch H. Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis. medRxiv preprint doi: <https://doi.org/10.1101/2020.09.30.20204693>.

LeFevre M. From Authority- to Evidence-Based Medicine: Are Clinical Practice Guidelines Moving us Forward or Backward? *Ann Fam Med*. 2017 Sep;15(5):410-412. doi: 10.1370/afm.2141. PMID: 28893809; PMCID: PMC5593722.

Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ*. 2020:m1844. doi:10.1136/bmj.m1844.

Mavrogenis AF, Panagopoulos GN, Megaloikonomos PD, Panagopoulos VN, Mauffrey C, Quaile A, Scarlat MM. Scientific Misconduct (Fraud) in Medical Writing. *Orthopedics*. 2018 Mar 1;41(2):e176-e183. doi: 10.3928/01477447-20180123-06. Epub 2018 Jan 29. PMID: 29377051.

McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, Katz N, Lepor NE, Vijay K, Carter H, Singh B, McCullough SP, Bhambi BK, Palazzuoli A, De Ferrari GM, Milligan GP, Safder T, Tecson KM, Wang DD, McKinnon JE, O'Neill WW, Zervos M, Risch HA. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. *Am J Med*. 2021 Jan;134(1):16-22. doi: 10.1016/j.amjmed.2020.07.003. Epub 2020 Aug 7. PMID: 32771461; PMCID: PMC7410805.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet*. 2020 May 22:S0140-6736(20)31180-6. doi: 10.1016/S0140-6736(20)31180-6. Epub ahead of print. Retraction in: *Lancet*. 2020 Jun 5;:null. Erratum in: *Lancet*. 2020 May 30;: PMID: 32450107; PMCID: PMC7255293.

Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild COVID-19: A randomized-controlled trial. *Clin Infect Dis* 2020a Jul 16:ciaa1009. <https://doi.org/10.1093/cid/ciaa1009>.

Mitjà O, Ubals M, Corbacho-Monné M, et al. A cluster-randomized trial of hydroxychloroquine as prevention of COVID-19 transmission and disease. Preprints July 26, 2020b. <https://doi.org/10.1101/2020.07.20.2015765>.

Oscanoa TJ, Vidal X, Kanters JK, Romero-Ortuno R. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. *Int J Antimicrob Agents*. 2020 Dec;56(6):106212. doi: 10.1016/j.ijantimicag.2020.106212. Epub 2020 Oct 24. PMID: 33164789; PMCID: PMC7584880.

Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med*. 2017 Aug;10(3):233-240. doi: 10.1111/jebm.12266. PMID: 28857505.

Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Preprints September 21, 2020.

<https://www.medrxiv.org/content/10.1101/2020.09.18.20197327v1>

Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. *N Engl J Med*. 1988 Jan 7;318(1):1-6. doi: 10.1056/NEJM198801073180101. PMID: 3336379.

Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020;323:2493. doi:10.1001/jama.2020.8630.

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. 1996. *Clin Orthop Relat Res*. 2007 Feb;455:3-5. PMID: 17340682.

Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. *Ann Intern Med*. 2020;173:623–31. doi:10.7326/m20-4207.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020;m1849. doi:10.1136/bmj.m1849.

Twa MD. Evidence-Based Clinical Practice: Asking Focused Questions (PICO). *Optom Vis Sci*. 2016 Oct;93(10):1187-8. doi: 10.1097/OPX.0000000000001006. PMID: 27662360.

Verbeek J, Ruotsalainen J, Hoving JL. Synthesizing study results in a systematic review. *Scand J Work Environ Health*. 2012 May;38(3):282-90. doi: 10.5271/sjweh.3201. Epub 2011 Oct 21. PMID: 22015561.

Atenciosamente,

Regis Bruni Andriolo

Apêndice

Estratégia de busca e estudos recuperados em diferentes bases de dados eletrônicas sobre o uso de hidroxiquina para COVID-19 (Medline via Pubmed, The Cochrane Library, BVS, Lilacs, Current Controlled Trials e ClinicalTrials.gov).

Fase 1:

(COVID 19) OR (COVID-19 Virus Disease) OR (COVID 19 Virus Disease) OR (COVID-19 Virus Diseases) OR (COVID-19 Virus Infection) OR (COVID 19 Virus Infection) OR (COVID-19 Virus Infections) OR (2019-nCoV Infection) OR (2019 nCoV Infection) OR (2019-nCoV Infections) OR (Coronavirus Disease-19) OR (Coronavirus Disease 19) OR (2019 Novel Coronavirus Disease) OR (2019 Novel Coronavirus Infection) OR (2019-nCoV Disease) OR (2019 nCoV Disease) OR (2019-nCoV Diseases) OR (COVID19) OR (Coronavirus Disease 2019) OR (SARS Coronavirus 2 Infection) OR (SARS-CoV-2 Infection) OR (SARS CoV 2 Infection) OR (SARS-CoV-2 Infections) OR (COVID-19 Pandemic) OR (COVID 19 Pandemic) OR (COVID-19 Pandemics)

Fase 2:

(Hydroxychloroquine) OR (Oxychlorochin) OR (Oxychloroquine) OR (Hydroxychlorochin) OR (Plaquenil) OR (Hydroxychloroquine Sulfate) OR (Hydroxychloroquine Sulfate (1:1) Salt) OR (Chloroquine) OR (Chlorochin) OR (Chingamin) OR (Khingamin) OR (Nivaquine) OR (Chloroquine Sulfate) OR (Chloroquine Sulphate) OR (Sulphate, Chloroquine) OR (Aralen) OR (Arequin) OR (Arechine)

FASE 3 (PUBMED – adaptável para demais bases de dados):

((randomized controlled trial [pt]) OR (controlled clinical trial [pt]) OR (randomized [tiab]) OR (placebo [tiab]) OR (drug therapy [sh]) OR (randomly [tiab]) OR (trial [tiab]) OR (groups [tiab])) AND (humans [mh])

Resultado da busca, após remoção de referências bibliográficas repetidas nas diferentes bases de dados (N = 2147 referências).

Medline via Pubmed (N = 1281), The Cochrane Library (N = 605), BVS (N = 955), Lilacs (N = 187), Current Controlled Trials (N = 11) e ClinicalTrials.gov (N = 270).

1. Abdulrahman A, AlSayed I, AlMadhi M, AlArayed J, Mohammed SJ, Sharif AK, et al. The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort. 2021; Available from: <https://dx.doi.org/10.1007/s40121-021-00397-8>
2. Becker ML, Snijders D, van Gemeren CW, Kingma HJ, van Lelyveld SFL, Giezen TJ. QTc Prolongation in COVID-19 Patients Using Chloroquine. *Cardiovasc toxicol* [Internet]. 2021; Available from: <https://dx.doi.org/10.1007/s12012-020-09621-2>
3. Chen S, Lin W, Wen J, Xie B, Chen L, Chen G. Is glucagon-like peptide 1 receptor analogues effective and safe in severe COVID-19 patients with type 2 diabetes?-a case report. *Ann palliat med* [Internet]. 2021; Available from: <https://dx.doi.org/10.21037/apm-20-1982>
4. Cohen SL, Gianos E, Barish MA, Chatterjee S, Kohn N, Lesser M, et al. Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients. *Thromb haemost* [Internet]. 2021; Available from: <https://dx.doi.org/10.1055/a-1366-9656>
5. Egeli BH, Sparks JA, Kim AHJ, Liew JW. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? *Best Pr Res Clin Rheumatol* [Internet]. 2021;101658. Available from: <https://dx.doi.org/10.1016/j.berh.2020.101658>
6. Falcão F, Viegas E, Carmo I, Soares J, Falcao M, Solano M, et al. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report. 2021; Available from: <https://dx.doi.org/10.1136/ejhpharm-2020-002613>

7. Farid N, Rola N, Koch EAT, Nakhoul N. Active vitamin D supplementation and COVID-19 infections: review. *Ir j med sci* [Internet]. 2021; Available from: <https://dx.doi.org/10.1007/s11845-020-02452-8>
8. Karunanathan S, Welch VA, Tugwell P, Cuervo LG. When is systematic review replication useful, and when is it wasteful? 2021; Available from: <https://iris.paho.org/handle/10665.2/53189>
9. Khoubnasabjafari M, Jouyban A, Malek Mahdavi A, Namvar L, Esalatmanesh K, Hajjalilo M, et al. Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA: a multicentre cross-sectional study. *Postgrad med j* [Internet]. 2021; Available from: <https://dx.doi.org/10.1136/postgradmedj-2020-139561>
10. Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla P V. Telogen effluvium associated with COVID-19 infection. *Dermatol Ther* [Internet]. 2021;e14761–e14761. Available from: <https://dx.doi.org/10.1111/dth.14761>
11. Perez J, Roustit M, Lepelley M, Revol B, Cracowski J-L, Khouri C. Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. *Ann intern med* [Internet]. 2021; Available from: <https://dx.doi.org/10.7326/M20-7918>
12. Pezzarossa E, Ungari M, Caresana G, Sagrafi F, Cimardi L, Pan A, et al. Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia. *Am j dermatopathol* [Internet]. 2021; Publish Ahead of Print. Available from: <https://dx.doi.org/10.1097/DAD.0000000000001819>
13. Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? *J Travel med* [Internet]. 2021; Available from: <https://dx.doi.org/10.1093/jtm/taab005>
14. Rangel LK, Shah P, Lo Sicco K, Caplan AS, Femia A. Chronic Hydroxychloroquine Therapy and COVID-19 Outcomes: A Retrospective Case-Control Analysis. *J Am Acad Dermatol* [Internet]. 2021; Available from: <https://dx.doi.org/10.1016/j.jaad.2020.10.098>
15. Rebold N, Holger D, Alosaimy S, Morrisette T, Rybak M. COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. 2021; Available from: <https://dx.doi.org/10.1007/s40121-021-00399-6>
16. Ribeiro TB, Mazotti TA, Silva NA de O, Stein AT, Diaz-Quijano FA, Melo DO de. Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil. *TT - Avaliação da resposta inicial de desenvolvimento de ensaios clínicos para COVID-19 no Brasil. Rev Bras Epidemiol* [Internet]. 2021;23:e200104–e200104. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
17. Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, Bakoubayi AW, Tchankoni MK, Bitty-Anderson AM, et al. Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo. *BMC Public Health* [Internet]. 2021;21(1):58. Available from: <https://dx.doi.org/10.1186/s12889-020-10145-1>
18. Sakshi C, Harikrishnan A, Jayaraman S, Choudhury AR, Veena V. Predictive medicinal metabolites from *Momordica dioica*; against comorbidity related proteins of SARS-CoV-2 infections. *J Biomol Struct Dyn* [Internet]. 2021;1–14. Available from: <https://dx.doi.org/10.1080/07391102.2020.1868340>
19. Smit M, Marinosci A, Agoritsas T, Ford N, Calmy A. Prophylaxis for COVID-19: a systematic review. *Clin microbiol infect* [Internet]. 2021; Available from: <https://dx.doi.org/10.1016/j.cmi.2021.01.013>

20. Tan J, Yuan Y, Xu C, Song C, Liu D, Ma D, et al. A retrospective comparison of drugs against COVID-19. *Virus Res* [Internet]. 2021;294:198262. Available from: <https://dx.doi.org/10.1016/j.virusres.2020.198262>
21. Thakar A, Panda S, Sakthivel P, Brijwal M, Dhakad S, Choudekar A, et al. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial. *Indian J Med Res* [Internet]. 2021; Available from: https://dx.doi.org/10.4103/ijmr.IJMR_3665_20
22. Wambier CG, Saad MO. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial". *Int J Antimicrob Agents* [Internet]. 2021;57(1):106171. Available from: <https://dx.doi.org/10.1016/j.ijantimicag.2020.106171>
23. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Intern Med*. 2021 Feb;181(2):195–202.
24. Ali T, Al-Ali A, Fajji L, Hammad E, Nazmi A, Alahmadi I, et al. Coronavirus Disease-19: Disease Severity and Outcomes of Solid Organ Transplant Recipients: Different Spectrums of Disease in Different Populations? *Transplantation*. 2021 Jan;105(1):121–7.
25. Ambar Akkaoui M, Lejoyeux M, Geoffroy PA. Chloroquine-Induced First-Episode Psychosis in a Patient Self-medicated for COVID-19. Vol. 89, *Biological psychiatry*. 2021. p. e9.
26. Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. *Ann Med*. 2021 Dec;53(1):117–34.
27. Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, et al. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Jan;27(1):105–11.
28. Bernardini A, Ciconte G, Negro G, Rondine R, Mecarocci V, Viva T, et al. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. *Int J Cardiol*. 2021 Feb;324:242–8.
29. Beyzarov E, Chen Y, Julg R, Naim K, Shah J, Gregory WW, et al. Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor’s Perspective. *Drug Saf*. 2021 Jan;44(1):95–105.
30. Burgos-Blasco B, Güemes-Villahoz N, Vidal-Villegas B, Donate-Lopez J, Garcia-Feijoo J. Evaluation of retinotoxicity of COVID-19 treatment: Hydroxychloroquine and lopinavir/ritonavir. Vol. 93, *Journal of medical virology*. 2021. p. 644–6.
31. Calabrese EJ, Hanekamp JC, Hanekamp YN, Kapoor R, Dhawan G, Agathokleous E. Chloroquine commonly induces hormetic dose responses. *Sci Total Environ*. 2021 Feb;755(Pt 1):142436.
32. Cavalcanti AB, Berwanger O, Zampieri FG. Hydroxychloroquine with or without Azithromycin in Covid-19. Reply. Vol. 384, *The New England journal of medicine*. United States; 2021. p. 191.
33. Ceccarelli G, Alessandri F, Oliva A, Dell’Isola S, Rocco M, Ruberto F, et al. Superinfections in patients treated with Teicoplanin as anti-SARS-CoV-2 agent. Vol. 51, *European journal of clinical investigation*. 2021. p. e13418.
34. Çelik HG, Keske Ş, Şener Ü, Tekbaş M, Kapmaz M, Şahin ŞT, et al. Why we should be more careful using hydroxychloroquine in influenza season during COVID-19 pandemic? *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2021 Jan;102:389–91.

35. Chen J, Liu D, Yin L, Zhang L, Lu H. Can we use hydroxychloroquine to treat COVID-19 now? Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106173.
36. Cismaru CA, Cismaru GL, Seyed Nabavi F, Seyed Nabavi M, Berindan-Neagoe I. COVID-19 and antimalarials. Have we been doing it wrong all along? *Eur J Pharmacol*. 2021 Jan;891:173694.
37. Colombi D, Bodini FC, Morelli N, Silva M, Milanese G, Cavanna L, et al. COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients. Vol. 27, *Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy*. 2021. p. 99–102.
38. Colson P, La Scola B, Lagier J-C, Gautret P, Raoult D. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106238.
39. Daou F, Abou-Sleymane G, Badro DA, Khanafer N, Tobaiqy M, Al Faraj A. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. *Int J Environ Res Public Health*. 2021 Jan;18(3).
40. Devarajan A, Vaseghi M. Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. *Redox Biol*. 2021 Jan;38:101810.
41. Di Mascio D, D'Antonio F. Perinatal mortality and morbidity of SARS-COV-2 infection during pregnancy in European countries: Findings from an international study. Vol. 256, *European journal of obstetrics, gynecology, and reproductive biology*. 2021. p. 505–7.
42. Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. *Clin Toxicol (Phila)*. 2021 Jan;59(1):12–23.
43. Ekobena P, Ivanyuk A, Livio F. [Pharmacovigilance update]. *Rev Med Suisse*. 2021 Jan;17(720–1):80–4.
44. Emani VR, Goswami S, Nandanoor D, Emani SR, Reddy NK, Reddy R. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. *Int J Antimicrob Agents*. 2021 Jan;57(1):106222.
45. Ewers M, Ioannidis JPA, Plesnila N. Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. *J Clin Epidemiol*. 2021 Feb;130:143–6.
46. Ferreira A, Oliveira-E-Silva A, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. *J Med Virol*. 2021 Feb;93(2):755–9.
47. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response. Vol. 27, *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2021. p. 138–40.
48. Gagliotti C, Buttazzi R, Ricchizzi E, Di Mario S, Tedeschi S, Moro ML. Community use of antibiotics during the COVID-19 lockdown. Vol. 53, *Infectious diseases (London, England)*. England; 2021. p. 142–4.
49. García-Fernández A, Ramos-Ruiz P, Ibáñez-Criado A, Moreno-Pérez Ó, Cambra-Poveda C, Martínez-Martínez JG. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients. Vol. 74, *Revista espanola de cardiologia (English ed.)*. 2021. p. 108–11.

50. García-Meniño I, Forcelledo L, Rosete Y, García-Prieto E, Escudero D, Fernández J. Spread of OXA-48-producing *Klebsiella pneumoniae* among COVID-19-infected patients: The storm after the storm. Vol. 14, *Journal of infection and public health*. 2021. p. 50–2.
51. García-Rodríguez D, Remior P, García-Izquierdo E, Toquero J, Castro V, Fernández Lozano I. Drug-induced QT prolongation in COVID-19 pneumonia: influence on in-hospital survival. Vol. 74, *Revista española de cardiología (English ed.)*. 2021. p. 111–2.
52. Gautret P, Hoang VT, Lagier J-C, Raoult D. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106239.
53. Gautret P, Honoré S, Lagier J-C, Raoult D. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106236.
54. Gautret P, Lagier J-C, Honoré S, Hoang VT, Colson P, Raoult D, et al. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106176.
55. Gautret P, Lagier J-C, Honoré S, Hoang VT, Raoult D. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106242.
56. Goldman JD, Diaz G, Urba WJ. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106174.
57. Guerra I, Algaba A, Jiménez L, Mar Aller M, Garza D, Bonillo D, et al. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. *Inflamm Bowel Dis*. 2021 Jan;27(1):25–33.
58. Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Vol. 80, *Annals of the rheumatic diseases*. England; 2021. p. e10.
59. Gyselinck I, Janssens W, Verhamme P, Vos R. Rationale for azithromycin in COVID-19: an overview of existing evidence. *BMJ open Respir Res*. 2021 Jan;8(1).
60. Hosseini FS, Malektojari A, Ghazizadeh S, Hassaniazad M, Davoodian P, Dadvand H, et al. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Vol. 22, *Trials*. 2021. p. 4.
61. Hussain I, Hussain A, Alajmi MF, Rehman MT, Amir S. Impact of repurposed drugs on the symptomatic COVID-19 patients. *J Infect Public Health*. 2021 Jan;14(1):24–38.
62. Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. *Expert Rev Anti Infect Ther*. 2021 Jan;19(1):5–16.
63. Ip A, Ahn J, Zhou Y, Goy AH, Hansen E, Pecora AL, et al. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. *BMC Infect Dis*. 2021 Jan;21(1):72.
64. Jodłowski PJ, Kurowski G, Kuterasiński Ł, Sitarz M, Jeleń P, Jaśkowska J, et al. Cracking the Chloroquine Conundrum: The Application of Defective UiO-66 Metal-Organic Framework

Materials to Prevent the Onset of Heart Defects-In Vivo and In Vitro. ACS Appl Mater Interfaces. 2021 Jan;13(1):312–23.

65. Karatza E, Ismailos G, Marangos M, Karalis V. Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. *Xenobiotica*. 2021 Feb;51(2):127–38.
66. Kashour Z, Riaz M, Garbati MA, AlDosary O, Tlayjeh H, Gerberi D, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2021 Jan;76(1):30–42.
67. Keane MJ, Choudhary R, Bohra GK, Kumar D. Hydroxychloroquine with or without Azithromycin in Covid-19. Vol. 384, *The New England journal of medicine*. United States; 2021. p. 190.
68. Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, et al. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2021 Jan;102:538–43.
69. Kiedrowski M, Kapala P, Kiedrowska M, Skoczynska A, Czerw A, Deptała A. Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. *Med Hypotheses*. 2021 Jan;146:110434.
70. Kim MG, Stein AA, Overby P, Kleinman G, Nuoman R, Gulko E, et al. Fatal Cerebral Edema in a Child With COVID-19. Vol. 114, *Pediatric neurology*. 2021. p. 77–8.
71. Kivrak A, Ulaş B, Kivrak H. A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. *Int Immunopharmacol*. 2021 Jan;90:107232.
72. Komissarov A, Molodtsov I, Ivanova O, Maryukhnich E, Kudryavtseva S, Mazus A, et al. High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. *PLoS One*. 2021;16(1):e0246396.
73. Kumar M, Madan J, Sodhi RK, Singh SB, Katyál A. Decoding the silent walk of COVID-19: Halting its spread using old bullets. *Biomed Pharmacother*. 2021 Jan;133:110891.
74. Lewis K, Chaudhuri D, Alshamsi F, Carayannopoulos L, Dearness K, Chagla Z, et al. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials. *PLoS One*. 2021;16(1):e0244778.
75. Li D, Hu J, Li D, Yang W, Yin S-F, Qiu R. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. *Top Curr Chem*. 2021 Jan;379(1):4.
76. Malaty M, Kayes T, Amarasekera AT, Kodsi M, MacIntyre CR, Tan TC. Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. *Eur J Clin Invest*. 2021 Feb;51(2):e13428.
77. Malek AE, Granwehr BP. Doxycycline as an Alternative to Azithromycin in Elderly Patients. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106168.
78. Manchanda K, Singh J, Bhagat R, Tiwana IK, Singh H. Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. *Int J Risk Saf Med*. 2021;32(1):3–17.
79. Mégarbane B. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Vol. 59, *Clinical toxicology (Philadelphia, Pa.)*. England; 2021. p. 70–1.

80. Mendel A, Bernatsky S, Askanase A, Bae S-C, Clarke AE, Costedoat-Chalumeau N, et al. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. Vol. 80, *Annals of the rheumatic diseases*. England; 2021. p. 1–2.
81. Million M, Roussel Y, Gautret P, Raoult D. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106240.
82. Mohana A, Sulaiman T, Mahmoud N, Hassanein M, Alfaifi A, Alenazi E, et al. Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2021 Jan;102:110–4.
83. Morad R, Akbari M, Rezaee P, Koochaki A, Maaza M, Jamshidi Z. First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles. *Sci Rep*. 2021 Jan;11(1):2131.
84. Nguyen T V. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106169.
85. O’Connell TF, Bradley CJ, Abbas AE, Williamson BD, Rusia A, Tawney AM, et al. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. *JACC Clin Electrophysiol*. 2021 Jan;7(1):16–25.
86. Ohe M, Furuya K, Goudarzi H. Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19? Vol. 14, *Bioscience trends*. Japan; 2021. p. 467–8.
87. Ong W-Y, Go M-L, Wang D-Y, Cheah IK-M, Halliwell B. Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. *Mol Neurobiol*. 2021 Jan;58(1):106–17.
88. Oymak Y, Karapinar TH, Devrim İ. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine? Vol. 43, *Journal of pediatric hematology/oncology*. United States; 2021. p. 35–6.
89. Özdemir İH, Özlek B, Özen MB, Gündüz R, Çetin N, Bilge AR. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. *Int J Clin Pract*. 2021 Feb;75(2):e13896.
90. P KM, Sivashanmugam K, Kandasamy M, Subbiah R, Ravikumar V. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF- β signalling in COVID-19 survivors. *Life Sci*. 2021 Feb;266:118883.
91. Parra-Lara LG, Martinez-Arboleda JJ, Isaza-Pierotti DF, Rosso F, Gautret P, Hoang VT, et al. Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. Vol. 57, *International journal of antimicrobial agents*. 2021. p. 106237.
92. Paul M. Has the door closed on hydroxychloroquine for SARS-COV-2? *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Jan;27(1):3–5.
93. Payares-Herrera C, Martínez-Muñoz ME, Vallhonrat IL, de Molina RM, Torres MP, Trisan A, et al. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial. Vol. 22, *Trials*. 2021. p. 9.
94. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics

- drugs: integrated evidence from 4 databases and a systematic review. *Psychopharmacology (Berl)*. 2021 Feb;238(2):329–40.
95. Prashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, et al. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. *J Mol Graph Model*. 2021 Jan;102:107769.
 96. Printz C. Research shows racial disparity, mortality data for patients with cancer and COVID-19. *Cancer*. 2021 Feb;127(3):333.
 97. Punyaratabandhu P, Chirachanakul P. Cutaneous eruption in COVID-19-infected patients in Thailand: An observational descriptive study. *J Dermatol*. 2021 Jan;48(1):14–20.
 98. Quintana-Ortega C, Remesal A, Ruiz de Valbuena M, de la Serna O, Laplaza-González M, Álvarez-Rojas E, et al. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. *Mod Rheumatol case reports*. 2021 Jan;5(1):101–7.
 99. Rahman MT, Idid SZ. Can Zn Be a Critical Element in COVID-19 Treatment? *Biol Trace Elem Res*. 2021 Feb;199(2):550–8.
 100. Raj V, Park JG, Cho K-H, Choi P, Kim T, Ham J, et al. Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches. *Int J Biol Macromol*. 2021 Jan;168:474–85.
 101. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. *Chest*. 2021 Jan;159(1):85–92.
 102. Raoult D. Rational for meta-analysis and randomized treatment: the COVID-19 example. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021 Jan;27(1):6–8.
 103. Raza HA, Tariq J, Agarwal V, Gupta L. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. *Rheumatol Int*. 2021 Feb;41(2):257–73.
 104. Refaat H, Mady FM, Sarhan HA, Rateb HS, Alaaeldin E. Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19. *Int J Pharm*. 2021 Jan;592:120028.
 105. Rezaee H, Pourkarim F, Pourtaghi-Anvarian S, Entezari-Maleki T, Asvadi-Kermani T, Nouri-Vaskeh M. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. *Pharmacol Res Perspect*. 2021 Feb;9(1):e00705.
 106. Ribeiro TB, Mazotti TA, Silva NA de O, Stein AT, Diaz-Quijano FA, Melo DO de. Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil. *Rev Bras Epidemiol*. 2021;23:e200104.
 107. Robinson K. A false promise of COVID-19 “big” health data? Health data integrity and the ethics and realities of Australia’s health information management practice. *Heal Inf Manag J Heal Inf Manag Assoc Aust*. 2021;50(1–2):9–12.
 108. Rodgers F, Pepperrell T, Keestra S, Pilkington V. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. *Trials*. 2021 Jan;22(1):59.
 109. Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuet JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. *Rheumatology (Oxford)*. 2021 Jan;60(1):399–407.

110. Saad MO. Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. Vol. 57, International journal of antimicrobial agents. 2021. p. 106171.
111. Shah RR. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. *J Clin Pharm Ther.* 2021 Feb;46(1):17–27.
112. Shan G, Wang W. Advanced statistical methods and designs for clinical trials for COVID-19. Vol. 57, International journal of antimicrobial agents. 2021. p. 106167.
113. Singh H, Chauhan P, Kakkar AK. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. *Eur J Pharmacol.* 2021 Jan;890:173717.
114. Su Y, Ling Y, Ma Y, Tao L, Miao Q, Shi Q, et al. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. *Biosci Trends.* 2021 Jan;14(6):408–14.
115. Svenningsen EB, Thyrted J, Blay-Cadanet J, Liu H, Lin S, Moyano-Villameriel J, et al. Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro. *Antiviral Res.* 2021 Jan;185:104988.
116. Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. *Int Immunopharmacol.* 2021 Jan;90:107205.
117. Udupa A, Leverenz D, Balevic SJ, Sadun RE, Tarrant TK, Rogers JL. Hydroxychloroquine and COVID-19: a Rheumatologist’s Take on the Lessons Learned. *Curr Allergy Asthma Rep.* 2021 Jan;21(1):5.
118. Vainio PJ, Hietasalo P, Koivisto A-L, Kääriäinen S, Turunen J, Virtala M, et al. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial. Vol. 22, *Trials.* 2021. p. 44.
119. Waffo Tchounga CA, Sacre PY, Ciza P, Ngono R, Ziemons E, Hubert P, et al. Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19 pandemic. *J Pharm Biomed Anal.* 2021 Feb;194:113761.
120. Wambier CG. Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. Vol. 57, International journal of antimicrobial agents. 2021. p. 106175.
121. Winthrop KL, Brunton AE, Beekmann S, Polgreen P, Baddley J, Saag KG, et al. SARS CoV-2 infection among patients using immunomodulatory therapies. Vol. 80, *Annals of the rheumatic diseases.* England; 2021. p. 269–71.
122. Zequn Z, Yujia W, Dingding Q, Jiangfang L. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. *Eur J Pharmacol.* 2021 Feb;893:173813.
123. Zhong Q, Peng J. Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19. *J Clin Lab Anal.* 2021 Jan;35(1):e23607.
124. Dauby N, Cateau L, Hautekiet J, Montourcy M, Bottieau E, Goetghebeur E, et al. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality. *Int J Antimicrob Agents* [Internet]. 2021 Feb;57(2):106254. Available from: <https://dx.doi.org/10.1016/j.ijantimicag.2020.106254>

125. Da Silveira VG, Coltro PS, Gonçalves HOC, Hohl DH, Silva GMA, Farina-Junior JA. Cirurgia reparadora no contexto da Covid-19: complicações evolutivas no tratamento de ferida complexa inguinal TT - Reconstructive surgery in the context of Covid-19: complications in the treatment of an inguinal complex wound. *Rev bras cir plást* [Internet]. 2020;35(3):353–7. Available from: <http://rbcp.org.br/details/2801/pt-BR/cirurgia-reparadora-no-contexto-da-covid-19--complicacoes-evolutivas-no-tratamento-de-ferida-complexa-inguinal>
126. Campos DMO, Oliveira CBS, Andrade JMA, Oliveira JIN. Fighting COVID-19 TT - Combatendo a COVID-19. *Braz j biol* [Internet]. 2020;80(3):698–701. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
127. García-Saavedra MB, Rosales-Gutiérrez RR, Valverde E, Chumbes-Aguirre M, Alvarado R, Polo R, et al. Implicaciones cardiovasculares de la infección por SARS-CoV-2: revisión de literatura TT - Cardiovascular implications of SARS-CoV-2 infection: A literature review. *Medwave* [Internet]. 2020;20(7). Available from: <https://www.medwave.cl/link.cgi/Medwave/Revisiones/RevisionClinica/8008.act>
128. Orellana Centeno JE, Morales Castillo V, Guerrero Sotelo RN. Generalidades, manejos, cuidados y manifestaciones clínicas del SARS-CoV-2 TT - Overview, management, care and clinical manifestations of SARS-CoV-2. *Rev ADM* [Internet]. 2020;77(3):153–5. Available from: <http://fi-admin.bvsalud.org/document/view/bhj2>
129. Zaidel EJ, Wyss Quintana FS, Sosa Liprandi Á, Mendoza I, Márquez MF, Nuñez E, et al. Hidroxicloroquina: Mensajes desde la cardiología en tiempos de pandemia por Coronavirus. *Med* [Internet]. 2020;80(3):271–4. Available from: http://www.scielo.org.ar/scielo.php?script=sci_arttext&
130. Accinelli RA, Zhang Xu CM, Ju Wang J-D, Yachachin-Chávez JM, Cáceres-Pizarro JA, Tafur-Bances KB, et al. COVID-19: la pandemia por el nuevo virus SARS-CoV-2. *Rev peru med exp salud publica* [Internet]. 2020;37(2):302–11. Available from: http://www.scielosp.org/scielo.php?script=sci_arttext&
131. dAvila A, Melo MFV, Lopes RD. Pandemônio Durante a Pandemia: Qual o Papel dos Profissionais da Saúde e a Ciência? TT - Pandemonium During the Pandemic: What is the Role of Health and Science Professionals? *Arq bras cardiol* [Internet]. 2020;114(5):753–4. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
132. Saúde G (Estado). S da. A Hidroxicloroquina é eficaz e segura no tratamento da COVID-19? TT - Is Hydroxychloroquine effective and safe in the treatment of COVID-19? [Internet]. 2020. Available from: https://www.saude.go.gov.br/files//banner_coronavirus/protocolos-notas/5 - Sínteses de Evidências/Cloroquina e Hidroxicloroquina no Tratamento COVID-19.pdf
133. Toledo M. Guías para el manejo de pacientes con COVID-19 y enfermedad renal crónica/trasplante renal en el Hospital General San Juan de Dios, Guatemala TT - Guidelines for the management of patients with COVID-19 and Chronic Renal Disease/Renal Transplant at Hospital General San Juan de Dios, Guatemala. *Rev Col méd cir* [Internet]. 2020;159(1):3–8. Available from: <http://bibliomed.usac.edu.gt/revistas/revcolmed/2020/159/1/02>
134. Llaro-Sánchez MK, Gamarra-Villegas BE, Campos-Correa KE. Características clínico-epidemiológicas y análisis de sobrevivencia en fallecidos por COVID-19 atendidos en establecimientos de la Red Sabogal-Callao 2020 TT - Clinical-epidemiological characteristics and survival time of deceased COVID-19 patients treated at hospitals belonging to Red Sabogal-Callao in 2020. *Horiz méd* [Internet]. 2020;20(2):e1229–e1229. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&
135. Pareja Cruz A, Luque Espino JC. Alternativas terapéuticas farmacológicas para COVID-19 TT - Therapeutic alternatives for COVID-19. *Horiz méd* [Internet]. 2020;20(2):e1216–e1216. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&

136. Saúde G (Estado). S da. Tratamento - COVID-19 TT - Treatment - COVID-19 [Internet]. 2020. Available from: https://www.saude.gov.br/files//banner_coronavirus/protocolos-notas/5 - Sínteses de Evidências/Tratamento COVID-19.pdf
137. (Brasil) CN de S de S. Republicada a RDC Anvisa n. 352 que dispõe sobre a autorização prévia para fins de exportação de cloroquina e hidroxicloroquina, azitromicina e seus sais destinados ao combate da Covid-19 TT - RDC Anvisa n. 352 which provides for prior authorization for the purpose of exporting chloroquine and hydroxychloroquine, azithromycin and their salts for combating Covid-19 [Internet]. Vol. 112, CONASS informa. 2020. Available from: <http://www.conass.org.br/conass-informa-n-111-2020-publicado-o-decreto-n-10289-que-altera-o-decreto-no-10-277-de-16-de-marco-de-2020-para-instituir-o-centro-de-coordenacao-de-operacoes-no-ambito-do-comite/>
138. Huaroto F, Reyes N, Huamán K, Bonilla C, Curisínche-Rojas M, Carmona G, et al. Intervenciones farmacológicas para el tratamiento de la Enfermedad por Coronavirus (COVID-19) TT - Pharmacological interventions for the treatment of Coronavirus Disease (COVID-19). *An Fac Med* [Internet]. 2020;81(1):71–9. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&
139. Chávez ET, Saavedra Leveau C, Ticona Huaroto C, Hidalgo García A. COVID-19: En este momento podría ser útil el tratamiento antiviral en casos leves TT - COVID-19: Antiviral treatment in mild cases could be useful at this time. *An Fac Med* [Internet]. 2020;81(1):87–91. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&
140. Pacheco TJA, Souza DG de, Lima LI de, Longo JPF. Panorama mundial de estudos com a hidroxicloroquina para o tratamento da COVID-19 TT - Global perspective of studies with hydroxychloroquine for the treatment of COVID-19. *J Heal Biol Sci* [Internet]. 2020;8(1):1–4. Available from: <https://periodicos.unichristus.edu.br/jhbs/article/view/3288>
141. Alves Neto UE, Pires AC. Drogas e medicamentos investigados para o tratamento do COVID-19 TT - Drugs and medicines investigated for the treatment of COVID-19. *J Heal Biol Sci* [Internet]. 2020;8(1):1–7. Available from: <https://periodicos.unichristus.edu.br/jhbs/article/view/3284>
142. Soto A. Cuando la vehemencia supera la evidencia: el caso del uso de hidroxicloroquina para el tratamiento del COVID-19 TT - When vehemence surpasses evidence: The case of hydroxychloroquine use for the therapy of COVID-19 infection. *Acta méd peru* [Internet]. 2020;37(1):110–1. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&
143. Saúde BS da. Nota técnica COE saúde nº 77 de 21 de julho de 2020: novas orientações sobre uso compassonado da hidroxicloroquina no tratamento da Covid-19 TT - COE health technical note 77 of July 21, 2020: new guidelines on compassionate use of hydroxychloroquine in the treatment of Covid-19 [Internet]. 2020. p. 6. Available from: <http://www.saude.ba.gov.br/wp-content/uploads/2020/07/NT-nº77-Revogação-da-Nota-Técnica-Coes-Saúde-nº-41-e-Novas-Orientações-HIDROXICLOROQUINA-1.pdf>
144. Saúde G (Estado). S da. Atualiza informações sobre o uso da Cloroquina como terapia adjuvante no tratamento de formas graves do COVID-19 TT - Updates information on the use of chloroquine as an adjunct therapy in the treatment of severe forms of COVID-19 [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/gpa4w>
145. Saúde G (Estado). S da. Orientações para a utilização de cloroquina e hidroxicloroquina no tratamento de pacientes com COVID-19 TT - Guidelines for the use of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/z39a7>
146. Broche del Pino L, Granados Campos L, Pérez Leal L, López Rodríguez VM. Neumonía por SARS CoV-2 en lactante de cinco meses TT - Pneumonia by SARS CoV-2 in five months old

newborn. Rev Cuba pediatr [Internet]. 2020;92(supl.1):e1172–e1172. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&

147. Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment TT - Ensayos clínicos de reposicionamiento de medicamentos para el tratamiento de la COVID-19 TT - Ensaios clínicos de reposicionamento de medicamentos para o tratamento do COVID-19. Rev panam salud pública [Internet]. 2020;44:e40–e40. Available from: http://www.scielosp.org/scielo.php?script=sci_arttext&
148. Corrêa MCDV, Vilarinho L, Barroso WBG. Controvérsias em torno do uso experimental da cloroquina / hidroxicloroquina contra a Covid-19: "no magic bullet" TT - Controversies about the experimental use of chloroquine / hydroxychloroquine against Covid-19: "no magic bullet" Physis (Rio J) [Internet]. 2020;30(2):e300217–e300217. Available from: http://www.scielosp.org/scielo.php?script=sci_arttext&
149. Silva M, Azize RL. Substâncias sob suspeita: regulações e incitações suscitadas pelo coronavírus TT - Suspected substances: coronavirus regulations and incitement. Physis (Rio J) [Internet]. 2020;30(2):e300204–e300204. Available from: http://www.scielosp.org/scielo.php?script=sci_arttext&
150. Mimica D M, Massardo V L. Los reumatólogos en la pandemia COVID-19 TT - Rheumatologists in the COVID-19 pandemic. Rev chil Reum [Internet]. 2020;36(1):10–6. Available from: <http://www.sochire.cl/bases/r-916-1-1592327828.pdf>
151. Zañartu C MP. Antimaláricos y SARS-CoV-2: nuevas propiedades en el 2020 TT - Antimalarials and SARS-CoV-2: new properties in 2020. Rev chil Reum [Internet]. 2020;36(1):17–9. Available from: <http://www.sochire.cl/bases/r-917-1-1592327858.pdf>
152. Fuentes Finkelstein A. Reumatología y COVID-19: una oportunidad única TT - Rheumatology and COVID-19: a unique opportunity. Rev chil Reum [Internet]. 2020;36(1):20–3. Available from: <http://www.sochire.cl/bases/r-918-1-1592327909.pdf>
153. Teich VD, Klajner S, Almeida FAS de, Dantas ACB, Laselva CR, Torritesi MG, et al. Epidemiologic and clinical features of patients with COVID-19 in Brazil TT - Características epidemiológicas e clínicas dos pacientes com COVID-19 no Brasil. Einstein (São Paulo) [Internet]. 2020;18:eAO6022–eAO6022. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
154. Moura-Neto JA, Misael AM, Silva DR da, Davila R, Andreoli MCC, Kraychete A, et al. Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function TT - Nota da Sociedade Brasileira de Nefrologia em relação ao ajuste das drogas cloroquina e hidroxicloroquina pela função renal. J bras nefrol [Internet]. 2020;42(2,supl.1):49–50. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
155. Soares R de A, Vedovello RS, Medeiros SCG de, Nunes CZ, Sian CA, Jorge PD de M. COVID-19 diagnosis in a patient with critical limb ischemia: complications and clinical outcomes TT - Diagnóstico de COVID-19 em paciente com isquemia crítica do membro: complicações e desfechos clínicos. J vasc bras [Internet]. 2020;19:e20200071–e20200071. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
156. Neves ALM das, Ferreira B de O. Narrativas entre ciência e política no ativismo da cloroquina TT - Narrativas entre ciencia y política en el activismo de cloroquina TT - Narratives between science and politics in chloroquine activism. Psicol soc [Internet]. 2020;32:e020006–e020006. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
157. Fernández Rodríguez C, Monsalve ME. Presentación de dos pacientes con enfermedad COVID-19 TT - Presentation of two patients with COVID-19 disease. Med interna [Internet]. 2020;36(1):30. Available from: <https://www.svmi.web.ve/ojs/index.php/medint/article/view/544>

158. Navas Blanco TM. Cloroquina y COVID-19 TT - Chloroquine and COVID-19. *Med interna* [Internet]. 2020;36(1):16–29. Available from: <https://www.svmi.web.ve/ojs/index.php/medint/article/view/537>
159. Carvajal de Carvajal AC, Rísquez Parra A, Fernández Silano M, Barrios Briceño MM, Rojas Rosales M, Cuadra Sánchez C, et al. Nuevo coronavirus (SARS-COV-2): una amenaza global TT - New Coronavirus (SARS-COV-2): a global threat. *Med interna* [Internet]. 2020;36(1):3–15. Available from: <https://www.svmi.web.ve/ojs/index.php/medint/article/view/536>
160. Villasmil Prieto GJ. COVID-19: sin "bala de plata" y ante el desafío de nuestras vidas TT - COVID-19: without a "silver bullet" and facing the challenge of our lives. *Med interna* [Internet]. 2020;36(1):1–2. Available from: <https://www.svmi.web.ve/ojs/index.php/medint/article/view/535>
161. Silva RDFC, Gonçalves LAP. As pílulas do Messias: salvação, negação e política de morte em tempos de pandemia TT - The Messiah pills: salvation, denial and death policy in times of pandemic. *Physis (Rio J)* [Internet]. 2020;30(2):e300208–e300208. Available from: http://www.scielo.org/scielo.php?script=sci_arttext&
162. Paumgartten FJR, Oliveira ACAX de. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues TT - Uso off label, compassivo e irracional de medicamentos na pandemia de Covid-19, consequências para a saúde e questões éticas. *Ciênc Saúde Colet* [Internet]. 2020;25(9):3413–9. Available from: http://www.scielo.org/scielo.php?script=sci_arttext&
163. Saúde BM da. Orientações do Ministério da Saúde para manuseio medicamentoso precoce de pacientes com diagnóstico da COVID-19 TT - Ministry of Health guidelines for early drug handling of patients diagnosed with COVID-19 [Internet]. 2020. Available from: <https://saude.gov.br/images/pdf/2020/June/18/COVID-FINAL-16JUNHO-Livreto-1-V3.pdf>
164. Brasil. Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde T. Informe diário de evidências COVID-19: busca referente aos dias 1, 2 e 3 de agosto de 2020 TT - COVID-19 daily evidence report: search related to August 1, 2 and 3, 2020 [Internet]. 2020. Available from: <http://saude.gov.br/images/pdf/2020/August/12/N90-InformeDiario-referente-11-08.pdf>
165. Registries Offer Insights on COVID-19-Cancer Connection. *Cancer Discov* [Internet]. 2020;10(7):894. Available from: <https://dx.doi.org/10.1158/2159-8290.CD-NB2020-050>
166. Abbas HM, Al-Jumaili AA, Nassir KF, Al-Obaidy MW, Al Jubouri AM, Dakhil BD, et al. Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial. *Int J Clin Pr* [Internet]. 2020;e13856–e13856. Available from: <https://dx.doi.org/10.1111/ijcp.13856>
167. Agrawal R, Testi I, Lee CS, Tsui E, Blazes M, Thorne JE, et al. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic. 2020; Available from: <https://dx.doi.org/10.1136/bjophthalmol-2020-316776>
168. Agstam S, Yadav A, Kumar-M P, Gupta A. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis. *Indian Pacing Electrophysiol J* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.ipej.2020.10.002>
169. Agusti A, Guillen E, Ayora A, Anton A, Aguilera C, Vidal X, et al. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. *Enferm infeccc microbiol clin (Ed impr)* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.eimc.2020.10.023>
170. Akdur A, Karakaya E, Ayvazoglu Soy EH, Alshalabi O, Kirnap M, Arslan H, et al. Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience.

Exp Clin Transpl [Internet]. 2020;18(3):270–4. Available from: <https://dx.doi.org/10.6002/ect.2020.0193>

171. Akula SM, McCubrey JA. Where are we with understanding of COVID-19? *Adv Biol Regul* [Internet]. 2020;77:100745. Available from: <https://dx.doi.org/10.1016/j.jbior.2020.100745>
172. Al-Darzi W, Aurora L, Michaels A, Cowger J, Grafton G, Selektor Y, et al. Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience. *Clin Transpl* [Internet]. 2020;e14091–e14091. Available from: <https://dx.doi.org/10.1111/ctr.14091>
173. Alam MM, Mahmud S, Rahman MM, Simpson J, Aggarwal S, Ahmed Z. Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York. *Cureus* [Internet]. 2020;12(8):e9658–e9658. Available from: <https://dx.doi.org/10.7759/cureus.9658>
174. Alifano M, Alifano P, Forgez P, Iannelli A. Renin-angiotensin system at the heart of COVID-19 pandemic. *Biochimie* [Internet]. 2020;174:30–3. Available from: <https://dx.doi.org/10.1016/j.biochi.2020.04.008>
175. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. *Autoimmun Rev* [Internet]. 2020;19(7):102569. Available from: <https://dx.doi.org/10.1016/j.autrev.2020.102569>
176. Almazrou SH, Almalki ZS, Alanazi AS, Alqahtani AM, AlGhamd SM. Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study. *Saudi Pharm J* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.jsps.2020.09.019>
177. Alvarez A, Cabia L, Trigo C, Bandrés AC, Bestué M. Prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain. 2020; Available from: <https://dx.doi.org/10.1136/ejhpharm-2020-002476>
178. Amirfakhryan H, Safari F. Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. *Hell j cardiol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.hjc.2020.05.007>
179. Andrade KRC de, Carvalho VK da S, Farinasso CM, Lima AA de, Silva RB, Wachira VK, et al. Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida TT - Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. *Ciênc Saúde Colet* [Internet]. 2020;25(9):3517–54. Available from: http://www.scielo.org/scielo.php?script=sci_arttext&
180. Anikwe CC, Ogah CO, Anikwe IH, Okorochukwu BC, Ikeoha CC. Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. *Int J Gynaecol Obs* [Internet]. 2020;151(2):197–202. Available from: <https://dx.doi.org/10.1002/ijgo.13293>
181. Anthi A, Konstantonis D, Theodorakopoulou M, Apostolopoulou O, Karampela I, Konstantopoulou G, et al. A Severe COVID-19 Case Complicated by Right Atrium Thrombus. *Am J Case Rep* [Internet]. 2020;21:e926915–e926915. Available from: <https://dx.doi.org/10.12659/AJCR.926915>
182. Antioquia U de. Tratamiento farmacológico de la infección COVID-19 en adultos. Actualización TT - Pharmacological interventions for adults with COVID-19 infection: Rapid synthesis (Up to date) [Internet]. 2020. p. 34. Available from: <http://fi-admin.bvsalud.org/document/view/4ehmq>

183. Asfuroglu Kalkan E, Ates I. A case of subacute thyroiditis associated with Covid-19 infection. *J Endocrinol Invest* [Internet]. 2020;43(8):1173–4. Available from: <https://dx.doi.org/10.1007/s40618-020-01316-3>
184. Ashinyo ME, Duti V, Dubik SD, Amegah KE, Kutsoati S, Oduro-Mensah E, et al. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. *Pan Afr Med J* [Internet]. 2020;37(Suppl 1):9. Available from: <https://dx.doi.org/10.11604/pamj.suppl.2020.37.9.25718>
185. Atallah ÁN, Puga ME dos S, Amaral JLG do, Person OC. Intervenção com cloroquina/hidroxicloroquina com ou sem azitromicina para COVID-19 (SARS-Cov 2): sinopse baseada em evidências TT - Chloroquine / hydroxychloroquine intervention with or without azithromycin for COVID-19 (SARS-Cov 2): evidence-based synopsis. *Diagn Trat* [Internet]. 2020;25(2):1–7. Available from: <http://fi-admin.bvsalud.org/document/view/9behe>
186. Babapoor-Farrokhran S, Port Z, Wiener PC, Amanullah A, Mainigi SK. Polymorphic Ventricular Tachycardia with a Normal QTc Interval in a Patient with COVID-19 and Fever: Case Report. *SN Compr Clin Med* [Internet]. 2020;1–4. Available from: <https://dx.doi.org/10.1007/s42399-020-00531-6>
187. Baburaj G, Thomas L, Rao M. Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. *Arch med res* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.arcmed.2020.11.006>
188. Badell-Grau RA, Cuff JP, Kelly BP, Waller-Evans H, Lloyd-Evans E. Investigating the Prevalence of Reactive Online Searching in the COVID-19 Pandemic: Infeveillance Study. *J Med Internet Res* [Internet]. 2020;22(10):e19791–e19791. Available from: <https://dx.doi.org/10.2196/19791>
189. Bai Y-X, Xu Y-H, Wang X, Sun C, Guo Y, Qiu S, et al. Advances in SARS-CoV-2: a systematic review. *Eur Rev Med Pharmacol Sci* [Internet]. 2020;24(17):9208–15. Available from: https://dx.doi.org/10.26355/eurrev_202009_22873
190. Balkrishna A, Mittal R, Arya V. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach Against COVID-19. *Curr pharm biotechnol* [Internet]. 2020; Available from: <https://dx.doi.org/10.2174/1389201021999201110204116>
191. Barja LD, Maurice MF, González EC. Hidroxicloroquina y azitromicina: riesgo cardiovascular, prolongación de QTc y muerte súbita en el nuevo escenario de la pandemia por COVID-19 TT - Hydroxychloroquine and azithromycin: cardiovascular risk, QTc prolongation and sudden death in the new COVID-19 outbreak. *CorSalud* [Internet]. 2020;12(1). Available from: <http://www.revcorsalud.sld.cu/index.php/cors/article/view/601/1108>
192. Bellido V, Pérez A. Consequences of COVID-19 on people with diabetes. TT - Consecuencias de la COVID-19 sobre las personas con diabetes. *Endocrinol Diabetes Nutr* [Internet]. 2020;67(6):355–6. Available from: <https://dx.doi.org/10.1016/j.endinu.2020.04.001>
193. Belloso WH. Hora de analizar la evidencia de izquierda a derecha TT - It is time to analyze the evidence from left to right. *Evid actual práct ambul* [Internet]. 2020;23(2):e002053–e002053. Available from: <http://www.evidencia.org/index.php/Evidencia/article/view/4281/1843>
194. Bernal Édgar, López-Zea Ana Isabel, Salazar-Rey Milton, Gómez-Laiton Édgar, Camacho-López PA. Hidroxicloroquina para manejo de infección por SARS-CoV-2 Una revisión exploratoria TT - Hydroxychloroquine for treatment of SARS-CoV-2 infection An exploratory review. *Acta méd colomb* [Internet]. 2020;45(3):28–40. Available from: http://www.scielo.org.co/scielo.php?script=sci_arttext&

195. Bernardes F, Soares D, Ribeiro A, Ferreira V, Vasconcelos J, Maia M, et al. Lemierre's Syndrome: Case Report Of 'The Forgotten Disease'; In Current Covid-19 Pandemic. *Rev Port Cir Cardiorac Vasc* [Internet]. 2020;27(4):295–6. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-33280320>
196. Bertoli F, Veritti D, Danese C, Samassa F, Sarao V, Rassu N, et al. Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. *J Ophthalmol* [Internet]. 2020;2020:4827304. Available from: <https://dx.doi.org/10.1155/2020/4827304>
197. Bhumbra S, Malin S, Kirkpatrick L, Khaitan A, John CC, Rowan CM, et al. Clinical Features of Critical Coronavirus Disease 2019 in Children. *Pediatr Crit Care Med* [Internet]. 2020;21(10):e948–53. Available from: <https://dx.doi.org/10.1097/PCC.0000000000002511>
198. Bienvenu A-L, Marty AM, Jones MK, Picot S. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. *One Heal* [Internet]. 2020;10:100141. Available from: <https://dx.doi.org/10.1016/j.onehlt.2020.100141>
199. Bigna JJ, Kamtchum-Tatuene J, Noubiap JJ. Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence. *Travel Med Infect Dis* [Internet]. 2020;38:101886. Available from: <https://dx.doi.org/10.1016/j.tmaid.2020.101886>
200. Bisogno G, Provenzi M, Zama D, Tondo A, Meazza C, Colombini A, et al. Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: A Study From the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. *J Pediatr Infect Dis Soc* [Internet]. 2020;9(5):530–4. Available from: <https://dx.doi.org/10.1093/jpids/piaa088>
201. Bousquet G, Falgarone G, Deutsch D, Derolez S, Lopez-Sublet M, Goudot F-X, et al. ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19. *Aging (Albany NY)* [Internet]. 2020;12(12):11306–13. Available from: <https://dx.doi.org/10.18632/aging.103583>
202. Boyer L, Auquier P, Fond G. [Real-life data and Covid-19: The third avenue of reseach]. *TT - Données de vie réelle et Covid-19 : la troisième voie. Encephale* [Internet]. 2020;46(3S):S114–5. Available from: <https://dx.doi.org/10.1016/j.encep.2020.04.003>
203. Brasil. Ministério da Saúde. Secretaria de Ciência T e IE em S. Informe diário de evidências Covid-19: busca realizada em 07 de abril de 2020: 2 revisões não sistemáticas e 1 artigo de opinião encontrados *TT - Covid-19 daily evidence report: search conducted on April 7, 2020: 2 non-systematic reviews and 1 opinion article found* [Internet]. 2020. p. 9. Available from: <https://portalarquivos.saude.gov.br/images/pdf/2020/Abril/24/InformeDiario-referente-08-04.pdf>
204. Brasil. Ministério da Saúde. Secretaria de Ciência T e IE em S. Segurança da cloroquina e hidroxicloroquina em pacientes com deficiência de glicose-6-fosfato desidrogenase (G6PD) e rastreamento da deficiência de G6PD em pacientes elegíveis para tratamento com cloroquina ou hidroxicloroquina devido à infecção por COVID-19 *TT - Safety of chloroquine and hydroxychloroquine in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and screening for G6PD deficiency in eligible patients for treatment with chloroquine or hydroxychloroquine due to COVID-19 infection* [Internet]. 2020. Available from: <https://portalarquivos.saude.gov.br/images/pdf/2020/May/11/Seguranca-CloroquinaeHidroxicloquina-COVID19.pdf>
205. Brasil. Ministério da Saúde. Secretaria de Ciência T em IE em S. Tratamento farmacológico para casos internados com SARS-COV-2, do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo *TT - Pharmacological treatment for hospitalized cases with SARS-COV-2, Hospital das Clínicas, Faculty of Medicine Medicine of*

Ribeirão Preto, University of São Paulo [Internet]. 2020. Available from: <https://portalarquivos.saude.gov.br/images/pdf/2020/May/11/TratamentoFarmacologico-SARS-COV-2-HC.RP.pdf>

206. Bruno Heberto A, Corona Juan Carlos P, Rubio José Antonio C, Pérez Patricia P, Rasgado Enrique T, Portano Julieta Danira M, et al. " IMPLICATIONS OF MYOCARDIAL INJURY IN MEXICAN HOSPITALIZED PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19). *Int J Cardiol Hear Vasc* [Internet]. 2020;100638. Available from: <https://dx.doi.org/10.1016/j.ijcha.2020.100638>
207. Caillard S, Anglicheau D, Matignon M, Durrbach A, Greze C, Frimat L, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. *Kidney Int* [Internet]. 2020;98(6):1549–58. Available from: <https://dx.doi.org/10.1016/j.kint.2020.08.005>
208. Cairoli E, Espinosa G. [Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence]. TT - Hidroxicloroquina en el tratamiento del COVID-19: cómo utilizarla a la espera de evidencia científica concluyente. *Med Clin* [Internet]. 2020;155(3):134–5. Available from: <https://dx.doi.org/10.1016/j.medcli.2020.05.006>
209. Cañas M, Urtasun MA. La evidencia en tiempos de coronavirus (COVID-19) TT - Evidence in times of coronavirus (COVID-19). *Evid actual práct ambul* [Internet]. 2020;23(2):e002057–e002057. Available from: <http://www.evidencia.org/index.php/Evidencia/article/view/4285/1851>
210. Caraffa R, Bagozzi L, Fiocco A, Bifulco O, Nadali M, Ponzoni M, et al. Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. *Eur J Cardiothorac Surg* [Internet]. 2020;58(5):899–906. Available from: <https://dx.doi.org/10.1093/ejcts/ezaa323>
211. Carannante N, Fiorentino G, Corcione A, Di Sarno R, Spatarella M, Maturo N, et al. Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report. *Front Med* [Internet]. 2020;7:388. Available from: <https://dx.doi.org/10.3389/fmed.2020.00388>
212. Casanueva Cabeza HC, Méndez Sánchez T de J, González Blanco Y, Naranjo Fernández RM, Sibello Deustua S. SARS-COV-2 y su relación con el sistema visual TT - SARS-CoV-2 and its relationship to the visual system. *Rev Cuba oftalmol* [Internet]. 2020;33(2):e956–e956. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&
213. Casas-Rojo JM, Antón-Santos JM, Millán-Núñez-Cortés J, Lumbreras-Bermejo C, Ramos-Rincón JM, Roy-Vallejo E, et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. TT - Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19. *Rev clin esp (Ed impr)* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.rce.2020.07.003>
214. Cassone A, Iacoviello L, Cauda R. Chloroquine/hydroxychloroquine and COVID-19: need to know more about. *Futur microbiol*, [Internet]. 2020; Available from: <https://dx.doi.org/10.2217/fmb-2020-0247>
215. Cavalli G, De Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol* [Internet]. 2020;2(6):e325–31. Available from: [https://dx.doi.org/10.1016/S2665-9913\(20\)30127-2](https://dx.doi.org/10.1016/S2665-9913(20)30127-2)
216. Celotto S, Veronese N, Barbagallo M, Ometto F, Smith L, Pardhan S, et al. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of

- Hydroxychloroquine and chloroquine therapy. *Int J Infect Dis* [Internet]. 2020;103:599–606. Available from: <https://dx.doi.org/10.1016/j.ijid.2020.12.018>
217. Cespedes M da S, Souza JCRP de. Sars-CoV-2: A clinical update - II. *Rev Assoc Med Bras* [Internet]. 2020;66(4):547–57. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
218. Chen TY, Farghaly S, Cham S, Tatem LL, Sin JH, Rauda R, et al. COVID-19 pneumonia in kidney transplant recipients: Focus on immunosuppression management. *Transpl Infect Dis* [Internet]. 2020;22(5):e13378–e13378. Available from: <https://dx.doi.org/10.1111/tid.13378>
219. Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. *J Pediatric Infect Dis Soc* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/jpids/piaa045>
220. Ciapponi A. El escándalo de la cloroquina TT - The chloroquine scandal. *Evid actual práct ambul* [Internet]. 2020;23(3):e002073–e002073. Available from: <http://www.evidencia.org/index.php/Evidencia/article/view/6862/4422>
221. Ciapponi A. Tratamientos farmacológicos para COVID-19: revisión sistemática viva y meta-análisis en red TT - Pharmacological treatments for COVID-19: living systematic review and network meta-analysis. *Evid actual práct ambul* [Internet]. 2020;23(3):e002092–e002092. Available from: <http://www.evidencia.org/index.php/Evidencia/article/view/6881/4455>
222. Cohen MS. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. *N Engl J Med* [Internet]. 2020;383(6):585–6. Available from: <https://dx.doi.org/10.1056/NEJMe2020388>
223. Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al. COVID-19 in transplant recipients: The Spanish experience. *Am j Transpl* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/ajt.16369>
224. Conto-Palomino NM, Cabrera-Bueno ML, Vargas-Ponce KG, Rondón-Abuhadba EA, Atamari-Anahui N. Encefalitis asociada a COVID-19 en una niña de 13 años: reporte de caso TT - Encephalitis associated with COVID-19 in a 13-year-old girl: A case report. *Medwave* [Internet]. 2020;20(7):e7984–e7984. Available from: <https://www.medwave.cl/link.cgi/Medwave/Estudios/Casos/7984.act>
225. Cook J, Pressler ML, Damle B, Alemayehu D, Knirsch CA. The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. *Clin Transl Sci* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/cts.12867>
226. Crespo M, Mazuecos A, Rodrigo E, Gavela E, Villanego F, Sánchez-Alvarez E, et al. Respiratory and Gastrointestinal COVID-19 Phenotypes in Kidney Transplant Recipients. *Transplantation* [Internet]. 2020;104(11):2225–33. Available from: <https://dx.doi.org/10.1097/TP.0000000000003413>
227. Cura Yayla BC, Özsüreği Y, Aykaç K, Derin Oygur P, Laçinel Gürlevik S, Ilbay S, et al. Characteristics and Management of Children with COVID-19 in Turkey. *Balk Med J* [Internet]. 2020;37(6):341–7. Available from: <https://dx.doi.org/10.4274/balkanmedj.galenos.2020.2020.7.52>
228. D'Amico F, Danese S, Peyrin-Biroulet L. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. *Clin Gastroenterol Hepatol* [Internet]. 2020;18(12):2689–700. Available from: <https://dx.doi.org/10.1016/j.cgh.2020.08.003>

229. da Silveira Cespedes M, Souza JC. SARS-CoV-2: a clinical update TT - SARS-CoV-2: uma revisão para o clínico [Internet]. 2020. Available from: <https://preprints.scielo.org/index.php/scielo/preprint/view/26>
230. Dattilo M. The role of host defences in Covid 19 and treatments thereof. *Mol Med* [Internet]. 2020;26(1):90. Available from: <https://dx.doi.org/10.1186/s10020-020-00216-9>
231. de Boer MGJ, Gieling EM, van der Linden PD, Sinha BNM, Vollaard AM. [The medicinal treatment of COVID-19: a brief update]. TT - Medicamenteuze behandeling van COVID-19. *Ned tijdschr geneeskd* [Internet]. 2020;164. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-33331727>
232. De Rossi N, Scarpazza C, Filippini C, Cordioli C, Rasia S, Mancinelli CR, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. *EClinicalMedicine* [Internet]. 2020;100459. Available from: <https://dx.doi.org/10.1016/j.eclinm.2020.100459>
233. Defoort-Dhellemmes S. [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?] TT - Faut-il une surveillance ophtalmologique en cas de traitement de courte durée par hydroxychloroquine en cette période d'épidémie au COVID-19 ? *J Fr Ophtalmol* [Internet]. 2020;43(6):548–9. Available from: <https://dx.doi.org/10.1016/j.jfo.2020.04.014>
234. Deshpande R, Dash S, Bahadur MM, Thamba A, Pathan AK, Dave K, et al. Study of COVID-19 Pandemic in Representative Dialysis Population Across Mumbai, India: An Observational Multicentric Analysis. *J Assoc Physicians India* [Internet]. 2020;68(10):13–7. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32978919>
235. Dhampalwar S, Saigal S, Soin AS. Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. 2020; Available from: <https://dx.doi.org/10.1016/j.jceh.2020.07.001>
236. Dhont S, Callens R, Stevens D, Bauters F, De Bleecker JL, Derom E, et al. Myotonic dystrophy type 1 as a major risk factor for severe COVID-19? *Acta neurol Belg* [Internet]. 2020; Available from: <https://dx.doi.org/10.1007/s13760-020-01514-z>
237. Di Pasquale G, Maggioni AP. [COVID-19 trials: surfing between expectations and illusions, looking forward to evidence]. TT - Studi clinici per la malattia COVID-19: navigando tra speranze e illusioni, in attesa di certezze. *G Ital Cardiol* [Internet]. 2020;21(7):479–82. Available from: <https://dx.doi.org/10.1714/3386.33632>
238. Diriba K, Awulachew E, Getu E. The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis. *Eur J Med Res* [Internet]. 2020;25(1):39. Available from: <https://dx.doi.org/10.1186/s40001-020-00439-w>
239. Dirim AB, Demir E, Safak S, Garayeva N, Ucar AR, Oto OA, et al. Hydroxychloroquine-Associated Hypoglycemia in Hemodialysis Patients With COVID-19. 2020; Available from: <https://dx.doi.org/10.1016/j.ekir.2020.06.039>
240. Dirim AB, Demir E, Ucar AR, Garayeva N, Safak S, Oto OA, et al. Fatal SARS-CoV-2 infection in a renal transplant recipient. *CEN Case Rep* [Internet]. 2020;9(4):409–12. Available from: <https://dx.doi.org/10.1007/s13730-020-00496-4>
241. Dongala T, Katari NK, Palakurthi AK, Katakam LNR, Mariseti VM. Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach. *Chromatographia* [Internet]. 2020;1–13. Available from: <https://dx.doi.org/10.1007/s10337-020-03945-5>

242. Dragojevic Simic V, Miljkovic M, Stamenkovic D, Vekic B, Ratkovic N, Simic R, et al. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. *Int J Clin Pr* [Internet]. 2020;e13825–e13825. Available from: <https://dx.doi.org/10.1111/ijcp.13825>
243. Dube T, Ghosh A, Mishra J, Kompella UB, Panda JJ. Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. *Adv Ther* [Internet]. 2020;2000172. Available from: <https://dx.doi.org/10.1002/adtp.202000172>
244. Duculan R, Jannat-Khah D, Mehta B, Mandl LA, Barbhैया M, Bass AR, et al. Variables Associated With Perceived Risk of Contracting SARS-CoV-2 Infection During the COVID-19 Pandemic Among Patients With Systemic Rheumatic Diseases. *J clin rheumatol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1097/RHU.0000000000001686>
245. Echarte-Morales J, Minguito-Carazo C, Del Castillo-García S, Borrego-Rodríguez J, Rodríguez-Santamarta M, Sánchez-Muñoz E, et al. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19. *J Electrocardiol* [Internet]. 2020;64:30–5. Available from: <https://dx.doi.org/10.1016/j.jelectrocard.2020.11.012>
246. El Boussadani B, Benajiba C, Aajal A, Ait Brik A, Ammour O, El Hangouch J, et al. [COVID-19 pandemia: Impact on the cardiovascular system. Data of 1st April 2020]. *TT - Pandémie COVID-19 : impact sur le système cardiovasculaire. Données disponibles au 1^{er} avril 2020. Ann Cardiol Angeiol* [Internet]. 2020;69(3):107–14. Available from: <https://dx.doi.org/10.1016/j.ancard.2020.04.001>
247. Elsayah HK, Elsayah MA, Elrazzaz MG, Elshafie AH. Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. *J med virol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1002/jmv.26442>
248. Emamaullee J, Bowdish M, Yan PY, Rodina V, Sher LS. Rapid Adaptation of a Surgical Research Unit to Conduct Clinical Trials During the COVID-19 Pandemic. *J Surg Res* [Internet]. 2020;256:76–82. Available from: <https://dx.doi.org/10.1016/j.jss.2020.06.049>
249. Enyama D, Chelo D, Noukeu Njinkui D, Mayouego Kouam J, Fokam Djike Puepi Y, Mekone Nkwele I, et al. Impact of the COVID-19 pandemic on pediatricians; clinical activity in Cameroon. *Arch Pediatr* [Internet]. 2020;27(8):423–7. Available from: <https://dx.doi.org/10.1016/j.arcped.2020.09.004>
250. Enzmann MO, Erickson MP, Grindeland CJ, Lopez SMC, Hoover SE, Leedahl DD. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas. *Epidemiol Infect* [Internet]. 2020;148:e124–e124. Available from: <https://dx.doi.org/10.1017/S0950268820001351>
251. Escobar G, Matta J, Taype Huamaní W, Ayala R, Amado J. Características clínicoepidemiológicas de pacientes fallecidos por COVID-19 en un hospital nacional de Lima, Perú *TT - Clinical - Epidemiological Characteristics Of Patients Deceased By COVID-19 In A National Hospital In Lima, Peru. Rev Fac Med Hum* [Internet]. 2020;20(2):180–5. Available from: http://www.scielo.org.pe/scielo.php?script=sci_arttext&
252. Estella Á, Garnacho-Montero J. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic]. *TT - Del empirismo a la evidencia científica en el tratamiento con antivíricos en los casos graves de infección por coronavirus en tiempos de epidemia. Med Intensiva* [Internet]. 2020;44(8):509–12. Available from: <https://dx.doi.org/10.1016/j.medin.2020.04.009>
253. ETS RAP de. Tratamiento farmacológico específico con cloroquina en caso de infección por COVID-19 *TT - Specific pharmacological treatment with chloroquine in case of COVID-19 infection* [Internet]. 2020. Available from: <http://fi-admin.bvsalud.org/document/view/j44wp>

254. Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with COVID-19. *Am J Trop Med Hyg* [Internet]. 2020;102(6):1214–6. Available from: <https://dx.doi.org/10.4269/ajtmh.20-0276>
255. Favalli EG, De Lucia O, Biggioggero M, Del Papa N, Caporali R. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. *Ann rheum dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-218068>
256. Favalli EG, Gerosa M, Murgo A, Caporali R. Are patients with systemic lupus erythematosus at increased risk for COVID-19? *Ann rheum dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217787>
257. Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain. *Am J Transpl* [Internet]. 2020;20(7):1849–58. Available from: <https://dx.doi.org/10.1111/ajt.15929>
258. Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E, Ivaturi K, et al. A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. *Am J Nephrol* [Internet]. 2020;51(5):337–42. Available from: <https://dx.doi.org/10.1159/000507417>
259. Fox MP, Agostino McGowan L, James BD, Lessler J, Mehta SH, Murray EJ. Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High Risk Outpatients with COVID-19 by Dr. Harvey Risch. *Am j epidemiol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/aje/kwaa189>
260. Fram G, Wang DD, Malette K, Villablanca P, Kang G, So K, et al. Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19. *Curr Cardiol Rev* [Internet]. 2020; Available from: <https://dx.doi.org/10.2174/1573403X16666201014144022>
261. Franco JVA. La hidroxiclороquina no reduciría la portación viral del nuevo coronavirus (COVID-19) TT - Hydroxychloroquine would not reduce viral carrying of the new coronavirus (COVID-19). *Evid actual práct ambul* [Internet]. 2020;23(1):e002051–e002051. Available from: <http://www.evidencia.org/index.php/Evidencia/article/view/4277/1835>
262. Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz Hernandez B, Zink RC, et al. Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States. *Clin infect dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/cid/ciaa1268>
263. Friedman DM, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon CK, et al. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. *Circ Arrhythm Electrophysiol* [Internet]. 2020;13(10):e008686–e008686. Available from: <https://dx.doi.org/10.1161/CIRCEP.120.008686>
264. Fteiha B, Karameh H, Kurd R, Ziff-Werman B, Feldman I, Bnaya A, et al. QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study. *Int J Clin Pr* [Internet]. 2020;e13767–e13767. Available from: <https://dx.doi.org/10.1111/ijcp.13767>
265. Funck-Brentano C, Salem J-E, Nguyen LS, Drici M-D, Roden DM. Response to the editorial “COVID-19 in patients with cardiovascular diseases”: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. *Arch Cardiovasc Dis* [Internet]. 2020;113(5):367–8. Available from: <https://dx.doi.org/10.1016/j.acvd.2020.04.001>
266. Garatti A, Castelvechio S, Daprati A, Molfetta R, Volpe M, De Vincentiis C, et al. Clinical Course of COVID-19 Infection in Patients Urgently Operated of Cardiac Surgical Procedures.

Ann Surg [Internet]. 2020;272(4):e275–9. Available from:
<https://dx.doi.org/10.1097/SLA.0000000000004393>

267. Garazzino S, Montagnani C, Donà D, Meini A, Felici E, Vergine G, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro surveill [Internet]. 2020;25(18). Available from: <https://dx.doi.org/10.2807/1560-7917.ES.2020.25.18.2000600>
268. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis I-G, et al. Emerging treatment strategies for COVID-19 infection. Clin exp med [Internet]. 2020; Available from: <https://dx.doi.org/10.1007/s10238-020-00671-y>
269. Gbinigie K, Frie K. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. 2020; Available from: <https://dx.doi.org/10.3399/bjgpopen20X101069>
270. Gegúndez-Fernández JA, Zarranz-Ventura J, Garay-Aramburu G, Muñoz-Negrete FJ, Mendicute Del Barrio J, Pablo-Júlvez L, et al. Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19. TT - Recomendaciones para la atención oftalmológica durante el estado de alarma por la pandemia de enfermedad por coronavirus COVID-19. Arch Soc Esp Oftalmol [Internet]. 2020;95(6):300–10. Available from: <https://dx.doi.org/10.1016/j.ofal.2020.04.002>
271. Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev [Internet]. 2020;19(7):102566. Available from: <https://dx.doi.org/10.1016/j.autrev.2020.102566>
272. Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. 2020; Available from: [https://dx.doi.org/10.1016/S2665-9913\(20\)30305-2](https://dx.doi.org/10.1016/S2665-9913(20)30305-2)
273. Giacomelli A, Pagani G, Ridolfo AL, Oreni L, Conti F, Pezzati L, et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J med virol [Internet]. 2020; Available from: <https://dx.doi.org/10.1002/jmv.26407>
274. Goenka M, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, et al. Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India. J Assoc Physicians India [Internet]. 2020;68(11):14–9. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-33187030>
275. Goldman A, Bomze D, Dankner R, Hod H, Meirson T, Boursi B, et al. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. 2020; Available from: <https://dx.doi.org/10.1111/bcp.14546>
276. Gómez Antúnez M, Muiño Míguez A, Bendala Estrada AD, Maestro de la Calle G, Monge Monge D, Boixeda R, et al. Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2. Int J Chron Obs Pulmon Dis [Internet]. 2020;15:3433–45. Available from: <https://dx.doi.org/10.2147/COPD.S276692>
277. Gómez Tejeda JJ, Dieguez Guach RA, Pérez Abreu MR. Alternativas terapéuticas para el manejo de la COVID-19 TT - Therapeutic alternatives for the management of COVID-19. Rev habanera cienc méd [Internet]. 2020;19(supl.1):e3328–e3328. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&
278. Gomides A, Ferreira G, Kakehasi A, Lacerda M, Marques C, Mota L, et al. Impact of Chronic Use of Antimalarials on SARS-CoV-2 Infection in Patients With Immune-Mediated Rheumatic

Diseases: Protocol for a Multicentric Observational Cohort Study. *JMIR Res Protoc* [Internet]. 2020;9(10):e23532–e23532. Available from: <https://dx.doi.org/10.2196/23532>

279. Gonzales-Zamora JA, Quiroz T, Vega AD. Tratamiento exitoso con Remdesivir y corticoides en un paciente con neumonía asociada a COVID-19: reporte de un caso TT - Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report. *Medwave* [Internet]. 2020;20(7):e7998–e7998. Available from: <https://www.medwave.cl/link.cgi/Medwave/Estudios/Casos/7998.act>
280. Götzinger F, Santiago-García B, Noguera-Julián A, Lanasma M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Heal* [Internet]. 2020;4(9):653–61. Available from: [https://dx.doi.org/10.1016/S2352-4642\(20\)30177-2](https://dx.doi.org/10.1016/S2352-4642(20)30177-2)
281. Grant-Kels JM. Response to: ‘Risks of hydroxychloroquine use for COVID-19 prophylaxis’. *J Am Acad Dermatol* [Internet]. 2020;83(1):e75–6. Available from: <https://dx.doi.org/10.1016/j.jaad.2020.04.112>
282. Gudadappanavar AM, Benni J. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. *J basic clin physiol pharmacol* [Internet]. 2020;31(6). Available from: <https://dx.doi.org/10.1515/jbcpp-2020-0113>
283. Guijarro-Castro C, Rosón-González M, Abreu A, García-Arratibel A, Ochoa-Mulas M. [Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases]. TT - Síndrome de Guillain-Barré tras infección por SARS-CoV-2. Comentarios tras la publicación de 16 nuevos casos. *Neurología* [Internet]. 2020;35(6):412–5. Available from: <https://dx.doi.org/10.1016/j.nrl.2020.06.002>
284. Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). *EClinicalMedicine* [Internet]. 2020;100591. Available from: <https://dx.doi.org/10.1016/j.eclinm.2020.100591>
285. Gupta PC, Kumar MP, Ram J. COVID-19 pandemic from an ophthalmology point of view. *Indian J Med Res* [Internet]. 2020;151(5):411–8. Available from: https://dx.doi.org/10.4103/ijmr.IJMR_1369_20
286. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. 2020; Available from: <https://dx.doi.org/10.1001/jamainternmed.2020.3596>
287. Hasdeu S, Montero G, Tortosa F, Sanguine V, Balaciano G, Izcovich A, et al. Tratamiento con Hidroxicloroquina en pacientes con COVID-19 Informe rápido de evaluación de tecnología sanitaria TT - Hydroxychloroquine treatment in patients with COVID-19: Rapid Health Technology Assessment Report. *Rev argent salud publica* [Internet]. 2020;12(Suplemento Covid-19):1–9. Available from: http://rasp.ms.gov.ar/rasp/articulos/vol12supl/REV_Hasdeue16.pdf
288. Hathout RM, Abdelhamid SG, Metwally AA. Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. *Inf Med Unlocked* [Internet]. 2020;21:100446. Available from: <https://dx.doi.org/10.1016/j.imu.2020.100446>
289. Heras E, Garibaldi P, Boix M, Valero O, Castillo J, Curbelo Y, et al. COVID-19 mortality risk factors in older people in a long-term care center. 2020; Available from: <https://dx.doi.org/10.1007/s41999-020-00432-w>

290. Hoang T, Tho Thi Anh T. Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. 2020; Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32869558>
291. Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study. *Yonsei Med J* [Internet]. 2020;61(5):431–7. Available from: <https://dx.doi.org/10.3349/ymj.2020.61.5.431>
292. Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. *BMC Med* [Internet]. 2020;18(1):216. Available from: <https://dx.doi.org/10.1186/s12916-020-01673-z>
293. Hsu JJ, Gaynor P, Kamath M, Fan A, Al-Saffar F, Cruz D, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. *Am J Transpl* [Internet]. 2020;20(7):1911–5. Available from: <https://dx.doi.org/10.1111/ajt.15936>
294. Huang HD, Jneid H, Aziz M, Ravi V, Sharma PS, Larsen T, et al. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study. *Cardiol Ther* [Internet]. 2020;9(2):523–34. Available from: <https://dx.doi.org/10.1007/s40119-020-00201-7>
295. Huang Y, Chen Z, Wang Y, Han L, Qin K, Huang W, et al. Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study. *Ann Rheum Dis* [Internet]. 2020;79(9):1163–9. Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217425>
296. Huang Y, Cai C, Zang J, Xie J, Xu D, Zheng F, et al. Treatment strategies of hospitalized patients with coronavirus disease-19. *Aging (Albany NY)* [Internet]. 2020;12(12):11224–37. Available from: <https://dx.doi.org/10.18632/aging.103370>
297. Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. *Hepatology* [Internet]. 2020;72(4):1169–76. Available from: <https://dx.doi.org/10.1002/hep.31487>
298. Huybrechts KF, Bateman BT, Zhu Y, Straub L, Mogun H, Kim SC, et al. Hydroxychloroquine early in pregnancy and risk of birth defects. *Am j Obs gynecol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.ajog.2020.09.007>
299. Imoto AM, Gottens LBD, Castelo Branco HP, Santana LA, Monteiro OLR, Fernandes SES, et al. Cloroquina e Hidroxicloroquina no tratamento da COVID-19: Sumário de Evidências TT - Chloroquine and Hydroxychloroquine in the treatment of COVID-19: Summary of Evidence. *Comun ciênc saúde* [Internet]. 2020;31(suppl.1). Available from: <http://www.escs.edu.br/revistaccs/index.php/comunicacaoemcienciasdasaude/article/view/653/289>
300. Investigación PEI de E de T en S e. Cloroquina, hidroxiclороquina, azitromicina como tratamiento para casos de COVID-19 moderado y severo TT - Chloroquine, hydroxychloroquine, azithromycin as treatment for cases of moderate and severe COVID-19 [Internet]. 2020. Available from: <http://fi-admin.bvsalud.org/document/view/cpqaq>
301. Investigación PEI de E de T en S e. Uso de fosfato de cloroquina e hidroxiclороquina para el tratamiento de pacientes con COVID-19 TT - Use of chloroquine phosphate and hydroxychloroquine for the treatment of patients with COVID-19 [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/99whc>
302. Jacobs JP, Stammers AH, St Louis J, Hayanga JWA, Firstenberg MS, Mongero LB, et al. Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac

- Compromise in Coronavirus Disease 2019: Experience with 32 Patients. *ASAIO J* [Internet]. 2020;66(7):722–30. Available from: <https://dx.doi.org/10.1097/MAT.0000000000001185>
303. Jain S, Workman V, Ganeshan R, Obasare ER, Burr A, DeBiasi RM, et al. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. *Heart Rhythm* [Internet]. 2020;17(9):1417–22. Available from: <https://dx.doi.org/10.1016/j.hrthm.2020.04.047>
 304. Janda A, Schuetz C, Heeg M, Minden K, Hedrich CM, Kallinich T, et al. [COVID-19: treatment strategies of German-speaking pediatric rheumatologists : Results of an online survey]. *TT - COVID-19: Behandlungsstrategien der deutschsprachigen Kinderrheumatologen : Ergebnisse einer Online-Umfrage. Z Rheumatol* [Internet]. 2020;79(7):710–7. Available from: <https://dx.doi.org/10.1007/s00393-020-00854-8>
 305. Jannelli E, Castelli A, Ferranti Calderoni E, Annunziata S, Maccario G, Ivone A, et al. Fractures in Patients With COVID-19 Infection: Early Prognosis and Management. A Case Series of 20 Patients in a Single Institution in Lombardy, Northern Italy. *J Orthop Trauma* [Internet]. 2020;34(10):e389–97. Available from: <https://dx.doi.org/10.1097/BOT.0000000000001905>
 306. Jarmolinski T, Matkowska-Kocjan A, Rosa M, Olejnik I, Gorczynska E, Kalwak K, et al. SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-A case report. *Pediatr Transpl* [Internet]. 2020;e13875–e13875. Available from: <https://dx.doi.org/10.1111/ptr.13875>
 307. Jung S-Y, Kim M-S, Kim M-C, Choi S-H, Chung J-W, Choi ST. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. *Clin microbiol infect* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.cmi.2020.12.003>
 308. Junqueira DR, Rowe BH. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. 2020; Available from: <https://dx.doi.org/10.1111/bcp.14598>
 309. Kang CK, Seong M-W, Choi S-J, Kim TS, Choe PG, Song SH, et al. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. *Korean J Intern Med* [Internet]. 2020;35(4):782–7. Available from: <https://dx.doi.org/10.3904/kjim.2020.157>
 310. Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, et al. Cardiovascular manifestations and treatment considerations in COVID-19. *Heart* [Internet]. 2020;106(15):1132–41. Available from: <https://dx.doi.org/10.1136/heartjnl-2020-317056>
 311. Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A, et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. *Indian Pacing Electrophysiol J* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.ipej.2020.04.003>
 312. Karalis V, Ismailos G, Karatza E. Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. *Saf Sci* [Internet]. 2020;129:104842. Available from: <https://dx.doi.org/10.1016/j.ssci.2020.104842>
 313. Karolyi M, Pawelka E, Mader T, Omid S, Kelani H, Ely S, et al. Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort. *Wien klin Wochenschr* [Internet]. 2020; Available from: <https://dx.doi.org/10.1007/s00508-020-01720-y>
 314. Kaul D. An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications. 2020; Available from: <https://dx.doi.org/10.1016/j.cmrp.2020.04.001>

315. Keller N, Chantrel F, Krummel T, Bazin-Kara D, Faller AL, Muller C, et al. Impact of first-wave COroNaVirus disease 2019 infection in patients on haemoDIALysis in Alsace: the observational COVIDIAL study. *Nephrol Dial Transpl* [Internet]. 2020;35(8):1338–411. Available from: <https://dx.doi.org/10.1093/ndt/gfaa170>
316. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna K V, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. *EClinicalMedicine* [Internet]. 2020;24:100418. Available from: <https://dx.doi.org/10.1016/j.eclinm.2020.100418>
317. Kirenga B, Muttamba W, Kayongo A, Nsereko C, Siddharthan T, Lusiba J, et al. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. 2020;7(1). Available from: <https://dx.doi.org/10.1136/bmjresp-2020-000646>
318. Kotecha P, Light A, Checcucci E, Amparore D, Fiori C, Porpiglia F, et al. Repurposing of drugs for Covid-19: a systematic review and meta-analysis. *Panminerva med* [Internet]. 2020; Available from: <https://dx.doi.org/10.23736/S0031-0808.20.04024-0>
319. Kulkarni R, Rajput U, Dawre R, Sonkawade N, Pawar S, Sonteke S, et al. Severe Malnutrition and Anemia Are Associated with Severe COVID in Infants. *J trop pediatr* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/tropej/fmaa084>
320. Kumar G, Adams A, Hererra M, Rojas ER, Singh V, Sakhuja A, et al. Predictors and Outcomes of HAIs in COVID-19 Patients. *Int j infect dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.ijid.2020.11.135>
321. Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. 2020; Available from: [https://dx.doi.org/10.1016/S2665-9913\(20\)30276-9](https://dx.doi.org/10.1016/S2665-9913(20)30276-9)
322. Lee TC, MacKenzie LJ, McDonald EG, Tong SYC. An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction. *Int J Infect Dis* [Internet]. 2020;98:216–7. Available from: <https://dx.doi.org/10.1016/j.ijid.2020.06.095>
323. Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. *BMJ* [Internet]. 2020;369:m1335–m1335. Available from: <https://dx.doi.org/10.1136/bmj.m1335>
324. Louhaichi S, Allouche A, Baili H, Jrad S, Radhouani A, Greb D, et al. Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series. *Tunis Med* [Internet]. 2020;98(4):261–5. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32395788>
325. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. 2020; Available from: <https://dx.doi.org/10.1016/j.medj.2020.06.001>
326. Mahase E. Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence. *BMJ* [Internet]. 2020;368:m1166–m1166. Available from: <https://dx.doi.org/10.1136/bmj.m1166>
327. Mahase E. Covid-19: WHO halts hydroxychloroquine trial to review links with increased mortality risk. *BMJ* [Internet]. 2020;369:m2126–m2126. Available from: <https://dx.doi.org/10.1136/bmj.m2126>
328. Maraj I, Hummel JP, Taoutel R, Chamoun R, Workman V, Li C, et al. Incidence and determinants of QT interval prolongation in COVID-19 patients treated with

- hydroxychloroquine and azithromycin. *J Cardiovasc Electrophysiol* [Internet]. 2020;31(8):1904–7. Available from: <https://dx.doi.org/10.1111/jce.14594>
329. Maraolo AE, Grossi A. Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials. *Immun Inflamm Dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1002/iid3.374>
 330. Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Akopyan ZA, Plisyk AG, et al. [Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)”]. *Kardiologiya* [Internet]. 2020;60(8):4–15. Available from: <https://dx.doi.org/10.18087/cardio.2020.8.n1307>
 331. Marinaki S, Tsiakas S, Korogiannou M, Grigorakos K, Papalois V, Boletis I. A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients’ Lives and Allografts. 2020;9(9). Available from: <https://dx.doi.org/10.3390/jcm9092986>
 332. Maritati F, Cerutti E, Zuccatosta L, Fiorentini A, Finale C, Ficosecco M, et al. SARS-CoV-2 infection in kidney transplant recipients: Experience of the Italian Marche region. *Transpl Infect Dis* [Internet]. 2020;22(5):e13377–e13377. Available from: <https://dx.doi.org/10.1111/tid.13377>
 333. Márquez-González H, Miranda-Novales MG, Solórzano-Santos F, Klunder-Klunder M, Garduño-Espinoza J, Méndez-Galván JF. COVID-19 pandemic: challenges ahead TT - Pandemia de COVID-19: retos por enfrentar. *Bol méd Hosp Infant Méx* [Internet]. 2020;77(5):242–51. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&
 334. Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. *Br J Haematol* [Internet]. 2020;190(1):e16–20. Available from: <https://dx.doi.org/10.1111/bjh.16801>
 335. Marvisi M, Ferrozzi F, Balzarini L, Mancini C, Ramponi S, Uccelli M. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution. *Int J Infect Dis* [Internet]. 2020;99:485–8. Available from: <https://dx.doi.org/10.1016/j.ijid.2020.08.054>
 336. Mathian A, Amoura Z. Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli & et al. *Ann rheum dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217859>
 337. Mayayo-Vicente S, Rodríguez Salvanés F, Gallego-Arenas A, Sánchez-Gómez LM, Ruiz-López M, Sierra García B, et al. [Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. TT - Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxiclороquina/cloroquina en el tratamiento de COVID-19. *Semergen* [Internet]. 2020;46 Suppl 1:20–7. Available from: <https://dx.doi.org/10.1016/j.semerg.2020.06.016>
 338. McConachie S, Martirosov D, Wang B, Desai N, Jarjosa S, Hsaiky L. Surviving the surge: Evaluation of early impact of COVID-19 on inpatient pharmacy services at a community teaching hospital. *Am j Heal Syst pharm* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/ajhp/zxaa189>
 339. McMahon JH, Lydeamore MJ, Stewardson AJ. Bringing evidence from press release to the clinic in the era of COVID-19. *J antimicrob chemother* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/jac/dkaa506>

340. Medetalibeyoglu A, Senkal N, Çapar G, Köse M, Tükek T. Characteristics of the initial patients hospitalized for COVID-19: a single-center report. *Turk J Med Sci* [Internet]. 2020;50(5):1436–9. Available from: <https://dx.doi.org/10.3906/sag-2004-98>
341. Médicas UN de LPF de C. Cloroquina, hidroxicloroquina, lopinavir/ritonavir, para el tratamiento de infección por COVID-19 TT - Chloroquine, hydroxychloroquine, lopinavir/ritonavir, for the treatment of COVID-19 infection [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/wk6hq>
342. Medjeral-Thomas NR, Thomson T, Ashby D, Muthusamy A, Nevin M, Duncan N, et al. Cohort study of outpatient hemodialysis management strategies for COVID-19 in North-West London. 2020; Available from: <https://dx.doi.org/10.1016/j.ekir.2020.08.022>
343. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet* [Internet]. 2020; Available from: [https://dx.doi.org/10.1016/S0140-6736\(20\)31180-6](https://dx.doi.org/10.1016/S0140-6736(20)31180-6)
344. Menezes CR, Sanches C, Chequer FMD. Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento? TT - Effectiveness and toxicity of chloroquine and hydroxychloroquine associated (or not) with azithromycin for the treatment of COVID-19. What do we know so far? *J Heal Biol Sci* [Internet]. 2020;8(1). Available from: <https://periodicos.unichristus.edu.br/jhbs/article/download/3206/1097>
345. Meo SA, Zaidi SZA, Shang T, Zhang JY, Al-Khlaiwi T, Bukhari IA, et al. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. 2020; Available from: <https://dx.doi.org/10.1016/j.jksus.2020.09.002>
346. Merza MA, Haleem Al Mezori AA, Mohammed HM, Abdulah DM. COVID-19 outbreak in Iraqi Kurdistan: The first report characterizing epidemiological, clinical, laboratory, and radiological findings of the disease. *Diabetes Metab Syndr* [Internet]. 2020;14(4):547–54. Available from: <https://dx.doi.org/10.1016/j.dsx.2020.04.047>
347. Micallef S, Piscopo T V, Casha R, Borg D, Vella C, Zammit M-A, et al. The first wave of COVID-19 in Malta; a national cross-sectional study. *PLoS One* [Internet]. 2020;15(10):e0239389–e0239389. Available from: <https://dx.doi.org/10.1371/journal.pone.0239389>
348. Michaud V, Dow P, Al Rihani SB, Deodhar M, Arwood M, Cicali B, et al. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs. *Clin Transl Sci* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/cts.12882>
349. Mikami T, Miyashita H, Yamada T, Harrington M, Steinberg D, Dunn A, et al. Risk Factors for Mortality in Patients with COVID-19 in New York City. *J gen intern med* [Internet]. 2020; Available from: <https://dx.doi.org/10.1007/s11606-020-05983-z>
350. Million M, Giraud-Gatineau A, Lagier J-C, Parola P, Gautret P, Raoult D. Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin. *Travel Med Infect Dis* [Internet]. 2020;39:101954. Available from: <https://dx.doi.org/10.1016/j.tmaid.2020.101954>
351. Ministerio de salud IN de S. Posibles estrategias de tratamiento para COVID-19 TT - Possible treatment strategies for COVID-19. *Alerta* (San Salvador [Internet]. 2020;3(2). Available from: <https://www.lamjol.info/index.php/alerta/article/view/9626/11108>
352. Mitra AR, Fergusson NA, Lloyd-Smith E, Wormsbecker A, Foster D, Karpov A, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in

- Vancouver, Canada: a case series. *CMAJ* [Internet]. 2020;192(26):E694–701. Available from: <https://dx.doi.org/10.1503/cmaj.200794>
353. Moey MYY, Sengodan PM, Shah N, McCallen JD, Eboh O, Nekkanti R, et al. Electrocardiographic Changes and Arrhythmias in Hospitalized Patients With COVID-19. *Circ Arrhythm Electrophysiol* [Internet]. 2020;13(10):e009023–e009023. Available from: <https://dx.doi.org/10.1161/CIRCEP.120.009023>
 354. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarne D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect* [Internet]. 2020;50(4):384. Available from: <https://dx.doi.org/10.1016/j.medmal.2020.03.006>
 355. Monteiro EMR, Nascimento MFL, Brito TRC, Lima MC, Sefair LR, Pedrosa MM. Chloroquine and COVID-19: Should We Care about Ototoxicity? *Int arch otorhinolaryngol* [Internet]. 2020;24(3):359–63. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
 356. Morrisette T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. *Infect Dis Ther* [Internet]. 2020;9(3):561–72. Available from: <https://dx.doi.org/10.1007/s40121-020-00325-2>
 357. Murt A, Dincer MT, Karaca C. Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases. *Blood Purif* [Internet]. 2020;1–3. Available from: <https://dx.doi.org/10.1159/000511392>
 358. Nili A, Zarei E, Ghamari A, Farid AS, Tavakolpour S, Daneshpazhooh M, et al. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital. *Int Immunopharmacol* [Internet]. 2020;89(Pt B):107093. Available from: <https://dx.doi.org/10.1016/j.intimp.2020.107093>
 359. Núñez-Gil IJ, Fernández-Pérez C, Estrada V, Becerra-Muñoz VM, El-Battrawy I, Uribarri A, et al. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry. *Intern emerg med* [Internet]. 2020; Available from: <https://dx.doi.org/10.1007/s11739-020-02543-5>
 360. Núñez-Gil IJJ, Fernández-Ortiz A, Maroud Eid C, Huang J, Romero R, Becerra-Muñoz VM, et al. Underlying heart diseases and acute COVID-19 outcomes. *Cardiol j* [Internet]. 2020; Available from: <https://dx.doi.org/10.5603/CJ.a2020.0183>
 361. Oleribe OO, Oskouipour P, Nwanyanwu O, Taylor-Robinson SD. The Covid-19 Era: The View From Nigeria. *QJM* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/qjmed/hcaa297>
 362. Oltean M, Søfteland JM, Bagge J, Ekelund J, Felldin M, Schult A, et al. Covid-19 in kidney transplant recipients: a systematic review of the case series available three months into the pandemic. *Infect Dis* [Internet]. 2020;52(11):830–7. Available from: <https://dx.doi.org/10.1080/23744235.2020.1792977>
 363. Organization PAH. Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews - 11 August 2020 [Internet]. 2020. p. 91. Available from: <https://iris.paho.org/handle/10665.2/52193>
 364. Organization PAH. Safety of COVID-19 Patients and Use of Medicines without Scientific Evidence of Their Benefit, 26 May 2020 [Internet]. 2020. Available from: <https://iris.paho.org/handle/10665.2/52256>
 365. Ortiz Molina E, Hernandez Pailos R, Pola Guillen M, Pascual Pedreno A, Rodriguez Rodriguez E, Hernandez Martinez A. COVID-19 infection in symptomatic pregnant women at the

- midpoint of the pandemic in Spain: a retrospective analysis. *Ginekol Pol* [Internet]. 2020;91(12):755–63. Available from: <https://dx.doi.org/10.5603/GP.a2020.0130>
366. Özdemir IH, Özlek B, Özen MB, Gündüz R, Çetin N, Bilge AR. Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID-19. *Int J Clin Pr* [Internet]. 2020;e13896–e13896. Available from: <https://dx.doi.org/10.1111/ijcp.13896>
 367. Paccoud O, Tubach F, Baptiste A, Bleibtreu A, Hajage D, Monsel G, et al. Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. *Clin infect dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/cid/ciaa791>
 368. Pachiega J, Afonso AJDS, Sinhorin GT, Alencar BT de, Araújo MDSM de, Longhi FG, et al. Chronic heart diseases as the most prevalent comorbidities among deaths by COVID-19 in Brazil. *Rev Inst Med Trop Sao Paulo* [Internet]. 2020;62:e45–e45. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
 369. Pan Z-Y, Chang Y-X, Han N, Hou F-Y, Lee B-J, Zhi F-C, et al. Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice. *Life Sci* [Internet]. 2020;118450. Available from: <https://dx.doi.org/10.1016/j.lfs.2020.118450>
 370. Panigrahi SK, Majumdar S, Pal A, Parija PP, Bharath DU. Covid-19 chemoprophylaxis: Ethics of prevention based on anecdotal evidence. *Indian J Med Ethics* [Internet]. 2020;1–6. Available from: <https://dx.doi.org/10.20529/IJME.2020.066>
 371. Panoutsopoulos AA. Known drugs and small molecules in the battle for COVID-19 treatment. 2020; Available from: <https://dx.doi.org/10.1016/j.gendis.2020.06.007>
 372. Patel J, Patel R, Rodriguez L-M, Blanco A, Hamza A. Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review. *Cureus* [Internet]. 2020;12(7):e9151–e9151. Available from: <https://dx.doi.org/10.7759/cureus.9151>
 373. Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, et al. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. 2020;7(1). Available from: <https://dx.doi.org/10.1136/bmjresp-2020-000650>
 374. Patel NA. Pediatric COVID-19: Systematic review of the literature. *Am J Otolaryngol* [Internet]. 2020;41(5):102573. Available from: <https://dx.doi.org/10.1016/j.amjoto.2020.102573>
 375. Picot S, Marty A, Bienvenu A-L, Blumberg LH, Dupouy-Camet J, Carnevale P, et al. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. *One Heal* [Internet]. 2020;100131. Available from: <https://dx.doi.org/10.1016/j.onehlt.2020.100131>
 376. Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. *Am J Obs Gynecol MFM* [Internet]. 2020;2(3):100134. Available from: <https://dx.doi.org/10.1016/j.ajogmf.2020.100134>
 377. Piva S, Filippini M, Turla F, Cattaneo S, Margola A, De Fulviis S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. *J Crit Care* [Internet]. 2020;58:29–33. Available from: <https://dx.doi.org/10.1016/j.jcrc.2020.04.004>
 378. Prata-Barbosa A, Lima-Setta F, Santos GR dos, Lanziotti VS, Castro REV de, Souza DC de, et al. Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective

- multicenter study, TT - Pacientes pediátricos com COVID-19 admitidos em Unidades de Terapia Intensiva no Brasil: um estudo prospectivo multicêntrico,. *J pediatr (Rio J)* [Internet]. 2020;96(5):582–92. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
379. Prodromos CC. Hydroxychloroquine is protective to the heart, not Harmful: A systematic review. *New Microbes New Infect* [Internet]. 2020;100747. Available from: <https://dx.doi.org/10.1016/j.nmni.2020.100747>
 380. Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review. *New Microbes New Infect* [Internet]. 2020;100776. Available from: <https://dx.doi.org/10.1016/j.nmni.2020.100776>
 381. Purohit R, Kanwal A, Pandit A, Patel BM, Meininger GR, Brown JJ, et al. Acute Myopericarditis with Pericardial Effusion and Cardiac Tamponade in a Patient with COVID-19. *Am J Case Rep* [Internet]. 2020;21:e925554–e925554. Available from: <https://dx.doi.org/10.12659/AJCR.925554>
 382. Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, et al. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. *Arthritis rheumatol (Malden Online)* [Internet]. 2020; Available from: <https://dx.doi.org/10.1002/art.41469>
 383. Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al. COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. *Transpl Rev* [Internet]. 2020;35(1):100588. Available from: <https://dx.doi.org/10.1016/j.trre.2020.100588>
 384. Ramirez GA, Gerosa M, Beretta L, Bellocchi C, Argolini LM, Moroni L, et al. COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. *Semin Arthritis Rheum* [Internet]. 2020;50(5):1150–7. Available from: <https://dx.doi.org/10.1016/j.semarthrit.2020.06.012>
 385. Rathi M, Singh P, Bi HP, Shivanna A, Kavadiachanda C, Tripathy SR, et al. Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort. *Lupus* [Internet]. 2020;961203320962855–961203320962855. Available from: <https://dx.doi.org/10.1177/0961203320962855>
 386. Razmi M, Hashemi F, Gheytauchi E, Dehghan Manshadi M, Ghods R, Madjd Z. Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. *Int Immunopharmacol* [Internet]. 2020;88:106942. Available from: <https://dx.doi.org/10.1016/j.intimp.2020.106942>
 387. Redondo-Sendino Á, González Sánchez IC, de Victoria Fernández B. [Skin manifestations associated with the new coronavirus SARS-CoV-2 disease]. TT - Manifestaciones cutáneas asociadas a la enfermedad por el nuevo coronavirus SARS-CoV-2. *Med Clin* [Internet]. 2020;155(9):414–5. Available from: <https://dx.doi.org/10.1016/j.medcli.2020.04.057>
 388. Ribeiro TB, Mazotti TA, Silva NA de O, Stein AT, Diaz-Quijano FA, Melo DO de. Evaluation of the initial response in clinical trials efforts for COVID-19 in Brazil TT - Avaliação da resposta inicial de desenvolvimento de ensaios clínicos para COVID-19 no Brasil [Internet]. 2020. Available from: <https://preprints.scielo.org/index.php/scielo/preprint/view/1242>
 389. Risch HA. Risch Responds to “How to Consider Low Reported Death Rates in COVID-19”. *Am J Epidemiol* [Internet]. 2020;189(11):1230–1. Available from: <https://dx.doi.org/10.1093/aje/kwaa156>
 390. Rivera-Izquierdo M, Valero-Ubierna MDC, R-delAmo JL, Fernández-García MÁ, Martínez-Diz S, Tahery-Mahmoud A, et al. [Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. TT - Agentes terapéuticos utilizados en 238 pacientes

hospitalizados por COVID-19 y su relación con la mortalidad. *Med Clin* [Internet]. 2020;155(9):375–81. Available from: <https://dx.doi.org/10.1016/j.medcli.2020.06.025>

391. Rodríguez Venegas E de la C, Hernández-García OL, Denis Piedra DA. Seguridad de la cloroquina y la hidroxicloroquina para el tratamiento de pacientes con COVID-19 TT - Safety of chloroquine and hydroxychloroquine for treating COVID-19 patients. *Rev Cuba med* [Internet]. 2020;59(3):e1387–e1387. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&
392. Rodriguez-Gonzalez C, Chamorro-de-Vega E, Valerio M, Amor-Garcia MA, Tejerina F, Sancho-Gonzalez M, et al. COVID-19 in hospitalized patients in Spain: a cohort study in Madrid. *Int J Antimicrob Agents* [Internet]. 2020;106249. Available from: <https://dx.doi.org/10.1016/j.ijantimicag.2020.106249>
393. Romani S, Gérard A, Fresse A, Viard D, Van-Obberghen É, Micallef J, et al. Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic. *Clin Transl Sci* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/cts.12883>
394. Romão VC, Cruz-Machado AR, Fonseca JE. Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli & et al. *Ann rheum dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-218175>
395. Ronsisvalle S, Panarello F, Di Mauro R, Bernardini R, Volti GL, Cantarella G. Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. *Curr pharm des* [Internet]. 2020; Available from: <https://dx.doi.org/10.2174/1381612826666201210092736>
396. Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. *J antimicrob chemother* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/jac/dkaa501>
397. Roy S. Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint. *SN Compr Clin Med* [Internet]. 2020;1–6. Available from: <https://dx.doi.org/10.1007/s42399-020-00370-5>
398. Sachdeva M, Shah M, Ziv M, Leshem E, Dodiuk-Gad RP. Risks of hydroxychloroquine use for COVID-19 prophylaxis. *J Am Acad Dermatol* [Internet]. 2020;83(1):e73–4. Available from: <https://dx.doi.org/10.1016/j.jaad.2020.04.111>
399. Saez-Giménez B, Berastegui C, Barrecheguren M, Revilla-López E, Los Arcos I, Alonso R, et al. COVID-19 in lung transplant recipients: A multicenter study. *Am j Transpl* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/ajt.16364>
400. Salud CN de ET en. Perspectivas de tratamiento para COVID-19 (en progreso) TT - Treatment prospects for COVID-19 (in progress) [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/yf5n6>
401. Salud OP de la. Seguridad de los pacientes con COVID-19 en relación con el uso de medicamentos sin evidencia científica sobre su beneficio TT - Safety of COVID-19 Patients and Use of Medicines without Scientific Evidence of Their Benefit, 26 May 2020 [Internet]. 2020. p. 4. Available from: <https://fi-admin.bvsalud.org/document/view/4b3u6>
402. Salud PM de SIN de. Utilidad de la cloroquina e hidroxicloroquina frente a COVID-19: profilaxis y tratamiento TT - Utility of chloroquine and hydroxychloroquine against COVID-19: prophylaxis and treatment [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/5v3rj>

403. Salvarani C, Mancuso P, Gradellini F, Viani N, Pandolfi P, Reta M, et al. Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population Based Study in Emilia-Romagna, Northern Italy. *Arthritis rheumatol (Malden Online)* [Internet]. 2020; Available from: <https://dx.doi.org/10.1002/art.41475>
404. Sanitaria I de EC y. Cloroquina e hidroxicloroquina en infección por COVID-19 TT - Chloroquine and hydroxychloroquine in COVID-19 infection [Internet]. 2020. Available from: <http://fi-admin.bvsalud.org/document/view/y2fcm>
405. Santos CS, Morales CM, Álvarez ED, Castro CÁ, Robles AL, Sandoval TP. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. *Clin Rheumatol* [Internet]. 2020;39(9):2789–96. Available from: <https://dx.doi.org/10.1007/s10067-020-05301-2>
406. Sato K, Mano T, Iwata A, Toda T. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. *Biosci Trends* [Internet]. 2020;14(2):139–43. Available from: <https://dx.doi.org/10.5582/bst.2020.03082>
407. Saúde AHM de VN de A de T em, Saúde HAOCU de A de T em, Saúde HSLN de A de T em. Associação hidroxicloroquina /cloroquina e azitromicina para COVID-19: revisão sistemática rápida TT - Hydroxychloroquine / chloroquine and azithromycin association for COVID-19: rapid systematic review [Internet]. 2020. Available from: <http://fi-admin.bvsalud.org/document/view/rwere>
408. Saúde G (Estado). S de E da, Saúde S de, Evidências N de. 'Kit COVID-19' TT - 'COVID-19 Kit' [Internet]. 2020. p. 1–7. Available from: https://www.saude.gov.br/files//banner_coronavirus/protocolos-notas/5 - Sínteses de Evidências/KIT COVID-19.pdf
409. Saúde HS-LN de A de T em. Hidroxicloroquina e cloroquina para COVID-19: revisão sistemática rápida TT - Hydroxychloroquine and chloroquine for COVID-19: rapid systematic review [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/pc2gj>
410. Sbidian E, Penso L, Herlemont P, Botton J, Baricault B, Semenzato L, et al. Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19'; by König et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France. *Ann rheum dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-218647>
411. Schiffer VMMM, Janssen EBNJ, van Bussel BCT, Jorissen LLM, Tas J, Sels J-WEM, et al. The 'sex gap' in COVID-19 trials: a scoping review. *EClinicalMedicine* [Internet]. 2020;100652. Available from: <https://dx.doi.org/10.1016/j.eclinm.2020.100652>
412. Sciacaluga C, Cameli M, Menci D, Mandoli GE, Sisti N, Cameli P, et al. COVID-19 and the burning issue of drug interaction: never forget the ECG. *Postgrad med j* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/postgradmedj-2020-138093>
413. Sen S, Werner A, Shekhar A. Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy. *Drugs Ther Perspect* [Internet]. 2020;1–2. Available from: <https://dx.doi.org/10.1007/s40267-020-00741-x>
414. SeyedAlinaghi S, Ghadimi M, Gharabaghi MA, Ghiasvand F. Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report. *Infect Disord Drug targets* [Internet]. 2020; Available from: <https://dx.doi.org/10.2174/1871526520666201209145001>

415. Shah K, Tiwaskar M, Chawla P, Kale M, Deshmane R, Sowani A. Hypoglycemia at the time of Covid-19 pandemic. *Diabetes Metab Syndr* [Internet]. 2020;14(5):1143–6. Available from: <https://dx.doi.org/10.1016/j.dsx.2020.07.003>
416. Shah S, Shah K, Turagam MK, Lakkireddy D, Garg J. Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. *Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators. Am j ther* [Internet]. 2020; Publish Ahead of Print. Available from: <https://dx.doi.org/10.1097/MJT.0000000000001238>
417. Sharma AK, Ahmed A, Baig VN, Dhakar P, Dalela G, Kacker S, et al. Characteristics and Outcomes of Hospitalized Young Adults with Mild Covid -19. *J Assoc Physicians India* [Internet]. 2020;68(8):62–5. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32738843>
418. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, et al. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatr* [Internet]. 2020;174(9):868–73. Available from: <https://dx.doi.org/10.1001/jamapediatrics.2020.1948>
419. Shetty R, Lalgudi VG, Khamar P, Gupta K, Sethu S, Nair A, et al. Potential ocular and systemic COVID-19 prophylaxis approaches for healthcare professionals. *Indian J Ophthalmol* [Internet]. 2020;68(7):1349–56. Available from: https://dx.doi.org/10.4103/ijo.IJO_1589_20
420. Singh AK, Misra A. Editorial: Herd mentality, herds of migrants/people, and COVID-19 in India. *Diabetes Metab Syndr* [Internet]. 2020;14(4):497. Available from: <https://dx.doi.org/10.1016/j.dsx.2020.05.004>
421. Singh AK, Singh A, Singh R, Misra A. “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.” *Diabetes Metab Syndr* [Internet]. 2020;14(4):589–96. Available from: <https://dx.doi.org/10.1016/j.dsx.2020.05.017>
422. Sinkeler FS, Berger FA, Muntinga HJ, Jansen MMPM. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine. *Neth Hear J* [Internet]. 2020;28(7–8):418–23. Available from: <https://dx.doi.org/10.1007/s12471-020-01462-6>
423. Skalny A V, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. Zinc and respiratory tract infections: Perspectives for COVID19 (Review). *Int J Mol Med* [Internet]. 2020;46(1):17–26. Available from: <https://dx.doi.org/10.3892/ijmm.2020.4575>
424. Sobol I, Yuzefpolskaya M, Roth Z, Colombo PC, Horn E, Takeda K, et al. Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19. *J Card Fail* [Internet]. 2020;26(10):895–7. Available from: <https://dx.doi.org/10.1016/j.cardfail.2020.09.011>
425. Sociaux IN d’Excellence en S et en S. COVID-19 et Chloroquine/hydroxychloroquin TT - COVID-19 and Chloroquine / hydroxychloroquin [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/zp69r>
426. Sociaux IN d’Excellence en S et en S. COVID-19 et grossesse/allaitement TT - COVID-19 and pregnancy/lactation [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/vv9gq>
427. Sönmez Güngör E, Yalçın M, Yerebakan Tüzer M, Besikçi Keles D, Öcek Bas T, Ergelen M, et al. Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy. *Int J Psychiatry Clin Pr* [Internet]. 2020;1–5. Available from: <https://dx.doi.org/10.1080/13651501.2020.1843182>

428. Srivastava R, Tripathi S, Unni S, Hussain A, Haque S, Dasgupta N, et al. Silybin B and Cianidanol Inhibit M pro and Spike Protein of SARS-CoV-2: Evidence from in Silico Molecular Docking Studies. *Curr pharm des* [Internet]. 2020; Available from: <https://dx.doi.org/10.2174/1381612826666201210122726>
429. Svensson M. [Potential harms associated with 4-aminoquinoline treatment]. *TT - Behandling med 4-aminokinoliner vid covid-19 kan ge allvarliga biverkningar. Lakartidningen* [Internet]. 2020;117. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32365215>
430. T K S, G S. Will the antimalarial drug take over to combat COVID-19? *Z Gesundh Wiss* [Internet]. 2020;1–4. Available from: <https://dx.doi.org/10.1007/s10389-020-01293-0>
431. Takla M, Jeevaratnam K. Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety. *Saudi Pharm J* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.jsps.2020.11.003>
432. Talaie H, Hosseini SM, Nazari M, Fakhri Y, Mousavizadeh A, Vatanpour H, et al. Is there any potential management against COVID-19? A systematic review and meta-analysis. *Daru* [Internet]. 2020;28(2):765–77. Available from: <https://dx.doi.org/10.1007/s40199-020-00367-4>
433. Taskforce NC-19 CE. Australian guidelines for the clinical care of people with COVID-19 - Australian National COVID-19 Clinical Evidence Taskforce [Internet]. 2020. p. 215. Available from: https://files.magicapp.org/guideline/85607342-3e97-4942-b6da-49b315367f0f/published_guideline_4372-15_0.pdf
434. Teich VD, Klajner S, Almeida FAS de, Dantas ACB, Laselva CR, Torritesi MG, et al. Epidemiologic and clinical features of patients with COVID-19 in Brazil. *Einstein (Sao Paulo)* [Internet]. 2020;18:eAO6022–eAO6022. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
435. Tejada Cifuentes F, Lloret Callejo Á, Tirado Peláez MJ, Rubio Pulido O, Ruiz-Morote Aragón M, Fernández Urrusuno R, et al. Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine. *TT - Incidencia de la COVID-19 en pacientes en tratamiento crónico con hidroxiclороquina. Med clin (Ed impr)* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.medcli.2020.10.006>
436. Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. *J Wound Care* [Internet]. 2020;29(Sup5a):S4–8. Available from: <https://dx.doi.org/10.12968/jowc.2020.29.Sup5a.S4>
437. Timerbulatov S V, Timerbulstov M V, Gainullina EN, Gafarova AR, Timerbulatov VM. [Drug treatment of coronavirus disease COVID-19: evidence exists?] *TT - Medikamentoznoe lechenie koronavirusnoi bolezni COVID-19: sushchestvuet li dokazatel'nyy naya baza? Khirurgiia (Mosk)* [Internet]. 2020;(6):90–7. Available from: <https://dx.doi.org/10.17116/hirurgia202006190>
438. Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, et al. Use of Baricitinib in Patients with Moderate and Severe COVID-19. *Clin infect dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/cid/ciaa879>
439. Tleyjeh IM, Kashour Z, AlDosary O, Riaz M, Tlayjeh H, Garbati MA, et al. The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis. 2020; Available from: <https://dx.doi.org/10.1016/j.mayocpiqo.2020.10.005>
440. Tomcsányi J, Tomcsányi K. Hazard of acquired long QT syndrome during coronavirus pandemic. *Focus on hydroxychloroquine TT - [A szerzett hosszú-QT-szindróma veszélye a*

- koronavírus-járvány idején. Fókuszban a hidroxiklorokin]. *Orv Hetil* [Internet]. 2020;161(17):689–91. Available from: <https://dx.doi.org/10.1556/650.2020.31817>
441. Torres-Costa S, Lima-Fontes M, Falcão-Reis F, Falcão M. SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice. *Acta Med Port* [Internet]. 2020;33(9):593–600. Available from: <https://dx.doi.org/10.20344/amp.14118>
442. Tselios K, Skendros P. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. *Eur J Rheumatol* [Internet]. 2020;7(Suppl 2):S110–6. Available from: <https://dx.doi.org/10.5152/eurjrheum.2020.2064>
443. Varshneya M, Irurzun-Arana I, Campana C, Dariolli R, Gutierrez A, Pullinger TK, et al. Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions. *CPT pharmacomet syst pharmacol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1002/psp4.12573>
444. Vashistha P, Gupta AK, Arya M, Kumar Singh V, Dubey A, Chandra Koner B. Biclonal gammopathy in a case of severe COVID-19. *Clin Chim Acta* [Internet]. 2020;511:342–5. Available from: <https://dx.doi.org/10.1016/j.cca.2020.10.040>
445. Verdejo C, Vergara-Merino L, Meza N, Pérez-Bracchiglione J, Carvajal-Juliá N, Madrid E, et al. Macrólidos para el tratamiento de COVID-19: una revisión sistemática viva TT - Macrolides for the treatment of COVID-19: a living, systematic review. *Medwave* [Internet]. 2020;20(11). Available from: <https://www.medwave.cl/link.cgi/English/Original/SystReviews/8073.act>
446. Vieira SC, Fontinele DR da S, Barjud MB, Carvalho Junior JM de, Melo LMC, Fonseca Filho JW, et al. Tratamento precoce para COVID-19 baseado em evidência científica TT - Early treatment of COVID-19 based on scientific evidence TT - Tratamiento precoz para COVID-19 basado en evidencia científica. *Rev bras promoç saúde* [Internet]. 2020;33:1–11. Available from: <https://periodicos.unifor.br/RBPS/article/view/10993>
447. Vogel JP, Tendal B, Giles M, Whitehead C, Burton W, Chakraborty S, et al. Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. *Aust N Z j Obs gynaecol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/ajo.13270>
448. Vollaard A, Gieling EM, van der Linden PD, Sinha B, de Boer MGJ. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness]. TT - Hydroxychloroquine en chloroquine bij COVID-19. *Ned tijdschr geneeskd* [Internet]. 2020;164. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32749808>
449. Wang M, Wu T, Zuo Z, You Y, Yang X, Pan L, et al. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. *BMJ Support palliat care* [Internet]. 2020; Available from: <https://dx.doi.org/10.1136/bmjspcare-2020-002554>
450. Westover JB, Ferrer G, Vazquez H, Bethencourt-Mirabal A, Go CC. In Vitro Virucidal Effect of Intranasally Delivered Chlorpheniramine Maleate Compound Against Severe Acute Respiratory Syndrome Coronavirus 2. *Cureus* [Internet]. 2020;12(9):e10501–e10501. Available from: <https://dx.doi.org/10.7759/cureus.10501>
451. Widhani A, Rengganis I, Susanto AJ, Surachmanto EE, Hasibuan AS, Fetarayani D, et al. Factors Related to Knowledge, Perception, and Practices Towards COVID-19 Among Patients with Autoimmune Diseases: A Multicenter Online Survey. *Acta Med Indones* [Internet]. 2020;52(3):214–26. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-33020333>
452. Willis VC, Arriaga Y, Weeraratne D, Reyes F, Jackson GP. A narrative review of emerging therapeutics for COVID-19. 2020; Available from: <https://dx.doi.org/10.1016/j.mayocpiqo.2020.07.004>

453. Wright C, Ross C, Mc Goldrick N. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)? *Evid Based Dent* [Internet]. 2020;21(2):64–5. Available from: <https://dx.doi.org/10.1038/s41432-020-0098-2>
454. Wu J, Yu J, Shi X, Li W, Song S, Zhao L, et al. Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study. *J viral hepat* [Internet]. 2020; Available from: <https://dx.doi.org/10.1111/jvh.13404>
455. Xie M, Chen Q. Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV. *Int J Infect Dis* [Internet]. 2020;94:119–24. Available from: <https://dx.doi.org/10.1016/j.ijid.2020.03.071>
456. Yahya AS, Khawaja S, Chukwuma J. The Use of “Novel Pharmacology” in the Treatment of COVID-19 and Potential Psychiatric Risks. *Prim care companion CNS disord* [Internet]. 2020;22(3). Available from: <https://dx.doi.org/10.4088/PCC.20com02638>
457. Yang B, Fulcher JA, Ahn J, Berro M, Goodman-Meza D, Dhody K, et al. Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab. *Clin infect dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/cid/ciaa1583>
458. Yang T-H, Chou C-Y, Yang Y-F, Chien C-S, Yarmishyn AA, Yang T-Y, et al. Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine in Treating COVID-19 Patients. *J Chin Med Assoc* [Internet]. 2020; Available from: <https://dx.doi.org/10.1097/JCMA.0000000000000425>
459. Yaqinuddin A, Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. *Med Hypotheses* [Internet]. 2020;140:109777. Available from: <https://dx.doi.org/10.1016/j.mehy.2020.109777>
460. Ye Q, Wang B, Mao J, Fu J, Shang S, Shu Q, et al. Epidemiological analysis of COVID-19 and practical experience from China. *J Med Virol* [Internet]. 2020;92(7):755–69. Available from: <https://dx.doi.org/10.1002/jmv.25813>
461. Yenerçag M, Arslan U, Dogdus M, Günal Ö, Öztürk ÇE, Aksan G, et al. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. *J Electrocardiol* [Internet]. 2020;62:5–9. Available from: <https://dx.doi.org/10.1016/j.jelectrocard.2020.07.005>
462. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, et al. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. *JAMA Pediatr* [Internet]. 2020;174(10):e202430–e202430. Available from: <https://dx.doi.org/10.1001/jamapediatrics.2020.2430>
463. Zaidel EJ, Wyss Quintana FS, Sosa Liprandi Á, Mendoza I, Márquez MF, Nuñez E, et al. [Hydroxychloroquine. Cardiology’s viewpoint in times of coronavirus pandemic]. *TT - Hidroxicloroquina. Mensajes desde la cardiología en tiempos de pandemia por coronavirus. Med (B Aires)* [Internet]. 2020;80(3):271–4. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-32442941>
464. Zang Y, Han X, He M, Shi J, Li Y. Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. *Naunyn-Schmiedeberg arch pharmacol* [Internet]. 2020; Available from: <https://dx.doi.org/10.1007/s00210-020-01964-5>
465. Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study.

Lancet Rheumatol [Internet]. 2020;2(9):e557–64. Available from: [https://dx.doi.org/10.1016/S2665-9913\(20\)30227-7](https://dx.doi.org/10.1016/S2665-9913(20)30227-7)

466. Ziadé N, El Kibbi L, Hmamouchi I, Abdulateef N, Halabi H, Hamdi W, et al. Impact of the COVID-19 pandemic on patients with chronic rheumatic diseases: A study in 15 Arab countries. *Int J Rheum Dis* [Internet]. 2020;23(11):1550–7. Available from: <https://dx.doi.org/10.1111/1756-185X.13960>
467. Ziadé N, Hmamouchi I, El Kibbi L, Abdulateef N, Halabi H, Abutiban F, et al. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. *Clin Rheumatol* [Internet]. 2020;39(11):3205–13. Available from: <https://dx.doi.org/10.1007/s10067-020-05428-2>
468. Zlámál M, Stechovská K, Holub M. A case of severe course of COVID-19 treated with experimental therapy. *Cas Lek Ces* [Internet]. 2020;159(5):181–4. Available from: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-33297704>
469. Zuccon W, Comassi P, Adriani L, Bergamaschini G, Bertin E, Borromeo R, et al. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy. *Am j emerg med* [Internet]. 2020; Available from: <https://dx.doi.org/10.1016/j.ajem.2020.08.005>
470. Santos-Sánchez NF, Salas-Coronado R. Origen, características estructurales, medidas de prevención, diagnóstico y fármacos potenciales para prevenir y controlar COVID-19 TT - Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19. *Medwave* [Internet]. 2020;20(8):e8037–e8037. Available from: <https://dx.doi.org/10.5867/medwave.2020.08.8037>
471. Brasil. Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde T. Informe diário de evidências COVID-19: busca realizada em 30 de julho de 2020 TT - COVID-19 daily evidence report: search conducted on July 30, 2020 [Internet]. 2020. Available from: <http://saude.gov.br/images/pdf/2020/August/03/N83-InformeDiario-referente-31-07.pdf>
472. Cespedes M da S, Souza JCRP de. Coronavirus: a clinical update of Covid-19. *Rev Assoc Med Bras* [Internet]. 2020;66(2):116–23. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
473. Bendezu-Quispe G, Rodríguez-Zúñiga MJM, Roman YM, Mori-Llontop LM, Peralta V, Fiestas F. Agentes potencialmente terapéuticos contra el SARS-CoV-2: revisión rápida de la evidencia. *Rev peru med exp salud publica* [Internet]. 2020;37(2):320–6. Available from: <https://dx.doi.org/10.17843/rpmesp.2020.372.5409>
474. Brasil. Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde T. Informe diário de evidências COVID-19: busca realizada em 6 de agosto de 2020 TT - Daily evidence report COVID-19: Search conducted on August 6, 2020 [Internet]. 2020. Available from: <http://portalarquivos2.saude.gov.br/images/pdf/2020/August/10/N88-InformeDiario-referente-07-08.pdf>
475. Salud PM de SIN de. Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 (COVID-19) TT - Pharmacological interventions for the treatment of coronavirus disease 2019 (COVID-19) [Internet]. 2020. Available from: <http://fi-admin.bvsalud.org/document/view/z98z4>
476. Salud PM de SIN de. Efectividad y seguridad de la Hidroxicloroquina y Cloroquina en el tratamiento de la infección asintomática y casos leves de COVID-19 TT - Effectiveness and safety of Hydroxychloroquine and Chloroquine in the treatment of asymptomatic infection and mild cases of COVID-19 [Internet]. 2020. Available from: <https://fi-admin.bvsalud.org/document/view/99cmk>

477. Soto A, Quiñones-Laveriano DM, Garcia PJ, Gotuzzo E, Henao-Restrepo AM. Respuestas rápidas a la pandemia de COVID-19 a través de la ciencia y la colaboración global: el ensayo clínico Solidaridad. *Rev Peru Med Exp Salud Publica* [Internet]. 2020;37(2):356–60. Available from: http://www.scielo.org/scielo.php?script=sci_arttext&
478. Falavigna M, Colpani V, Stein C, Azevedo LCP, Bagattini AM, Brito GV de, et al. Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia TT - Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. *Rev bras ter intensiva* [Internet]. 2020;32(2):166–96. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
479. Pimentel J, Andersson N. Chloroquine and its derivatives in the management of COVID-19: A scoping review TT - [Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria]. *Biomédica (Bogotá)* [Internet]. 2020;40(Supl. 2):80–95. Available from: <https://dx.doi.org/10.7705/biomedica.5478>
480. Brasil. Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde T, Brasil. Ministério da Saúde. Secretaria de Ciência T e IE em S, Brasil. Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde T, Brasil. Ministério da Saúde. Secretaria de Ciência T e IE em S, Brasil. Ministério da Saúde. Secretaria de Ciência Inovação e Insumos Estratégicos em Saúde T, Brasil. Ministério da Saúde. Secretaria de Ciência T e IE em S, et al. Informe diário de evidências COVID-19: busca realizada em 28 de maio de 2020 TT - COVID-19 daily evidence report: search conducted on May 28, 2020 [Internet]. Vol. 13. 2020. p. 17. Available from: <https://portalarquivos.saude.gov.br/images/pdf/2020/June/19/N54-InformeDiario-referente-19-06.pdf>
481. Abd-Elsalam S, Soliman S, Esmail ES, Khalaf M, Mostafa EF, Medhat MA, et al. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. *Biol Trace Elem Res* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213757/full>
482. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: a Randomized Clinical Trial. *JAMA Intern Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02192557/full>
483. ACTRN12620000417987. Chloroquine Chemorophylaxis Countermeasure against COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12620000417987> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165248/full>
484. ACTRN12620000445976. To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12620000445976> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165263/full>
485. ACTRN12620000457943. Hydroxychloroquine for the Community-Based Treatment of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12620000457943> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165272/full>
486. ACTRN12620000501943. COVID-19 prophylaxis with hydroxychloroquine in Front-line Health and Allied-Health Care Workers: the COVID-SHIELD Trial.

- <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12620000501943> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165294/full>
487. ACTRN12620000557932. International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12620000557932> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165325/full>
488. Barnabas R V, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : a Randomized Trial. *Ann Intern Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02210453/full>
489. Brown SM, Peltan I, Kumar N, Leither L, Webb BJ, Starr N, et al. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): results of a Randomized, Active Comparator Trial. *Ann Am Thorac Soc* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02201665/full>
490. Burdick H, Lam C, Mataraso S, Siefkas A, Braden G, Dellinger RP, et al. Is machine learning a better way to identify COVID-19 patients who might benefit from hydroxychloroquine treatment?-the IDENTIFY trial. *J Clin Med* [Internet]. 2020;9(12):1-18. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02210742/full>
491. Cegolon L, Javanbakht M, Mastrangelo G. Nasal disinfection for the prevention and control of COVID-19: a scoping review on potential chemo-preventive agents. *Int J Hyg Environ Health* [Internet]. 2020;230:113605-. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02177460/full>
492. ChiCTR2000029740. Efficacy of therapeutic effects of hydroxychloroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029740> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165561/full>
493. ChiCTR2000029741. Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029741> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165562/full>
494. ChiCTR2000029760. Cancelled due to lack of patient A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029760> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165569/full>
495. ChiCTR2000029761. Cancelled due to lack of patient Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029761> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165570/full>
496. ChiCTR2000029762. Cancelled due to lack of patient Clinical study for the effect and. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029762> [Internet]. 2020;

Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165571/full>

497. ChiCTR2000029803. A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029803> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165587/full>
498. ChiCTR2000029826. Cancelled by the investigator A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029826> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165591/full>
499. ChiCTR2000029868. Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029868> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165603/full>
500. ChiCTR2000029899, ChiCTR2000029898. Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Common Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029898> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165614/full>
501. ChiCTR2000029939. A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029939> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165620/full>
502. ChiCTR2000029992. A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029992> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165635/full>
503. ChiCTR2000030031, ChiCTR2000029837. Cancelled by the investigator A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COV. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029837> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165595/full>
504. ChiCTR2000030054. A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030054> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165657/full>
505. ChiCTR2000030718. Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030718> [Internet]. 2020;

Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165786/full>

506. ChiCTR2000030987. A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000030987> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165819/full>
507. ChiCTR2000031204. A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000031204> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02165849/full>
508. ChiCTR2000032915. A randomized controlled trial for the efficacy and safety of artemisinin-pipecquine tablets in the treatment of the mild and common type novel coronavirus pneumonia (COVID-19) patients whose nCoV Nucleic acid did not turn negative after treated by hydroxychloroquine and Abidor. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000032915> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02166193/full>
509. CTRI/2020/03/024402. Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection -A Tertiary Hospital based study. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/03/024402> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167593/full>
510. CTRI/2020/04/024479. Study of the effect of Hydroxychloroquine in addition to standard therapy in COVID-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/04/024479> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167640/full>
511. CTRI/2020/04/024773. A clinical trial to study the effects of additional treatments for patients hospitalized and receiving treatment due to COVID -19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/04/024773> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167788/full>
512. CTRI/2020/04/024904. Treatment of COVID19 : a randomised controlled trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/04/024904> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167855/full>
513. CTRI/2020/04/024948. A clinical Trial to Study the Effects of Hydroxychloroquine, Ciclesonide and Ivermectin in treatment of moderate COVID-19 illness. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/04/024948> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167880/full>
514. CTRI/2020/05/025022. Hydroxychloroquine in patients with mild COVID-19 illness with risk factors for severe disease. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/05/025022> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167921/full>

515. CTRI/2020/05/025067. A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/05/025067> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167943/full>
516. CTRI/2020/05/025171. Ayurveda protocol & COVID-19 exposed individuals: clinical trial of an Ayurveda Intervention.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/05/025171> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168000/full>
517. CTRI/2020/05/025178. Evaluation of the Immuno-Stimulatory Potential (Shareera Bala) of an Ayurveda Management Protocol in Cohort of Quarantined Delhi Police under Covid-19 Care Centers- An Exploratory Clinical Study.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/05/025178> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168003/full>
518. CTRI/2020/05/025332. Ashwagandha for prevention against SARS-CoV-2 Infection: a Randomized Hydroxychloroquine Controlled drug trial in high risk Health Care Providers.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/05/025332> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168079/full>
519. CTRI/2020/06/025557. A clinical study of Ayurvedic formulations in the treatment of Mild to Moderate COVID-19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/025557> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168193/full>
520. CTRI/2020/06/025625. Study of the effect of Siddha Treatment in addition to standard therapy in COVID-19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/025625> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168235/full>
521. CTRI/2020/06/025704. Ulinastatin for COVID-19 in patients with breathlessness.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/025704> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168281/full>
522. CTRI/2020/06/025849. Study to Evaluate the Safety and Efficacy of a Combination of Nitazoxanide and Hydroxychloroquine Versus Hydroxychloroquine Alone in COVID-19 Patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/025849> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168355/full>
523. CTRI/2020/06/025856. Evaluation of siddha regimen in the management of covid 19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/025856> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168358/full>
524. CTRI/2020/06/026193. A study of drug Lithium on patients of Covid 19 disease.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/026193> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168542/full>

525. CTRI/2020/06/026196. Prevention of Respiratory Complications In At Surgery in COVID-19 Pandemic. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/026196> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168545/full>
526. CTRI/2020/06/026221. Intervention of Ayurvedic Medicine (Arogya Kashayam) in Covid-19 positive cases (Asymptomatic and Mild Symptomatic). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/06/026221> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168560/full>
527. CTRI/2020/07/026560. Neem Prophylaxis for Subjects Coming in Contact with COVID-19 Patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/07/026560> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185324/full>
528. CTRI/2020/07/026839. Study of Shreepad Shree Vallabh SSV Formulation in management of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/07/026839> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185460/full>
529. CTRI/2020/07/026840. A study to assess the effectiveness of Ayurvedic formulation Guduchi Ghan vati in Covid-19 cases. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/07/026840> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185461/full>
530. CTRI/2020/08/027163. Ashwagandha in the prevention of COVID-19 in Health Care workers. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/08/027163> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185631/full>
531. CTRI/2020/08/027222. Unani formulations for prevention of COVID-19 infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/08/027222> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185660/full>
532. CTRI/2020/08/027394. Assessment of response of ivermectin on virological clearance in COVID 19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/08/027394> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02185751/full>
533. CTRI/2020/09/027938. Study of Particle Life Sciences Formulation in management of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/09/027938> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186037/full>
534. CTRI/2020/09/028007. Prophylactic study of Ashwagandha and HCQ in health care providers. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/09/028007> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186081/full>
535. CTRI/2020/10/028234. Study to compare the effect of different antiviral medicines in COVID-19 infected sick children. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/10/028234> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186197/full>

536. CTRI/2020/10/028335. A clinical study to assess the efficacy and safety of Tinefcon in patients with moderate COVID-19 infection.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/10/028335> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186249/full>
537. CTRI/2020/10/028547. IND02 for prevention against SARS-CoV-2 Infection: a Randomized controlled study in moderate to high risk population.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/10/028547> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186365/full>
538. Cui J, Ke Y. Comparative analysis of nine COVID-19 convalescent plasma protocols registered by cochrane central register of controlled trials. Iran red crescent Med J [Internet]. 2020;22(8). Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02212802/full>
539. DRKS00021573. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Covid-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00021573> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168902/full>
540. DRKS00022203. Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: a randomized, controlled study.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00022203> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02168949/full>
541. Emani VR, Goswami S, Nandanoor D, Emani SR, Reddy NK, Reddy R. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs. Int J Antimicrob Agents [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205275/full>
542. EUCTR2020-000936-23-FR. Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRY.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-000936-23-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169599/full>
543. EUCTR2020-000982-18-SE. A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-000982-18-SE> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169601/full>
544. EUCTR2020-001010-38-NO. NORWEGIAN CORONAVIRUS DISEASE 2019 [NO-COVID-19] STUDY: a TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001010-38-NO> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169602/full>
545. EUCTR2020-001031-27-ES. Treatment of non-severe confirmed cases of coronavirus and treatment of their contacts as prevention.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001031-27-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169604/full>

546. EUCTR2020-001188-96-FR. Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001188-96-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169614/full>
547. EUCTR2020-001198-55-DK. Early Treatment to Patients with Coronavirus (COVID). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001198-55-DK> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169616/full>
548. EUCTR2020-001209-22-GB. Platform Randomised trial of INterventions against COVID-19 In older people. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001209-22-GB> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169619/full>
549. EUCTR2020-001246-18-FR. Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001246-18-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169625/full>
550. EUCTR2020-001257-51-DK. Hydroxychloroquine for prevention of COVID-19 in patients on chronic dialysis. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001257-51-DK> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169627/full>
551. EUCTR2020-001262-11-ES. Clinical trial to assess the efficacy and safety of cyclosporin A treatment associated with standard treatment versus standard treatment only in hospitalized patients with confirmed coronavirus infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001262-11-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169628/full>
552. EUCTR2020-001265-36-IE. A trial to compare standard of care (SOC) alone with SOC plus hydroxychloroquine or SOC with a combination of hydroxychloroquine and azithromycin in the treatment of coronavirus. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001265-36-IE> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169630/full>
553. EUCTR2020-001270-29-DK. Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001270-29-DK> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169632/full>
554. EUCTR2020-001271-33-FR. HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d'aggravation secondaire : étude prospective multicentrique randomisée en double aveugle. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001271-33-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169633/full>
555. EUCTR2020-001281-11-FR. Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001281-11-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169637/full>

556. EUCTR2020-001290-74-ES. Efficacy and safety of sarilumab in the early treatment of hospitalized patients with mild-moderate pneumonia and COVID19 infection versus standard of care. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001290-74-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169639/full>
557. EUCTR2020-001321-31-ES. Clinical trial phase II to evaluate the efficacy of 3 types of treatment in patients with pneumonia by COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001321-31-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169647/full>
558. EUCTR2020-001331-26-GB. Preventative Drug Treatment for COVID-19 Infectious Disease. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001331-26-GB> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169652/full>
559. EUCTR2020-001333-13-FR. Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001333-13-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169653/full>
560. EUCTR2020-001363-85-DK. Medication for prevention of Corona-virus for Danish nursing home residents. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001363-85-DK> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169655/full>
561. EUCTR2020-001364-29-ES. Study with stem cells from allogenic adipose tissue, in patients with coronavirus severe pneumonia. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001364-29-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169656/full>
562. EUCTR2020-001367-88-DK, NCT04345289. Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001367-88-DK> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089735/full>
563. EUCTR2020-001373-70-FR. Study comparing the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001373-70-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169660/full>
564. EUCTR2020-001385-11-ES. EPICOS - Experimental clinical trial for Prevention or COronavirus in health Care professionals. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001385-11-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169665/full>
565. EUCTR2020-001406-27-FR. efficacy and safety of a bitherapy by hydroxychloroquine + azythromycin vs monotherapy by hydroxychloroquine in adult patients with documented infection by covid19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001406-27-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169671/full>

566. EUCTR2020-001417-21-BE. An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001417-21-BE> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169676/full>
567. EUCTR2020-001421-31-ES. Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001421-31-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169678/full>
568. EUCTR2020-001440-26-ES. Study for the prevention of COVID-19 infection in healthcare personnel. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001440-26-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169681/full>
569. EUCTR2020-001441-39-IT. Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001441-39-IT> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169682/full>
570. EUCTR2020-001449-38-GB. A Randomised Controlled Trial of Early Intervention in Patients Hospitalised with COVID-19: favipiravir versus Hydroxychloroquine & Azithromycin & Zinc versus Standard Care. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001449-38-GB> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169686/full>
571. EUCTR2020-001456-18-CZ. Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase III. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001456-18-CZ> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169688/full>
572. EUCTR2020-001457-43-FR. Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001457-43-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169689/full>
573. EUCTR2020-001469-35-PL. A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001469-35-PL> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169690/full>
574. EUCTR2020-001482-37-DE. Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 Patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001482-37-DE> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169693/full>
575. EUCTR2020-001501-24-IT. PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001501-24-IT> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169698/full>

576. EUCTR2020-001527-14-NL. COVID-19: addition of azithromycin to chloroquine treatment. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001527-14-NL> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169703/full>
577. EUCTR2020-001528-32-IT. Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001528-32-IT> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169704/full>
578. EUCTR2020-001558-23-IT. Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001558-23-IT> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169711/full>
579. EUCTR2020-001565-37-ES. Prevention of novel Coronavirus infection with hydroxychloroquine. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001565-37-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169712/full>
580. EUCTR2020-001570-30-FR. ICAR (IgIV in Covid-related ARds). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001570-30-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169713/full>
581. EUCTR2020-001587-29-ES. Preventing SARS-CoV-2 virus infection and severity of COVID-19 diseases during pregnancy with hydroxychloroquine. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001587-29-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169716/full>
582. EUCTR2020-001605-23-ES. Effectiveness of the combined treatment with hydroxycloquine and azithromycin vs lopinavir/ritonavir + hydroxycloquine in hospitalized patients with confirmed COVID-19 infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001605-23-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169723/full>
583. EUCTR2020-001606-33-ES. Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001606-33-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169724/full>
584. EUCTR2020-001618-39-ES. Study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome in adult severely ill patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001618-39-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169727/full>
585. EUCTR2020-001622-64-ES. OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001622-64-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169728/full>

586. EUCTR2020-001635-27-FR. Evaluation of a combination of Masitinib and Isoquercetin in the Treatment of Hospitalized COVID-19 Patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001635-27-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169732/full>
587. EUCTR2020-001697-30-ES. PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001697-30-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169747/full>
588. EUCTR2020-001704-42-ES. Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19).
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001704-42-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169749/full>
589. EUCTR2020-001723-13-FR. A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization: OUTCOV Study.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001723-13-FR> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169755/full>
590. EUCTR2020-001825-29-ES. CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001825-29-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169776/full>
591. EUCTR2020-001827-15-ES. EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICIODS. RANDOMIZED CONTROLLED CLINICAL TRIAL.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001827-15-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169777/full>
592. EUCTR2020-001854-23-IT. A study with immunotherapy for Moderate COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001854-23-IT> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169780/full>
593. EUCTR2020-001890-56-ES. Clinical trial to evaluate the efficacy and safety of gammaglobulins in COVID-19 treatment.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001890-56-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186990/full>
594. EUCTR2020-001971-33-ES. Pragmatic study “CORIVER”: ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID19).
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001971-33-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186994/full>
595. EUCTR2020-001987-28-IT. PRECOV: a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001987-28-IT> [Internet].

- 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169799/full>
596. EUCTR2020-002035-30-IT. Multicenter, randomized, open trial comparing Tofacitinb together with Hydroxychloroquine vs Hydroxychloroquine alone in patients affected by COVID-19 related pneumonitis. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002035-30-IT> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169803/full>
597. EUCTR2020-002038-33-FI. Trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002038-33-FI> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02186998/full>
598. EUCTR2020-002123-11-ES. CLINICAL STUDY IN WHICH PATIENTS ARE RANDOMIZED TO RECEIVE HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE TO COMPARE THEIR EFFICACY IN THE TREATMENT OF COVID-19 PNEUMONIA. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002123-11-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169812/full>
599. EUCTR2020-002186-34-ES. Efficacy of the early use of corticotherapy in CoV-2 infection to prevent the progression of acute respiratory distress syndrome (ARDS). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002186-34-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187007/full>
600. EUCTR2020-002287-31-ES. COVID 19 prevention in nursing homes. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002287-31-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169817/full>
601. EUCTR2020-002449-41-ES. Pilot trial on early treatment with hydroxychloroquine in patients with COVID-19 who do not have hospital admission at diagnosis. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-002449-41-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187025/full>
602. Guharoy R, Krenzelok EP. FDA Emergency Use Authorization: glass Half Empty? Clin Infect Dis [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202560/full>
603. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet [Internet]. 2020;396(10259):1345-1352. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202579/full>
604. IRCT20080901001165N51. Investigating the efficacy and safety of Hydroxychloroquine nasal spray in controlling the symptoms of patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20080901001165N51> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169840/full>
605. IRCT20100228003449N27. Interferon ã in treatment of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20100228003449N27> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169921/full>

606. IRCT20100228003449N28. Interferon in treatment of COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20100228003449N28> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169922/full>
607. IRCT20100228003449N29. ?Effect of sofosbuvir/ ledipasvir on COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20100228003449N29> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169923/full>
608. IRCT20120215009014N353. Effect of plasma of patients recovered from covid-19 versus control group on treatment of covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120215009014N353> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170022/full>
609. IRCT20120225009124N4. Efficacy of dexamethasone, IV-IG and Interferone beta for treatment of patients with severe COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120225009124N4> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170031/full>
610. IRCT20120826010664N6. Effect of hydroxychloroquine on prevention of covid-19 virus.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20120826010664N6> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170062/full>
611. IRCT20130812014333N145. Comparative assessment of the efficacy and safety of add ontreatment with “Sofosbuvir standard of care therapeutic regimenVelpatasvir” to “standard of caretherapeutic regimen” in patients with COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20130812014333N145> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170132/full>
612. IRCT20130812014333N147. Comparative assessment of the efficacy and safety of addon treatment with “Sofosbuvir-Daclatasvir”, “Lithium”, and “Trifluoprazine” to “standard of care in three groups of patients with COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20130812014333N147> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170133/full>
613. IRCT20130917014693N10. Evaluation the effects of Hydroxychloroquine administration for COVID-19 prophylaxis.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20130917014693N10> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170144/full>
614. IRCT20150716023235N15. sex hormones in coronavirus.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150716023235N15> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170286/full>
615. IRCT20150808023559N20. Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150808023559N20> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170297/full>

616. IRCT20150914024017N1. Recigen for treatment of Covid-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150914024017N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170302/full>
617. IRCT20151222025660N2. The prophylactic effect of Hydroxychloroquine on Novel Corona virus. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20151222025660N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170321/full>
618. IRCT20151227025726N20. Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20151227025726N20> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187320/full>
619. IRCT20160118026097N5. Effect of plasmapheresis in the treatment of high-risk covid patients in Qom province. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20160118026097N5> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187334/full>
620. IRCT20161204031229N3. Evaluation the Effect of Ticoplanin in Patients With Coronavirus Disease. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20161204031229N3> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170423/full>
621. IRCT20170207032444N3. Thalidomide in COVID19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20170207032444N3> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170438/full>
622. IRCT20171105037262N4. Adalimumab effect on COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20171105037262N4> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170515/full>
623. IRCT20180425039414N2. The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180425039414N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170558/full>
624. IRCT20180425039414N3. The effect of vitamin C and E in the treatment and clinical course of patients with SARS-cov2 (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180425039414N3> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170559/full>
625. IRCT20180712040446N2. Investigating the effect of sweet almond on symptoms of COVID 19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180712040446N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170604/full>
626. IRCT20180725040596N2. Effect of Arbidol in treatment of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180725040596N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170617/full>

627. IRCT20180922041089N4. Evaluation of the effect of oral Ivermectin on patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180922041089N4> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187485/full>
628. IRCT20180923041093N6. The efficacy of barely-based traditional remedy on COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180923041093N6> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170641/full>
629. IRCT20190122042450N4. The effect of hydroxychloroquine to prevent coronavirus disease. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190122042450N4> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170696/full>
630. IRCT20190312043030N2. The effect of selenium, vitamin C and methylprednisolone combination on mortality and morbidity of Covid-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190312043030N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187540/full>
631. IRCT20190418043307N1. Effect of selenium on covid-19 disease. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190418043307N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170763/full>
632. IRCT20190727044343N1. ?Effect of febuxostat against coronavirus. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190727044343N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170880/full>
633. IRCT20190727044343N2. Atorvastatin effect on COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190727044343N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170881/full>
634. IRCT20190810044500N5. Effect of colchicine in treatment of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190810044500N5> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02170901/full>
635. IRCT20190810044500N7. Evaluation of Levamisole efficacy in treatment of Covid-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190810044500N7> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187602/full>
636. IRCT20200314046764N1. Pirfenidone in SARS-COV2. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200314046764N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171561/full>
637. IRCT20200317046797N3. Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200317046797N3> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171575/full>
638. IRCT20200318046812N1. Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200318046812N1>

- [Internet]. 2020; Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171584/full>
639. IRCT20200318046812N2. evaluation of Safety and efficacy of anti inflammatory regimens in COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200318046812N2> [Internet]. 2020; Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171585/full>
640. IRCT20200322046833N1. Umifenovir effectiveness in the treatment of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200322046833N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171589/full>
641. IRCT20200324046850N1. Comparison of vitamin D3 and N-acetylcysteine prescription in COVID-19 patients and their effect on recovery process. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200324046850N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171596/full>
642. IRCT20200324046850N2. Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200324046850N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171597/full>
643. IRCT20200324046850N3. The effect of naproxen on the healing process of patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200324046850N3> [Internet]. 2020; Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171598/full>
644. IRCT20200324046850N5. Study of the effect of vitamin C in patients with Covid-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200324046850N5> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171600/full>
645. IRCT20200324046852N1. Comparison of efficacy of oral Levamisole and Formoterol+Budesonide inhaler with standard treatment of Corona infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200324046852N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171602/full>
646. IRCT20200325046859N2. effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chloroquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200325046859N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171606/full>
647. IRCT20200328046885N1. Comparison of the effectiveness of two treatment regimens in patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200328046885N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187763/full>
648. IRCT20200328046886N2. Evaluation of the efficacy and safety of Atazanavir/Ritonavir plus Hydroxychloroquine regimen in patients with moderate COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200328046886N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187764/full>

649. IRCT20200403046926N1. The effect of SOVODAK in the treatment of COVID-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200403046926N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171632/full>
650. IRCT20200404046935N1. Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200404046935N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171636/full>
651. IRCT20200405046953N1. Comparison of therapies for COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200405046953N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171650/full>
652. IRCT20200405046958N1. Prevention of Novel Coronavirus Disease by Hydroxychloroquine in cancer patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200405046958N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171651/full>
653. IRCT20200406046963N1. Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200406046963N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171656/full>
654. IRCT20200406046968N3. effect of Interfron-beta1(zifron) on clinical improvement and prognosis of COVID-19 in Tabriz Imam-Reza hospital. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200406046968N3> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171660/full>
655. IRCT20200408046988N1. Evaluation of the efficacy of melatonin tablets as auxiliary medication in accelerating the improvement of the COVID-19 symptoms and clinical findings. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200408046988N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171674/full>
656. IRCT20200408046992N1. Effect of Trifluoperazine in treatment of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200408046992N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171677/full>
657. IRCT20200409047007N1. Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200409047007N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171682/full>
658. IRCT20200410047009N1. The effect of Naproxen in recovery and reducing mortality in patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200410047009N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171683/full>
659. IRCT20200411047025N1. Effect of Intravenous vitamin c in Patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200411047025N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171693/full>

660. IRCT20200412047042N1. Evaluation the effect of raltegravir, and raltegravir/interferon beta combination on covid 19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200412047042N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171700/full>
661. IRCT20200413047053N1. Evaluation the effect of asafoetida in the treatment of coronavirus infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200413047053N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171707/full>
662. IRCT20200414047070N1. Effect of ppd on recovery of covid disease 19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200414047070N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171713/full>
663. IRCT20200415047092N1. The effect of azithromycin in treatment of COVID19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200415047092N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171720/full>
664. IRCT20200420047147N1. ?Evaluation the effects of Sitagliptin administration in patients with COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200420047147N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171742/full>
665. IRCT20200421047155N1. Efficacy of tenofovir in covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200421047155N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171745/full>
666. IRCT20200422047168N1. Clinical trial study on the therapeutic effect of Tenofovir besides Kaletra and Chloroquine in patients with Coronavirus disease 2019 (COVID-19).
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200422047168N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171749/full>
667. IRCT20200422047168N2. Clinical trial study of the therapeutic effect of Ivermectin, besides Kaletra and Chloroquine in patients with Coronavirus disease 2019 (COVID-19).
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200422047168N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171750/full>
668. IRCT20200426047206N1. The effect of NBS powder in treatment of patients with COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200426047206N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171761/full>
669. IRCT20200426047212N1. Effect of of Inhalation of Thyme Oil in COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200426047212N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171763/full>
670. IRCT20200428047228N1. Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200428047228N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171774/full>

671. IRCT20200428047228N2. Hydroxychloroquine in comparison with hydroxychloroquine + azithromycin in patients with covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200428047228N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171775/full>
672. IRCT20200501047259N1. IVIG and COVID19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200501047259N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171788/full>
673. IRCT20200506047323N1. The effects of Ginger in treatment COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200506047323N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171811/full>
674. IRCT20200506047323N2. Effects of Licorice in treatment of COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200506047323N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171812/full>
675. IRCT20200506047323N4. Desferal in COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200506047323N4> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187810/full>
676. IRCT20200506047323N5, IRCT20200922048804N1. Melatonin in COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200506047323N5> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02188224/full>
677. IRCT20200509047364N1. Effect of erythropoietin on COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200509047364N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187815/full>
678. IRCT20200509047364N2. Famotidine and COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200509047364N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187816/full>
679. IRCT20200510047383N1. Evaluation of the effect of Tocilizumab on outcomes of the severe COVID-19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200510047383N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171831/full>
680. IRCT20200511047396N1. Efficacy evaluation of inhalation therapy (nasal spray) of Interferon Beta-1a in hospitalized Covid-19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200511047396N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171837/full>
681. IRCT20200511047399N1. Effect of omega-3 on diabetic patients with Covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200511047399N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187817/full>

682. IRCT20200513047426N1. The prophylactic effect of oral hydroxy-chloroquine in close contacts of COVID-19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200513047426N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171848/full>
683. IRCT20200517047485N1. Comparison of combination therapies of COVID_19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200517047485N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171866/full>
684. IRCT20200522047545N1. Evaluation of herbal compound containing Anacyclus pyrethrum, Senna, Ferrula asafoetida and Terminalia chebula in COVID19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200522047545N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187840/full>
685. IRCT20200523047550N1. Effect of Umifenovir in treatment of covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200523047550N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171880/full>
686. IRCT20200607047682N1. Clinical trial of Annual SZ drug in Covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200607047682N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187865/full>
687. IRCT20200609047707N1. Effective of Elman tablet on COVID-19 infection severity.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200609047707N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02171919/full>
688. IRCT20200616047792N1. A study of therapeutic effect of blood ozone therapy of severe Covid-19 patients.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200616047792N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187892/full>
689. IRCT20200623047897N1. Efficacy of N-acetylcysteine in patients with COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200623047897N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187918/full>
690. IRCT20200705048013N1. The effect of Pentoxifylline in patients with Covid-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200705048013N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187945/full>
691. IRCT20200718048129N1. Evaluation of the effectiveness of Hydroxychloroquine and Clarithromycin in dyspnea and caught caused by COVID-19 in recovery phase.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200718048129N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187993/full>
692. IRCT20200730048253N1. Evaluating the effectiveness of intravenous ozonized saline in COVID-19 disease.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200730048253N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02188049/full>

693. IRCT20200825048514N1. Effect of β -interferon and methylprednisolone in COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200825048514N1> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02188137/full>
694. IRCT20200927048848N2. squalene and COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20200927048848N2> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02188236/full>
695. ISRCTN14326006. Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus? <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN14326006> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02172044/full>
696. ISRCTN21363594. Therapeutic plasma exchange (removal of the non-cell portion of blood) in critically ill adult patients with serious SARS CoV-2 disease (COVID-19). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN21363594> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02172156/full>
697. ISRCTN83971151. Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN83971151> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02172315/full>
698. ISRCTN86534580. PRINCIPLE: a trial evaluating treatments for suspected COVID-19 in people aged 50 years and above with pre-existing conditions and those aged 65 years and above. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN86534580> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02172322/full>
699. ISRCTN88057279. Preventative treatment for patients at risk of COVID-19 infection (PROTECT). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN88057279> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02172328/full>
700. Jha AK, Kumar R, Goenka MK, Dayal VM. Emerging Treatment and Prevention Strategies against COVID-19: a Brief Update. *J Dig Endosc* [Internet]. 2020;11(1):69-72. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213387/full>
701. KCT0005003. Clinical efficacy of Nafamostat for COVID-19 pneumonia. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=KCT0005003> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173159/full>
702. Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, et al. Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia. *Int J Infect Dis* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02201688/full>
703. Kim J-W, Kim EJ, Kwon HH, Jung CY, Kim KC, Choe J-Y, et al. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. *Korean J Intern Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02141325/full>

704. Kuhn A, Caproni M, Doria A. Management of refractory skin lupus. *Lupus Sci Med* [Internet]. 2020;7(SUPPL 2):A9-A10. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02203160/full>
705. Lam C, Mataraso S, Lynn-Palevsky A, Green-Saxena A, Barnes G, Hoffman J, et al. Identification of a COVID-19 subpopulation responsive to hydroxychloroquine using machine learning: the IDENTIFY Trial. *Res Pract Thromb Haemost* [Internet]. 2020;4(SUPPL 2):7-8. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213115/full>
706. LBCTR2020043495, EUCTR2020-001366-11-ES, EUCTR2020-002060-31-CZ. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001366-11-ES> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169806/full>
707. Lee C, Ahn MY, Byeon K, Choi J-P, Hahm C, Kim H, et al. Clinical experience with use of remdesivir in the treatment of severe acute respiratory syndrome coronavirus 2: a case series. *Infect Chemother* [Internet]. 2020;52(3):369-380. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02203122/full>
708. Littlejohn E. Hydroxychloroquine use in the COVID-19 patient. *Cleve Clin J Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02122153/full>
709. Maghen D, Lutz G, Schneider A. COVID-19 INFECTION IN A PATIENT WITH SECONDARY HYPOGAMMAGLOBULINEMIA. *Ann allergy, asthma Immunol* [Internet]. 2020;125(5):S106-. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02191036/full>
710. Mitja O, Corbacho-Monne M, Ubals M, Tebe C, Penafiel J, Tobias A, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. *Clin Infect Dis* [Internet]. 2020; Available from: <https://dx.doi.org/10.1093/cid/ciaa1009>
711. Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. *N Engl j med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02211792/full>
712. NCT04261517. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV). <https://clinicaltrials.gov/show/NCT04261517> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02080235/full>
713. NCT04286503. The Clinical Study of Carrimycin on Treatment Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04286503> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02088563/full>
714. NCT04303299. Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : a Randomized Control Trial. <https://clinicaltrials.gov/show/NCT04303299> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02088948/full>
715. NCT04303507. Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting. <https://clinicaltrials.gov/show/NCT04303507> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02088952/full>

716. NCT04304053. Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic. <https://clinicaltrials.gov/show/NCT04304053> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02088965/full>
717. NCT04307693. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19). <https://clinicaltrials.gov/show/NCT04307693> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02083413/full>
718. NCT04308668. Post-exposure Prophylaxis for SARS-Coronavirus-2. <https://clinicaltrials.gov/show/NCT04308668> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089085/full>
719. NCT04315896. Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial). <https://clinicaltrials.gov/show/NCT04315896> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089240/full>
720. NCT04316377. Norwegian Coronavirus Disease 2019 Study. <https://clinicaltrials.gov/show/NCT04316377> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02090922/full>
721. NCT04318015. Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial). <https://clinicaltrials.gov/show/NCT04318015> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089289/full>
722. NCT04318444. Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19). <https://clinicaltrials.gov/show/NCT04318444> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02090976/full>
723. NCT04321278. Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). <https://clinicaltrials.gov/show/NCT04321278> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091040/full>
724. NCT04321616. The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2. <https://clinicaltrials.gov/show/NCT04321616> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089345/full>
725. NCT04322396. Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04322396> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091061/full>
726. NCT04323345. Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus. <https://clinicaltrials.gov/show/NCT04323345> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091088/full>
727. NCT04323527. Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2. <https://clinicaltrials.gov/show/NCT04323527> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091098/full>
728. NCT04323631. Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death. <https://clinicaltrials.gov/show/NCT04323631> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091101/full>

729. NCT04324463. Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial. <https://clinicaltrials.gov/show/NCT04324463> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089428/full>
730. NCT04325893. Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease. <https://clinicaltrials.gov/show/NCT04325893> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091159/full>
731. NCT04328272. Effectiveness of Hydroxychloroquine in Covid-19 Patients. <https://clinicaltrials.gov/show/NCT04328272> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091214/full>
732. NCT04328285. Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers. <https://clinicaltrials.gov/show/NCT04328285> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089494/full>
733. NCT04328467. Pre-exposure Prophylaxis for SARS-Coronavirus-2. <https://clinicaltrials.gov/show/NCT04328467> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091219/full>
734. NCT04328480. The ECLA PHRI COLCOVID Trial. <https://clinicaltrials.gov/show/NCT04328480> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091220/full>
735. NCT04328493. The Vietnam Chloroquine Treatment on COVID-19. <https://clinicaltrials.gov/show/NCT04328493> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091221/full>
736. NCT04328961. Hydroxychloroquine for COVID-19 PEP. <https://clinicaltrials.gov/show/NCT04328961> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091233/full>
737. NCT04329520. EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel. <https://clinicaltrials.gov/show/NCT04329520> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091244/full>
738. NCT04329611. ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease. <https://clinicaltrials.gov/show/NCT04329611> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091248/full>
739. NCT04329832. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19. <https://clinicaltrials.gov/show/NCT04329832> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089510/full>
740. NCT04329923. The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine). <https://clinicaltrials.gov/show/NCT04329923> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089513/full>
741. NCT04330144. Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial). <https://clinicaltrials.gov/show/NCT04330144> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091260/full>
742. NCT04330495. Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection. <https://clinicaltrials.gov/show/NCT04330495> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089516/full>

743. NCT04330586. A Trial of Ciclesonide in Adults With Mild COVID-19. <https://clinicaltrials.gov/show/NCT04330586> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091274/full>
744. NCT04331054. Protective Role of Inhaled Steroids for Covid-19 Infection. <https://clinicaltrials.gov/show/NCT04331054> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091288/full>
745. NCT04331470. Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04331470> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091299/full>
746. NCT04331600. ChloroQUine As antiViral treAtmeNT In coroNavirus infEction 2020. <https://clinicaltrials.gov/show/NCT04331600> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091302/full>
747. NCT04331834. Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic. <https://clinicaltrials.gov/show/NCT04331834> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089536/full>
748. NCT04332107. Azithromycin for COVID-19 Treatment in Outpatients Nationwide. <https://clinicaltrials.gov/show/NCT04332107> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091314/full>
749. NCT04332835. Convalescent Plasma for Patients With COVID-19: a Randomized, Open Label, Parallel, Controlled Clinical Study. <https://clinicaltrials.gov/show/NCT04332835> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091334/full>
750. NCT04332991. Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among Inpatients With Symptomatic Disease. <https://clinicaltrials.gov/show/NCT04332991> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089549/full>
751. NCT04333628. Chloroquine for Mild Symptomatic and Asymptomatic COVID-19. <https://clinicaltrials.gov/show/NCT04333628> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091358/full>
752. NCT04333654. Hydroxychloroquine in Outpatient Adults With COVID-19. <https://clinicaltrials.gov/show/NCT04333654> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091359/full>
753. NCT04333732. CROWN CORONATION: chloroquine Repurposing to healthWorkers for Novel CORONAvirus mitigaTION. <https://clinicaltrials.gov/show/NCT04333732> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091361/full>
754. NCT04333914. Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection. <https://clinicaltrials.gov/show/NCT04333914> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091364/full>
755. NCT04334148. Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine. <https://clinicaltrials.gov/show/NCT04334148> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089584/full>
756. NCT04334382. Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19. <https://clinicaltrials.gov/show/NCT04334382> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089588/full>

757. NCT04334928. Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel. <https://clinicaltrials.gov/show/NCT04334928> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091384/full>
758. NCT04334967. Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care. <https://clinicaltrials.gov/show/NCT04334967> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091386/full>
759. NCT04335552. Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection. <https://clinicaltrials.gov/show/NCT04335552> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091400/full>
760. NCT04336332. Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19. <https://clinicaltrials.gov/show/NCT04336332> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091426/full>
761. NCT04336748. HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers. <https://clinicaltrials.gov/show/NCT04336748> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091436/full>
762. NCT04338698. Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: an RCT. <https://clinicaltrials.gov/show/NCT04338698> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089644/full>
763. NCT04338906. Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19. <https://clinicaltrials.gov/show/NCT04338906> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091483/full>
764. NCT04339816. Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: randomised Controlled Trial. <https://clinicaltrials.gov/show/NCT04339816> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091500/full>
765. NCT04340349. Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals. <https://clinicaltrials.gov/show/NCT04340349> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091509/full>
766. NCT04340544. Hydroxychloroquine for the Treatment of Mild COVID-19 Disease. <https://clinicaltrials.gov/show/NCT04340544> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091511/full>
767. NCT04341441. Will Hydroxychloroquine Impede or Prevent COVID-19. <https://clinicaltrials.gov/show/NCT04341441> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091535/full>
768. NCT04341493. Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04341493> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091536/full>
769. NCT04341727. Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection. <https://clinicaltrials.gov/show/NCT04341727> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091545/full>

770. NCT04341870. Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO. <https://clinicaltrials.gov/show/NCT04341870> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091549/full>
771. NCT04342156. Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): a Cluster Randomized Controlled Trial. <https://clinicaltrials.gov/show/NCT04342156> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091554/full>
772. NCT04342169. University of Utah COVID-19 Hydrochloroquine Trial. <https://clinicaltrials.gov/show/NCT04342169> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091555/full>
773. NCT04342221. Hydroxychloroquine for COVID-19. <https://clinicaltrials.gov/show/NCT04342221> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091557/full>
774. NCT04342650. Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection. <https://clinicaltrials.gov/show/NCT04342650> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089705/full>
775. NCT04343092. Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients. <https://clinicaltrials.gov/show/NCT04343092> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089709/full>
776. NCT04343677. Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study. <https://clinicaltrials.gov/show/NCT04343677> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091583/full>
777. NCT04343768. An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regimen in Moderate to Severe COVID-19: a Randomized Clinical Trial. <https://clinicaltrials.gov/show/NCT04343768> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091584/full>
778. NCT04344379. Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus. <https://clinicaltrials.gov/show/NCT04344379> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089726/full>
779. NCT04344444. Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease. <https://clinicaltrials.gov/show/NCT04344444> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089727/full>
780. NCT04345419. A Real-life Experience on Treatment of Patients With COVID 19. <https://clinicaltrials.gov/show/NCT04345419> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091620/full>
781. NCT04345523. Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients. <https://clinicaltrials.gov/show/NCT04345523> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091624/full>
782. NCT04345692. A Randomized Controlled Clinical Trial: hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients. <https://clinicaltrials.gov/show/NCT04345692> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091626/full>

783. NCT04345861. Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial). <https://clinicaltrials.gov/show/NCT04345861> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089767/full>
784. NCT04346147. Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19. <https://clinicaltrials.gov/show/NCT04346147> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091642/full>
785. NCT04346329. Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19. <https://clinicaltrials.gov/show/NCT04346329> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091644/full>
786. NCT04346446. Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04346446> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091646/full>
787. NCT04346667. Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With chloroquinE Compounds. <https://clinicaltrials.gov/show/NCT04346667> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091654/full>
788. NCT04347031. An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19. <https://clinicaltrials.gov/show/NCT04347031> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091668/full>
789. NCT04347512. Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study. <https://clinicaltrials.gov/show/NCT04347512> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091680/full>
790. NCT04347889. Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers: RCT. <https://clinicaltrials.gov/show/NCT04347889> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089790/full>
791. NCT04347915. The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19. <https://clinicaltrials.gov/show/NCT04347915> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091690/full>
792. NCT04347980. Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19. <https://clinicaltrials.gov/show/NCT04347980> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091693/full>
793. NCT04348695. Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19. <https://clinicaltrials.gov/show/NCT04348695> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091714/full>
794. NCT04349228. Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals. <https://clinicaltrials.gov/show/NCT04349228> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089824/full>

795. NCT04349241. Efficacy and Safety of Favipiravir in Management of COVID-19. <https://clinicaltrials.gov/show/NCT04349241> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091724/full>
796. NCT04349371. Saved From COVID-19. <https://clinicaltrials.gov/show/NCT04349371> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091725/full>
797. NCT04349410. The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol. <https://clinicaltrials.gov/show/NCT04349410> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091726/full>
798. NCT04349592. Qatar Prospective RCT Of Therapy Eliminating Covid Transmission. <https://clinicaltrials.gov/show/NCT04349592> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091730/full>
799. NCT04350281. Double Therapy With IFN-beta 1b and Hydroxychloroquine. <https://clinicaltrials.gov/show/NCT04350281> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091747/full>
800. NCT04350671. Interferon Beta 1a in COVID-19: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. <https://clinicaltrials.gov/show/NCT04350671> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091758/full>
801. NCT04350684. Umifenovir in COVID-19: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. <https://clinicaltrials.gov/show/NCT04350684> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02091759/full>
802. NCT04351191. PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using chloroquinE Compounds. <https://clinicaltrials.gov/show/NCT04351191> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089846/full>
803. NCT04351347. The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment. <https://clinicaltrials.gov/show/NCT04351347> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103239/full>
804. NCT04352933. PROLIFIC ChemoprophylaxisTrial (COVID-19). <https://clinicaltrials.gov/show/NCT04352933> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103272/full>
805. NCT04352946. HEalth Care Worker pROphylaxis Against COVID-19: the HERO Trial. <https://clinicaltrials.gov/show/NCT04352946> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093646/full>
806. NCT04353037. PATCH 2&3: prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine. <https://clinicaltrials.gov/show/NCT04353037> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103274/full>
807. NCT04353180. Assessment the Activity Value of 13- Cis-Retinoic Acid (Isotretinoin) in the Treatment of COVID-19 (Randomized). <https://clinicaltrials.gov/show/NCT04353180> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103277/full>
808. NCT04353271. Trial of Hydroxychloroquine In Covid-19 Kinetics. <https://clinicaltrials.gov/show/NCT04353271> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093652/full>

809. NCT04353336. Efficacy of Chloroquine in COVID-19 Treatment. <https://clinicaltrials.gov/show/NCT04353336> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103281/full>
810. NCT04354428. Treatment for SARS-CoV-2 in High-Risk Adult Outpatients. <https://clinicaltrials.gov/show/NCT04354428> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093677/full>
811. NCT04354441. Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women. <https://clinicaltrials.gov/show/NCT04354441> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103301/full>
812. NCT04354597. Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04354597> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103303/full>
813. NCT04355026. Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia. <https://clinicaltrials.gov/show/NCT04355026> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180433/full>
814. NCT04355052. Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to “no Treatment” in SARS CoV 2 Virus. <https://clinicaltrials.gov/show/NCT04355052> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180434/full>
815. NCT04356534. Convalescent Plasma Trial in COVID -19 Patients. <https://clinicaltrials.gov/show/NCT04356534> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103332/full>
816. NCT04358068. Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19. <https://clinicaltrials.gov/show/NCT04358068> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103357/full>
817. NCT04358081. Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease. <https://clinicaltrials.gov/show/NCT04358081> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103358/full>
818. NCT04359095. Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia. <https://clinicaltrials.gov/show/NCT04359095> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103381/full>
819. NCT04359316. Azithromycin in Hospitalized COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04359316> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103387/full>
820. NCT04359537. Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19. <https://clinicaltrials.gov/show/NCT04359537> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103392/full>
821. NCT04359615. Favipiravir in Hospitalized COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04359615> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103393/full>

822. NCT04359901. Sarilumab for Patients With Moderate COVID-19 Disease. <https://clinicaltrials.gov/show/NCT04359901> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103402/full>
823. NCT04360759. Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19. <https://clinicaltrials.gov/show/NCT04360759> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103425/full>
824. NCT04361318. Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19. <https://clinicaltrials.gov/show/NCT04361318> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103441/full>
825. NCT04361422. Isotretinoin in Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04361422> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180469/full>
826. NCT04361461. Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19). <https://clinicaltrials.gov/show/NCT04361461> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180470/full>
827. NCT04362189. Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04362189> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093755/full>
828. NCT04362332. Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients Admitted With Moderate to Severe COVID-19. <https://clinicaltrials.gov/show/NCT04362332> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103462/full>
829. NCT04363060. Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit. <https://clinicaltrials.gov/show/NCT04363060> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103477/full>
830. NCT04363203. VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL). <https://clinicaltrials.gov/show/NCT04363203> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103481/full>
831. NCT04363437. Colchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19. <https://clinicaltrials.gov/show/NCT04363437> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103485/full>
832. NCT04363450. Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP). <https://clinicaltrials.gov/show/NCT04363450> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093761/full>
833. NCT04363827. Protect: a Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19). <https://clinicaltrials.gov/show/NCT04363827> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093766/full>
834. NCT04363866. A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19). <https://clinicaltrials.gov/show/NCT04363866> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093767/full>
835. NCT04364022. Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland.

- <https://clinicaltrials.gov/show/NCT04364022> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093771/full>
836. NCT04364815. The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial. <https://clinicaltrials.gov/show/NCT04364815> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093789/full>
837. NCT04365231. Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial. <https://clinicaltrials.gov/show/NCT04365231> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180484/full>
838. NCT04365582. Outpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome. <https://clinicaltrials.gov/show/NCT04365582> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103531/full>
839. NCT04366089. Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora. <https://clinicaltrials.gov/show/NCT04366089> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103543/full>
840. NCT04366245. Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection. <https://clinicaltrials.gov/show/NCT04366245> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103549/full>
841. NCT04369742. Treating COVID-19 With Hydroxychloroquine (TEACH). <https://clinicaltrials.gov/show/NCT04369742> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103614/full>
842. NCT04370015. Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers. <https://clinicaltrials.gov/show/NCT04370015> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103616/full>
843. NCT04370262. Multi-site Adaptive Trials Using Hydroxychloroquine for COVID-19. <https://clinicaltrials.gov/show/NCT04370262> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103620/full>
844. NCT04370782. Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting. <https://clinicaltrials.gov/show/NCT04370782> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103632/full>
845. NCT04371406. Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04371406> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103639/full>
846. NCT04371523. Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers. <https://clinicaltrials.gov/show/NCT04371523> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093858/full>
847. NCT04371926. Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk. <https://clinicaltrials.gov/show/NCT04371926> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103648/full>
848. NCT04372017. Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection.

- <https://clinicaltrials.gov/show/NCT04372017> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093865/full>
849. NCT04372082. Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04372082> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103653/full>
850. NCT04372628. Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19. <https://clinicaltrials.gov/show/NCT04372628> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093879/full>
851. NCT04373733. A Randomised Controlled Trial of Early Intervention in COVID-19: favipiravir Verses Hydroxychloroquine & Azithromycin & Zinc versus Standard Care. <https://clinicaltrials.gov/show/NCT04373733> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103688/full>
852. NCT04374019. Novel Agents for Treatment of High-risk COVID-19 Positive Patients. <https://clinicaltrials.gov/show/NCT04374019> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180530/full>
853. NCT04374552. Asymptomatic COVID-19 Trial. <https://clinicaltrials.gov/show/NCT04374552> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103702/full>
854. NCT04374903. Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04374903> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103708/full>
855. NCT04374942. Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus? <https://clinicaltrials.gov/show/NCT04374942> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103709/full>
856. NCT04376814. Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19. <https://clinicaltrials.gov/show/NCT04376814> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180543/full>
857. NCT04377503. Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04377503> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103767/full>
858. NCT04377646. A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers. <https://clinicaltrials.gov/show/NCT04377646> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02094010/full>
859. NCT04379271. A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19). <https://clinicaltrials.gov/show/NCT04379271> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103801/full>
860. NCT04379492. A Study of Hydroxychloroquine Compared to Placebo as Treatment for People With COVID-19. <https://clinicaltrials.gov/show/NCT04379492> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02094057/full>

861. NCT04381936. Randomized Evaluation of COVID-19 Therapy. <https://clinicaltrials.gov/show/NCT04381936> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103853/full>
862. NCT04381988. A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy. <https://clinicaltrials.gov/show/NCT04381988> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02094125/full>
863. NCT04382625. Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial. <https://clinicaltrials.gov/show/NCT04382625> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124509/full>
864. NCT04382846. Novel Regimens in COVID-19 Treatment. <https://clinicaltrials.gov/show/NCT04382846> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124516/full>
865. NCT04382950, NCT04375046. Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising COVID-19 Infection- and Lung Injury Preventing Drug Better Than Recombinant Human ACE2. <https://clinicaltrials.gov/show/NCT04382950> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103715/full>
866. NCT04383717. Levamisole and Isoprinosine in the Treatment of COVID19: a Proposed Therapeutic Trial. <https://clinicaltrials.gov/show/NCT04383717> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124535/full>
867. NCT04384380. Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04384380> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124551/full>
868. NCT04385264. #StayHome: early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19. <https://clinicaltrials.gov/show/NCT04385264> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124573/full>
869. NCT04386447. Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19. <https://clinicaltrials.gov/show/NCT04386447> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124604/full>
870. NCT04387760. Favipiravir vs Hydroxychloroquine in COVID -19. <https://clinicaltrials.gov/show/NCT04387760> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124639/full>
871. NCT04388709. Interferon Lambda Therapy for COVID-19. <https://clinicaltrials.gov/show/NCT04388709> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124651/full>
872. NCT04389359. PROphylaxis for paTiEnts at Risk of COVID-19 infecTion. <https://clinicaltrials.gov/show/NCT04389359> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124658/full>
873. NCT04389580. Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus. <https://clinicaltrials.gov/show/NCT04389580> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02180583/full>

874. NCT04389801. Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection. <https://clinicaltrials.gov/show/NCT04389801> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124662/full>
875. NCT04390061. TOFAcitinib Plus Hydroxycloquine vs Hydroxycloquine in Patients With COVID-19 Interstitial Pneumonia. <https://clinicaltrials.gov/show/NCT04390061> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124668/full>
876. NCT04390152. Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19. <https://clinicaltrials.gov/show/NCT04390152> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124671/full>
877. NCT04390594. Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal. <https://clinicaltrials.gov/show/NCT04390594> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124685/full>
878. NCT04391101. Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19). <https://clinicaltrials.gov/show/NCT04391101> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124694/full>
879. NCT04391127. Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection. <https://clinicaltrials.gov/show/NCT04391127> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124696/full>
880. NCT04392128. Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies. <https://clinicaltrials.gov/show/NCT04392128> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118264/full>
881. NCT04392713. Efficacy of Ivermectin in COVID-19. <https://clinicaltrials.gov/show/NCT04392713> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124727/full>
882. NCT04392973. FAvipiravir and HydroxyChloroquine Combination Therapy. <https://clinicaltrials.gov/show/NCT04392973> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124732/full>
883. NCT04393051. Baricitinib Compared to Standard Therapy in Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04393051> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124735/full>
884. NCT04394442. Hydroxychloroquine in COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04394442> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118293/full>
885. NCT04395768. International ALLIANCE Study of Therapies to Prevent Progression of COVID-19. <https://clinicaltrials.gov/show/NCT04395768> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124784/full>
886. NCT04396067. Combination With Inhibitor of Neutrophil Elastase (All-trans Retinoic Acid) and Isotretinoin May Enhances Neutralizing Antibodies in COVID -19 Infected Patients Better Than COVID-19 Inactivated Vaccines. <https://clinicaltrials.gov/show/NCT04396067> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124788/full>

887. NCT04397328. COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada. <https://clinicaltrials.gov/show/NCT04397328> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124818/full>
888. NCT04397497. Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19). <https://clinicaltrials.gov/show/NCT04397497> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118356/full>
889. NCT04397718. Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization. <https://clinicaltrials.gov/show/NCT04397718> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124828/full>
890. NCT04400019. Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM). <https://clinicaltrials.gov/show/NCT04400019> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124865/full>
891. NCT04401475. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 Pneumonia. <https://clinicaltrials.gov/show/NCT04401475> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124894/full>
892. NCT04403100. Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: “The Hope Coalition - 1.” <https://clinicaltrials.gov/show/NCT04403100> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124930/full>
893. NCT04403477. Convalescent Plasma Therapy in Severe COVID-19 Infection. <https://clinicaltrials.gov/show/NCT04403477> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124941/full>
894. NCT04403555. Ivermectin and Doxycycline in COVID-19 Treatment. <https://clinicaltrials.gov/show/NCT04403555> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118430/full>
895. NCT04405921. Hydroxychloroquine, Azithromycin in the Treatment of Covid-19. <https://clinicaltrials.gov/show/NCT04405921> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124982/full>
896. NCT04409522. Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients. <https://clinicaltrials.gov/show/NCT04409522> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125047/full>
897. NCT04410562. Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy. <https://clinicaltrials.gov/show/NCT04410562> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125072/full>
898. NCT04411433. Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19. <https://clinicaltrials.gov/show/NCT04411433> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125093/full>
899. NCT04414241, PER-011-20. Hydroxychloroquine to Prevent SARS-CoV-2 Infection. <https://clinicaltrials.gov/show/NCT04414241> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173548/full>

900. NCT04418128. Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia. <https://clinicaltrials.gov/show/NCT04418128> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125254/full>
901. NCT04420247. Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19. <https://clinicaltrials.gov/show/NCT04420247> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118697/full>
902. NCT04421664. Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada). <https://clinicaltrials.gov/show/NCT04421664> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125328/full>
903. NCT04425707. Ivermectin In Treatment of COVID 19 Patients. <https://clinicaltrials.gov/show/NCT04425707> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125421/full>
904. NCT04429867. Hydroxychloroquine Use in Hospitalized Patients With COVID-19: impact on Progression to Severe or Critical Disease. <https://clinicaltrials.gov/show/NCT04429867> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125520/full>
905. NCT04432298. Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease. <https://clinicaltrials.gov/show/NCT04432298> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125560/full>
906. NCT04434248. An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04434248> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125608/full>
907. NCT04435587. Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19. <https://clinicaltrials.gov/show/NCT04435587> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02125634/full>
908. NCT04437693. Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04437693> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133728/full>
909. NCT04438837. Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers. <https://clinicaltrials.gov/show/NCT04438837> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133759/full>
910. NCT04439006. Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization. <https://clinicaltrials.gov/show/NCT04439006> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133763/full>
911. NCT04441424. Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients. <https://clinicaltrials.gov/show/NCT04441424> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133793/full>
912. NCT04443725. Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04443725> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133848/full>

913. NCT04443881. Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS). <https://clinicaltrials.gov/show/NCT04443881> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133851/full>
914. NCT04446104. A Preventive Treatment for Migrant Workers at High-risk of Covid-19. <https://clinicaltrials.gov/show/NCT04446104> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133893/full>
915. NCT04447534. Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04447534> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02133925/full>
916. NCT04459702. A Study of Combination Therapies to Treat COVID-19 Infection. <https://clinicaltrials.gov/show/NCT04459702> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02134195/full>
917. NCT04466280. Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19. <https://clinicaltrials.gov/show/NCT04466280> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02130055/full>
918. NCT04466540. Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19). <https://clinicaltrials.gov/show/NCT04466540> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02130059/full>
919. NCT04473053. Rapid Experimental Medicine for COVID-19. <https://clinicaltrials.gov/show/NCT04473053> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145287/full>
920. NCT04475588, CTRI/2020/05/024959. Efficacy and Safety of Itolizumab in COVID-19 Complications. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2020/05/024959> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02167888/full>
921. NCT04477083. Development and Validation of “Ready-to-Use” Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04477083> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145365/full>
922. NCT04483960. Australasian COVID-19 Trial (ASCOT). <https://clinicaltrials.gov/show/NCT04483960> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145522/full>
923. NCT04491994. Clearing the Fog: is Hydroxychloroquine Effective in Reducing COVID-19 Progression. <https://clinicaltrials.gov/show/NCT04491994> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145685/full>
924. NCT04501783. Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19. <https://clinicaltrials.gov/show/NCT04501783> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02137646/full>
925. NCT04501965. Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients. <https://clinicaltrials.gov/show/NCT04501965> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145870/full>

926. NCT04502342. Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients. <https://clinicaltrials.gov/show/NCT04502342> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145877/full>
927. NCT04519125. Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia. <https://clinicaltrials.gov/show/NCT04519125> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02181095/full>
928. NCT04519385. Tocilizumam Versus Dexamethasone in Severe Covid-19 Cases. <https://clinicaltrials.gov/show/NCT04519385> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02162941/full>
929. NCT04528927. Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia. <https://clinicaltrials.gov/show/NCT04528927> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02163176/full>
930. NCT04530422. Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment. <https://clinicaltrials.gov/show/NCT04530422> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02163214/full>
931. NCT04548557. Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial. <https://clinicaltrials.gov/show/NCT04548557> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02163654/full>
932. NCT04573153. Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients. <https://clinicaltrials.gov/show/NCT04573153> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02181681/full>
933. NCT04575558. HOPE: a Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19. <https://clinicaltrials.gov/show/NCT04575558> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02181739/full>
934. NCT04581291. The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: a Pilot Randomized Control Trial. <https://clinicaltrials.gov/show/NCT04581291> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02181886/full>
935. NCT04597775. Chemoprevention Clinical Trial of COVID-19: hydroxychloroquine Post Exposure Prophylaxis. <https://clinicaltrials.gov/show/NCT04597775> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02196750/full>
936. NCT04605588. A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19. <https://clinicaltrials.gov/show/NCT04605588> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02196947/full>
937. NCT04615429. Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19. <https://clinicaltrials.gov/show/NCT04615429> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02184090/full>
938. NCT04635605. Methylene Blue Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04635605> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205730/full>

939. NCT04646109. Ivermectin for Severe COVID-19 Management. <https://clinicaltrials.gov/show/NCT04646109> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205950/full>
940. NCT04647669. WHO COVID-19 Solidarity Trial for COVID-19 Treatments. <https://clinicaltrials.gov/show/NCT04647669> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205994/full>
941. NCT04652648. Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: hydroxychloroquine Prophylaxis in COVID-19 Household Contacts. <https://clinicaltrials.gov/show/NCT04652648> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02206113/full>
942. NCT04668469. Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic. <https://clinicaltrials.gov/show/NCT04668469> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02206439/full>
943. NCT04680949. suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19. <https://clinicaltrials.gov/show/NCT04680949> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02209581/full>
944. Nelson BC, Laracy J, Shoucri S, Dietz D, Zucker J, Patel N, et al. Clinical Outcomes Associated with Methylprednisolone in Mechanically Ventilated Patients with COVID-19. *Clin Infect Dis* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02159482/full>
945. NL8490. An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=NL8490> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173234/full>
946. NL8726. Effect of hydroxychloroquine treatment on the general immunocompetence. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=NL8726> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173260/full>
947. Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle P V, Thomas CE, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. *Eclinicalmedicine* [Internet]. 2020;29-30. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02211046/full>
948. PACTR202004801273802. Lagos COVID-19 Chloroquine Treatment Trial (LACCTT). <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202004801273802> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173416/full>
949. PACTR202005622389003. Hydroxychloroquine, Azithromycine and Zinc for the treatment of SARS-Cov2 infection in Senegal. COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202005622389003> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173443/full>
950. PACTR202006537901307. An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202006537901307> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173479/full>

951. PACTR202009483194545. Evaluation of phytopharmaceuticals to improve the prognosis of Covid-19 disease in Togo. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202009483194545> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189177/full>
952. PACTR202009642148520. Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202009642148520> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189187/full>
953. PACTR202009786901147. Hydroxychloroquine for prevention of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202009786901147> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189203/full>
954. PACTR202010519682638. Efficacy of two hydroxychloroquine based drug combination regimens in comparison to standard of care in The Treatment of Hospitalized COVID-19 Patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202010519682638> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189221/full>
955. PACTR202010718451278. Factors affecting transmission of SARS-CoV-2 in Households of SARS-CoV-2 patients in Sub-Saharan Africa Ancillary study of the ANTICOV Study: an open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202010718451278> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189243/full>
956. PACTR202010781639956. The impact of COVID-19 treatment on the type, strength and duration of antibody and cellular immune responses in SARS-CoV-2 patients in sub-Saharan Africa Ancillary Study of the ANTICOV Study: an open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=PACTR202010781639956> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189251/full>
957. Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02210696/full>
958. Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. *Clin Infect Dis* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02191246/full>
959. Rajter JC, Sherman MS, Fattah N, Vogel F, Sacks J, Rajter J-J. Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study). *Chest* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02191447/full>
960. RBR-3k4wxb. Evaluation of the use of Hydroxychloroquine in Chinese flu. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-3k4wxb> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173647/full>

961. RBR-7bxhrt. Chemoprophylaxis with chloroquine in a high-risk population for the prevention of SARS-CoV-2 infections severity of infection. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-7bxhrt> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189437/full>
962. RBR-8h7q82. The effect of chloroquine, hydroxychloroquine OR ivermectin in patients with severe manifestations of coronavirus. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-8h7q82> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189474/full>
963. RBR-8jyhxx. Clinical trial for the treatment of COVID-19 with Chloroquine and Colchicine. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-8jyhxx> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189479/full>
964. RBR-95yjmj. Placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxychloroquine and azithromycin in relation to placebo in the negative viral load of participants with SARS-CoV2 flu syndrome and who do not have an indication for hospitalization. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-95yjmj> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173959/full>
965. RBR-9d8z6m. Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RBR-9d8z6m> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02173984/full>
966. Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. *lancet Rheumatol* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205253/full>
967. RPCEC00000307. ESPERANZA study. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RPCEC00000307> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02174018/full>
968. RPCEC00000320. Rectal Ozone in the COVID-19 treatment. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=RPCEC00000320> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02174024/full>
969. Sallard E, Belhadi D, Lescure F-X, Yazdanpanah Y, Peiffer-Smadja N. Clinical trial protocols of repurposed prophylaxis for COVID-19: a review. *Med Mal Infect* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02191843/full>
970. Sanchez-Guijo F, Garcia-Arranz M, Lopez-Parra M, Monedero P, Mata-Martinez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. *Eclinicalmedicine* [Internet]. 2020;25. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02193344/full>
971. Sankari Niveditha A, Arivarasu L. Awareness and knowledge of hydroxychloroquine among public. *Eur J Mol Clin Med* [Internet]. 2020;7(1):476-485. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02211198/full>
972. Singh AP, Tousif S, Umbarkar P, Lal H. A pharmacovigilance study of hydroxychloroquine cardiac safety profile: potential implication in COVID-19 mitigation. *J Clin Med* [Internet].

2020;9(6):1-13. Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02143535/full>

973. Singh H, Chauhan P, Kakkar AK. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: the journey so far and the road ahead. *Eur J Pharmacol* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02214214/full>
974. Singh P, Mishra N, Singh N, Nisha R, Pal RR, Singh S, et al. Credible Protein Targets and Curative Strategies for COVID-19: a Review. *SN Compr Clin Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02193951/full>
975. SLCTR/2020/011. Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=SLCTR/2020/011> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02174036/full>
976. Tabarsi P, Barati S, Jamaati H, Haseli S, Marjani M, Moniri A, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial. *Int Immunopharmacol* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02205216/full>
977. Tascini C, Sermann G, Pagotto A, Sozio E, De Carlo C, Giacinta A, et al. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. *Intern Emerg Med* [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02202274/full>
978. TCTR20200404004. Comparative effectiveness of Chloroquine and Vitamin C prophylaxis in household contacts of confirmed COVID-19 patients. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=TCTR20200404004> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02189703/full>
979. Ulrich RJ, Troxel AB, Carmody E, Eapen J, Backer M, DeHovitz JA, et al. Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients. *Open forum Infect Dis* [Internet]. 2020;7(10). Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02212488/full>
980. Zhaori G, Lu L, Liu C, Guo Y. Progresses in clinical studies on antiviral therapies for COVID-19—Experience and lessons in design of clinical trials. *Pediatr Investig* [Internet]. 2020;4(4):263-274. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02211021/full>
981. NCT04332094, EUCTR2020-001442-19-ES. Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19. <https://clinicaltrials.gov/show/NCT04332094> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169683/full>
982. PACTR202004893013257, EUCTR2020-001448-24-GB, NCT04386070. Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19. <https://clinicaltrials.gov/show/NCT04386070> [Internet]. 2020; Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02124596/full>
983. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. *Cochrane Database Syst Rev* [Internet]. 2020;(4). Available from: <https://doi.org/10.1002/14651858.CD013587>

984. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. *Eur J Intern Med.* 2020 Dec;82:38–47.
985. Update to living WHO guideline on drugs for covid-19. *BMJ.* 2020 Dec;371:m4779.
986. The race against COVID-19. Vol. 15, *Nature nanotechnology.* England; 2020. p. 239–40.
987. Some drugs for COVID-19. *Med Lett Drugs Ther.* 2020 Apr;62(1595):49–50.
988. Remdesivir (Veklury) for COVID-19. *Med Lett Drugs Ther.* 2020 Nov;62(1612):186–8.
989. Biggest COVID-19 trial tests repurposed drugs first. Vol. 38, *Nature biotechnology.* United States; 2020. p. 510.
990. A Note From the Editors. *Am J Epidemiol.* 2020 Nov;189(11):1215–7.
991. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese J Tuberc Respir Dis.* 2020 Mar;43(3):185–8.
992. Abbasi-Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. *Int J Surg.* 2020 Jul;79:143–53.
993. Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis.* 2020 Sep;83:104327.
994. Abd Ellah NH, Gad SF, Muhammad K, E Batiha G, Hetta HF. Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. *Nanomedicine (Lond).* 2020 Sep;15(21):2085–102.
995. Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. *Am J Trop Med Hyg.* 2020 Oct;103(4):1635–9.
996. Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA. Tackling the cytokine storm in COVID-19, challenges and hopes. *Life Sci.* 2020 Sep;257:118054.
997. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. *Am J Trop Med Hyg.* 2020 Jun;102(6):1184–8.
998. Abenza Abildúa MJ, Ramírez Prieto MT, Moreno Zabaleta R, Algarra Lucas C, Pérez López C. Myopathy associated with severe SARS-CoV-2 infection. Vol. 35, *Neurologia (Barcelona, Spain).* 2020. p. 706–8.
999. Abrams-Downey A, Saabiye J, Vidaurrazaga M. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. *Eur Urol Focus.* 2020 Sep;6(5):1028–31.
1000. Addeo A, Obeid M, Friedlaender A. COVID-19 and lung cancer: risks, mechanisms and treatment interactions. *J Immunother cancer.* 2020 May;8(1).
1001. Ader F. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. *BMJ Open.* 2020 Sep;10(9):e041437.

1002. Afra TP, Nampoothiri RV, Razmi T M, Hafi NAB. Linking hydroxychloroquine to hemolysis in a “suspected” glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal. Vol. 80, *European journal of internal medicine*. 2020. p. 101–2.
1003. Afra TP, T MR, Bishnoi A, Hafi NB. Hydroxychloroquine use in COVID-19: what is the basis for baseline tests? Vol. 20, *The Lancet. Infectious diseases*. 2020. p. 1120–1.
1004. Afshar H, Yassin Z, Kalantari S, Aloosh O, Lotfi T, Moghaddasi M, et al. Evolution and resolution of brain involvement associated with SARS- CoV2 infection: A close Clinical - Paraclinical follow up study of a case. Vol. 43, *Multiple sclerosis and related disorders*. 2020. p. 102216.
1005. Aggarwal G, Henry BM, Aggarwal S, Bangalore S. Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. *Am J Cardiol*. 2020 Aug;128:147–50.
1006. Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. *Monaldi Arch chest Dis = Arch Monaldi per le Mal del torace*. 2020 Mar;90(1).
1007. Aguilar J, Averbukh Y. Hemolytic Anemia in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient Receiving Hydroxychloroquine for COVID-19: A Case Report. *Perm J*. 2020;24.
1008. Ahmad A, Rehman MU, Alkharfy KM. An alternative approach to minimize the risk of coronavirus (Covid-19) and similar infections. *Eur Rev Med Pharmacol Sci*. 2020 Apr;24(7):4030–4.
1009. Ahmad SI. 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. *Med Hypotheses*. 2020 Sep;142:109754.
1010. Ahmadinejad Z, Assari R, Ayoobi Yazdi N, Mazloomi S-H, Javanshayani P, Khalili Afousi H, et al. COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with? *Reumatismo*. 2020 Nov;72(3):173–7.
1011. Ahn BY, Kang CK, Seo J Do, Choe PG, Song SH, Park WB, et al. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance. Vol. 35, *Journal of Korean medical science*. 2020. p. e231.
1012. Ahsan W, Javed S, Bratty M Al, Alhazmi HA, Najmi A. Treatment of SARS-CoV-2: How far have we reached? *Drug Discov Ther*. 2020 May;14(2):67–72.
1013. Akram J, Azhar S, Shahzad M, Latif W, Khan KS. Erratum: correction to: pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of Hydroxychloroquine, Oseltamivir and Azithromycin to treat newly diagnosed patients with COVID-19 infection: a structured summary of a study protocol for a randomized controlled trial (*Trials* (2020) 21 1 (702)). *Trials* [Internet]. 2020 Aug;21(1):733-. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02182908/full>
1014. Akula SM, Abrams SL, Steelman LS, Candido S, Libra M, Lerpriyapong K, et al. Cancer therapy and treatments during COVID-19 era. *Adv Biol Regul*. 2020 Aug;77:100739.
1015. Al Sarkhi AK. Hypothesis: The electrical properties of coronavirus. *Electromagn Biol Med*. 2020 Oct;39(4):433–6.
1016. Al-Bari AA. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. *Curr Drug Targets*. 2020;21(16):1703–21.
1017. Al-Kofahi M, Jacobson P, Boulware DR, Matas A, Kandaswamy R, Jaber MM, et al. Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. *Clin Pharmacol Ther*. 2020 Oct;108(4):766–9.

1018. Al-Tawfiq JA, Memish ZA. COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies. *Int J Antimicrob Agents*. 2020 May;55(5):105968.
1019. Alanagreh L, Alzoughool F, Atoum M. Risk of using hydroxychloroquine as a treatment of COVID-19. *Int J Risk Saf Med*. 2020;31(3):111–6.
1020. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. *Kidney Int*. 2020 Jul;98(1):20–6.
1021. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. *J Clin Epidemiol*. 2020 Jul;123:120–6.
1022. Alia E, Grant-Kels JM. Does hydroxychloroquine combat COVID-19? A timeline of evidence. Vol. 83, *Journal of the American Academy of Dermatology*. 2020. p. e33–4.
1023. Alkasir A, Lippmann S. COVID-19 and Cardiac Concerns for Psychiatric Patients. *Prim care companion CNS Disord*. 2020 Dec;22(6).
1024. Allahyari A, Rahimi H, Khadem-Rezaiyan M, Mozaheb Z, Seddigh-Shamsi M, Bary A, et al. Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 575.
1025. Allam MF, Andraous F. Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical? Vol. 28, *Central European journal of public health*. Czech Republic; 2020. p. 246–7.
1026. Allameh SF, Nemati S, Ghalehtaki R, Mohammadnejad E, Aghili SM, Khajavirad N, et al. Clinical Characteristics and Outcomes of 905 COVID-19 Patients Admitted to Imam Khomeini Hospital Complex in the Capital City of Tehran, Iran. *Arch Iran Med*. 2020 Nov;23(11):766–75.
1027. Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. *Int J Mol Sci*. 2020 Jul;21(13).
1028. Allison D, Campbell-Lee S, Crane J, Vidanovic V, Webb S, Fraidenburg D, et al. Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease? Vol. 35, *Journal of clinical apheresis*. 2020. p. 378–81.
1029. Alonso-Herreros JM, Berisa-Prado S, Cañete-Ramírez C, Dávila-Pousa C, Flox-Benítez MDP, Ladrón de Guevara-García M, et al. Hospital Pharmacy Compounding against COVID-19 pandemic. *Farm Hosp organo Of Expr Cient la Soc Esp Farm Hosp*. 2020 Jun;44(7):49–52.
1030. Alpern JD, Gertner E. Off-Label Therapies for COVID-19-Are We All In This Together? *Clin Pharmacol Ther*. 2020 Aug;108(2):182–4.
1031. Alqahtani SA, Aljumah AA, Hashim A, Alenazi TH, AlJawad M, Al Hamoudi WK, et al. Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. *Ann Saudi Med*. 2020;40(4):273–80.
1032. Alshaeri HK, Natto ZS. A contemporary look at COVID-19 medications: available and potentially effective drugs. *Eur Rev Med Pharmacol Sci*. 2020 Sep;24(17):9188–95.
1033. Alsharif MH, Alsharif YH, Albreem MA, Jahid A, Solyman AAA, Yahya K, et al. Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2. *Eur Rev Med Pharmacol Sci*. 2020 Nov;24(22):11977–81.

1034. AlShoaibi NA, Maghrabi K, Alanazi H, Harbi M Al, Alghamdi S. Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19. *Ann Saudi Med.* 2020;40(5):365–72.
1035. Alsuliman T, Alasadi L, Alkharat B, Srour M, Alrstom A. A review of potential treatments to date in COVID-19 patients according to the stage of the disease. *Curr Res Transl Med.* 2020 Aug;68(3):93–104.
1036. Álvarez Bravo G, Ramió I Torrentà L. Anti-NMDA receptor encephalitis secondary to SARS-CoV-2 infection. Vol. 35, *Neurologia (Barcelona, Spain).* 2020. p. 699–700.
1037. Alvi MM, Sivasankaran S, Singh M. Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19. *J Drug Target.* 2020;28(7–8):742–54.
1038. Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. *Ther Deliv.* 2020 Apr;11(4):245–68.
1039. Ambrosino I, Barbagelata E, Corbi G, Ciarambino T, Politi C, Moretti AM. Gender differences in treatment of Coronavirus Disease-2019. *Monaldi Arch chest Dis = Arch Monaldi per le Mal del torace.* 2020 Dec;90(4).
1040. Aminian A, Kermansaravi M, Azizi S, Alibeigi P, Safamanesh S, Mousavimaleki A, et al. Bariatric Surgical Practice During the Initial Phase of COVID-19 Outbreak. *Obes Surg.* 2020 Sep;30(9):3624–7.
1041. Anastasiou IA, Eleftheriadou I, Tentolouris A, Tsilingiris D, Tentolouris N. In Vitro Data of Current Therapies for SARS-CoV-2. *Curr Med Chem.* 2020;27(27):4542–8.
1042. Andrade KRC de, Carvalho VK da S, Farinasso CM, Lima AA de, Silva RB, Wachira VK, et al. Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. *Cien Saude Colet.* 2020 Sep;25(9):3517–54.
1043. Andreani J, Le Bideau M, Dufлот I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog.* 2020 Aug;145:104228.
1044. Annie FH, Sirbu C, Frazier KR, Broce M, Lucas BDJ. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. *Pharmacotherapy.* 2020 Nov;40(11):1072–81.
1045. Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier J-M, Lafaie L, Célarier T. Vitamin D and survival in COVID-19 patients: A quasi-experimental study. *J Steroid Biochem Mol Biol.* 2020 Nov;204:105771.
1046. Anupama BK, Adhikari S, Chaudhuri D. Prolonged QT Interval in a Patient With Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin. *J Investig Med high impact case reports.* 2020;8:2324709620948407.
1047. Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Vol. 79, *Annals of the rheumatic diseases.* England; 2020. p. 1381–2.
1048. Aquino YSJ, Cabrera N. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. *J Med Ethics.* 2020 Sep;46(9):574–8.
1049. Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. *Clin Transl Sci.* 2020 Jul;13(4):642–5.

1050. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020 Aug;97:396–403.
1051. Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, et al. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. *Clin Pharmacol Ther*. 2020 Oct;108(4):775–90.
1052. Asensio E, Acunzo R, Uribe W, Saad EB, Sáenz LC. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence. *J Interv Card Electrophysiol an Int J Arrhythm pacing*. 2020 Nov;59(2):315–20.
1053. Asif M, Saleem M, Saadullah M, Yaseen HS, Al Zarzour R. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. *Inflammopharmacology*. 2020 Oct;28(5):1153–61.
1054. Askanase AD, Khalili L, Buyon JP. Thoughts on COVID-19 and autoimmune diseases. *Lupus Sci Med*. 2020;7(1):e000396.
1055. Askin L, Tanriverdi O, Askin HS. The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases. *Arq Bras Cardiol*. 2020 Jun;114(5):817–22.
1056. Asli R, Abdullah MS, Chong PL, Metussin D, Momin RN, Mani BI, et al. Case Report: Right Bundle Branch Block and QTc Prolongation in a Patient with COVID-19 Treated with Hydroxychloroquine. *Am J Trop Med Hyg*. 2020 Jul;103(1):79–82.
1057. Ata F, Almasri H, Sajid J, Yousaf Z. COVID-19 presenting with diarrhoea and hyponatraemia. *BMJ Case Rep*. 2020 Jun;13(6).
1058. Atakla HG, Noudohounsi ACWH, Barry LF, Noudohounsi MMUD, Legba LD-G, Souare IS, et al. COVID-19 infection in known epileptic and non-epileptic children: what is the place of chloroquine sulfate? (a case report). Vol. 37, *The Pan African medical journal*. 2020. p. 177.
1059. Atkinson JG. Problems with the analysis in “Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19”. Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 37.
1060. Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. *Pain Physician*. 2020 Mar;23(2):E71–83.
1061. Attanasi M, Pasini S, Caronni A, Pellegrino GM, Faverio P, Di Pillo S, et al. Inpatient Care during the COVID-19 Pandemic: A Survey of Italian Physicians. *Respiration*. 2020;99(8):667–77.
1062. Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. *FEBS J*. 2020 Sep;287(17):3633–50.
1063. Austin D, John C, Hunt BJ, Carling RS. Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. *Clin Chem Lab Med*. 2020 Sep;58(12):2047–61.
1064. Aversa M, Benvenuto L, Anderson M, Shah L, Robbins H, Pereira M, et al. COVID-19 in lung transplant recipients: A single center case series from New York City. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2020 Nov;20(11):3072–80.

1065. Awasthi A, Vishwas S, Corrie L, Kumar R, Khursheed R, Kaur J, et al. OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. *Eur J Pharmacol.* 2020 Oct;884:173381.
1066. Ayele Mega T, Feyissa TM, Dessalegn Bosho D, Kumela Goro K, Zeleke Negera G. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. *Can Respir J.* 2020;2020:4312519.
1067. Ayerbe L, Risco-Risco C, Ayis S. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. *Intern Emerg Med.* 2020 Nov;15(8):1501–6.
1068. Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. *J Thromb Thrombolysis.* 2020 Aug;50(2):298–301.
1069. Bagheri M, Rashe Z, Ahur MH, Eidizadeh M. Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19? *Recent Pat Antiinfect Drug Discov.* 2020;15(2):113–8.
1070. Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). *Eur Respir Rev an Off J Eur Respir Soc.* 2020 Sep;29(157).
1071. Baicus C, Pinte L, Stoichitoiu LE, Badea C. Hydroxychloroquine for prophylaxis of COVID-19 physicians survey: Despite lack of evidence, many would take or give to dear ones, and despite the perceived necessity of an RCT, few would participate. *J Eval Clin Pract.* 2020 Dec;26(6):1579–82.
1072. Bailly C, Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? *Pharmacol Ther.* 2020 Oct;214:107618.
1073. Bajpai J, Pradhan A, Singh A, Kant S. Hydroxychloroquine and COVID-19 - A narrative review. *Indian J Tuberc.* 2020 Dec;67(4S):S147–54.
1074. Bakhshaliyev N, Uluganyan M, Enhos A, Karacop E, Ozdemir R. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. *J Electrocardiol.* 2020;62:59–64.
1075. Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, et al. Dr. Balevic, et al reply. Vol. 47, *The Journal of rheumatology.* Canada; 2020. p. 1587.
1076. Ballout RA, Sviridov D, Bukrinsky MI, Remaley AT. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. *FASEB J Off Publ Fed Am Soc Exp Biol.* 2020 Jun;34(6):7253–64.
1077. Bamba C, Singh SP, Choudhury S. Can mesenchymal stem cell therapy be the interim management of COVID-19? *Drug Discov Ther.* 2020 Jul;14(3):139–42.
1078. Banday AH, Shameem SA, Ajaz SJ. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. *SLAS Discov Adv life Sci R D.* 2020 Dec;25(10):1097–107.
1079. Banerjee A, Czinn SJ, Reiter RJ, Blanchard TG. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19. *Life Sci.* 2020 Aug;255:117842.
1080. Banerjee S, Sarkar S, Bandyopadhyay SN. Survey and analysis of knowledge, attitude and practice among otolaryngologists in a state in eastern India in relation to the coronavirus disease 2019 pandemic. *J Laryngol Otol.* 2020 Aug;134(8):696–702.

1081. Baralić K, Jorgovanović D, Živančević K, Antonijević Miljaković E, Antonijević B, Buha Djordjevic A, et al. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. *Toxicol Appl Pharmacol*. 2020 Nov;406:115237.
1082. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. *Pharmacotherapy*. 2020 May;40(5):416–37.
1083. Barnabas R V, Brown E, Bershteyn A, Miller RS, Wener M, Celum C, et al. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 475.
1084. Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of COVID-19? Vol. 55, *International journal of antimicrobial agents*. 2020. p. 105944.
1085. Baroutjian A, Sanchez C, Boneva D, McKenney M, Elkbuli A. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence. *Am J Emerg Med*. 2020 Nov;38(11):2405–15.
1086. Barrachina-Esteve O, Palau Domínguez A, Hidalgo-Torrice I, Viguera Martínez ML. Guillain-Barré syndrome as the first manifestation of SARS-CoV-2 infection. Vol. 35, *Neurologia (Barcelona, Spain)*. 2020. p. 710–2.
1087. Bartiromo M, Borchì B, Botta A, Bagalà A, Lugli G, Tilli M, et al. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). *Transpl Infect Dis*. 2020 Aug;22(4):e13286.
1088. Bartovská Z, Andrlé F, Beran O, Zlámál M, Řezáč D, Murinová I, et al. Data from the first wave of Covid-19 from the Central Military Hospital, Prague, Czech Republic. *Epidemiol Mikrobiol Imunol Cas Spol pro Epidemiol a Mikrobiol Ces Lek Spol JE Purkyne*. 2020;69(4):164–71.
1089. Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. Vol. 34, *Leukemia*. 2020. p. 1954–6.
1090. Bavdekar SB, Chandrasekaran A, Govindarajan RP, Malik S, Bajaj S, Javeri Y, et al. Physician Health in the Times of COVID-19. *J Assoc Physicians India*. 2020 Dec;68(12):21–7.
1091. Beauverd Y, Adam Y, Assouline B, Samii K. COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. *Eur J Haematol*. 2020 Sep;105(3):357–9.
1092. Becker RC. Covid-19 treatment update: follow the scientific evidence. Vol. 50, *Journal of thrombosis and thrombolysis*. 2020. p. 43–53.
1093. Bekci T. “Reversed halo sign” on 3D CT in COVID-19. *Diagn Interv Radiol*. 2020 Jul;26(4):379.
1094. Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, et al. Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients. Vol. 49, *Scandinavian journal of rheumatology*. England; 2020. p. 505–6.
1095. Bellido V, Pérez A. Consequences of COVID-19 on people with diabetes. *Endocrinol diabetes y Nutr*. 2020;67(6):355–6.

1096. Bénézit F, Le Bot A, Jouneau S, Lemaître F, Pronier C, Lentz P-A, et al. COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020. Vol. 26, Emerging infectious diseases. 2020. p. 2513–5.
1097. Benouna ME, Ech-Chenbouli A. Electrocardiogrammes d'un patient COVID-19 traité par l'association hydroxychloroquine et azithromycine. *Pan Afr Med J.* 2020;35(Suppl 2):112.
1098. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2020 Nov;26(11):1525–36.
1099. Berling I, King JD, Shepherd G, Hoffman RS, Alhatali B, Lavergne V, et al. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. *J Am Soc Nephrol.* 2020 Oct;31(10):2475–89.
1100. Berlivet L, Löwy I. Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. *Med Anthropol Q.* 2020 Dec;34(4):525–41.
1101. Bessière F, Rocchia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiol.* 2020 Sep;5(9):1067–9.
1102. Bhandari S, Singh A, Sharma R, Rankawat G, Banerjee S, Gupta V, et al. Characteristics, Treatment Outcomes and Role of Hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: An Epidemio-Clinical Study. *J Assoc Physicians India.* 2020 Jun;68(6):13–9.
1103. Bhargava S, Rathod D, Singh AK, Rokde R. Scarcity of Hydroxychloroquine and Personal Protective Equipment (PPE) during Challenging Times of COVID-19 Pandemic. *Skinmed.* 2020;18(3):188–9.
1104. Bhattacharyya A, Kumar S, Sarma P, Kaur H, Prajapat M, Shekhar N, et al. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. *Indian J Pharmacol.* 2020;52(4):313–23.
1105. Bhattacharyya D. Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2. Vol. 144, Medical hypotheses. 2020. p. 110046.
1106. Bibi N, Gul S, Ali J, Kamal MA. Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. *Eur J Pharmacol.* 2020 Oct;885:173496.
1107. Biguetti C, Marrelli MT, Brotto M. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)? *Rev Saude Publica.* 2020;54:68.
1108. Bilbul M, Papparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. *Psychosomatics.* 2020;61(5):411–27.
1109. Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. *In Vivo.* 2020 Jun;34(3 Suppl):1597–602.
1110. Binson G, Venisse N, Sauvaget A, Bacle A, Lazaro P, Dupuis A. Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in Syrspend(®) SF PH4 (dry). *Int J Antimicrob Agents.* 2020 Dec;56(6):106201.

1111. Boari GEM, Chiarini G, Bonetti S, Malerba P, Bianco G, Faustini C, et al. Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study. *Biosci Rep.* 2020 Dec;40(12).
1112. Bonam SR, Muller S, Bayry J, Klionsky DJ. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. *Autophagy.* 2020 Dec;16(12):2260–6.
1113. Bonny A, Talle MA, Ngantcha M, Tayebjee MH. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". *Travel Med Infect Dis* [Internet]. 2020;37:101861. Available from: <https://dx.doi.org/10.1016/j.tmaid.2020.101861>
1114. Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. Vol. 5, *JAMA cardiology.* United States; 2020. p. 986–7.
1115. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw open.* 2020 Apr;3(4):e208857.
1116. Bosaeed M, Mahmoud E, Hussein M, Alharbi A, Alsaedy A, Alothman A, et al. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials.* 2020. p. 904.
1117. Bossini N, Alberici F, Delbarba E, Valerio F, Manenti C, Possenti S, et al. Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2020 Nov;20(11):3019–29.
1118. Bouaré F, Laghmari M, Etouche FN, Arjidal B, Saidi I, Hajhouji F, et al. Unusual association of COVID-19, pulmonary tuberculosis and human immunodeficiency virus, having progressed favorably under treatment with chloroquine and rifampin. Vol. 35, *The Pan African medical journal.* 2020. p. 110.
1119. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med.* 2020 Aug;383(6):517–25.
1120. Boyarsky BJ, Po-Yu Chiang T, Werbel WA, Durand CM, Avery RK, Getsin SN, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2020 Jul;20(7):1809–18.
1121. Boyer L, Auquier P, Fond G. [Real-life data and Covid-19: The third avenue of research]. *Encephale.* 2020 Jun;46(3S):S114–5.
1122. Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Vol. 79, *Annals of the rheumatic diseases.* England; 2020. p. 1382–3.
1123. Bozzo R, Ibelli F, Scublinsky D. [Cardiovascular safety of hydroxychloroquine in the COVID-19 pandemic]. Vol. 80 Suppl 3, *Medicina.* Argentina; 2020. p. 89–90.
1124. Brandt N, Chou J. Optimizing Medication Management During the COVID-19 Pandemic: It Takes a Village. *J Gerontol Nurs.* 2020 Jul;46(7):3–8.
1125. Braz HLB, Silveira JA de M, Marinho AD, de Moraes MEA, Moraes Filho MO de, Monteiro HSA, et al. In silico study of azithromycin, chloroquine and hydroxychloroquine and

- their potential mechanisms of action against SARS-CoV-2 infection. *Int J Antimicrob Agents*. 2020 Sep;56(3):106119.
1126. Breslin N, Baptiste C, Miller R, Fuchs K, Goffman D, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 in pregnancy: early lessons. *Am J Obstet Gynecol MFM*. 2020 May;2(2):100111.
1127. Brest P, Benzaquen J, Kliensky DJ, Hofman P, Mograbi B. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype? *Autophagy*. 2020 Dec;16(12):2267–70.
1128. Brito-Azevedo A. Hydroxychloroquine in COVID-19: Taking care of statistics to take care of patients. Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 324.
1129. Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, et al. Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. *Ann Am Thorac Soc*. 2020 Aug;17(8):1008–15.
1130. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. *J Med Virol*. 2020 Jul;92(7):770–5.
1131. Budzinskaya M V, Durzhinskaya MH. [Differential diagnosis of hydroxychloroquine-induced retinal damage]. *Vestn Oftalmol*. 2020;136(4. Vyp. 2):265–71.
1132. Bull-Ottersen L, Gray EB, Budnitz DS, Strosnider HM, Schieber LZ, Courtney J, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Sep;69(35):1210–5.
1133. Bun S-S, Taghji P, Courjon J, Squara F, Scarlatti D, Theodore G, et al. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection. *Clin Pharmacol Ther*. 2020 Nov;108(5):1090–7.
1134. Burrage DR, Koushesh S, Sofat N. Immunomodulatory Drugs in the Management of SARS-CoV-2. *Front Immunol*. 2020;11:1844.
1135. Bygbjerg IC. [Brug af hydroxychloroquin til COVID-19]. *Ugeskr Laeger*. 2020 May;182(20).
1136. C Hsia B, Greige N, A Quiroz J, S Khokhar A, Daily J, Di Biase L, et al. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. *J Interv Card Electrophysiol* [Internet]. 2020 Nov;59(2):337–45. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02139367/full>
1137. Cag Y, Icten S, Isik-Goren B, Baysal NB, Bektas B, Selvi E, et al. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort. *Eur j clin microbiol infect dis* [Internet]. 2020 Feb;40(2):407–11. Available from: <https://dx.doi.org/10.1007/s10096-020-04016-1>
1138. Cai S, Sun W, Li M, Dong L. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. *Clin Rheumatol*. 2020 Sep;39(9):2797–802.
1139. Cairolì E, Espinosa G. Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence. Vol. 155, *Medicina clinica*. 2020. p. 134–5.
1140. Calderón JM, Zerón HM, Padmanabhan S, Calderon JM, Zeron HM, Padmanabhan S. Treatment with hydroxychloroquine vs hydroxychloroquine + nitazoxanide in covid-19 patients with risk factors for poor prognosis: a structured summary of a study protocol for a randomised

controlled trial. *Trials* [Internet]. 2020 Jun;21(1):504. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02139382/full>

1141. Calender A, Israel-Biet D, Valeyre D, Pacheco Y. Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis. *Trends Immunol.* 2020 Oct;41(10):856–9.
1142. Calò LA, Davis PA. Are the Clinical Presentations (Phenotypes) of Gitelman’s and Bartter’s Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their “pH” Enotype? *Int J Mol Sci.* 2020 Aug;21(16).
1143. Campos DMO, Oliveira CBS, Andrade JMA, Oliveira JIN. Fighting COVID-19. *Braz J Biol.* 2020 Sep;80(3):698–701.
1144. Campos DM de O, Fulco UL, de Oliveira CBS, Oliveira JIN. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. *J Evid Based Med.* 2020 Nov;13(4):255–60.
1145. Canedo-Marroquín G, Saavedra F, Andrade CA, Berrios R V, Rodríguez-Guilarte L, Opazo MC, et al. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments. *Front Immunol.* 2020;11:569760.
1146. Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. *Drugs.* 2020 Dec;80(18):1929–46.
1147. Canziani LM, Trovati S, Brunetta E, Testa A, De Santis M, Bombardieri E, et al. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. *J Autoimmun.* 2020 Nov;114:102511.
1148. Çap M, Bilge Ö, Işık F, Burak C, Karagöz A, İnci Ü, et al. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019. *J Electrocardiol.* 2020;63:115–9.
1149. Capoluongo E. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open. *Biomed Pharmacother.* 2020 Oct;130:110536.
1150. Capoluongo ED, Amato F, Castaldo G. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Vol. 58, *Clinical chemistry and laboratory medicine.* Germany; 2020. p. 1162–4.
1151. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med.* 2020 Jun;76:31–5.
1152. Capucci A, Santarelli A, Bartolomei M, Paolizzi C, Biagetti C, Dappozzo A, et al. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic. Vol. 21, *Journal of cardiovascular medicine (Hagerstown, Md.). United States;* 2020. p. 922–3.
1153. Carlsson H, Hjorton K, Abujrais S, Rönnblom L, Åkerfeldt T, Kultima K. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices. *Arthritis Res Ther.* 2020 Jun;22(1):125.
1154. Carlucci PM, Ahuja T, Petrilli C, Rajagopalan H, Jones S, Rahimian J. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. *J Med Microbiol.* 2020 Oct;69(10):1228–34.

1155. Caron P. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. *Ann Endocrinol (Paris)*. 2020 Oct;81(5):507–10.
1156. Carradori S. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus? Vol. 19, *Anti-inflammatory & anti-allergy agents in medicinal chemistry*. United Arab Emirates; 2020. p. 85–7.
1157. Casey JD, Johnson NJ, Semler MW, Collins SP, Aggarwal NR, Brower RG, et al. Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. *Ann Am Thorac Soc*. 2020 Sep;17(9):1144–53.
1158. Cassone A, Iacoviello L, Cauda R. Knowing more about chloroquine/hydroxychloroquine in COVID-19 patients. Vol. 15, *Future microbiology*. 2020. p. 1523–6.
1159. Castelli V, Cimini A, Ferri C. Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”. *Front Immunol*. 2020;11:2132.
1160. Casucci G, Acanfora D, Incalzi RA. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. *Drugs Aging*. 2020 Nov;37(11):779–85.
1161. Cattaneo D, Pasina L, Maggioni A Pietro, Giacomelli A, Oreni L, Covizzi A, et al. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. *Drugs Aging*. 2020 Dec;37(12):925–33.
1162. Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, et al. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. *Int J Antimicrob Agents*. 2020 Oct;56(4):106144.
1163. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020 Nov;383(21):2041–52.
1164. Cavalcanti DD, Raz E, Shapiro M, Dehkharghani S, Yaghi S, Lillemoe K, et al. Cerebral Venous Thrombosis Associated with COVID-19. *AJNR Am J Neuroradiol*. 2020 Aug;41(8):1370–6.
1165. Chai PR, Ferro EG, Kirshenbaum JM, Hayes BD, Culbreth SE, Boyer EW, et al. Intentional Hydroxychloroquine Overdose Treated with High-Dose Diazepam: an Increasing Concern in the COVID-19 Pandemic. *J Med Toxicol Off J Am Coll Med Toxicol*. 2020 Jul;16(3):314–20.
1166. Chandler LC, Yusuf IH, McClements ME, Barnard AR, MacLaren RE, Xue K. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. *Int J Mol Sci*. 2020 Jul;21(14).
1167. Chaney S, Basirat A, McDermott R, Keenan N, Moloney E. COVID-19 and hydroxychloroquine side-effects: glucose 6-phosphate dehydrogenase deficiency (G6PD) and acute haemolytic anaemia. *QJM*. 2020 Dec;113(12):890–1.
1168. Chang D, Saleh M, Gabriels J, Ismail H, Goldner B, Willner J, et al. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin. Vol. 75, *Journal of the American College of Cardiology*. 2020. p. 2992–3.
1169. Chang MC, Lee W, Hur J, Park D. Chest Computed Tomography Findings in Asymptomatic Patients with COVID-19. *Respiration*. 2020;99(9):748–54.
1170. Chary MA, Barbuto AF, Izadmehr S, Hayes BD, Burns MM. COVID-19: Therapeutics and Their Toxicities. *J Med Toxicol Off J Am Coll Med Toxicol*. 2020 Jul;16(3):284–94.

1171. Chatterjee P, Anand T, Singh KJ, Rasaily R, Singh R, Das S, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. *Indian J Med Res.* 2020 May;151(5):459–67.
1172. Chatterjee SS, Malathesh BC, Das S, Singh OP. Interactions of recommended COVID-19 drugs with commonly used psychotropics. Vol. 52, *Asian journal of psychiatry.* 2020. p. 102173.
1173. Chattopadhyay A, Chaudhuri K. COVID-19, hydroxychloroquine and the eighth alternative. Vol. 20, *Clinical medicine (London, England).* 2020. p. e132–3.
1174. Chaumont H, Etienne P, Roze E, Couratier C, Roger P-M, Lannuzel A. Acute meningoencephalitis in a patient with COVID-19. Vol. 176, *Revue neurologique.* 2020. p. 519–21.
1175. Chee YJ, Tan SK, Yeoh E. Dissecting the interaction between COVID-19 and diabetes mellitus. *J Diabetes Investig.* 2020 Sep;11(5):1104–14.
1176. Chen C, Pan K, Wu B, Li XX, Chen Z, Xu Q, et al. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. *Eur j clin pharmacol [Internet].* 2020 Jan;77(1):13–24. Available from: <https://dx.doi.org/10.1007/s00228-020-02962-5>
1177. Chen C-P, Lin Y-C, Chen T-C, Tseng T-Y, Wong H-L, Kuo C-Y, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). *PLoS One.* 2020;15(12):e0242763.
1178. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. *Zhejiang da xue xue bao Yi xue ban = J Zhejiang Univ Med Sci.* 2020 May;49(2):215–9.
1179. Chen X, Geiger JD. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. *Cell Signal.* 2020 Sep;73:109706.
1180. Cheng C-Y, Lee Y-L, Chen C-P, Lin Y-C, Liu C-E, Liao C-H, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. *J Microbiol Immunol Infect.* 2020 Jun;53(3):488–92.
1181. Chevalier MTM, Moncada SS, Medina MT, Moncada SS. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: a Primum non Nocere dilemma. *J Neurol Sci [Internet].* 2020 Aug;415:116972. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02139552/full>
1182. Chidambaram SK, Ali D, Alarifi S, Radhakrishnan S, Akbar I. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2. *J Infect Public Health.* 2020 Nov;13(11):1671–7.
1183. Choi MJ, Kang M, Shin SY, Noh JY, Cheong HJ, Kim WJ, et al. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. *Int J Infect Dis [Internet].* 2020 Jan;102:275–81. Available from: <https://dx.doi.org/10.1016/j.ijid.2020.10.062>
1184. Choi NH, Silver ES, Fremed M, Liberman L. COVID-19 reveals Brugada pattern in an adolescent patient. *Cardiol Young.* 2020 Nov;30(11):1735–7.
1185. Choi SW, Shin JS, Park S-J, Jung E, Park Y-G, Lee J, et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. *Antiviral Res.* 2020 Dec;184:104955.

1186. Chorin E, Dai M, Shulman E, Wadhvani L, Bar-Cohen R, Barbhayya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Vol. 26, *Nature medicine*. United States; 2020. p. 808–9.
1187. Chorin E, Wadhvani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. *Hear Rhythm*. 2020 Sep;17(9):1425–33.
1188. Chow R, Simone CB 2nd, Lock M. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials. Vol. 9, *Annals of palliative medicine*. China; 2020. p. 3716–20.
1189. Chowdhury MS, Rathod J, Gernsheimer J. A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. *Acad Emerg Med Off J Soc Acad Emerg Med*. 2020 Jun;27(6):493–504.
1190. Cingolani A, Tummolo AM, Montemurro G, Gremese E, Larosa L, Cipriani MC, et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. *Infection*. 2020 Oct;48(5):767–71.
1191. Ciorba A, Corazzi V, Skarżyński PH, Skarżyńska MB, Bianchini C, Pelucchi S, et al. Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic! Vol. 34, *International journal of immunopathology and pharmacology*. 2020. p. 2058738420941754.
1192. Ciorba A, Skarżyński PH, Pelucchi S, Hatzopoulos S. Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency. *J Glob Antimicrob Resist*. 2020 Dec;23:263–4.
1193. Cipriani A, Zorzi A, Ceccato D, Capone F, Parolin M, Donato F, et al. Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. *Int J Cardiol*. 2020 Oct;316:280–4.
1194. Cirino G, Ahluwalia A. The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question. Vol. 177, *British journal of pharmacology*. 2020. p. 3361–2.
1195. Coban C. The host targeting effect of chloroquine in malaria. *Curr Opin Immunol*. 2020 Oct;66:98–107.
1196. Cohen I V, Makunts T, Moumedjian T, Issa MA, Abagyan R. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. *Sci Rep*. 2020 Nov;10(1):19199.
1197. Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. *Front Immunol*. 2020;11:1439.
1198. Coleman I, Ruiz G, Brahmabhatt S, Ackerman L. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report. *J Med Case Rep*. 2020 Nov;14(1):210.
1199. Conto-Palomino NM, Cabrera-Bueno ML, Vargas-Ponce KG, Rondón-Abuhadba EA, Atamari-Anahui N. [Encephalitis associated with COVID-19 in a 13-year-old girl: A case report]. Vol. 20, *Medwave*. Chile; 2020. p. e7984.
1200. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care*. 2020 Jun;57:279–83.
1201. Cortegiani A, Ippolito M, Ingoglia G, Einav S. Chloroquine for COVID-19: rationale, facts, hopes. Vol. 24, *Critical care (London, England)*. 2020. p. 210.

1202. Cortegiani A, Ippolito M, Ingoglia G, Iozzo P, Giarratano A, Einav S. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. *J Crit Care*. 2020 Oct;59:176–90.
1203. Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. *Rheumatol Int*. 2020 Oct;40(10):1707–16.
1204. Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. *Curr Med Chem*. 2020;27(27):4536–41.
1205. Coumou J, de Vries PJ. [Chloroquine as a possible treatment for COVID-19]. *Ned Tijdschr Geneesk*. 2020 Mar;164.
1206. Crespo M, Pérez-Sáez MJ, Redondo-Pachón D, Llinàs-Mallol L, Montero MM, Villar-García J, et al. COVID-19 in elderly kidney transplant recipients. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2020 Oct;20(10):2883–9.
1207. Croft A, Bucca A, Jansen JH, Motzkus C, Herbert A, Wang A, et al. First-time Diabetic Ketoacidosis in Type 2 Diabetics With Covid-19 Infection: A Novel Case Series. *J Emerg Med*. 2020 Nov;59(5):e193–7.
1208. Cuadrado-Lavin A, Cuadrado-Lavin A, Olmos JM, Olmos JM, Cifrian JM, Cifrian JM, et al. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: a structured summary of a study protocol for a randomised controlled trial. *Trials* [Internet]. 2020 Jun;21(1):472. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02139725/full>
1209. Cui C, Tu S, En VSJ, Li X, Yao X, Li H, et al. Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19. *Curr Drug Metab*. 2020;21(6):427–35.
1210. D'Acquarica I, Agranat I. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19. *Drug Discov Today*. 2020 Jul;25(7):1121–3.
1211. d'Arminio Monforte A, Tavelli A, Bai F, Marchetti G, Cozzi-Lepri A. Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal? Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 75–6.
1212. d'Ettoire G, Recchia G, Ridolfi M, Siccardi G, Pinacchio C, Innocenti G Pietro, et al. Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report. *Med* [Internet]. 2020 Sep;99(36):e21803–e21803. Available from: <https://dx.doi.org/10.1097/MD.00000000000021803>
1213. D'Andrea S, Berardicurti O, Berardicurti A, Felzani G, Francavilla F, Francavilla S, et al. Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case-control study. *Spinal Cord Ser Cases* [Internet]. 2020 Aug;6(1):69. Available from: <https://dx.doi.org/10.1038/s41394-020-0319-0>
1214. D'Cruz M, D'Cruz M. The ICMR bulletin on targeted hydroxychloroquine prophylaxis for Covid-19: Need to interpret with caution. *Indian J Med Ethics* [Internet]. 2020;V(2):100–2. Available from: <https://dx.doi.org/10.20529/IJME.2020.040>

1215. Dadkhahfar S, Araghi F, Tabary M, Moravvej H. Considerations of Managing Lichen Planopilaris With Hydroxychloroquine During the COVID-19 Pandemic. *J Drugs Dermatol*. 2020 Jun;19(6):679–80.
1216. Dajti E, Cristini F, Tamanini G, Cescon M, Bazzoli F, Tamè M. COVID-19 in a young liver transplant recipient: caution for drug-drug interactions. Vol. 29, *Journal of gastrointestinal and liver diseases : JGLD*. Romania; 2020. p. 470.
1217. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. *Clin Pharmacol Ther*. 2020 Aug;108(2):201–11.
1218. Daneshpazhooh M, Soori T, Isazade A, Noormohammadpour P. Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report. *J Dermatolog Treat*. 2020 Aug;31(5):446–7.
1219. Dang A, Vallish BN, Dang S. Hydroxychloroquine and Remdesivir in COVID-19: A critical analysis of recent events. *Indian J Med Ethics*. 2020;V(3):202–7.
1220. Danion F, Ruch Y, Fourtage M, Kaeuffer C, Greigert V, Lefebvre N, et al. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19. Vol. 64, *Antimicrobial agents and chemotherapy*. 2020.
1221. Danjuma MI, Sinha U, Fatima H, Mohamed MFH, Nathoe H. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor. Vol. 50, *European journal of clinical investigation*. England; 2020. p. e13407.
1222. Dar SA, Wahid M, Haque S, Almalki SS, Akhter N. Hydroxychloroquine (HCQ) use in G6PD deficient COVID-19 patients and the risk of Acute Hemeolytic Anaemia (AHA). *Eur Rev Med Pharmacol Sci*. 2020 Aug;24(15):7923–4.
1223. Dariya B, Nagaraju GP. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. *Cytokine Growth Factor Rev*. 2020 Jun;53:43–52.
1224. Das RR, Behera B, Mishra B, Naik SS. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis. *Indian J Med Microbiol*. 2020;38(3 & 4):265–72.
1225. Das S, Bhowmick S, Tiwari S, Sen S. An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). *Clin Drug Investig*. 2020 Jul;40(7):591–601.
1226. Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol*. 2020 Jun;222(6):521–31.
1227. Dashti-Khavidaki S, Khalili H, Nourian A. Pharmacotherapy Considerations in CKD Patients With COVID-19, A Narrative Review. *Iran J Kidney Dis*. 2020 Jul;14(4):247–55.
1228. Dastan F, Nadji SA, Saffaei A, Marjani M, Moniri A, Jamaati H, et al. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. *Int Immunopharmacol*. 2020 Aug;85:106688.
1229. Davido B, Boussaid G, Vaugier I, Lansaman T, Bouchand F, Lawrence C, et al. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. *Int J Antimicrob Agents*. 2020 Oct;56(4):106129.
1230. Davis JS, Ferreira D, Denholm JT, Tong SY. Clinical trials for the prevention and treatment of COVID-19: current state of play. *Med J Aust*. 2020 Jul;213(2):86–93.

1231. Davoodi L, Abedi SM, Salehifar E, Alizadeh-Navaei R, Rouhanizadeh H, Khorasani G, et al. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. *Int J Clin Pract*. 2020 Nov;74(11):e13600.
1232. Davoodi L, Jafarpour H, Taghavi M, Razavi A. COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting. *J Investig Med high impact case reports*. 2020;8:2324709620931239.
1233. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β -1a in Treatment of Severe COVID-19. *Antimicrob Agents Chemother*. 2020 Aug;64(9).
1234. de Barros CM, Almeida CA de F, Pereira B, Costa KCM, Pinheiro FA, Maia LDB, et al. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine. *Pain Physician*. 2020 Aug;23(4S):S351–66.
1235. de Boer MGJ, Gieling EM, van der Linden PD, Sinha BNM, Vollaard AM. [The medicinal treatment of COVID-19: a brief update]. *Ned Tijdschr Geneesk*. 2020 Nov;164.
1236. De Franceschi L, Costa E, Dima F, Morandi M, Olivieri O. Glucose-6-phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out. Vol. 80, *European journal of internal medicine*. 2020. p. 103.
1237. De Gottardi A, Fratila C, Bertoli R, Cerny A, Magenta L, Gianella P, et al. Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection. Vol. 44, *Clinics and research in hepatology and gastroenterology*. 2020. p. e141–4.
1238. de la Cruz-Benito B, Lázaro-Del Campo P, Ramírez-López A, de Soto-Álvarez T, Sánchez-Vadillo I, García-Pérez E, et al. Managing the front-line treatment for diffuse large B cell lymphoma and high-grade B cell lymphoma during the COVID-19 outbreak. *Br J Haematol*. 2020 Nov;191(3):386–9.
1239. De Luna G, Habibi A, Deux J-F, Colard M, Pham Hung d’Alexandry d’Orengiani A-L, Schlemmer F, et al. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. *Am J Hematol*. 2020 Jul;95(7):876–8.
1240. de Miranda Santos IKF, Costa CHN. Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus. *Front Immunol*. 2020;11:1739.
1241. de Rojas T, Pérez-Martínez A, Cela E, Baragaño M, Galán V, Mata C, et al. COVID-19 infection in children and adolescents with cancer in Madrid. Vol. 67, *Pediatric blood & cancer*. 2020. p. e28397.
1242. Deb B, Shah H, Goel S. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. *J Biosci*. 2020;45(1).
1243. Decker A, Welzel M, Laubner K, Grundmann S, Kochs G, Panning M, et al. Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. Vol. 20, *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. p. 3239–45.
1244. Decloedt EH, Reuter H, Allwood B, Parker A, Koegelenberg CFN, Blockman M, et al. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease. Vol. 110, *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. South Africa; 2020. p. 12903.

1245. Defoort-Dhellemmes S. [Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]. Vol. 43, Journal francais d'ophtalmologie. 2020. p. 548–9.
1246. DeJong C, Wachter RM. The Risks of Prescribing Hydroxychloroquine for Treatment of COVID-19-First, Do No Harm. Vol. 180, JAMA internal medicine. United States; 2020. p. 1118–9.
1247. Del Castillo R, Martinez D, Sarria GJ, Pinillos L, Garcia B, Castillo L, et al. Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review. *Strahlenther Onkol.* 2020 Dec;196(12):1086–93.
1248. Delaleu J, Deniau B, Battistella M, de Masson A, Bensaid B, Jachiet M, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. *J allergy Clin Immunol Pract.* 2020 Sep;8(8):2777-2779.e1.
1249. Delang L, Neyts J. Medical treatment options for COVID-19. *Eur Hear journal Acute Cardiovasc care.* 2020 Apr;9(3):209–14.
1250. Della Porta A, Bornstein K, Coye A, Montrief T, Long B, Parris MA. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. *Am J Emerg Med.* 2020 Oct;38(10):2209–17.
1251. Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. *Ann Rheum Dis.* 2020 Oct;79(10):1277–85.
1252. Denholm JT, Davis J, Paterson D, Roberts J, Morpeth S, Snelling T, et al. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials.* 2020. p. 646.
1253. Depfenhart M, de Villiers D, Lemperle G, Meyer M, Di Somma S. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? *Intern Emerg Med.* 2020 Aug;15(5):801–12.
1254. Derendorf H. Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. *Int J Antimicrob Agents.* 2020 Jun;55(6):106007.
1255. Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19? *Med Hypotheses.* 2020 Sep;142:109815.
1256. Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. *Int J Antimicrob Agents.* 2020 Dec;56(6):106214.
1257. Desai A, Santonocito OG, Caltagirone G, Kogan M, Ghetti F, Donadoni I, et al. Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation. *Medicina (Kaunas).* 2020 Oct;56(11).
1258. Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents.* 2020 May;55(5):105938.

1259. Dhibar DP, Arora N, Kakkar A, Singla N, Mohindra R, Suri V, et al. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. *Int J Antimicrob Agents*. 2020 Dec;56(6):106224.
1260. Di Biagio A, Ricci E, Calza L, Squillace N, Menzaghi B, Rusconi S, et al. Factors associated with hospital admission for COVID-19 in HIV patients. Vol. 34, *AIDS (London, England)*. England; 2020. p. 1983–5.
1261. Di Lorenzo G, Buonerba L, Ingenito C, Crocetto F, Buonerba C, Libroia A, et al. Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. Vol. 98, *Oncology*. 2020. p. 743–7.
1262. Di Pasquale G, Maggioni AP. [COVID-19 trials: surfing between expectations and illusions, looking forward to evidence]. *G Ital Cardiol (Rome)*. 2020 Jul;21(7):479–82.
1263. Di Perri G. The rationale for Low-Molecular Weight Heparin (LMWH) use in SARS-CoV-2 infection. *Le Infez Med*. 2020 Jun;28(suppl 1):52–6.
1264. Diaby V, Almutairi RD, Chen Z, Moussa RK, Berthe A. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19. *Expert Rev Pharmacoecon Outcomes Res [Internet]*. 2020 Feb;21(1):1–9. Available from: <https://dx.doi.org/10.1080/14737167.2021.1851600>
1265. Diezma-Martín AM, Morales-Casado MI, García-Alvarado N, Vadillo Bermejo A, López-Ariztegui N, Sepúlveda Berrocal MA. Tremor and ataxia in COVID-19. Vol. 35, *Neurologia (Barcelona, Spain)*. 2020. p. 409–10.
1266. DiNicolantonio JJ, Barroso-Aranda J. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. Vol. 143, *Medical hypotheses*. 2020. p. 110051.
1267. DiNicolantonio JJ, McCarty M. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. *Open Hear*. 2020 Jun;7(1).
1268. Dinkin M, Gao V, Kahan J, Bobker S, Simonetto M, Wechsler P, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. *Neurology*. 2020 Aug;95(5):221–3.
1269. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. *Eur Rev Med Pharmacol Sci*. 2020 Apr;24(7):4040–7.
1270. Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H, et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). *J Cardiovasc Pharmacol*. 2020 May;75(5):359–67.
1271. Doboszewska U, Właż P, Nowak G, Młyniec K. Targeting zinc metalloenzymes in coronavirus disease 2019. *Br J Pharmacol*. 2020 Nov;177(21):4887–98.
1272. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther*. 2020;14(1):58–60.
1273. Doroshov D, Podolsky S, Barr J. Biomedical Research in Times of Emergency: Lessons From History. *Ann Intern Med*. 2020 Aug;173(4):297–9.
1274. Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. *Biomed Pharmacother*. 2020 Sep;129:110493.

1275. Douedi S, Miskoff J. Novel coronavirus 2019 (COVID-19): A case report and review of treatments. *Medicine (Baltimore)*. 2020 May;99(19):e20207.
1276. Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. *Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother*. 2020 Dec;53:100719.
1277. Du Y-X, Chen X-P. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. *Clin Pharmacol Ther*. 2020 Aug;108(2):242–7.
1278. Duan YJ, Liu Q, Zhao SQ, Huang F, Ren L, Liu L, et al. Trial of Chloroquines in the Treatment of COVID-19 and Its Research Progress in Forensic Toxicology. *Fa Yi Xue Za Zhi*. 2020 Apr;36(2):157–63.
1279. Duan Y, Zhu H-L, Zhou C. Advance of promising targets and agents against COVID-19 in China. Vol. 25, *Drug discovery today*. 2020. p. 810–2.
1280. Dubernet A, Larsen K, Masse L, Allyn J, Foch E, Bruneau L, et al. A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island. *J Glob Antimicrob Resist*. 2020 Dec;23:1–3.
1281. Durante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, et al. Early experience with remdesivir in SARS-CoV-2 pneumonia. *Infection*. 2020 Oct;48(5):779–82.
1282. Duska F, Waldauf P, Halacova M, Zvonicek V, Bala J, Balik M, et al. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19) - protocol of randomised controlled trial AZIQUINE-ICU. *Trials [Internet]*. 2020 Jul;21(1):631. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02160445/full>
1283. Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R, Journot V, et al. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Vol. 21, *Trials*. 2020. p. 846.
1284. Edwards CJ. Hydroxychloroquine and coronavirus disease 19. Vol. 29, *Lupus*. England; 2020. p. 669–70.
1285. Ektorpe E. Death threats after a trial on chloroquine for COVID-19. *Lancet Infect Dis*. 2020 Jun;20(6):661.
1286. Elavarasi A, Prasad M, Seth T, Sahoo RK, Madan K, Nischal N, et al. Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. *J Gen Intern Med*. 2020 Nov;35(11):3308–14.
1287. Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, et al. Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. *Ther Drug Monit*. 2020 Jun;42(3):360–8.
1288. Eljaaly K, Alireza KH, Alshehri S, Al-Tawfiq JA. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. *Travel Med Infect Dis*. 2020;36:101812.
1289. Emadi A, Chua J V, Talwani R, Bentzen SM, Baddley J. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 897.

1290. Emmanuel S, Östlundh L. Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic. Vol. 54, Asian journal of psychiatry. 2020. p. 102203.
1291. Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. *Autoimmun Rev*. 2020 Jul;19(7):102575.
1292. Engin AB, Engin ED, Engin A. Dual function of sialic acid in gastrointestinal SARS-CoV-2 infection. *Environ Toxicol Pharmacol*. 2020 Oct;79:103436.
1293. Enos T, Jeong HS, Vandergriff T, Jacobe HT, Chong BF. Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19. Vol. 33, *Dermatologic therapy*. 2020. p. e13834.
1294. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study". *J Steroid Biochem Mol Biol* [Internet]. 2020 Oct;203:105751. Available from: <https://dx.doi.org/10.1016/j.jsbmb.2020.105751>
1295. Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. *J Antimicrob Chemother*. 2020 Nov;75(11):3366–72.
1296. Esposito S, Noviello S, Pagliano P. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. *Le Infez Med*. 2020;28(2):198–211.
1297. Estella Á, Garnacho-Montero J. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic]. *Med intensiva*. 2020 Nov;44(8):509–12.
1298. Everaert BR, Muylle J, Bartholomeus Twickler T. Emerging cardiological issues during the COVID-19 pandemic. *Eur J Clin Invest*. 2020 Jul;50(7):e13270.
1299. Facheris P, Valenti M, Pavia G, Gargiulo L, Narcisi A, Costanzo A, et al. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab. Vol. 59, *International journal of dermatology*. 2020. p. e267–8.
1300. Faden YA, Alghilan NA, Alawami SH, Alsulmi ES, Alsum HA, Katib YA, et al. Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019. *Saudi Med J*. 2020 Aug;41(8):779–90.
1301. Faíco-Filho KS, Conte DD, de Souza Luna LK, Carvalho JMA, Perosa AHS, Bellei N. No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19. *Brazilian J Microbiol* [publication Brazilian Soc Microbiol. 2020 Dec;51(4):1765–9.
1302. Faisal H, Bloom A, Gaber AO. Unexplained Methemoglobinemia in Coronavirus Disease 2019: A Case Report. *A&A Pract*. 2020 Jul;14(9):e01287.
1303. Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, et al. Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2020 Dec;71(12):3232–6.
1304. Fan S, Xiao D, Wang Y, Liu L, Zhou X, Zhong W. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. *Future Med Chem*. 2020 Sep;12(17):1565–78.
1305. Fanin A, Calegari J, Beverina A, Tiraboschi S. Hydroxychloroquine and azithromycin as a treatment of COVID-19. *Intern Emerg Med*. 2020 Aug;15(5):841–3.

1306. Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. *Int J Antimicrob Agents*. 2020 Aug;56(2):106020.
1307. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. *Int J Antimicrob Agents*. 2020 May;55(5):105960.
1308. Faraone I, Labanca F, Ponticelli M, De Tommasi N, Milella L. Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. *Molecules*. 2020 Nov;25(22).
1309. Fassihi SC, Nabar NR, Fassihi R. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19. Vol. 177, *British journal of pharmacology*. 2020. p. 4997–8.
1310. Fatima U, Rizvi SSA, Fatima S, Hassan MI. Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin. *J Interf cytokine Res Off J Int Soc Interf Cytokine Res*. 2020 Oct;40(10):469–71.
1311. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? *Ann rheum dis [Internet]*. 2020 Feb;80(2):e18. Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217615>
1312. Feeney E, Wallace D, Cotter A, Tinago W, McCarthy C, Keane D, et al. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non-critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 430.
1313. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. *Clin Immunol*. 2020 Jun;215:108448.
1314. Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, Sancho-López A, Mills-Sánchez P, Centeno-Soto GA, et al. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. *Antimicrob Agents Chemother*. 2020 Aug;64(9).
1315. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. Vol. 369, *BMJ (Clinical research ed.)*. England; 2020. p. m1432.
1316. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. *Clin Rheumatol*. 2020 Nov;39(11):3195–204.
1317. Fidahic M, Nujic D, Runjic R, Civljak M, Markotic F, Lovric Makaric Z, et al. Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19. *BMC Med Res Methodol*. 2020 Jun;20(1):161.
1318. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. *Clin microbiol infect [Internet]*. 2020 Jan;27(1):19–27. Available from: <https://dx.doi.org/10.1016/j.cmi.2020.08.022>
1319. Fleury V. Does Combining Severe and Mild Cases of COVID-19 Produce Low Fatality Rates After Treatment With Hydroxychloroquine and Azithromycin? *Am J Epidemiol*. 2020 Nov;189(11):1227–9.

1320. Fontana F, Alfano G, Mori G, Amurri A, Tei L, Ballestri M, et al. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Vol. 20, *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. p. 1902–6.
1321. Friedrich S, Friede T. Causal inference methods for small non-randomized studies: Methods and an application in COVID-19. *Contemp Clin Trials*. 2020 Dec;99:106213.
1322. Frigerio M. Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research. Vol. 316, *International journal of cardiology*. 2020. p. 285–6.
1323. Frishman WH. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 2. Vol. 28, *Cardiology in review*. United States; 2020. p. 217–8.
1324. Fu C, Zhang W, Li H, Bai Y, Bae KT, Wang M, et al. FDG PET/CT evaluation of a patient recovering from COVID-19. *Eur J Nucl Med Mol Imaging*. 2020 Oct;47(11):2703–5.
1325. Fujii H, Tsuji T, Yuba T, Tanaka S, Suga Y, Matsuyama A, et al. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. *Clin Rheumatol*. 2020 Nov;39(11):3171–5.
1326. Funck-Brentano C, Salem J-E, Nguyen LS, Drici M-D, Roden DM. Response to the editorial “COVID-19 in patients with cardiovascular diseases”: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Vol. 113, *Archives of cardiovascular diseases*. 2020. p. 367–8.
1327. Funnell SGP, Dowling WE, Muñoz-Fontela C, Gsell P-S, Ingber DE, Hamilton GA, et al. Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. *Nat Commun*. 2020 Aug;11(1):4253.
1328. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet (London, England)*. 2020 Oct;396(10256):959–67.
1329. Gadebusch Bondio M, Marloth M. [The “Historic Study” SOLIDARITY-Research’s Answer to the Sars-CoV-2 Pandemic]. *NTM*. 2020 Jun;28(2):219–25.
1330. Gajurel K. Persistently positive severe acute respiratory syndrome coronavirus 2 (SARS-COV2) nasopharyngeal PCR in a kidney transplant recipient. Vol. 22, *Transplant infectious disease : an official journal of the Transplantation Society*. 2020. p. e13408.
1331. Galvis V, Spinelli FR, Tello A, Sossa CL, Higuera JD, Gómez ED, et al. Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials. Vol. 56, *Archivos de bronconeumologia*. Spain; 2020. p. 606–8.
1332. Gamboa-Alonso CM, Figueroa-Parra G, Galarza-Delgado DA. Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: “Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?”; by Xie & et al. *Ann rheum dis [Internet]*. 2020 Jan;80(1):e7. Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217633>
1333. Gangopadhyay KK, Sinha B, Ghosal S. “Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey”. *Diabetes Metab Syndr*. 2020;14(5):1413–8.
1334. Gao C, Zhu L, Jin CC, Tong YX, Xiao AT, Zhang S. Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. *Clin Immunol*. 2020 Dec;221:108611.

1335. Gao G, Wang A, Wang S, Qian F, Chen M, Yu F, et al. Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. *J Acquir Immune Defic Syndr*. 2020 Oct;85(2):239–43.
1336. Gao J, Hu S. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). *Biosci Trends*. 2020 May;14(2):156–8.
1337. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020 Mar;14(1):72–3.
1338. Gao Q. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)]. *Zhongguo xue xi chong bing fang zhi za zhi = Chinese J schistosomiasis Control*. 2020 Apr;32(2):119–22.
1339. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F, et al. Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. *Clin Pharmacol Ther*. 2020 Aug;108(2):253–63.
1340. García-Moguel I, Díaz Campos R, Alonso Charterina S, Fernández Rodríguez C, Fernández Crespo J. COVID-19, severe asthma, and biologics. Vol. 125, *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2020. p. 357-359.e1.
1341. García-Saavedra MB, Rosales-Gutiérrez RR, Valverde E, Chumbes-Aguirre M, Alvarado R, Polo R, et al. [Cardiovascular implications of SARS-CoV-2 infection: A literature review]. *Medwave*. 2020 Aug;20(7):e8008.
1342. Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. *Drug Saf*. 2020 Dec;43(12):1315–22.
1343. Gasperetti A, Biffi M, Duru F, Schiavone M, Ziacchi M, Mitacchione G, et al. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. *Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol*. 2020 Dec;22(12):1855–63.
1344. Gates LE, Hamed AA. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation. *J Med Internet Res*. 2020 Aug;22(8):e21169.
1345. Gautam SS, Gautam CS, Garg VK, Singh H. Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. *Expert Rev Clin Pharmacol*. 2020 Nov;13(11):1183–90.
1346. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020 Jul;56(1):105949.
1347. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel Med Infect Dis*. 2020;34:101663.
1348. Gazendam A, Nucci N, Ekhtiari S, Gohal C, Zhu M, Payne A, et al. Trials and tribulations: so many potential treatments, so few answers. *Int Orthop*. 2020 Aug;44(8):1467–71.

1349. Geier MR, Geier DA. Respiratory conditions in coronavirus disease 2019 (COVID-19): Important considerations regarding novel treatment strategies to reduce mortality. *Med Hypotheses*. 2020 Jul;140:109760.
1350. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020 Jun;382(25):2411–8.
1351. Gemcioglu E, Davutoglu M, Ozdemir EE, Erden A. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Vol. 42, *Multiple sclerosis and related disorders*. 2020. p. 102196.
1352. Gendrot M, Javelle E, Clerc A, Savini H, Pradines B. Chloroquine as a prophylactic agent against COVID-19? Vol. 55, *International journal of antimicrobial agents*. 2020. p. 105980.
1353. Gentile D, Fuochi V, Rescifina A, Furneri PM. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine. *Int J Mol Sci*. 2020 Aug;21(16).
1354. Gentile I, Maraolo AE, Piscitelli P, Colao A. COVID-19: Time for Post-Exposure Prophylaxis? *Int J Environ Res Public Health*. 2020 Jun;17(11).
1355. Georgiev T. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. Vol. 40, *Rheumatology international*. 2020. p. 825–6.
1356. Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvullemin A, et al. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. *Therapie [Internet]*. 2020;75(4):371–9. Available from: <https://dx.doi.org/10.1016/j.therap.2020.05.002>
1357. Gevers S, Kwa MSG, Wijnans E, van Nieuwkoop C. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19. Vol. 26, *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020. p. 1276–7.
1358. Ghazy RM, Almaghraby A, Shaaban R, Kamal A, Beshir H, Moursi A, et al. A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. *Sci Rep*. 2020 Dec;10(1):22139.
1359. Gheita TA, Salem MN, Eesa NN, Khalil NM, Gamal NM, Noor RA, et al. Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt. *Rheumatol Int*. 2020 Oct;40(10):1599–611.
1360. Giaime P, Guenoun M, Pedinielli N, Narbonne H, Bergounioux J-P, Solas C, et al. Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2020 Aug;35(8):1346–53.
1361. Giampreti A, Eleftheriou G, Gallo M, Butera R, Contessa G, Faraoni L, et al. Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy. *J Perinat Med*. 2020 Nov;48(9):1001–7.
1362. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis*. 2020 Jul;79(7):859–66.

1363. Gies V, Bekaddour N, Dieudonné Y, Guffroy A, Frenger Q, Gros F, et al. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. *Front Immunol.* 2020;11:1409.
1364. Giglia M, Beci G, Rosselli Del Turco E, Guardigni V, Amedeo A, Cucchetto G, et al. SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? *Monaldi Arch chest Dis = Arch Monaldi per le Mal del torace.* 2020 Dec;90(4).
1365. Gilzad-Kohan H, Jamali F. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2. *J Pharm Pharm Sci a Publ Can Soc Pharm Sci Soc Can des Sci Pharm.* 2020;23:259–77.
1366. Giovane RA, Rezai S, Cleland E, Henderson CE. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. *Rev Med Virol.* 2020 Sep;30(5):e2136.
1367. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). *Mayo Clin Proc.* 2020 Jun;95(6):1213–21.
1368. Gkogkou E, Barnasas G, Vougas K, Trougakos IP. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. *Redox Biol.* 2020 Sep;36:101615.
1369. Goicoechea M, Sánchez Cámara LA, Macías N, Muñoz de Morales A, Rojas ÁG, Bascuñana A, et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. *Kidney Int.* 2020 Jul;98(1):27–34.
1370. Gomes CP, Fernandes DE, Casimiro F, da Mata GF, Passos MT, Varela P, et al. Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. *Front Cell Infect Microbiol.* 2020;10:589505.
1371. Gómez-Enjuto S, Hernando-Requejo V, Lapeña-Motilva J, Ogando-Durán G, Fouz-Ruiz D, Domingo-García J, et al. Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient. *Seizure.* 2020 Aug;80:157–8.
1372. Gómez-Rial J, Currás-Tuala MJ, Rivero-Calle I, Gómez-Carballa A, Cebey-López M, Rodríguez-Tenreiro C, et al. Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology. *Front Immunol.* 2020;11:560381.
1373. Gong S, Su J, Yan X, Li F, Hu L, Liu S. Antiviral therapy for coronavirus disease 2019. *Zhong nan da xue xue bao Yi xue ban = J Cent South Univ Med Sci.* 2020 May;45(5):598–602.
1374. Gonzales-Zamora JA, Quiroz T, Vega AD. Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report. *Vol. 20, Medwave. Chile; 2020. p. e7998.*
1375. González R, García-Otero L, Pons-Duran C, Marbán-Castro E, Goncé A, Llurba E, et al. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial. <https://clinicaltrials.gov/show/NCT04410562> [Internet]. 2020 Jul;21(1):607. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02160470/full>
1376. Göpel S, Bethge W, Martus P, Kreth F, Iftner T, Joos S, et al. Test and treat COVID 65 plus-Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: a structured summary of a study protocol for a randomised controlled

trial. *Trials* [Internet]. 2020 Jul;21(1):635. Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02140502/full>

1377. Gopinathannair R, Merchant FM, Lakkireddy DR, Etheridge SP, Feigofsky S, Han JK, et al. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. *J Interv Card Electrophysiol an Int J Arrhythm pacing*. 2020 Nov;59(2):329–36.
1378. Gougis P, Fenioux C, Funck-Brentano C, Veyri M, Gligorov J, Solas C, et al. Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use? Vol. 136, *European journal of cancer (Oxford, England : 1990)*. 2020. p. 1–3.
1379. Gouveia CC, Campos L. Coronavirus Disease 2019: Clinical Review. *Acta Med Port*. 2020 Jul;33(7–8):505–11.
1380. Grabbe S, Beissert S, Enk A. Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards? *J der Dtsch Dermatologischen Gesellschaft = J Ger Soc Dermatology JDDG*. 2020 Aug;18(8):810–3.
1381. Grandolfo M, Romita P, Bonamonte D, Cazzato G, Hansel K, Stingeni L, et al. Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era. Vol. 33, *Dermatologic therapy*. 2020. p. e13499.
1382. Grange L, Guilpain P, Truchetet M-E, Cracowski J-L. Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. *Therapie*. 2020;75(4):335–42.
1383. Grau-Pujol B, Camprubí D, Marti-Soler H, Fernández-Pardos M, Guinovart C, Muñoz J, et al. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: a structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. <https://clinicaltrials.gov/show/NCT04331834> [Internet]. 2020 Jul;21(1):688. Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02160146/full>
1384. Gremese E, Ferraccioli ES, Alivernini S, Tolusso B, Ferraccioli G. Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. *Eur J Clin Invest*. 2020 Sep;50(9):e13342.
1385. Gressier F, Verstuyft C, Becquemont L, Falissard B, Corruble E. Psychiatric Side Effects of Chloroquine. Vol. 81, *The Journal of clinical psychiatry*. United States; 2020.
1386. Guastalegname M, Vallone A. Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment? Vol. 71, *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020. p. 888–9.
1387. Guharoy R, Krenzelok E. Searching for COVID-19 treatments: First, do no harm. *Am J Heal Pharm AJHP Off J Am Soc Heal Pharm*. 2020 Oct;77(22):1899–905.
1388. Guijarro-Castro C, Rosón-González M, Abreu A, García-Arratibel A, Ochoa-Mulas M. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases. Vol. 35, *Neurologia (Barcelona, Spain)*. 2020. p. 412–5.
1389. Guillan M, Villacieros-Alvarez J, Bellido S, Perez-Jorge Peremarch C, Suarez-Vega VM, Aragonés-García M, et al. Unusual simultaneous cerebral infarcts in multiple arterial territories in a COVID-19 patient. Vol. 193, *Thrombosis research*. 2020. p. 107–9.
1390. Gul MH, Htun ZM, Shaikat N, Imran M, Khan A. Potential specific therapies in COVID-19. *Ther Adv Respir Dis*. 2020;14:1753466620926853.

1391. Gunay S, Caliskan S, Sigirli D, Sahin E. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19. *Bratisl Lek Listy*. 2020;121(11):817–21.
1392. Gupta N, Agrawal S, Ish P. Chloroquine in COVID-19: the evidence. *Monaldi Arch chest Dis = Arch Monaldi per le Mal del torace*. 2020 Mar;90(1).
1393. Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). *Diabetes Metab Syndr*. 2020;14(3):251–4.
1394. Gurkan O, Yilmaz A, Cengel F, Altunok ES, Ekin EE. COVID-19 Pulmonary Infection with Pneumothorax in a Young Patient. Vol. 30, *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. Pakistan; 2020. p. 43–5.
1395. Gürsoy C, Tapan ÖO, Dogan E, Togan T, Demirbilek SG. COVID-19 Pneumonia during Hydroxychloroquine Treatment of Rheumatoid Arthritis. Vol. 30, *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP*. Pakistan; 2020. p. 168–70.
1396. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res*. 2020 Aug;116(10):1666–87.
1397. Guzman-Prado Y. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19. Vol. 130, *The American journal of cardiology*. 2020. p. 162–3.
1398. Gyanwali P, Sharma S, Pant S, Koirala P, Adhikari K, Koirala J, et al. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19. *J Nepal Health Res Counc*. 2020 Sep;18(2):151–8.
1399. Habibzadeh P, Moghadami M, Lankarani KB. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes. *Med Hypotheses*. 2020 Oct;143:109847.
1400. Hachfi W, Ben Lasfar N. COVID-19: Main therapeutic options. *Tunis Med*. 2020 Apr;98(4):299–303.
1401. Halm MA. COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits. *Am J Crit care an Off Publ Am Assoc Crit Nurses*. 2020 Nov;29(6):489–92.
1402. Hamm BS, Rosenthal LJ. Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. *Psychosomatics*. 2020;61(6):597–606.
1403. Hammami MB, Garibaldi B, Shah P, Liu G, Jain T, Chen P-H, et al. Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. Vol. 20, *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2020. p. 2254–9.
1404. Han Y-J, Ren Z-G, Li X-X, Yan J-L, Ma C-Y, Wu D-D, et al. Advances and challenges in the prevention and treatment of COVID-19. *Int J Med Sci*. 2020;17(12):1803–10.
1405. Harrigan JJ, Hubbard RA, Thomas S, Riello RJ 3rd, Bange E, Mamtani M, et al. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. Vol. 35, *Journal of general internal medicine*. 2020. p. 2826–8.

1406. Harsch IA, Skiba M, Lopatta E, Konturek PC. Hydroxychloroquine is no miracle cure for covid-19 infection -imaging and clinical course in an elderly female. *Wiad Lek.* 2020;73(7):1583–5.
1407. Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, Bukhari A, Alfaleh MA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. *Travel Med Infect Dis.* 2020;35:101735.
1408. Haşlak F, Yıldız M, Adrovic A, Barut K, Kasapçopur Ö, Haslak F, et al. Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon. *Balk Med J [Internet]*. 2020 Jun;37(4):184–8. Available from: <https://dx.doi.org/10.4274/balkanmedj.galenos.2020.2020.4.43>
1409. Hazafa A, Ur-Rahman K, Haq I-U-, Jahan N, Mumtaz M, Farman M, et al. The broad-spectrum antiviral recommendations for drug discovery against COVID-19. *Drug Metab Rev.* 2020 Aug;52(3):408–24.
1410. Hazra S, Chaudhuri AG, Tiwary BK, Chakrabarti N. Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. *Life Sci.* 2020 Sep;257:118096.
1411. He F, Luo Q, Lei M, Fan L, Shao X, Hu K, et al. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. *Clin Rheumatol.* 2020 Sep;39(9):2803–10.
1412. Hernandez A V, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. *Ann Intern Med.* 2020 Aug;173(4):287–96.
1413. Hernandez A V, Roman YM, Pasupuleti V, Barboza JJ, White CM. Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. Vol. 173, *Annals of internal medicine.* 2020. p. W128–9.
1414. Herth FJF, Sakoulas G, Haddad F. Use of Intravenous Immunoglobulin (Prevacen or Octagam) for the Treatment of COVID-19: Retrospective Case Series. *Respiration.* 2020;99(12):1145–53.
1415. Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM, Albano J, et al. The use of IV vitamin C for patients with COVID-19: a case series. *Expert Rev Anti Infect Ther.* 2020 Dec;18(12):1259–61.
1416. Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient. Vol. 40, *Pharmacotherapy.* 2020. p. 592–8.
1417. Hlavaty T, Krajcovicova A. Novel unorthodox strategies to reduce the case fatality rate of COVID-19 in high risk groups. *Bratisl Lek Listy.* 2020;121(7):462–5.
1418. Hoang BX, Han B. A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections. *Med Hypotheses.* 2020 Dec;145:110333.
1419. Hodge C, Marra F, Marzolini C, Boyle A, Gibbons S, Siccardi M, et al. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. *J Antimicrob Chemother.* 2020 Dec;75(12):3417–24.
1420. Hodkinson B, Singh P, Gcelu A, Bautista-Molano W, Pons-Estel G, Alpízar-Rodríguez D. Navigating COVID-19 in the developing world. Vol. 39, *Clinical rheumatology.* 2020. p. 2039–42.

1421. Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. *Nature*. 2020 Sep;585(7826):588–90.
1422. Hogan Ii RB, Hogan Iii RB, Cannon T, Rappai M, Studdard J, Paul D, et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. *Pulm Pharmacol Ther*. 2020 Aug;63:101942.
1423. Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. *Int J Antimicrob Agents*. 2020 Aug;56(2):106044.
1424. Hong SI, Ryu B-H, Chong YP, Lee S, Kim S, Kim HC, et al. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β -1b. Vol. 56, *International journal of antimicrobial agents*. 2020. p. 106052.
1425. Hong W. Combating COVID-19 with Chloroquine. *J Mol Cell Biol*. 2020 May;12(4):249–50.
1426. Hooks M, Bart B, Vardeny O, Westanmo A, Adabag S. Effects of hydroxychloroquine treatment on QT interval. *Hear Rhythm*. 2020 Nov;17(11):1930–5.
1427. Hor CP, Hussin N, Nalliah S, Ooi WT, Tang XY, Zachariah S, et al. Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend. Vol. 81, *The Journal of infection*. 2020. p. e117–9.
1428. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020 Nov;383(21):2030–40.
1429. Hossri S, Shadi M, Hamarsha Z, Schneider R, El-Sayegh D. Clinically significant anticardiolipin antibodies associated with COVID-19. Vol. 59, *Journal of critical care*. 2020. p. 32–4.
1430. Howard L, Baombe J, Reynard C. BET 2: Hydroxychloroquine in the treatment of COVID-19. *Emerg Med J*. 2020 Jul;37(7):451–3.
1431. Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. *Nat Nanotechnol*. 2020 Apr;15(4):247–9.
1432. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with Chloroquine. *J Mol Cell Biol*. 2020 May;12(4):322–5.
1433. Hummel JP, Maraj I, Taoutel R, Chamoun R, Workman VK, Tran L, et al. Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection. Vol. 13, *Circulation*. Arrhythmia and electrophysiology. 2020. p. e008841.
1434. Hushmandi K, Bokaie S, Hashemi M, Moghadam ER, Raei M, Hashemi F, et al. A review of medications used to control and improve the signs and symptoms of COVID-19 patients. *Eur J Pharmacol*. 2020 Nov;887:173568.
1435. Hussein MIH, Albashir AAD, Elawad OAMA, Homeida A. Malaria and COVID-19: unmasking their ties. *Malar J*. 2020 Dec;19(1):457.
1436. Iancu GM, Solomon A, Birlutiu V. Viral exanthema as manifestation of SARS-CoV-2 infection: A case report. *Medicine (Baltimore)*. 2020 Aug;99(35):e21810.
1437. Iannaccone G, Scacciavillani R, Del Buono MG, Camilli M, Ronco C, Lavie CJ, et al. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. *Cardiorenal Med*. 2020;10(5):277–87.

1438. Ibáñez S, Martínez O, Valenzuela F, Silva F, Valenzuela O. Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy? *Clin Rheumatol*. 2020 Aug;39(8):2461–5.
1439. Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. *Clin Immunol*. 2020 Oct;219:108544.
1440. Iglesias-Julián E, López-Veloso M, de-la-Torre-Ferrera N, Barraza-Vengoechea JC, Delgado-López PD, Colazo-Burlato M, et al. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients. *J Autoimmun*. 2020 Dec;115:102537.
1441. Imami AS, O'Donovan SM, Creeden JF, Wu X, Eby H, McCullumsmith CB, et al. Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach. *Physiol Genomics*. 2020 Sep;52(9):401–7.
1442. Imani-Saber Z, Vaseghi H, Mahdian M, Safari F, Ghadami M. Variable Clinical Manifestations of COVID-19: Viral and Human Genomes Talk. *Iran J Allergy Asthma Immunol*. 2020 Oct;19(5):456–70.
1443. Inama G, Dodi C, Provini M, Bossoni E, Inama L, Balzarini L, et al. Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect? *J Cardiovasc Med (Hagerstown)*. 2020 Oct;21(10):765–71.
1444. Infante M, Ricordi C, Fabbri A. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. *J Diabetes*. 2020 Sep;12(9):659–67.
1445. Ingraham NE, Boulware D, Sparks MA, Schacker T, Benson B, Sparks JA, et al. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. Vol. 24, *Critical care (London, England)*. 2020. p. 182.
1446. Intson K, Kumar S, Botta A, Neckles R, Leung C, Jawaid A. An independent appraisal and re-analysis of hydroxychloroquine treatment trial for COVID-19. *Swiss Med Wkly*. 2020 Apr;150:w20262.
1447. Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. *Eur J Clin Invest*. 2020 Dec;50(12):e13423.
1448. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclair BA, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. *PLoS One*. 2020;15(8):e0237693.
1449. Ippolito MM, Flexner C. Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter? *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2020 Dec;71(11):2965–7.
1450. Irvani SSN, Golmohammadi M, Pourhoseingholi MA, Shokouhi S, Darazam IA. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial. Vol. 21, *Trials*. 2020. p. 473.
1451. Islam M. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings. *J Coll Physicians Surg Pak*. 2020 Jun;30(6):78.
1452. Iwasaka S, Shono Y, Tokuda K, Nakashima K, Yamamoto Y, Maki J, et al. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate. Vol. 26,

- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2020. p. 1319–23.
1453. Iyer M, Jayaramayya K, Subramaniam MD, Lee S Bin, Dayem AA, Cho S-G, et al. COVID-19: an update on diagnostic and therapeutic approaches. Vol. 53, BMB reports. 2020. p. 191–205.
1454. Jaffe S. Regulators split on antimalarials for COVID-19. Vol. 395, Lancet (London, England). 2020. p. 1179.
1455. Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Vol. 26, Nature medicine. United States; 2020. p. 632.
1456. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. *Autoimmun Rev.* 2020 Jul;19(7):102567.
1457. Jamous F, Meyer N, Buus D, Ateeli H, Taggart K, Hanson T, et al. Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls. *S D Med.* 2020 Jul;73(7):312–7.
1458. Ján S, Tomáš Š, Natália P, Eva Z, Marek M, Patrik P, et al. The first cancer patient with COVID-19 in Slovakia. *Klin Onkol.* 2020;33(5):386–9.
1459. Janda A, Schuetz C, Heeg M, Minden K, Hedrich CM, Kallinich T, et al. [COVID-19: treatment strategies of German-speaking pediatric rheumatologists : Results of an online survey]. *Z Rheumatol.* 2020 Sep;79(7):710–7.
1460. Janiaud P, Axfors C, Van't Hooft J, Saccilotto R, Agarwal A, Appenzeller-Herzog C, et al. The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. *F1000Research.* 2020;9:1193.
1461. Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai M-C. QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. *Hear Rhythm.* 2020 Sep;17(9):1472–9.
1462. Jankowska EA, Sierpiński R, Tkaczyszyn M, Drozd M, Szachniewicz J, Duda-Sikuła M, et al. Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. *Kardiol Pol.* 2020 Aug;78(7–8):811–7.
1463. Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients? Vol. 86, *British journal of clinical pharmacology.* 2020. p. 1176–7.
1464. Javorac D, Grahovac L, Manić L, Stojilković N, Anđelković M, Bulat Z, et al. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. *Food Chem Toxicol an Int J Publ Br Ind Biol Res Assoc.* 2020 Oct;144:111639.
1465. Jawaid Akhtar M. COVID19 inhibitors: A prospective therapeutics. *Bioorg Chem.* 2020 Aug;101:104027.
1466. Jean S-S, Hsueh P-R. Old and re-purposed drugs for the treatment of COVID-19. *Expert Rev Anti Infect Ther.* 2020 Sep;18(9):843–7.
1467. Jean S-S, Lee P-I, Hsueh P-R. Treatment options for COVID-19: The reality and challenges. *J Microbiol Immunol Infect.* 2020 Jun;53(3):436–43.
1468. Jeevaratnam K. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety. Vol. 6, *European heart journal. Cardiovascular pharmacotherapy.* 2020. p. 256–7.

1469. Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, Suarez-Valle A, Saceda-Corralo D, Moreno-Garcia Del Real C, et al. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Vol. 45, *Clinical and experimental dermatology*. 2020. p. 892–5.
1470. Jiménez-Jáimez J, Macías-Ruiz R, Bermúdez-Jiménez F, Rubini-Costa R, Ramírez-Taboada J, Flores PIG, et al. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. *Sci Rep*. 2020 Dec;10(1):21417.
1471. Jin Y-H, Zhan Q-Y, Peng Z-Y, Ren X-Q, Yin X-T, Cai L, et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version). *Mil Med Res*. 2020 Sep;7(1):41.
1472. Jindal V, Mittal S, Kaur T, Bansal AS, Kaur P, Kaur G, et al. Knowledge, anxiety and the use of hydroxychloroquine prophylaxis among health care students and professionals regarding COVID-19 pandemic. *Adv Respir Med*. 2020;88(6):520–30.
1473. Jones CW, Woodford AL, Platts-Mills TF. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. *BMJ Open*. 2020 Sep;10(9):e041276.
1474. Joob B, Wiwanitkit V. Evidence of Protective Effect of Hydroxychloroquine on COVID-19. Vol. 47, *The Journal of rheumatology*. Canada; 2020. p. 1587.
1475. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, et al. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). *PLoS Med*. 2020 Sep;17(9):e1003293.
1476. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. *C Can Med Assoc J = J l'Association medicale Can*. 2020 Apr;192(17):E450–3.
1477. Juusela A, Nazir M, Gimovsky M. Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. *Am J Obstet Gynecol MFM*. 2020 May;2(2):100113.
1478. Kadono Y, Nakamura Y, Ogawa Y, Yamamoto S, Kajikawa R, Nakajima Y, et al. A case of COVID-19 infection presenting with a seizure following severe brain edema. *Seizure*. 2020 Aug;80:53–5.
1479. Kajani R, Apramian A, Vega A, Ubhayakar N, Xu P, Liu A. Neuroleptic malignant syndrome in a COVID-19 patient. *Brain Behav Immun*. 2020 Aug;88:28–9.
1480. Kalligeros M, Shehadeh F, Atalla E, Mylona EK, Aung S, Pandita A, et al. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study. *J Glob Antimicrob Resist*. 2020 Sep;22:842–4.
1481. Kamp TJ, Hamdan MH, January CT. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern? *J Am Heart Assoc*. 2020 Jun;9(12):e016887.
1482. Kang JE, Rhie SJ. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. *J Clin Pharm Ther*. 2020 Oct;45(5):1199–205.
1483. Kang Y, Wang H, Chen H, Wang B, Yang Y, Zhao X, et al. Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. *Int Heart J*. 2020 Sep;61(5):1056–8.
1484. Kannan R, Przekwas A. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to

assess toxicity and drug-induced damage in healthy subjects. *Int j numer method biomed eng.* 2020 Dec;36(12):e3403.

1485. Kara E, Demirkan K, Unal S. Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19. Vol. 56, *International journal of antimicrobial agents.* 2020. p. 106123.
1486. Karampela I, Dalamaga M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? *Arch Med Res.* 2020 Oct;51(7):741–2.
1487. Karlsen APH, Wiberg S, Laigaard J, Pedersen C, Rokamp KZ, Mathiesen O. A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment. *PLoS One.* 2020;15(8):e0237903.
1488. Karunajeewa H. Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic. Vol. 50, *Internal medicine journal.* Australia; 2020. p. 1307–10.
1489. Kashour T, Tleyjeh IM. It is time to drop hydroxychloroquine from our COVID-19 armamentarium. *Med Hypotheses.* 2020 Nov;144:110198.
1490. Kassi EN, Papavassiliou KA, Papavassiliou AG. G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Vol. 24, *Journal of cellular and molecular medicine.* 2020. p. 4913–4.
1491. Kastritis E, Kitas GD, Vassilopoulos D, Giannopoulos G, Dimopoulos MA, Sfrikakis PP. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. *Rheumatol Int.* 2020 Sep;40(9):1353–60.
1492. Kastritis E, Wechalekar A, Schönland S, Sanchorawala V, Merlini G, Palladini G, et al. Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. *Br J Haematol.* 2020 Aug;190(3):346–57.
1493. Kavanagh O, Marie Healy A, Dayton F, Robinson S, O'Reilly NJ, Mahoney B, et al. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. Vol. 143, *Medical hypotheses.* 2020. p. 110110.
1494. Kazama I. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy? *Drug Discov Ther.* 2020 Jul;14(3):143–4.
1495. Ke Y-Y, Peng T-T, Yeh T-K, Huang W-Z, Chang S-E, Wu S-H, et al. Artificial intelligence approach fighting COVID-19 with repurposing drugs. *Biomed J.* 2020 Aug;43(4):355–62.
1496. Keshtkar-Jahromi M, Bavari S. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19). *Am J Trop Med Hyg.* 2020 May;102(5):932–3.
1497. Khadka S, Yuchi A, Shrestha DB, Budhathoki P, Al-Subari SMM, Ziad Alhouzani TM, et al. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic. *Altern Ther Health Med.* 2020 Aug;26(S2):100–7.
1498. Khadke S, Ahmed N, Ahmed N, Ratts R, Raju S, Gallogly M, et al. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. *Virol J.* 2020 Oct;17(1):154.
1499. Khamis F, Al-Zakwani I, Al Naamani H, Al Lawati S, Pandak N, Omar MB, et al. Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman. *J Infect Public Health.* 2020 Jul;13(7):906–13.

1500. Khan AA, Khan Z. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation. *Chem Biol Interact.* 2020 Dec;332:109299.
1501. Khan MSI, Nabeka H, Akbar SMF, Al Mahtab M, Shimokawa T, Islam F, et al. Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers. *J Glob Health.* 2020 Dec;10(2):20378.
1502. Khan MA, Khan MA. A Case of 45-Year Man Who Succumbed to Coronavirus Disease 2019 (COVID-19). Vol. 30, *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.* Pakistan; 2020. p. 37–9.
1503. Khan MM, Noor A, Madni A, Shafiq M. Emergence of novel coronavirus and progress toward treatment and vaccine. *Rev Med Virol.* 2020 Jul;30(4):e2116.
1504. Khan S, Ahmad Z, Khan F, Asif H, Zia-Ur-Rahman A. Diarrhoea: An Atypical Presentation of COVID-19. Vol. 30, *Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.* Pakistan; 2020. p. 40–2.
1505. Khan Z, Karataş Y, Rahman H. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. *Adv Ther.* 2020 Jun;37(6):2575–9.
1506. Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. *Int J Antimicrob Agents.* 2020 Sep;56(3):106101.
1507. Kichloo A, Aljadah M, Albosta M, Wani F, Singh J, Solanki S. COVID-19 and Acute Lupus Pneumonitis: Diagnostic and Treatment Dilemma. *J Investig Med high impact case reports.* 2020;8:2324709620933438.
1508. Kilian A, Chock YP, Huang IJ, Graef ER, Upton LA, Khilnani A, et al. Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. *Semin Arthritis Rheum.* 2020 Oct;50(5):1191–201.
1509. Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Vol. 172, *Annals of internal medicine.* 2020. p. 819–21.
1510. Kim JY, Kim JM, Peck KR. The First Case of an HIV Patient Diagnosed with COVID-19 in Korea. Vol. 35, *Journal of Korean medical science.* 2020. p. e358.
1511. Kim MS, An MH, Kim WJ, Hwang T-H. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. *PLoS Med.* 2020 Dec;17(12):e1003501.
1512. Kim Y, Kwon O, Paek JH, Park WY, Jin K, Hyun M, et al. Two distinct cases with COVID-19 in kidney transplant recipients. Vol. 20, *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2020. p. 2269–75.
1513. Kim YS, Lee SY, Yoon JW, Kim D, Yu S, Kim JS, et al. Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes. Vol. 53, *BMB reports.* 2020. p. 545–50.
1514. Klimke A, Hefner G, Will B, Voss U. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. *Med Hypotheses.* 2020 Sep;142:109783.

1515. Knorr JP, Colomy V, Mauriello CM, Ha S. Tocilizumab in patients with severe COVID-19: A single-center observational analysis. *J Med Virol*. 2020 Nov;92(11):2813–20.
1516. Knowlson C, Torgerson DJ. Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial. *F1000Research*. 2020;9:1017.
1517. Koc G, Odabasi Z, Tan E. Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis. Vol. 22, *Journal of clinical neuromuscular disease*. United States; 2020. p. 60–2.
1518. Kocyigit BF, Akaltun MS, Sahin AR. YouTube as a source of information on COVID-19 and rheumatic disease link. *Clin Rheumatol*. 2020 Jul;39(7):2049–54.
1519. Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Vol. 79, *Annals of the rheumatic diseases*. England; 2020. p. 1386–8.
1520. Koren G, Korn L. Chloroquine for Covid 19: introducing drug repurposing to medical students. Vol. 11, *International journal of medical education*. England; 2020. p. 155–7.
1521. Korytkowski M, Antinori-Lent K, Drincic A, Hirsch IB, McDonnell ME, Rushakoff R, et al. A Pragmatic Approach to Inpatient Diabetes Management during the COVID-19 Pandemic. *J Clin Endocrinol Metab*. 2020 Sep;105(9).
1522. Kouzy R, Abi Jaoude J, Garcia Garcia CJ, El Alam MB, Taniguchi CM, Ludmir EB. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. *JAMA Netw open*. 2020 Jul;3(7):e2015100.
1523. Krouse HJ. Whatever Happened to Evidence-Based Practice During COVID-19? *Otolaryngol neck Surg Off J Am Acad Otolaryngol Neck Surg*. 2020 Aug;163(2):318–9.
1524. Kucharz EJ. Should coronavirus disease 2019 concern rheumatologists? *Polish Arch Intern Med*. 2020 Aug;130(7–8):655–61.
1525. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *Lancet (London, England)*. 2020 Jun;395(10241):1907–18.
1526. Kuipers MT, van Zwieten R, Heijmans J, Rutten CE, de Heer K, Kater AP, et al. Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine. Vol. 95, *American journal of hematology*. 2020. p. E194–6.
1527. Kumar R, Vinod KS, Mittal A, Adhikari S Das, Gupta N. Review of current clinical management guidelines for COVID-19 with special reference to India. *Drug Discov Ther*. 2020;14(4):171–6.
1528. Kumar S, Zhi K, Mukherji A, Gerth K. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. *Viruses*. 2020 Apr;12(5).
1529. Kumar S, Sil A, Das A. Hydroxychloroquine for COVID-19: Myths vs facts. Vol. 33, *Dermatologic therapy*. 2020. p. e13857.
1530. Kunte R, Yadav AK, Faujdar DS, Sahu R, Basannar D, Patrikar S, et al. Prophylactic use of hydroxychloroquine among healthcare workers in a case-control study. Vol. 152, *The Indian journal of medical research*. 2020. p. 127–8.
1531. Kupferschmidt K. Big studies dim hopes for hydroxychloroquine. Vol. 368, *Science (New York, N.Y.)*. United States; 2020. p. 1166–7.

1532. Kupferschmidt K. U.K. megatrial outshines other drug studies. Vol. 369, *Science* (New York, N.Y.). United States; 2020. p. 124–5.
1533. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Vol. 367, *Science* (New York, N.Y.). United States; 2020. p. 1412–3.
1534. Kuraitis D, Murina A. Facts, not Fear: Safety of Hydroxychloroquine. Vol. 360, *The American journal of the medical sciences*. United States; 2020. p. 199–200.
1535. Kurd R, Zuckerman M, Ben-Chetrit E. Hydroxychloroquine-related Rash in COVID-19 Infected Patient. *Isr Med Assoc J*. 2020 Aug;22(8):525.
1536. Kuroki Y, Hiyama K, Minami J, Takeuchi M, Shojima M, Matsueda S, et al. The first case of COVID-19 pneumonia in a hemodialysis patient in Japan. *CEN case reports*. 2020 Nov;9(4):404–8.
1537. Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic? Vol. 33, *Dermatologic therapy*. 2020. p. e13383.
1538. LaCourse S, John-Stewart G, Adams Waldorf KM. Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2020 Jul;71(15):879–81.
1539. Lacroix I, Bénévnt J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy: What do we know? Vol. 75, *Thérapie*. 2020. p. 384–5.
1540. Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. *Travel Med Infect Dis*. 2020;36:101791.
1541. Lahouati M, Mériglier E, Martin L, Bouchet S, Desclaux A, Bonnet F. COVID-19 infection also occurs in patients taking hydroxychloroquine. *J Antimicrob Chemother*. 2020 Jul;75(7):2014–5.
1542. Lai Y-J, Chang C-M, Lin C-K, Yang Y-P, Chien C-S, Wang P-H, et al. Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. *J Chin Med Assoc*. 2020 Sep;83(9):812–6.
1543. Lam S, Lombardi A, Ouanounou A. COVID-19: A review of the proposed pharmacological treatments. *Eur J Pharmacol*. 2020 Nov;886:173451.
1544. Lameijer JRC, van Houte J, van Berckel MMG, Canta LR, Yo LSF, Nijziel MR, et al. Severe arterial thromboembolism in patients with Covid-19. Vol. 60, *Journal of critical care*. 2020. p. 106–10.
1545. Lammers AJJ, Brohet RM, Theunissen REP, Koster C, Rood R, Verhagen DWM, et al. Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020 Dec;101:283–9.
1546. Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID-19 for the cardiovascular specialist. *Am Heart J*. 2020 Aug;226:29–44.
1547. Laplana M, Yuguero O, Fibla J. Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients. *PLoS One*. 2020;15(12):e0243598.
1548. Larrouquere L, Gabin M, Poingt E, Mouffak A, Hlavaty A, Lepelley M, et al. Genesis of an emergency public drug information website by the French Society of Pharmacology and

- Therapeutics during the COVID-19 pandemic. *Fundam Clin Pharmacol*. 2020 Jun;34(3):389–96.
1549. Lat TI, Patel CD, Ehrig JC, Moslander C, Sanchez JF. Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. *Am J Obstet Gynecol MFM*. 2020 Nov;2(4):100224.
1550. Lauriola M, Pani A, Ippoliti G, Mortara A, Milighetti S, Mazen M, et al. Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. *Clin Transl Sci*. 2020 Nov;13(6):1071–6.
1551. Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”. *Travel Med Infect Dis [Internet]*. 2020;36:101819. Available from: <https://dx.doi.org/10.1016/j.tmaid.2020.101819>
1552. Lebin JA, LeSaint KT. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management. *West J Emerg Med*. 2020 Jun;21(4):760–3.
1553. Lecronier M, Beurton A, Burrel S, Haudebourg L, Deleris R, Le Marec J, et al. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. *Crit Care*. 2020 Jul;24(1):418.
1554. Lecuit M. Chloroquine and COVID-19, where do we stand? Vol. 50, *Medecine et maladies infectieuses*. 2020. p. 229–30.
1555. Ledford H. Dozens of coronavirus drugs are in development - what happens next? Vol. 581, *Nature*. England; 2020. p. 247–8.
1556. Ledford H. Safety fears over drug hyped to treat the coronavirus spark global confusion. Vol. 582, *Nature*. England; 2020. p. 18–9.
1557. Ledford H. The coronavirus outbreak could make it quicker and easier to trial drugs. *Nature*. 2020 Jun;582(7811):172.
1558. Lee JD, Burger CD, Delossantos GB, Grinnan D, Ralph DD, Rayner SG, et al. A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. *Ann Am Thorac Soc*. 2020 Dec;17(12):1576–82.
1559. Lee KH, Kim JS, Hong SH, Seong D, Choi YR, Ahn YT, et al. Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles. *Eur Rev Med Pharmacol Sci*. 2020 Dec;24(24):13089–97.
1560. Lee S-G, Park GU, Moon YR, Sung K. Clinical Characteristics and Risk Factors for Fatality and Severity in Patients with Coronavirus Disease in Korea: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (HIRA) Database. *Int J Environ Res Public Health*. 2020 Nov;17(22).
1561. Lee Z, Rayner CR, Forrest JI, Nachega JB, Senchaudhuri E, Mills EJ. The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. *Am j trop med hyg [Internet]*. 2020 Jan;104(1):35–8. Available from: <https://dx.doi.org/10.4269/ajtmh.20-1320>
1562. Lei Z-N, Wu Z-X, Dong S, Yang D-H, Zhang L, Ke Z, et al. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. *Pharmacol Ther*. 2020 Dec;216:107672.

1563. Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, et al. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. *Fundam Clin Pharmacol*. 2020 Oct;34(5):530–47.
1564. Lenkens M, de Wit H, Danser AH, Esselink AC, Horikx A, Ten Oever J, et al. [Medication and comedication in COVID-19 patients]. *Ned Tijdschr Geneeskd*. 2020 Mar;164.
1565. Lentine KL, Lam NN, Caliskan Y, Alhamad T, Xiao H, Schnitzler MA, et al. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. *Clin Transplant*. 2020 Dec;34(12):e14118.
1566. Lentini G, Cavalluzzi MM, Habtemariam S. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help. *Molecules*. 2020 Apr;25(8).
1567. Li C, Wang L, Ren L. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. *Virus Res*. 2020 Sep;286:198073.
1568. Li C, Cheng G. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin? *Front Immunol*. 2020;11:1969.
1569. Li H, Yang L, Liu F-F, Ma X-N, He P-L, Tang W, et al. Overview of therapeutic drug research for COVID-19 in China. *Acta Pharmacol Sin*. 2020 Sep;41(9):1133–40.
1570. Li L, Wang X, Wang R, Hu Y, Jiang S, Lu X. Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. *Drug Des Devel Ther*. 2020;14:3001–13.
1571. Li S, Liu C, Guo F, Taleb SJ, Tong M, Shang D. Traditional Chinese Medicine as Potential Therapy for COVID-19. *Am J Chin Med*. 2020;48(6):1263–77.
1572. Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2020 May;34(5):6008–16.
1573. Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, et al. Is hydroxychloroquine beneficial for COVID-19 patients? *Cell Death Dis*. 2020 Jul;11(7):512.
1574. Li Z, Li X, Huang Y-Y, Wu Y, Liu R, Zhou L, et al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. *Proc Natl Acad Sci U S A*. 2020 Nov;117(44):27381–7.
1575. Licciardi F, Giani T, Baldini L, Favalli EG, Caporali R, Cimaz R. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. *Pediatr Rheumatol Online J*. 2020 Apr;18(1):35.
1576. Lima WG, Brito JCM, Overhage J, Nizer WS da C. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. *Arch Virol*. 2020 Aug;165(8):1729–37.
1577. Lipworth B, Chan R, Lipworth S, RuiWen Kuo C. Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection. Vol. 8, *The journal of allergy and clinical immunology. In practice*. 2020. p. 1798–801.
1578. Lipworth B, Kuo CR, Chan R. Emerging pharmacotherapy for COVID-19. *J R Coll Physicians Edinb*. 2020 Jun;50(2):133–7.
1579. Litaïem N, Hajlaoui K, Karray M, Slouma M, Zeglaoui F. Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Vol. 33, *Dermatologic therapy*. 2020. p. e13565.

1580. Liu M, Caputi TL, Dredze M, Kesselheim AS, Ayers JW. Internet Searches for Unproven COVID-19 Therapies in the United States. Vol. 180, *JAMA internal medicine*. 2020. p. 1116–8.
1581. Liu P, Huang Z, Yin M, Liu C, Chen X, Pan P, et al. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Vol. 21, *Trials*. 2020. p. 999.
1582. Liu P, Zhao L, Ferrere G, Alves-Costa-Silva C, Ly P, Wu Q, et al. Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. *Oncoimmunology*. 2020 Jul;9(1):1789284.
1583. Liu T, Luo S, Libby P, Shi G-P. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. *Pharmacol Ther*. 2020 Sep;213:107587.
1584. Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. [Not Available]. *C Can Med Assoc J = J l'Association medicale Can*. 2020 Nov;192(47):E1585–96.
1585. Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. *C Can Med Assoc J = J l'Association medicale Can*. 2020 Jul;192(27):E734–44.
1586. Liu X, Chen H, Shang Y, Zhu H, Chen G, Chen Y, et al. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. *Trials*. 2020 Jul;21(1):622.
1587. Liu X-H, Lu S-H, Chen J, Xia L, Yang Z-G, Charles S, et al. Clinical characteristics of foreign-imported COVID-19 cases in Shanghai, China. Vol. 9, *Emerging microbes & infections*. 2020. p. 1230–2.
1588. Liu Y, Fu X, Xie C. Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. 2020 Sep;99(37):e22031.
1589. Lodise TP, Rybak MJ. COVID-19: Important Therapy Considerations and Approaches in this Hour of Need. Vol. 40, *Pharmacotherapy*. 2020. p. 379–81.
1590. Lohse A, Klopfenstein T, Balblanc J-C, Royer P-Y, Bossert M, Gendrin V, et al. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). *Microbes Infect*. 2020 Oct;22(9):500–3.
1591. Loinaz C, Marcacuzco A, Fernández-Ruiz M, Caso O, Cambra F, San Juan R, et al. Varied clinical presentation and outcome of SARS-CoV-2 infection in liver transplant recipients: Initial experience at a single center in Madrid, Spain. *Transpl Infect Dis*. 2020 Oct;22(5):e13372.
1592. Lolachi S, Morin S, Coen M, Samii K, Calmy A, Serratrice J. Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report. *Medicine (Baltimore)*. 2020 Aug;99(32):e21570.
1593. London AJ, Kimmelman J. Against pandemic research exceptionalism. *Science*. 2020 May;368(6490):476–7.
1594. Lopez A, Duclos G, Pastene B, Bezulier K, Guilhaumou R, Solas C, et al. Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. *Int J Antimicrob Agents*. 2020 Nov;56(5):106136.
1595. Lothar SA, Abassi M, Agostinis A, Bangdiwala AS, Cheng MP, Drobot G, et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2

- (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. *Can J Anaesth*. 2020 Sep;67(9):1201–11.
1596. Louchet M, Sibiude J, Peytavin G, Picone O, Tréluyer J-M, Mandelbrot L. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. *Am J Obstet Gynecol MFM*. 2020 Aug;2(3):100159.
1597. Low ZY, Farouk IA, Lal SK. Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. *Viruses*. 2020 Sep;12(9).
1598. Lu C-C, Chen M-Y, Lee W-S, Chang Y-L. Potential therapeutic agents against COVID-19: What we know so far. *J Chin Med Assoc*. 2020 Jun;83(6):534–6.
1599. Lubetzky M, Aull MJ, Craig-Schapiro R, Lee JR, Marku-Podvorica J, Salinas T, et al. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*. 2020 Jul;35(7):1250–61.
1600. Lucchino B, Di Franco M, Conti F. COVID-19: an unexpected indication for anti-rheumatic therapies? Vol. 59, *Rheumatology (Oxford, England)*. 2020. p. 1200–3.
1601. Luo J, Rizvi H, Preeshagul IR, Egger J V, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. *Ann Oncol Off J Eur Soc Med Oncol*. 2020 Oct;31(10):1386–96.
1602. Ly TDA, Zanini D, Laforge V, Arlotto S, Gentile S, Mendizabal H, et al. Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020. *Int J Antimicrob Agents*. 2020 Dec;56(6):106219.
1603. Lyngbakken MN, Berdal J-E, Eskesen A, Kvale D, Olsen IC, Rangberg A, et al. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 485.
1604. Lyngbakken MN, Berdal J-E, Eskesen A, Kvale D, Olsen IC, Rueegg CS, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. *Nat Commun*. 2020 Oct;11(1):5284.
1605. Machado DJ de B, Ianhez LE. COVID-19 pneumonia in kidney transplant recipients-Where we are? *Transpl Infect Dis*. 2020 Oct;22(5):e13306.
1606. Machiels JD, Ter Avest M, Ten Oever J, Kramers C. [Chloroquine for COVID-19: a hype or not?]. *Ned Tijdschr Geneesk*. 2020 Dec;164.
1607. Machiels JD, Bleeker-Rovers CP, Ter Heine R, Rahamat-Langendoen J, de Mast Q, Ten Oever J, et al. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks? *Int J Antimicrob Agents*. 2020 Jul;56(1):106056.
1608. Maciorowski D, Idrissi SZ El, Gupta Y, Medernach BJ, Burns MB, Becker DP, et al. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. *SLAS Discov Adv life Sci R D*. 2020 Dec;25(10):1108–22.
1609. Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. *Virus Res*. 2020 Sep;286:198070.

1610. Magro G. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies? Vol. 37, Travel medicine and infectious disease. 2020. p. 101685.
1611. Mahalmani VM, Mahendru D, Sarma P, Prakash A, Medhi B. Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unknow. Vol. 52, Indian journal of pharmacology. 2020. p. 75–8.
1612. Maharaj AR, Wu H, Hornik CP, Balevic SJ, Hornik CD, Smith PB, et al. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. *JAMA Pediatr.* 2020 Oct;174(10):e202422.
1613. Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ.* 2020 May;369:m1844.
1614. Mahmoudjafari Z, Alexander M, Roddy J, Shaw R, Shigle TL, Timlin C, et al. American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States. *Biol blood marrow Transplant J Am Soc Blood Marrow Transplant.* 2020 Jun;26(6):1043–9.
1615. Maillart E, Leemans S, Van Noten H, Vandergraesen T, Mahadeb B, Salaouatchi MT, et al. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. *Infect Dis (London, England).* 2020 Sep;52(9):659–61.
1616. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. *Nature.* 2020 Sep;585(7826):584–7.
1617. Makarov V, Riabova O, Ekins S, Pluzhnikov N, Chepur S. The past, present and future of RNA respiratory viruses: influenza and coronaviruses. *Pathog Dis.* 2020 Oct;78(7).
1618. Malek SA, Bouchti I El. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease]. Vol. 35, The Pan African medical journal. 2020. p. 134.
1619. Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. *Medicine (Baltimore).* 2020 Dec;99(52):e23720.
1620. Mallhi TH, Ahmad A, Butt MH, Misbah S, Khan YH, Alotaibi NH. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals. *J Coll Physicians Surg Pak.* 2020 Oct;30(10):124–8.
1621. Malviya A. The continued dilemma about the usage of hydroxychloroquine: Respite is in randomized control trials. Vol. 99, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020. p. 310–1.
1622. Malviya A. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given. Vol. 72, Indian heart journal. 2020. p. 131–2.
1623. Manjunath BG, Tyagi D, Chaudhry D, Singh PK. Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception? Vol. 152, The Indian journal of medical research. 2020. p. 116–8.
1624. Manning TJ, Thomas-Richardson J, Cowan M, Beard T. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals. *Drug Discov Today.* 2020 Jun;25(6):956–8.

1625. Marciniec K, Beberok A, Pęczak P, Boryczka S, Wrześniok D. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. *Pharmacol Rep.* 2020 Dec;72(6):1553–61.
1626. Marcolino VA, Pimentel TC, Barão CE. What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. *Eur J Pharmacol.* 2020 Nov;887:173467.
1627. Mareev VY, Orlova YA, Pavlikova EP, Matskeplishvili ST, Akopyan ZA, Plisyk AG, et al. [Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronavirUs Infection requiring hospiTalization (BISCUIT)”]. *Kardiologija.* 2020 Sep;60(8):4–15.
1628. Marinaki S, Tsiakas S, Skalioti C, Lourida P, Argyraki A, Grigorakos K, et al. A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece. Vol. 56, *Medicina (Kaunas, Lithuania).* 2020.
1629. Marinho EM, Batista de Andrade Neto J, Silva J, Rocha da Silva C, Cavalcanti BC, Marinho ES, et al. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. *Microb Pathog.* 2020 Nov;148:104365.
1630. Marmor MF. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern? Vol. 213, *American journal of ophthalmology.* 2020. p. A3–4.
1631. Marotto D, Sarzi-Puttini P. What is the role of rheumatologists in the era of COVID-19? Vol. 19, *Autoimmunity reviews.* 2020. p. 102539.
1632. Marouf BH, Dizaye K. Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. *Drug Discov Ther.* 2020;14(3):109–16.
1633. Márquez-González H, Miranda-Navales MG, Solórzano-Santos F, Klunder-Klunder M, Garduño-Espinoza J, Méndez-Galván JF. COVID-19 pandemic: challenges ahead. *Bol Med Hosp Infant Mex.* 2020;77(5):242–51.
1634. Martin-Blondel G, Ruiz S, Murriss M, Faguer S, Duhalde V, Eyvrard F, et al. Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics. *Clin Infect Dis an Off Publ Infect Dis Soc Am.* 2020 Dec;71(11):2962–4.
1635. Martinez Navarro W, Ly L, Segal MS, Shukla AM. A Word of Caution in the Use of Hydroxychloroquine in the Elderly COVID-19 Population. Vol. 9, *Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). China;* 2020. p. 374–5.
1636. Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, Arias-Santiago S. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. *J Am Acad Dermatol.* 2020 Dec;83(6):1738–48.
1637. Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR. The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. *Curr Pharm Des.* 2020;26(35):4467–85.
1638. Martinez MA. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. *Antimicrob Agents Chemother.* 2020 Aug;64(9).
1639. Marto N, Monteiro EC. Medicines for the Treatment Of COVID-19: Awaiting the Evidence. *Acta Med Port.* 2020 Jul;33(7–8):500–4.

1640. Marzolini C, Stader F, Stoeckle M, Franzeck F, Egli A, Bassetti S, et al. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. *Antimicrob Agents Chemother*. 2020 Aug;64(9).
1641. Mason A, Rose E, Edwards CJ. Clinical management of Lupus patients during the COVID-19 pandemic. *Lupus*. 2020 Nov;29(13):1661–72.
1642. Massabeti R, Cipriani MS, Valenti I. Covid-19: A systemic disease treated with a wide-ranging approach: A case report. *J Popul Ther Clin Pharmacol = J la Ther des Popul la Pharmacol Clin*. 2020 Jul;27(S Pt 1):e26–30.
1643. Matangila JR, Nyembu RK, Telo GM, Ngoy CD, Sakobo TM, Massolo JM, et al. Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study. *PLoS One*. 2020;15(12):e0244272.
1644. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Vol. 79, *Annals of the rheumatic diseases*. England; 2020. p. 837–9.
1645. Mathies D, Rauschning D, Wagner U, Mueller F, Maibaum M, Binnemann C, et al. A case of SARS-CoV-2 pneumonia with successful antiviral therapy in a 77-year-old man with a heart transplant. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2020 Jul;20(7):1925–9.
1646. Mattioli M, Fustini E, Gennarini S. Heart transplant recipient patient with COVID-19 treated with tocilizumab. *Transpl Infect Dis*. 2020 Dec;22(6):e13380.
1647. Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, et al. Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. *Ann Rheum Dis*. 2020 Jun;79(6):724–6.
1648. Maxmen A. More than 80 clinical trials launch to test coronavirus treatments. Vol. 578, *Nature*. England; 2020. p. 347–8.
1649. Mayayo-Vicente S, Rodriguez Salvanés F, Gallego-Arenas A, Sánchez-Gómez LM, Ruiz-López M, Sierra García B, et al. [Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. *Semergen*. 2020 Aug;46 Suppl 1:20–7.
1650. Mazhar F, Hadi MA, Kow CS, Marran AMN, Merchant HA, Hasan SS. Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? *Int J Infect Dis IJID Off Publ Int Soc Infect Dis*. 2020 Dec;101:107–20.
1651. Mazzanti A, Briani M, Kukavica D, Bulian F, Marelli S, Trancuccio A, et al. Association of Hydroxychloroquine With QTc Interval in Patients With COVID-19. Vol. 142, *Circulation*. United States; 2020. p. 513–5.
1652. Mazzitelli M, Davoli C, Scaglione V, Fusco P, La Gamba V, Matera G, et al. Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. Vol. 37, *Travel medicine and infectious disease*. 2020. p. 101826.
1653. McDonald R. Cancer Progression Is Linked to Increased Risk of Death Within 30 Days of COVID-19 Diagnosis. *Oncology (Williston Park)*. 2020 Jul;34(7):249.
1654. McEniery CM, Fisk M, Miles K, Kaloyirou F, Hubsch A, Smith J, et al. Erratum: chemoPROphyLaxIs with hydroxychloroquine for covid-19 infeCtious disease (PROLIFIC) to

prevent covid-19 infection in frontline healthcare workers: a structured summary of a study protocol for a randomised controlled trial (Trials(2020)21(604)Doi: 10.1186/s13063-020-04543-4). *Trials* [Internet]. 2020 Jul;21(1):641. Available from: <https://dx.doi.org/10.1186/s13063-020-04578-7>

1655. McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. *Pharmacol Res.* 2020 Jul;157:104859.
1656. McLaughlin M. Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019. Vol. 13, *Journal of pediatric rehabilitation medicine.* Netherlands; 2020. p. 221–3.
1657. Medeiros-Domingo A, Carrasco OF, Berni-Betancourt A. Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2. *Arch Cardiol Mex.* 2020;90(Supl):36–40.
1658. Mégarbane B, Scherrmann J-M. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes? *J Clin Pharmacol.* 2020 Jul;60(7):808–14.
1659. Mégarbane B, Scherrmann J-M, Lê MP, Peiffer-Smadja N, Guedj J, Néant N, et al. Comment on: rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. *J Antimicrob Chemother* [Internet]. 2020 Jan;76(1):2376–80. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02199255/full>
1660. Mehta B, Moezinia CJ, Jannat-Khah D, Gibofsky A, Tornberg H, Pearce-Fisher D, et al. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists. *J Clin Rheumatol Pract reports Rheum Musculoskelet Dis.* 2020 Sep;26(6):224–8.
1661. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. *Am J Emerg Med.* 2020 Jul;38(7):1488–93.
1662. Mehta S, Bhandari S, Mehta S. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection? *J Glob Antimicrob Resist.* 2020 Sep;22:864–5.
1663. Meini S, Zini C, Passaleva MT, Frullini A, Fusco F, Carpi R, et al. Pneumatosis intestinalis in COVID-19. *BMJ open Gastroenterol.* 2020 Jun;7(1).
1664. Melgosa M, Madrid A, Álvarez O, Lumbreras J, Nieto F, Parada E, et al. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. *Pediatr Nephrol.* 2020 Aug;35(8):1521–4.
1665. Mella A, Mingozzi S, Gallo E, Lavacca A, Rossetti M, Clari R, et al. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. *Transpl Infect Dis.* 2020 Dec;22(6):e13348.
1666. Melody M, Nelson J, Hastings J, Propst J, Smerina M, Mendez J, et al. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. *Immunotherapy.* 2020 Oct;12(15):1121–6.
1667. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. *Eur Rev Med Pharmacol Sci.* 2020 Apr;24(8):4539–47.
1668. Mercurio NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol.* 2020 Sep;5(9):1036–41.

1669. Meriglier E, Rivoisy C, Hessamfar M, Bernard N, Aureau I, Lapoirie J, et al. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection. *J antimicrob chemother* [Internet]. 2020 Jan;76(2):482–6. Available from: <https://dx.doi.org/10.1093/jac/dkaa441>
1670. Merino JL, Martínez-Cossiani M, Iniesta A, Escobar C, Rey JR, Castrejón-Castrejón S. COVID-19 and QT interval prolongation: more than just drug toxicity? *Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol*. 2020 Oct;22(10):1479.
1671. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan M V, et al. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2020 May;34(5):6027–37.
1672. Miao H, Li H, Yao Y, Wu M, Lu C, Wang J, et al. Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol*. 2020 Dec;39(12):2211–23.
1673. Michelson M, Chow T, Martin NA, Ross M, Tee Qiao Ying A, Minton S. Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine. *J Med Internet Res*. 2020 Aug;22(8):e20007.
1674. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. *Arthritis Rheumatol (Hoboken, NJ)*. 2020 Aug;72(8):1241–51.
1675. Mikulska M, Nicolini LA, Signori A, Di Biagio A, Sepulcri C, Russo C, et al. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. *PLoS One*. 2020;15(8):e0237831.
1676. Millá Griñó E, Muniesa Royo MJ, Pazos López M. Therapeutic conflict in patients with COVID-19 and glaucoma. Vol. 155, *Medicina clinica*. 2020. p. 182.
1677. Millán-Oñate J, Millan W, Mendoza LA, Sánchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, et al. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. *Ann Clin Microbiol Antimicrob*. 2020 Apr;19(1):16.
1678. Miller-Handley H, Lockett K, Govil A. Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. *Adv Chronic Kidney Dis*. 2020 Sep;27(5):434–41.
1679. Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis*. 2020;35:101738.
1680. Million M, Roussel Y, Raoult D. Chloroquine and COVID-19: A western medical and scientific drift? Vol. 78, *European journal of internal medicine*. 2020. p. 4–5.
1681. Mills WR, Creasy SM, Sender S, Lichtefeld J, Romano N, Reynolds K, et al. Hydroxychloroquine Sulfate Prescribing Trends and Pharmacist-Led Outbreak Preparedness in Long-Term Care Pharmacy during Coronavirus Disease 2019. Vol. 21, *Journal of the American Medical Directors Association*. 2020. p. 1000–1.
1682. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. *Clin Rheumatol*. 2020 Jul;39(7):2055–62.
1683. Misra S, Nath M, Hadda V, Vibha D. Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis. *Eur J Clin Invest*. 2020 Nov;50(11):e13383.

1684. Mo L, Zheng P. [Chloroquine phosphate: therapeutic drug for COVID-19]. *Nan Fang Yi Ke Da Xue Xue Bao*. 2020 Apr;40(4):586–94.
1685. Modi AR, Koval CE, Taeye AJ, Modaresi Esfeh J, Eghtesad B, Narayanan Menon K V, et al. Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. *Transpl Infect Dis*. 2020 Oct;22(5):e13351.
1686. Mohamed K, Yazdanpanah N, Saghadzadeh A, Rezaei N. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. *Bioorg Chem [Internet]*. 2020 Jan;106:104490. Available from: <https://dx.doi.org/10.1016/j.bioorg.2020.104490>
1687. Mohanta TK, Sharma N, Arina P, Defilippi P. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues. *Biomed Res Int*. 2020;2020:8827752.
1688. Molina-Iturriza E, San-José-Muñiz I, Ganchegui-Aguirre M, Balerdi-Sarasola L, Ortiz-de-Zárata-Ibarra Z, Gainzarain-Arana JC, et al. Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain. Vol. 34, *AIDS (London, England)*. England; 2020. p. 1696–7.
1689. Montastruc J-L, Toutain P-L. A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study. *Drug Saf*. 2020 Jul;43(7):657–60.
1690. Monte Serrano J, Cruañes Monferrer J, García-García M, García-Gil MF. Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19. *Med Clin (Barc)*. 2020 Sep;155(5):231.
1691. Monteiro WM, Brito-Sousa JD, Baía-da-Silva D, Melo GC de, Siqueira AM, Val F, et al. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes. Vol. 53, *Revista da Sociedade Brasileira de Medicina Tropical*. 2020. p. e20200155.
1692. Montero F, Martínez-Barrío J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. *Rheumatol Int*. 2020 Oct;40(10):1593–8.
1693. Montrone M, Catino A, Palmieri VO, Longo V, Galetta D. Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib. Vol. 138, *European journal of cancer (Oxford, England : 1990)*. 2020. p. 109–12.
1694. Monzani A, Genoni G, Scopinaro A, Pistis G, Kozel D, Secco GG. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine. Vol. 50, *European journal of clinical investigation*. 2020. p. e13258.
1695. Moore N. Chloroquine for COVID-19 Infection. Vol. 43, *Drug safety*. 2020. p. 393–4.
1696. Morales-Ortega A, Bernal-Bello D, Llarena-Barroso C, Frutos-Pérez B, Duarte-Millán MÁ, García de Viedma-García V, et al. Imatinib for COVID-19: A case report. Vol. 218, *Clinical immunology (Orlando, Fla.)*. 2020. p. 108518.
1697. Morlacchi LC, Rossetti V, Gigli L, Amati F, Rosso L, Aliberti S, et al. COVID-19 in lung transplant recipients: A case series from Milan, Italy. *Transpl Infect Dis*. 2020 Dec;22(6):e13356.
1698. Morris G, Athan E, Walder K, Bortolasci CC, O’Neil A, Marx W, et al. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19? *Life Sci*. 2020 Dec;262:118541.

1699. Moschini L, Loffi M, Regazzoni V, Di Tano G, Gherbesi E, Danzi GB. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. *Hear Vessel* [Internet]. 2020 Jan;36(1):115–20. Available from: <https://dx.doi.org/10.1007/s00380-020-01671-4>
1700. Mosconi G, Spazzoli A, Bruno PF, Angelini ML, Cristino S, Lifrieri MF, et al. [Resilience in COVID-19 times: general considerations on the recovery of a 93-year-old patient on haemodialysis treatment]. Vol. 37, *Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia*. Italy; 2020.
1701. Motta I, Centis R, D'Ambrosio L, García-García J-M, Goletti D, Gualano G, et al. Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. *Pulmonology*. 2020;26(4):233–40.
1702. Moura-Neto JA, Misael AM, Silva DR da, D'Avila R, Andreoli MCC, Kraychete A, et al. Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function. *J Bras Nefrol 'orgao Of Soc Bras e Latino-Americana Nefrol*. 2020 Aug;42(2 suppl 1):49–50.
1703. Mubagwa K. Cardiac effects and toxicity of chloroquine: a short update. *Int J Antimicrob Agents*. 2020 Aug;56(2):106057.
1704. Mughal MS, Rehman R, Osman R, Kan N, Mirza H, Eng MH. Hilar lymphadenopathy, a novel finding in the setting of coronavirus disease (COVID-19): a case report. *J Med Case Rep*. 2020 Aug;14(1):124.
1705. Mukhtyar C. Hydroxychloroquine and coronavirus disease 2019. Vol. 50, *The journal of the Royal College of Physicians of Edinburgh*. Scotland; 2020. p. 102–4.
1706. Muñoz P, Galar A, Catalán P, Valerio M, Aldamiz-Echevarría T, Cólliga C, et al. The first 100 cases of COVID-19 in a Hospital in Madrid with a 2-month follow-up. *Rev Esp Quimioter Publ Of la Soc Esp Quimioter*. 2020 Oct;33(5):369–78.
1707. Mvumbi DM. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings. Vol. 143, *Medical hypotheses*. 2020. p. 109912.
1708. Nachege JB, Ishoso DK, Otokoye JO, Hermans MP, Machezano RN, Sam-Agudu NA, et al. Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. *Am J Trop Med Hyg*. 2020 Dec;103(6):2419–28.
1709. Nagaraja BS, Ramesh KN, Dhar D, Mondal MS, Dey T, Saha S, et al. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. *J Public Health (Oxf)*. 2020 Aug;42(3):493–503.
1710. Naghipour S, Ghodousi M, Rahsepar S, Elyasi S. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. *Expert Rev Anti Infect Ther*. 2020 Nov;18(11):1119–33.
1711. Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. *Eur Hear journal Acute Cardiovasc care*. 2020 Apr;9(3):215–21.
1712. Nanni O, Viale P, Vertogen B, Lilli C, Zingaretti C, Donati C, et al. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial. *Trials*. 2020 Jul;21(1):689.

1713. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. *Mycoses*. 2020 Aug;63(8):766–70.
1714. Nasiri S, Dadkhahfar S, Abasifar H, Mortazavi N, Gheisari M. Urticarial vasculitis in a COVID-19 recovered patient. *Int J Dermatol*. 2020 Oct;59(10):1285–6.
1715. Nath KA. The COVID-19 Pandemic and Mayo Clinic Proceedings. Vol. 95, Mayo Clinic proceedings. 2020. p. 835–6.
1716. Nau J-Y. [Not Available]. Vol. 16, *Revue medicale suisse*. Switzerland; 2020. p. 756–7.
1717. Nawar T, Morjaria S, Kaltsas A, Patel D, Perez-Johnston R, Daniyan AF, et al. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow? Vol. 95, *American journal of hematology*. 2020. p. E210–3.
1718. Naymagon L, Berwick S, Kessler A, Lancman G, Gidwani U, Troy K. The emergence of methemoglobinemia amidst the COVID-19 pandemic. Vol. 95, *American journal of hematology*. 2020. p. E196–7.
1719. Nessaibia I, Siciliano D, Tahraoui A. Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19? *Int J Health Plann Manage*. 2020 Nov;35(6):1311–3.
1720. Neves FS. Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2. Vol. 152, *The Indian journal of medical research*. 2020. p. 124–6.
1721. Nguyen VT, Rivière P, Ripoll P, Barnier J, Vuillemot R, Ferrand G, et al. Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. *J Clin Epidemiol* [Internet]. 2020 Feb;130:107–16. Available from: <https://dx.doi.org/10.1016/j.jclinepi.2020.10.010>
1722. Ngwa W, Kumar R, Thompson D, Lyerly W, Moore R, Reid T-E, et al. Potential of Flavonoid-Inspired Phytomedicines against COVID-19. *Molecules*. 2020 Jun;25(11).
1723. Niburski K, Niburski O. Impact of Trump’s Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study. *J Med Internet Res*. 2020 Nov;22(11):e20044.
1724. Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D, et al. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. *Clin Pharmacol Ther*. 2020 Dec;108(6):1135–49.
1725. Nie NF, He Y. [Potential therapeutic drugs for novel coronavirus pneumonia]. *Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese J Tuberc Respir Dis*. 2020 Nov;43(11):970–4.
1726. Nikoupour H, Kazemi K, Arasteh P, Ghazimoghadam S, Eghlimi H, Dara N, et al. Pediatric liver transplantation and COVID-19: a case report. *BMC Surg*. 2020 Oct;20(1):224.
1727. Nina PB, Dash AP. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? *Indian J Public Health*. 2020 Jun;64(Supplement):S125–7.
1728. Niriella MA, Ediriweera DS, De Silva AP, Premarathne R, Balasooriya P, Duminda KD, et al. Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial. *Trials*. 2020 Aug;21(1):748.

1729. Nittari G, Pallotta G, Amenta F, Tayebati SK. Current pharmacological treatments for SARS-COV-2: A narrative review. *Eur J Pharmacol.* 2020 Sep;882:173328.
1730. Niu J, Shen L, Huang B, Ye F, Zhao L, Wang H, et al. Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice. *Antiviral Res.* 2020 Jan;173:104646.
1731. Niwas R, S AS, Garg MK, Nag VL, Bhatia PK, Dutt N, et al. Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience. *Adv Respir Med.* 2020;88(6):515–9.
1732. Nojomi M, Yassin Z, Keyvani H, Makiani MJ, Roham M, Laali A, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. *BMC Infect Dis.* 2020 Dec;20(1):954.
1733. Norinder U, Tuck A, Norgren K, Munic Kos V. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19. *Biomed Pharmacother.* 2020 Oct;130:110582.
1734. Novara E, Molinaro E, Benedetti I, Bonometti R, Lauritano EC, Boverio R. Severe acute dried gangrene in COVID-19 infection: a case report. *Eur Rev Med Pharmacol Sci.* 2020 May;24(10):5769–71.
1735. Nowak JK, Walkowiak J. Lithium and coronaviral infections. A scoping review. *F1000Research.* 2020;9:93.
1736. Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Vol. 79, *Annals of the rheumatic diseases.* 2020. p. 1659–61.
1737. O’Kelly B, McGettrick P, Angelov D, Fay M, McGinty T, Cotter AG, et al. Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2. Vol. 190, *British journal of haematology.* 2020. p. e1–3.
1738. Obeidat M, Isaacson AL, Chen SJ, Ivanovic M, Holanda D. Zebra-like bodies in COVID-19: is phospholipidosis evidence of hydroxychloroquine induced acute kidney injury? Vol. 44, *Ultrastructural pathology.* England; 2020. p. 519–23.
1739. Offerhaus JA, Wilde AAM, Remme CA. Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. *Hear Rhythm.* 2020 Sep;17(9):1480–6.
1740. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: Will this be the way forward? *Biosci Trends.* 2020 May;14(2):159–60.
1741. Okafor EC, Pastick KA, Rajasingham R, Khan M-S, Butler J, Avidan MS, et al. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Vol. 383, *The New England journal of medicine.* United States; 2020. p. 1088–9.
1742. Okour M, Al-Kofahi M, Austin D. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. *J Pharmacokinet Pharmacodyn.* 2020 Jun;47(3):187–8.
1743. Oldenburg CE, Doan T. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19. Vol. 102, *The American journal of tropical medicine and hygiene.* 2020. p. 1154–5.
1744. Oliva M, Hsu K, Alsamarai S, Chavez V de, Ferrara L. Clinical improvement of severe COVID-19 pneumonia in a pregnant patient after caesarean delivery. *BMJ Case Rep.* 2020 Jul;13(7).

1745. Oliveira J E Silva L, Vidor M V, Zarpellon de Araújo V, Bellolio F. Flexibilization of Science, Cognitive Biases, and the COVID-19 Pandemic. *Mayo Clin Proc.* 2020 Sep;95(9):1842–4.
1746. Ordoñez-Boschetti L, Torres-Romero CM, Ortiz de Leo MJ. Associated posterior reversible encephalopathy syndrome (PRES) to SARS-CoV-2. Case report. Vol. 35, *Neurologia* (Barcelona, Spain). 2020. p. 696–8.
1747. Oren O, Yang EH, Gluckman TJ, Michos ED, Blumenthal RS, Gersh BJ. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. *Circ Arrhythm Electrophysiol.* 2020 Jun;13(6):e008688.
1748. Oroojalian F, Haghbin A, Baradaran B, Hemmat N, Shahbazi M-A, Baghi HB, et al. Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. *Int J Biol Macromol.* 2020 Dec;165(Pt A):18–43.
1749. Ortega JT, Serrano ML, Jastrzebska B. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis. *Biomolecules.* 2020 Jun;10(6).
1750. Ortega JT, Zambrano JL, Jastrzebska B, Liprandi F, Rangel HR, Pujol FH. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. *Intervirology.* 2020;63(1–6):2–9.
1751. Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? *Int J Antimicrob Agents.* 2020 Sep;56(3):106078.
1752. Oscanoa TJ, Vidal X, Kanters JK, Romero-Ortuno R. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis. *Int J Antimicrob Agents.* 2020 Dec;56(6):106212.
1753. Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. Covid-19 and exacerbation of psoriasis. Vol. 33, *Dermatologic therapy.* 2020. p. e13632.
1754. Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. *Ann Rheum Dis.* 2020 Dec;79(12):1544–9.
1755. Padilla S, Telenti G, Guillén L, García JA, García-Abellán J, Ding C, et al. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. *Int J Antimicrob Agents.* 2020 Oct;56(4):106142.
1756. Pagliano P, Piazza O, De Caro F, Ascione T, Filippelli A. Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019? Vol. 71, *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.* 2020. p. 887–8.
1757. Pahan P, Pahan K. Smooth or Risky Revisit of an Old Malaria Drug for COVID-19? *J neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol.* 2020 Jun;15(2):174–80.
1758. Pahlajani D. Hydroxychloroquin for COVID-19 Why was so much hype? *J Assoc Physicians India.* 2020 Aug;68(8):94–6.
1759. Painvin B, Guillot P, Verdier M-C, Gacouin A, Maamar A. Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study. Vol. 46, *Intensive care medicine.* 2020. p. 1772–3.

1760. Paital B, Das K, Parida SK. Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. *Sci Total Environ.* 2020 Aug;728:138914.
1761. Paliani U, Cardona A. COVID-19 and hydroxychloroquine: Is the wonder drug failing? Vol. 78, *European journal of internal medicine.* 2020. p. 1–3.
1762. Paliani U, Cardona A. COVID-19 and hydroxychloroquine: Let the available data speak for themselves. Vol. 80, *European journal of internal medicine.* 2020. p. 121.
1763. Palmeira VA, Costa LB, Perez LG, Ribeiro VT, Lanza K, Silva ACSE. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19? *Clinics (Sao Paulo).* 2020;75:e1928.
1764. Pan X, Dong L, Yang L, Chen D, Peng C. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. *Virus Res.* 2020 Sep;286:198057.
1765. Panda PK, Bandyopadhyay A, Singh BC, Moirangthem B, Chikara G, Saha S, et al. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Vol. 21, *Trials.* 2020. p. 866.
1766. Pandolfi L, Fossali T, Frangipane V, Bozzini S, Morosini M, D'Amato M, et al. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome. *BMC Pulm Med.* 2020 Nov;20(1):301.
1767. Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. *Int J Antimicrob Agents.* 2020 Aug;56(2):106053.
1768. Pareek A, Bhandari S, Mehta RT. Hydroxychloroquine for prophylaxis in COVID-19: Need to revisit dosing regimen. Vol. 152, *The Indian journal of medical research.* 2020. p. 130–2.
1769. Parisi S, Ditto MC, Finucci A, Fusaro E. How to manage rheumatic patients during the coronavirus pandemic. Vol. 62, *Panminerva medica. Italy;* 2020. p. 176–7.
1770. Park S-J, Yu K-M, Kim Y-I, Kim S-M, Kim E-H, Kim S-G, et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. *MBio.* 2020 May;11(3).
1771. Parra-Lara LG, Martínez-Arboleda JJ, Rosso F. Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going. *J Glob Antimicrob Resist.* 2020 Sep;22:680–4.
1772. Parrotta E, Kister I, Charvet L, Sammarco C, Saha V, Charlson RE, et al. COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. *Neurol Neuroimmunol neuroinflammation.* 2020 Sep;7(5).
1773. Pascarella G, Strumia A, Piliago C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. *J Intern Med.* 2020 Aug;288(2):192–206.
1774. Patel J, Coulthard P. Hydroxychloroquine shortage. Vol. 228, *British dental journal.* 2020. p. 810.
1775. Patel TK, Barvaliya M, Kevadiya BD, Patel PB, Bhalla HL. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. *J neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol.* 2020 Sep;15(3):350–8.
1776. Pathak DSK, Salunke DAA, Thivari DP, Pandey A, Nandy DK, Harish V K Ratna D, et al. No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis

of Randomized Controlled Trials". *Diabetes Metab Syndr* [Internet]. 2020;14(6):1673–80. Available from: <https://dx.doi.org/10.1016/j.dsx.2020.08.033>

1777. Pathoulas JT, Flanagan KE, Walker CJ, Pupo Wiss IM, Hagigeorges D, Senna MM. Hydroxychloroquine use and COVID-19 concerns among alopecia patients: A cross-sectional survey study. Vol. 33, *Dermatologic therapy*. United States; 2020. p. e14529.
1778. Pati S, Houston T. Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. *Epilepsy Res*. 2020 Sep;165:106399.
1779. Patil VM, Singhal S, Masand N. A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. *Life Sci*. 2020 Aug;254:117775.
1780. Patri A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? Vol. 82, *Journal of the American Academy of Dermatology*. 2020. p. e221.
1781. Patrono D, Lupo F, Canta F, Mazza E, Mirabella S, Corcione S, et al. Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy. *Transpl Infect Dis*. 2020 Oct;22(5):e13353.
1782. Paumgartten FJR, Delgado IF, Pitta L da R, Oliveira ACAX de. Chloroquine and hydroxychloroquine repositioning in times of COVID-19 pandemics, all that glitters is not gold. *Cad Saude Publica*. 2020;36(5):e00088520.
1783. Paumgartten FJR, Oliveira ACAX de. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. *Cien Saude Colet*. 2020 Sep;25(9):3413–9.
1784. Pelle MC, Tassone B, Ricchio M, Mazzitelli M, Davoli C, Procopio G, et al. Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. *J Med Case Rep*. 2020 Dec;14(1):246.
1785. Peña-Salazar C, López Cuiña M, Chavarría V, Robles Olmo B. Convulsive status epilepticus as a possible symptom of COVID-19 in a patient with intellectual disability and autistic spectrum disorder. Vol. 35, *Neurologia (Barcelona, Spain)*. 2020. p. 703–5.
1786. Pereda R, González D, Rivero HB, Rivero JC, Pérez A, López LDR, et al. Therapeutic Effectiveness of Interferon- α 2b Against COVID-19: The Cuban Experience. *J Interf cytokine Res Off J Int Soc Interf Cytokine Res*. 2020 Sep;40(9):438–42.
1787. Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, Perez-Medina T. Clinical course of coronavirus disease-2019 in pregnancy. *Acta Obstet Gynecol Scand*. 2020 Jul;99(7):839–47.
1788. Pereira BB. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. *J Toxicol Environ Health B Crit Rev*. 2020 May;23(4):177–81.
1789. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2020 Jul;20(7):1800–8.
1790. Pérez-Belmonte LM, López-Carmona MD, Quevedo-Marín JL, Ricci M, Martín-Carmona J, Sanz-Cánovas J, et al. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. *Int J Environ Res Public Health*. 2020 Sep;17(18).

1791. Perinel S, Launay M, Botelho-Nevers É, Diconne É, Louf-Durier A, Lachand R, et al. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2020 Nov;71(16):2227–9.
1792. Perišić O. Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues. *Biomolecules*. 2020 Sep;10(9).
1793. Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. *J Autoimmun*. 2020 Jul;111:102468.
1794. Pers Y-M, Padern G. Revisiting the cardiovascular risk of hydroxychloroquine in RA. *Nat Rev Rheumatol*. 2020 Dec;16(12):671–2.
1795. Peschken CA. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. Vol. 47, *The Journal of rheumatology*. Canada; 2020. p. 787–90.
1796. Pianta L, Vinciguerra A, Bertazzoni G, Morello R, Mangiatordi F, Lund VJ, et al. Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19. *Eur Arch oto-rhinolaryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology - Head Neck Surg*. 2020 Oct;277(10):2921–4.
1797. Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. *Int J Mol Sci*. 2020 May;21(9).
1798. Pillat MM, Krüger A, Guimarães LMF, Lameu C, de Souza EE, Wrenger C, et al. Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. *Cytometry A*. 2020 Sep;97(9):872–81.
1799. Pilotto A, Odolini S, Masciocchi S, Comelli A, Volonghi I, Gazzina S, et al. Steroid-Responsive Encephalitis in Coronavirus Disease 2019. *Ann Neurol*. 2020 Aug;88(2):423–7.
1800. Pimentel J, Andersson N. Chloroquine and its derivatives in the management of COVID-19: A scoping review. *Biomedica*. 2020 Oct;40(Supl. 2):80–95.
1801. Pirjani R, Soori T, Dehpour AR, Sepidarkish M, Moini A, Shizarpour A, et al. Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 467.
1802. Piszczatoski CR, Powell J. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. *Ann Pharmacother*. 2020 Aug;54(8):827–31.
1803. Pivetta E. The COVID-19 pandemic: a stress test for clinical epidemiology. Vol. 44, *Epidemiologia e prevenzione*. Italy; 2020. p. 28–9.
1804. Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Dulière V, et al. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. *Antiviral Res*. 2020 Sep;181:104878.
1805. Płusa T. [Options for controlling new Corona virus infection - 2019-nCoV]. *Pol Merkur Lekarski*. 2020 Apr;48(284):112–9.
1806. Płusa T, Lengier-Krajewska M, Baranowska A, Krawczyk J. Chloroquine in controlling biological infections. *Pol Merkur Lekarski*. 2020 Jun;48(285):199–203.

1807. Podlasin RB, Kowalska JD, Pihowicz A, Wojtycha-Kwaśnica B, Thompson M, Dyda T, et al. How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. *Eur J Med Res.* 2020 Aug;25(1):37.
1808. Popescu CP, Fischer PR. Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous? Vol. 35, *Travel medicine and infectious disease.* 2020. p. 101764.
1809. Porta-Etessam J, Yus M, González García N, Valcarcel A, Barrado-Cuchillo J, Pérez-Somarriba J. Brain inflammatory thrombogenic vasculopathy related with SARS-CoV-2 infection. Vol. 35, *Neurologia (Barcelona, Spain).* 2020. p. 701–3.
1810. Pothen L, Yildiz H, De Greef J, Penaloza A, Beuloye C, Belkhir L, et al. Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center. Vol. 36, *Travel medicine and infectious disease.* 2020. p. 101788.
1811. Prajapati S, Sharma M, Kumar A, Gupta P, Narasimha Kumar G V. An update on novel COVID-19 pandemic: a battle between humans and virus. *Eur Rev Med Pharmacol Sci.* 2020 May;24(10):5819–29.
1812. Prata-Barbosa A, Lima-Setta F, Santos GR Dos, Lanziotti VS, de Castro REV, de Souza DC, et al. Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study. *J Pediatr (Rio J).* 2020;96(5):582–92.
1813. Prayuenyong P, Kasbekar A V, Baguley DM. Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. *Front public Heal.* 2020;8:252.
1814. Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. *Lancet Infect Dis.* 2020 Oct;20(10):1118.
1815. Procacci P, Macchiagodena M, Pagliai M, Guarnieri G, Iannone F. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations. *Chem Commun (Camb).* 2020 Aug;56(62):8854–6.
1816. Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. *Rev Cardiovasc Med.* 2020 Dec;21(4):611–4.
1817. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Humphrey LL, Miller MC, Abraham GM, et al. Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. *Ann Intern Med.* 2020 Jul;173(2):137–42.
1818. Quiros Roldan E, Biasiotto G, Magro P, Zanella I. The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? *Pharmacol Res.* 2020 Aug;158:104904.
1819. R Karim HM, Ahmed G. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers. Vol. 152, *The Indian journal of medical research.* 2020. p. 119–20.
1820. Rabby MII, Hossain F. Study of ongoing registered clinical trials on COVID-19: a narrative review. *Sao Paulo Med J.* 2020;138(5):441–56.
1821. Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Jalalabadi NZ, et al. Interferon β -1b in treatment of severe COVID-19: A randomized clinical trial. *Int Immunopharmacol.* 2020 Nov;88:106903.

1822. Rahmani H, Davoudi-Monfared E, Nourian A, Nabiee M, Sadeghi S, Khalili H, et al. Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. *Daru*. 2020 Dec;28(2):625–34.
1823. Rahmanzade R, Rahmanzadeh R, Hashemian SM. Respiratory Distress in Postanesthesia Care Unit: First Presentation of Coronavirus Disease 2019 in a 17-Year-Old Girl: A Case Report. *A&A Pract*. 2020 May;14(7):e01227.
1824. Rajaiah R, Abhilasha K V, Shekar MA, Vogel SN, Vishwanath BS. Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. *Cell Immunol*. 2020 Dec;358:104240.
1825. Ramachandran V, Marimuthu RR, Chinnambedu RS. World War against COVID-19: How strong is our armamentarium? Vol. 75, *The Medical journal of Malaysia*. Malaysia; 2020. p. 314–5.
1826. Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. *J Am Heart Assoc*. 2020 Jun;9(12):e017144.
1827. Rani S, Grover S, Mehra A, Sahoo S. Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients. Vol. 52, *Indian journal of pharmacology*. 2020. p. 229–31.
1828. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. *Lancet Infect Dis*. 2020 Oct;20(10):1118–9.
1829. Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: A report of two cases. Vol. 81, *The Journal of infection*. 2020. p. e72–3.
1830. Redondo-Sendino Á, González Sánchez IC, de Victoria Fernández B. Skin manifestations associated with the new coronavirus SARS-CoV-2 disease. Vol. 155, *Medicina clinica*. 2020. p. 414–5.
1831. Regazzoni V, Loffi M, Garini A, Danzi GB. Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia - Something to Be Concerned About? *Circ J*. 2020 Sep;84(10):1887.
1832. Rein N, Haham N, Orenbuch-Harroch E, Romain M, Argov Z, Vaknin-Dembinsky A, et al. Description of 3 patients with myasthenia gravis and COVID-19. *J Neurol Sci*. 2020 Oct;417:117053.
1833. Rendic S, Guengerich FP. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. *Curr Drug Metab*. 2020;21(14):1127–35.
1834. Retsas S. Clinical trials and the COVID-19 pandemic. *Hell J Nucl Med*. 2020;23(1):4–5.
1835. Richard SA, Kampo S, Hechavarria ME, Sackey M, Buunaaim ADB, Kuugbee ED, et al. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. *J Immunol Res*. 2020;2020:4582612.
1836. Richardson PJ, Ottaviani S, Prella A, Stebbing J, Casalini G, Corbellino M. CNS penetration of potential anti-COVID-19 drugs. Vol. 267, *Journal of neurology*. 2020. p. 1880–2.
1837. Ridgway JP, Farley B, Benoit J-L, Frohne C, Hazra A, Pettit N, et al. A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois. *AIDS Patient Care STDS*. 2020 Aug;34(8):331–5.
1838. Righi G, Del Popolo G. COVID-19 tsunami: the first case of a spinal cord injury patient in Italy. *Spinal cord Ser cases*. 2020 Apr;6(1):22.

1839. Rilinger J, Kern W V, Duerschmied D, Supady A, Bode C, Staudacher DL, et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 470.
1840. Risch HA. Risch Responds to “How to Consider Low Reported Death Rates in COVID-19”. *Am J Epidemiol*. 2020 Nov;189(11):1230–1.
1841. Risch HA, Peiffer-Smadja N, Costagliola D. RE: “EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS”. *Am J Epidemiol* [Internet]. 2020 Nov;189(11):1443–4. Available from: <https://dx.doi.org/10.1093/aje/kwaa151>
1842. Riva E, Sainaghi PP, Turriziani O, Antonelli G, Patti G. SARS-CoV-2 infection: diagnostic testing results occasionally require special attention. Vol. 9, *Emerging microbes & infections*. United States; 2020. p. 1955–7.
1843. Rivera-Izquierdo M, Valero-Ubierna MDC, R-delAmo JL, Fernández-García MÁ, Martínez-Diz S, Tahery-Mahmoud A, et al. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. *Med Clin (Barc)*. 2020 Nov;155(9):375–81.
1844. Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu C-Y, et al. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. *Cancer Discov*. 2020 Oct;10(10):1514–27.
1845. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmacologic Immunomodulatory Therapy in COVID-19. *Drugs*. 2020 Sep;80(13):1267–92.
1846. Rizzi S, Wensink MJ, Lindahl-Jacobsen R, Tian L, Lu Y, Eisenberg ML. Risk of pre-term births and major birth defects resulting from paternal intake of COVID-19 medications prior to conception. *BMC Res Notes*. 2020 Nov;13(1):509.
1847. Robustelli Test E, Vezzoli P, Carugno A, Raponi F, Gianatti A, Rongioletti F, et al. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19). Vol. 34, *Journal of the European Academy of Dermatology and Venereology : JEADV*. 2020. p. e457–9.
1848. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. *Circulation*. 2020 May;141(24):2623–4.
1849. Rodrigo C, Fernando SD, Rajapakse S. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2020 Aug;26(8):979–87.
1850. Rodríguez-Martínez CE, Fernandes RM, Hawcutt DB, Sinha IP, Pacheco RL. Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence. *Acta Paediatr*. 2020 Sep;109(9):1711–2.
1851. Rodríguez-Valero N, Vera I, Torralvo MR, De Alba T, Ferrer E, Camprubi D, et al. Malaria prophylaxis approach during COVID-19 pandemic. Vol. 38, *Travel medicine and infectious disease*. 2020. p. 101716.
1852. Rogado J, Obispo B, Pangua C, Serrano-Montero G, Martín Marino A, Pérez-Pérez M, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. *Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex*. 2020 Dec;22(12):2364–8.

1853. Rogado J, Pangua C, Serrano-Montero G, Obispo B, Marino AM, Pérez-Pérez M, et al. Covid-19 and lung cancer: A greater fatality rate? *Lung Cancer*. 2020 Aug;146:19–22.
1854. Rokohl AC, Loreck N, Wawer Matos PA, Mor JM, Zwingelberg S, Grajewski RS, et al. [The role of ophthalmology in the COVID-19 pandemic]. *Ophthalmologie*. 2020 Jul;117(7):642–7.
1855. Romano MR, Raimondi R, Montericcio A, Allegrini D. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium. Vol. 258, *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie*. 2020. p. 2871.
1856. Romão VC, Cruz-Machado AR, Fonseca JE. No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: response to the comment by Joob and Wiwanitkit. *Ann rheum dis* [Internet]. 2020 Feb;80(2):e22. Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217665>
1857. Rome BN, Avorn J. Drug Evaluation during the Covid-19 Pandemic. *N Engl J Med*. 2020 Jun;382(24):2282–4.
1858. Roomi S, Ullah W, Ahmed F, Farooq S, Sadiq U, Chohan A, et al. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. *J Med Internet Res*. 2020 Sep;22(9):e21758.
1859. Roongta R, Ghosh A. Managing rheumatoid arthritis during COVID-19. *Clin Rheumatol*. 2020 Nov;39(11):3237–44.
1860. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020 Jun;323(24):2493–502.
1861. Rosenberg ES, Holtgrave DR, Udo T. Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19. Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 38–9.
1862. Rosendaal FR. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2020, DOI:10.1016/j.ijantimicag.2020.105949. *Int J Antimicrob Agents* [Internet]. 2020 Jul;56(1):106063. Available from: <https://dx.doi.org/10.1016/j.ijantimicag.2020.106063>
1863. Rosenke K, Jarvis MA, Feldmann F, Schwarz B, Okumura A, Lovaglio J, et al. Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. *JCI insight*. 2020 Dec;5(23).
1864. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk Factors Associated With In-Hospital Mortality in a US National Sample of Patients With COVID-19. *JAMA Netw open*. 2020 Dec;3(12):e2029058.
1865. Ross SB, Wilson MG, Papillon-Ferland L, Elsayed S, Wu PE, Battu K, et al. COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. *J Am Geriatr Soc*. 2020 Aug;68(8):1636–46.
1866. Rossi E, Lasagni C, Trakatelli M, Wertzberger Rowan S, Magnoni C. Acute maculopapular eruption in Covid-19 patient: A case report. *Dermatol Ther*. 2020 Nov;33(6):e13812.
1867. Rossi G, Ferrari SA, Sommaruga S, Muzzarelli L, Piconi S. An infection-oriented approach for thoracic endovascular aortic repair in a SARS-CoV-2 positive patient. A case report. *Ann Ital Chir*. 2020;91:273–6.

1868. Roustit M, Guilhaumou R, Molimard M, Drici M-D, Laporte S, Montastruc J-L. Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. *Therapie*. 2020;75(4):363–70.
1869. Rowland Yeo K, Zhang M, Pan X, Ban Ke A, Jones HM, Wesche D, et al. Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. *Clin Pharmacol Ther*. 2020 Nov;108(5):976–84.
1870. Ruamviboonsuk P, Lai TYY, Chang A, Lai C-C, Mieler WF, Lam DSC. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. *Asia-Pacific J Ophthalmol (Philadelphia, Pa)*. 2020;9(2):85–7.
1871. Ruamviboonsuk P, Lai TYY, Chang A, Lai C-C, Mieler WF, Lam DSC. Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19). Vol. 9, *Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)*. China; 2020. p. 375–6.
1872. Rubin EJ, Baden LR, Morrissey S. Audio Interview: Diagnosis and Early Treatment of Covid-19. Vol. 382, *The New England journal of medicine*. United States; 2020. p. e103.
1873. Rubin EJ, Baden LR, Morrissey S. Audio Interview: New Data on Remdesivir in Covid-19. Vol. 382, *The New England journal of medicine*. United States; 2020. p. e94.
1874. Rubin EJ, Baden LR, Morrissey S. Audio Interview: New Research on Possible Treatments for Covid-19. Vol. 382, *The New England journal of medicine*. United States; 2020. p. e30.
1875. Rubin EJ, Baden LR, Morrissey S. Audio Interview: Studying Potential Covid-19 Therapies. Vol. 382, *The New England journal of medicine*. United States; 2020. p. e72.
1876. Rubin EJ, Harrington DP, Hogan JW, Gatsonis C, Baden LR, Hamel MB. The Urgency of Care during the Covid-19 Pandemic - Learning as We Go. Vol. 382, *The New England journal of medicine*. 2020. p. 2461–2.
1877. Rughiniş C, Dima L, Vasile S, Rughinis C, Dima L, Vasile S. Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. *Am J Ther [Internet]*. 2020;27(6):e573–83. Available from: <https://dx.doi.org/10.1097/MJT.0000000000001294>
1878. Ruiz-Irastorza G, Martín-Iglesias D, Soto-Peleteiro A. Update on antimalarials and systemic lupus erythematosus. *Curr Opin Rheumatol*. 2020 Nov;32(6):572–82.
1879. Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J. Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. *J Am Acad Dermatol*. 2020 Aug;83(2):579–86.
1880. Sacher F, Fauchier L, Boveda S, de Chillou C, Defaye P, Deharo JC, et al. Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. *Arch Cardiovasc Dis*. 2020 May;113(5):293–6.
1881. Sadasivam B, Atal S, Ray A, Sharma S. The significance of correct dosing of hydroxychloroquine in clinical trials of COVID-19. Vol. 100, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 25–6.
1882. Sagheb S, Lamsehchi A, Jafary M, Atef-Yekta R, Sadeghi K. Two seriously ill neonates born to mothers with COVID-19 pneumonia- a case report. *Ital J Pediatr*. 2020 Sep;46(1):137.
1883. Saha BK, Bonnier A, Chong W. Antimalarials as Antivirals for COVID-19: Believe it or Not! *Am J Med Sci*. 2020 Dec;360(6):618–30.

1884. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. *Int J Antimicrob Agents*. 2020 Apr;55(4):105945.
1885. Saida I Ben, Ennouri E, Nachi R, Meddeb K, Mahmoud J, Thabet N, et al. Very severe COVID-19 in the critically ill in Tunisia. *Pan Afr Med J*. 2020;35(Suppl 2):136.
1886. Saitz R, Schwitzer G. Communicating Science in the Time of a Pandemic. *JAMA*. 2020 Aug;324(5):443–4.
1887. Saiz-Rodríguez M, Peña T, Lázaro L, González Á, Martínez A, Cordero JA, et al. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 632.
1888. Saleh M, Gabriels J, Chang D, Fishbein J, Qiu M, Mountantonakis SE, et al. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era. *Circ Arrhythm Electrophysiol*. 2020 Nov;13(11):e008937.
1889. Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E, et al. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. *Circ Arrhythm Electrophysiol*. 2020 Jun;13(6):e008662.
1890. Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. *Biomed Pharmacother*. 2020 Aug;128:110267.
1891. Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. *Eur J Pharmacol*. 2020 Sep;883:173375.
1892. Samuel S, Friedman RA, Sharma C, Ganigara M, Mitchell E, Schleien C, et al. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval. *Hear Rhythm*. 2020 Nov;17(11):1960–6.
1893. Sánchez-Álvarez JE, Pérez Fontán M, Jiménez Martín C, Blasco Pelicano M, Cabezas Reina CJ, Sevillano Prieto AM, et al. SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). *Nefrologia*. 2020;40(3):272–8.
1894. Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Vol. 79, *Annals of the rheumatic diseases*. 2020. p. 988–90.
1895. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA*. 2020 May;323(18):1824–36.
1896. Saniasiaya J, Kulasegarah J. Auditory Cinchonism in COVID Era. Vol. 99, *Ear, nose, & throat journal*. United States; 2020. p. 597–8.
1897. Sankar J, Dhochak N, Kabra SK, Lodha R. COVID-19 in Children: Clinical Approach and Management. *Indian J Pediatr*. 2020 Jun;87(6):433–42.
1898. Santillán-García A, Bravo-Jeria R, Verdugo-Paiva F, Rada G. Living evidence in response to controversies about the use of antimalarials in COVID-19. Vol. 73, *Revista española de cardiología (English ed.)*. 2020. p. 693–4.

1899. Santos-Sánchez NF, Salas-Coronado R. Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19. *Medwave*. 2020 Sep;20(8):e8037.
1900. Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. *Can J Cardiol*. 2020 Jun;36(6):948–51.
1901. Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. *Res soc adm pharm [Internet]*. 2020 Feb;17(2):483–6. Available from: <https://dx.doi.org/10.1016/j.sapharm.2020.04.016>
1902. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? *Aging (Albany NY)*. 2020 Mar;12(8):6511–7.
1903. Sargin G, Yavaşoğlu Sİ, Yavasoglu I. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria? Vol. 140, *Medical hypotheses*. 2020. p. 109756.
1904. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. *J Med Virol*. 2020 Jul;92(7):776–85.
1905. Sarzi-Puttini P, Marotto D, Caporali R, Montecucco CM, Favalli EG, Franceschini F, et al. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. *J Autoimmun [Internet]*. 2020 Jan;116:102545. Available from: <https://dx.doi.org/10.1016/j.jaut.2020.102545>
1906. Saseedharan S, Kadam V, Karanam R, Baghel P. CT Scan Findings of Five Mildly Symptomatic COVID Patients from India. *J Coll Physicians Surg Pak*. 2020 Jun;30(6):48–9.
1907. Satlin MJ, Goyal P, Magleby R, Maldarelli GA, Pham K, Kondo M, et al. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. *PLoS One*. 2020;15(7):e0236778.
1908. Sattui SE, Liew JW, Graef ER, Coler-Reilly A, Berenbaum F, Duarte-García A, et al. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. *Expert Rev Clin Immunol*. 2020 Jul;16(7):659–66.
1909. Saxena A. Drug targets for COVID-19 therapeutics: Ongoing global efforts. *J Biosci*. 2020;45(1).
1910. Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. *Ann Rheum Dis*. 2020 Oct;79(10):1286–9.
1911. Scheen AJ, Moutschen M. [Pharmacological therapies against COVID-19 : state of the art, between hopes and disappointments]. *Rev Med Liege*. 2020;75(S1):162–9.
1912. Scherrmann JM. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. *AAPS J*. 2020 Jun;22(4):86.
1913. Schlagenhauf P, Grobusch MP, Maier JD, Gautret P. Repurposing antimalarials and other drugs for COVID-19. Vol. 34, *Travel medicine and infectious disease*. 2020. p. 101658.

1914. Schluenz LA, Ramos-Otero GP, Nawarskas JJ. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe? *Cardiol Rev.* 2020;28(5):266–71.
1915. Schluger NW. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale. Vol. 173, *Annals of internal medicine.* 2020. p. 662–3.
1916. Schmitt W, Marchiori E. Covid-19: Round and oval areas of ground-glass opacity. Vol. 26, *Pulmonology.* 2020. p. 246–7.
1917. Schrezenmeier E V, Burmester GR, Eckardt K-U, Dörner T. Role for antimalarials in the management of COVID-19. *Curr Opin Rheumatol.* 2020 Sep;32(5):449–57.
1918. Schwartz RA, Janniger CK. Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. *Dermatol Ther.* 2020 May;33(3):e13380.
1919. Schwartz RA, Suskind RM. Azithromycin and COVID-19 Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration. *Dermatol Ther* [Internet]. 2020 Jul;33(4):e13785. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02143373/full>
1920. Scuccimarri R, Sutton E, Fitzcharles M-A. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. Vol. 47, *The Journal of rheumatology.* Canada; 2020. p. 783–6.
1921. Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. *Int J Antimicrob Agents.* 2020 Oct;56(4):106143.
1922. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA.* 2020 Dec;324(21):2165–76.
1923. Senna G, Caminati M, Castells M. Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic. Vol. 20, *Current opinion in allergy and clinical immunology.* United States; 2020. p. 429–30.
1924. Serafin MB, Bottega A, Foletto VS, da Rosa TF, Hörner A, Hörner R. Drug repositioning is an alternative for the treatment of coronavirus COVID-19. *Int J Antimicrob Agents.* 2020 Jun;55(6):105969.
1925. Serebrovska ZO, Chong EY, Serebrovska T V, Tumanovska L V, Xi L. Hypoxia, HIF-1 α , and COVID-19: from pathogenic factors to potential therapeutic targets. *Acta Pharmacol Sin.* 2020 Dec;41(12):1539–46.
1926. Serpa Neto A, Hodgson C. Will Evidence-based Medicine Survive the COVID-19 Pandemic? Vol. 17, *Annals of the American Thoracic Society.* 2020. p. 1060–1.
1927. Servick K, Enserink M. The pandemic's first major research scandal erupts. Vol. 368, *Science* (New York, N.Y.). United States; 2020. p. 1041–2.
1928. Seyahi E, Poyraz BC, Sut N, Akdogan S, Hamuryudan V. The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. *Rheumatol Int.* 2020 Aug;40(8):1229–38.
1929. Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. *Virology.* 2020 Dec;551:1–9.

1930. Seyhan AU, Doganay F, Yilmaz E, Topal NP, Ak R. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19. *J Coll Physicians Surg Pak*. 2020 Oct;30(10):153–7.
1931. Sgubbi P, Savoia F, Calderoni O, Longo R, Stinchi C, Tabanelli M. Alopecia areata in a patient with SARS-Cov-2 infection. Vol. 33, *Dermatologic therapy*. United States; 2020. p. e14295.
1932. Shader RI. COVID-19 and Depression. *Clin Ther*. 2020 Jun;42(6):962–3.
1933. Shah M, Sachdeva M, Dodiuk-Gad RP. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic. Vol. 33, *Dermatologic therapy*. 2020. p. e13524.
1934. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). *Int J Rheum Dis*. 2020 May;23(5):613–9.
1935. Shaikh K, Shrestha C, Dutta D. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus. *J Pak Med Assoc*. 2020 May;70(Suppl 3)(5):S69–73.
1936. Shamim S, Khan M, Kharaba ZJ, Ijaz M, Murtaza G. Potential strategies for combating COVID-19. *Arch Virol*. 2020 Nov;165(11):2419–38.
1937. Shamshirian A, Hessami A, Heydari K, Navaei RA, Ebrahimzadeh MA, Yip GW, et al. The Role of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. *Ann Acad Med Singapore*. 2020 Oct;49(10):789–800.
1938. Shamsoddin E. A COVID-19 pandemic guideline in evidence-based medicine. *Evid Based Dent*. 2020 Jun;21(2):71–3.
1939. Sharma A, Kumar Sharma S, Shi Y, Bucci E, Carafoli E, Melino G, et al. BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic? *Cell Death Dis*. 2020 Jul;11(7):516.
1940. Sharma A. Chloroquine paradox may cause more damage than help fight COVID-19. Vol. 22, *Microbes and infection*. 2020. p. 154–6.
1941. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. *Int J Antimicrob Agents*. 2020 Aug;56(2):106054.
1942. Sharma P, Chen V, Fung CM, Troost JP, Patel VN, Combs M, et al. COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-Control Study. *Transplantation [Internet]*. 2020 Jan;105(1):128–37. Available from: <https://dx.doi.org/10.1097/TP.0000000000003447>
1943. Sharmeen S, Elghawy A, Zarlisht F, Yao Q. COVID-19 in rheumatic disease patients on immunosuppressive agents. *Semin Arthritis Rheum*. 2020 Aug;50(4):680–6.
1944. Sheha D, El-Shayeb M, Eid Y, Amin M, Saeed A, Abdou D, et al. Unfolding of sickle cell trait by coronavirus disease 2019 (COVID-19) infection. Vol. 191, *British journal of haematology*. 2020. p. e38–40.
1945. Sher DJ. An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. *Int J Radiat Oncol Biol Phys*. 2020 Oct;108(2):333–6.
1946. Shih RD, Johnson HM, Maki DG, Hennekens CH. Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions. Vol. 133, *The American journal of medicine*. 2020. p. 1007–8.

1947. Shishak M, Sarkar R. Dermatological therapies with relevance to COVID-19. *Dermatol Ther.* 2020 Nov;33(6):e13813.
1948. Shittu MO, Afolami OI. Improving the efficacy of Chloroquine and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives - A better synergy for future COVID-19 clinical trials. *Le Infez Med.* 2020;28(2):192–7.
1949. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ.* 2020 Jul;370:m2980.
1950. Siemieniuk R, Rochweg B, Agoritsas T, Lamontagne F, Leo Y-S, Macdonald H, et al. A living WHO guideline on drugs for covid-19. *BMJ.* 2020 Sep;370:m3379.
1951. Sieni E, Pegoraro F, Casini T, Tondo A, Bortone B, Moriondo M, et al. Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression. Vol. 189, *British journal of haematology.* 2020. p. e222–4.
1952. Silva Arouche T da, Reis AF, Martins AY, S Costa JF, Carvalho Junior RN, J C Neto AM. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking. *J Nanosci Nanotechnol.* 2020 Dec;20(12):7311–23.
1953. Silvestri C, Di Stante S, Bertuzzi V, Martello M, Palladino M, Grabocka X, et al. [SARS CoV-2 related disease features in a population of chronic hemodialysis patients]. *G Ital di Nefrol organo Uff della Soc Ital di Nefrol.* 2020 Dec;37(6).
1954. Simmering JE, Polgreen LA, Polgreen PM, Teske RE, Comellas AP, Carter BL. The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. *Pharmacotherapy.* 2020 Sep;40(9):978–83.
1955. Simpson I. Therapeutic delivery: industry update covering June 2020. *Ther Deliv.* 2020 Nov;11(11):677–83.
1956. Simsek Yavuz S, Ünal S, Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. *Turk J Med Sci [Internet].* 2020 Apr;50(SI-1):611–9. Available from: <https://dx.doi.org/10.3906/sag-2004-145>
1957. Singh A, Sonpar A. In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19; trial stopped for futility. *Ann Intern Med.* 2020 Oct;173(8):JC41.
1958. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. *Diabetes Metab Syndr.* 2020;14(3):241–6.
1959. Singh AK, Singh A, Singh R, Misra A. “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”. *Diabetes Metab Syndr.* 2020;14(4):589–96.
1960. Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. *Pharmacol Rep.* 2020 Dec;72(6):1479–508.
1961. Sinha N, Balayla G. Hydroxychloroquine and COVID-19. *Postgrad Med J.* 2020 Sep;96(1139):550–5.
1962. Sivapalan P, Ulrik CS, Bojesen RD, Lapperre TS, Eklöf JV, Håkansson KEJ, et al. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With

COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 513.

1963. Sivapalan P, Ulrik CS, Lappere TS, Eklöf JV, Shaker SB, Bødtger UCS, et al. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. *Trials*. 2020 Oct;21(1):867.
1964. Şık N, Özlü C, Karaoğlu Asrak H, Erbaş İC, Çakıl Güzin A, Atakul G, et al. [Evaluation of SARS-CoV-2 PCR Positive Cases in the Pediatric Emergency Department]. *Mikrobiyol Bul*. 2020 Oct;54(4):629–37.
1965. Skariyachan S, Gopal D, Chakrabarti S, Kempanna P, Uttarkar A, Muddebihalkar AG, et al. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs. *Comput Biol Med*. 2020 Nov;126:104054.
1966. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. *Ann Intern Med*. 2020 Oct;173(8):623–31.
1967. Smit C, Peeters MYM, van den Anker JN, Knibbe CAJ. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. *Clin Pharmacokinet*. 2020 Jun;59(6):659–69.
1968. So H, Mak JW-Y, So J, Lui G, Lun F, Lee J, et al. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. *Semin Arthritis Rheum*. 2020 Oct;50(5):885–9.
1969. Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P, et al. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Vol. 176, *Revue neurologique*. 2020. p. 507–15.
1970. Song G, Cheng MQ, Wei XW. Analysis of the WHO ICTRP for novel coronavirus clinical trial registrations. *Medicine (Baltimore)*. 2020 Oct;99(43):e22840.
1971. Song J, Kang S, Choi SW, Seo KW, Lee S, So MW, et al. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs. *Rheumatol Int*. 2020 Jun;40(6):991–5.
1972. Song Y, Zhang M, Yin L, Wang K, Zhou Y, Zhou M, et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). *Int J Antimicrob Agents*. 2020 Aug;56(2):106080.
1973. Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol*. 2020 Jul;31(5):565–9.
1974. Soriano V, Barreiro P, Ramos JM, Eirós JM, de Mendoza C. COVID-19 Comes 40 Years After AIDS - Any Lesson? *AIDS Rev*. 2020 Jul;22(2):63–77.
1975. Sosa-García JO, Gutiérrez-Villaseñor AO, García-Briones A, Romero-González JP, Juárez-Hernández E, González-Chon O. Experience in the management of severe COVID-19 patients in an intensive care unit. *Cir Cir*. 2020;88(5):569–75.
1976. Soto A, Quiñones-Laveriano DM, Garcia PJ, Gotuzzo E, Henao-Restrepo AM, Farfán-López M, et al. [Not Available]. *Rev Peru Med Exp Salud Publica*. 2020;37(2):320–6.

1977. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. *Clin Rheumatol*. 2020 Jul;39(7):2085–94.
1978. Spada F, Pellicori S, Zampino G, Funicelli L, Gervaso L, Laffi A, et al. SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view. *Endocrine*. 2020 Oct;70(1):6–10.
1979. Spezzani V, Piunno A, Iselin H-U. Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple. *Swiss Med Wkly*. 2020 Apr;150:w20246.
1980. Stahlmann R, Lode H. Medication for COVID-19-an Overview of Approaches Currently Under Study. *Dtsch Arztebl Int*. 2020 Mar;117(13):213–9.
1981. Standing JF. Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data. Vol. 108, *Clinical pharmacology and therapeutics*. 2020. p. 187.
1982. Stevens RW, Estes L, Rivera C. Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program’s prospective review. *Infect Control Hosp Epidemiol*. 2020 Sep;41(9):1108–10.
1983. Stevenson A, Kirresh A, Conway S, White L, Ahmad M, Little C. Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified? *Open Hear*. 2020 Aug;7(2).
1984. Stojkovic-Filipovic J, Bosic M. Treatment of COVID 19-Repurposing drugs commonly used in dermatology. *Dermatol Ther*. 2020 Sep;33(5):e13829.
1985. Stoll F, Blank A, Mikus G, Czock D, Foerster KI, Hermann S, et al. Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial. Vol. 21, *Trials*. 2020. p. 584.
1986. Stremmel C, Kellnar A, Massberg S, Käab S. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. *J Cardiovasc Pharmacol Ther*. 2020 Nov;25(6):497–502.
1987. Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). *Future Oncol*. 2020 Jul;16(20):1425–32.
1988. Sturley SL, Rajakumar T, Hammond N, Higaki K, Márka Z, Márka S, et al. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity. *J Lipid Res*. 2020 Jul;61(7):972–82.
1989. Su Y-B, Kuo M-J, Lin T-Y, Chien C-S, Yang Y-P, Chou S-J, et al. Cardiovascular manifestation and treatment in COVID-19. *J Chin Med Assoc*. 2020 Aug;83(8):704–9.
1990. Suarez-Valle A, Fernandez-Nieto D, Melian-Olivera A, Dominguez-Santas M, Diaz-Guimaraens B, Garcia Del Real CM, et al. Comment on “Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine”: Report of a COVID-19 patient with particular findings. Vol. 33, *Dermatologic therapy*. 2020. p. e13852.
1991. Subramanian K, Nalli A, Senthil V, Jain S, Nayak A, Bhat A. Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. *Adv Ther*. 2020 Oct;37(10):4107–31.
1992. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. *Drug Saf*. 2020 Aug;43(8):691–8.

1993. Sun J, Chen Y, Fan X, Wang X, Han Q, Liu Z. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. *Postgrad Med.* 2020 Sep;132(7):604–13.
1994. Sun X, Ni Y, Zhang M. Rheumatologists' view on the use of hydroxychloroquine to treat COVID-19. Vol. 9, *Emerging microbes & infections.* 2020. p. 830–2.
1995. Svensson M. [Potential harms associated with 4-aminoquinoline treatment]. *Lakartidningen.* 2020 Apr;117.
1996. Szekely Y, Lichter Y, Shrkhi BA, Bruck H, Oster HS, Viskin S. Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019. *Hear Rhythm.* 2020 Sep;17(9):1452–5.
1997. Szente Fonseca SN, de Queiroz Sousa A, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, et al. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. *Travel Med Infect Dis.* 2020;38:101906.
1998. Taccone FS, Gorham J, Vincent J-L. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. *Lancet Respir Med.* 2020 Jun;8(6):539–41.
1999. Tadolini M, Codecasa LR, García-García J-M, Blanc F-X, Borisov S, Alffenaar J-W, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Vol. 56, *The European respiratory journal.* 2020.
2000. Tang D, Li J, Zhang R, Kang R, Klionsky DJ. Chloroquine in fighting COVID-19: good, bad, or both? *Autophagy.* 2020 Dec;16(12):2273–5.
2001. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ.* 2020 May;369:m1849.
2002. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. *Front Immunol.* 2020;11:1708.
2003. Tanriverdi O, Ozcan M. Questions asked through two examples of dilemmas of publication ethics in the process of COVID-19. Vol. 37, *Medical oncology (Northwood, London, England).* 2020. p. 86.
2004. Tapia L. COVID-19 and Fake News in the Dominican Republic. *Am J Trop Med Hyg.* 2020 Jun;102(6):1172–4.
2005. Taramasso L, Di Biagio A, Mikulska M, Giacobbe DR, Vena A, Dentone C, et al. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. Vol. 50, *European journal of clinical investigation.* 2020. p. e13358.
2006. Tarek M, Savarino A. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. *Eur J Drug Metab Pharmacokinet.* 2020 Dec;45(6):715–23.
2007. Tariq A, Mateen RM, Afzal MS, Saleem M. Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis.* 2020 Sep;98:166–75.
2008. Taştumur Ş, Ataseven H. Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis? *Med Hypotheses.* 2020 Oct;143:110018.
2009. Teherán AA, Camero G, Hernández C, Perez-Garcia L, Gúzman R, Paniz-Mondolfi A, et al. Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia. *J Med Virol.* 2020 Nov;92(11):2254–6.

2010. Thangaraju P, Gurunthalingam MP, Venkatesan S, Thangaraju E. COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice? Vol. 13, *Journal of infection and public health*. 2020. p. 899–900.
2011. Thémans P, Belkhir L, Dauby N, Yombi J-C, De Greef J, Delongie K-A, et al. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. *Eur J Drug Metab Pharmacokinet*. 2020 Dec;45(6):703–13.
2012. Thoguluva Chandrasekar V, Venkatesalu B, Patel HK, Spadaccini M, Manteuffel J, Ramesh M. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. *J med virol* [Internet]. 2020 Feb;93(2):775–85. Available from: <https://dx.doi.org/10.1002/jmv.26302>
2013. Thomson K, Nachlis H. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval. *JAMA*. 2020 Oct;324(13):1282–3.
2014. Thorp HH. Not throwing away our shot. Vol. 370, *Science* (New York, N.Y.). United States; 2020. p. 266.
2015. Tilangi P, Desai D, Khan A, Soneja M. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. Vol. 20, *The Lancet. Infectious diseases*. 2020. p. 1119–20.
2016. Timerbulatov S V, Timerbulstov M V, Gainullina EN, Gafarova AR, Timerbulatov VM. [Drug treatment of coronavirus disease COVID-19: evidence exists?]. *Khirurgiia (Sofia)*. 2020;(6):90–7.
2017. Tirupakuzhi Vijayaraghavan BK, Jha V, Rajbhandari D, Myatra SN, John O, Ghosh A, et al. Hydroxychloroquine plus personal protective equipment versus standard personal protective equipment alone for the prevention of COVID-19 infections among frontline healthcare workers: the HydrOxychloroquine Prophylaxis Evaluation(HOPE) trial: A structured summary of a study protocol for a randomized controlled trial. Vol. 21, *Trials*. 2020. p. 754.
2018. Tomcsányi J, Tomcsányi K. [Hazard of acquired long QT syndrome during coronavirus pandemic. Focus on hydroxychloroquine]. *Orv Hetil*. 2020 Apr;161(17):689–91.
2019. Torres-Atencio I, Goodridge A, Vega S. COVID-19: Panama stockpiles unproven drugs. Vol. 587, *Nature*. England; 2020. p. 548.
2020. Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*. 2020 May;177:104762.
2021. Trevenzoli M, Guarnaccia A, Alberici I, Fassan M, Di Meco E, Farinati F, et al. SARS-CoV-2 and hepatitis. Vol. 29, *Journal of gastrointestinal and liver diseases : JGLD*. Romania; 2020. p. 473–5.
2022. Tripathi PK, Upadhyay S, Singh M, Raghavendhar S, Bhardwaj M, Sharma P, et al. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2. *Int J Biol Macromol*. 2020 Dec;164:2622–31.
2023. Tripathy JP. Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India? *J Med Virol*. 2020 Sep;92(9):1391–3.
2024. Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. *Int J Antimicrob Agents*. 2020 Aug;56(2):106028.

2025. Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. *Eur Rev Med Pharmacol Sci*. 2020 Dec;24(23):12593–608.
2026. Troldborg A, Bartels LE, Deleuran B. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection]. *Ugeskr Laeger*. 2020 May;182(20).
2027. Trujillo H, Caravaca-Fontán F, Sevillano Á, Gutiérrez E, Fernández-Ruiz M, López-Medrano F, et al. Tocilizumab use in Kidney Transplant Patients with COVID-19. *Clin Transplant*. 2020 Nov;34(11):e14072.
2028. Tu Y-F, Chien C-S, Yarmishyn AA, Lin Y-Y, Luo Y-H, Lin Y-T, et al. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. *Int J Mol Sci*. 2020 Apr;21(7).
2029. Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. *Drug Saf*. 2020 Aug;43(8):699–709.
2030. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. *Turkish J Med Sci*. 2020 Apr;50(SI-1):620–32.
2031. Tuncer T, Karaci M, Boga A, Durmaz H, Guven S. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019. *Cardiol Young*. 2020 Oct;30(10):1482–5.
2032. Türsen Ü, Türsen B, Lotti T. Cutaneous side-effects of the potential COVID-19 drugs. *Dermatol Ther*. 2020 Jul;33(4):e13476.
2033. Tzitzoglaki C, McGuire K, Lagarias P, Konstantinidi A, Hoffmann A, Fokina NA, et al. Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels. *ACS Chem Biol*. 2020 Sep;15(9):2331–7.
2034. Udwadia ZF, Malu KN, Rana D, Joshi SR. Hydroxychloroquine for COVID-19: What is our Current State of Knowledge? *J Assoc Physicians India*. 2020 Jun;68(6):48–52.
2035. Uribarri A, Núñez-Gil IJ, Aparisi A, Becerra-Muñoz VM, Feltes G, Trabattoni D, et al. Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. *J Nephrol*. 2020 Aug;33(4):737–45.
2036. Uvais NA. The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia. *Prim care companion CNS Disord*. 2020 Apr;22(3).
2037. Uzun T, Toptaş O, Aydın Türkoğlu Ş. Could Artesunate Have a Positive Effect on the Neurological Complications Related to Infection When It Is Used in the Treatment of COVID-19? *ACS Chem Neurosci*. 2020 Dec;11(24):4001–6.
2038. Uzunova K, Filipova E, Pavlova V, Vekov T. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. *Biomed Pharmacother*. 2020 Nov;131:110668.
2039. Vahedi E, Ghanei M, Ghazvini A, Azadi H, Izadi M, Panahi Y, et al. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study. *Daru*. 2020 Dec;28(2):507–16.
2040. Vaidyanathan G. Scientists criticize use of unproven COVID drugs in India. Vol. 587, *Nature*. England; 2020. p. 187–8.

2041. Valderrama EV, Humbert K, Lord A, Frontera J, Yaghi S. Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke. *Stroke*. 2020 Jul;51(7):e124–7.
2042. Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. *Cochrane database Syst Rev*. 2020 May;5(5):CD013600.
2043. Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Vol. 21, *Trials*. 2020. p. 965.
2044. Varghese GM, John R, Manesh A, Karthik R, Abraham OC. Clinical management of COVID-19. *Indian J Med Res*. 2020 May;151(5):401–10.
2045. Varisco TJ, Johnson ML, Thornton D. Comment on Arshad et al.: Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 373.
2046. Vastarella M, Patri A, Annunziata MC, Cantelli M, Nappa P, Tasso M, et al. Can hydroxychloroquine be useful in the prevention of COVID-19? An Italian survey in dermatologic and rheumatologic patients already under treatment. Vol. 83, *Journal of the American Academy of Dermatology*. 2020. p. e77–9.
2047. Venkatesulu BP, Thoguluva Chandrasekar V, Giridhar P, V P, Patel HK, Manteuffel J. The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review. *J med virol [Internet]*. 2020 Feb;93(2):843–53. Available from: <https://dx.doi.org/10.1002/jmv.26338>
2048. Verdejo C, Vergara-Merino L, Meza N, Pérez-Bracchiglione J, Carvajal-Juliá N, Madrid E, et al. Macrolides for the treatment of COVID-19: a living, systematic review. *Medwave*. 2020 Dec;20(11):e8074.
2049. Vernaz N, Agoritsas T, Calmy A, Gayet-Ageron A, Gold G, Perrier A, et al. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs. *Swiss Med Wkly*. 2020 Dec;150:w20446.
2050. Verscheijden LFM, van der Zanden TM, van Bussel LPM, de Hoop-Sommen M, Russel FGM, Johnson TN, et al. Chloroquine Dosing Recommendations for Pediatric COVID-19 Supported by Modeling and Simulation. *Clin Pharmacol Ther*. 2020 Aug;108(2):248–52.
2051. Viale P, Bartoletti M. Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin. *Le Infez Med*. 2020 Jun;28(suppl 1):118–21.
2052. Vicenzi M, Di Cosola R, Ruscica M, Ratti A, Rota I, Rota F, et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. Vol. 56, *The European respiratory journal*. 2020.
2053. Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). *Mayo Clin Proc*. 2020 Jul;95(7):1454–66.
2054. Vitte J, Michel M, Mezouar S, Diallo AB, Boumaza A, Mege J-L, et al. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. *Front Immunol*. 2020;11:2159.
2055. Vlachogianni G, Hassapopoulou-Matamis H, Politis C, Fylaki E, Mentis A. A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the

- donor's critically ill father. Vol. 27, *Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine*. 2020. p. 269–70.
2056. Voisin O, Lorc'h E le, Mahé A, Azria P, Borie M-F, Hubert S, et al. Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. *Mayo Clin Proc*. 2020 Aug;95(8):1696–700.
2057. Vollaard A, Gieling EM, van der Linden PD, Sinha B, de Boer MGJ. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness]. *Ned Tijdschr Geneeskd*. 2020 Jun;164.
2058. Vouri SM, Thai TN, Winterstein AG. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. *Res soc adm pharm [Internet]*. 2020 Jan;17(1):2012–7. Available from: <https://dx.doi.org/10.1016/j.sapharm.2020.04.031>
2059. Wang B, Lai J, Yan X, Jin F, Yi B, An C, et al. COVID-19 Clinical Trials Registered Worldwide for Drug Intervention: An Overview and Characteristic Analysis. *Drug Des Devel Ther*. 2020;14:5097–108.
2060. Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. *J Infect Public Health*. 2020 Oct;13(10):1405–14.
2061. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Vol. 30, *Cell research*. 2020. p. 269–71.
2062. Wang N, Han S, Liu R, Meng L, He H, Zhang Y, et al. Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. *Phytomedicine*. 2020 Dec;79:153333.
2063. Wang Y-L, Wang S-H, Yang A-Y. Pharmacist's perspective on HCQ treatment of COVID-19. Vol. 36, *The Kaohsiung journal of medical sciences*. 2020. p. 660.
2064. Wang Y, Chen L. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. *Eur J Pharmacol*. 2020 Dec;889:173634.
2065. Wang Y, Zhu L-Q. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. *World J Pediatr*. 2020 Jun;16(3):271–4.
2066. Wang Y, Foo R, Thum T. Using “old” medications to fight new COVID-19: Re-purposing with a purpose. Vol. 146, *Journal of molecular and cellular cardiology*. 2020. p. 41–2.
2067. Watanabe LM, Pires IF, Noronha NY, Pinhel MA de S, Nonino CB. The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19. *Clinics (Sao Paulo)*. 2020;75:e2181.
2068. Waters L, Rockstroh JK. COVID-19 research: an opinion piece. *HIV Med*. 2020 Sep;21(8):536–40.
2069. Watson JA, Tarning J, Hoglund RM, Baud FJ, Megarbane B, Clemessy J-L, et al. Concentration-dependent mortality of chloroquine in overdose. *Elife*. 2020 Jul;9.
2070. Weehuizen JM, Hoepelman AIM. An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)-Protocol publication. Vol. 50, *European journal of clinical investigation*. 2020. p. e13297.

2071. West TA, Malik S, Nalpantidis A, Tran T, Cannon C, Bhonagiri D, et al. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients. *Int J Rheum Dis.* 2020 Aug;23(8):1030–9.
2072. Weston S, Coleman CM, Haupt R, Logue J, Matthews K, Li Y, et al. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. *J Virol.* 2020 Oct;94(21).
2073. White CM, Hernandez A V. Why Your Patients’ Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVID-19 Is 100% Dangerous. *J Clin Pharmacol.* 2020 Aug;60(8):949–53.
2074. White NJ, Watson JA, Hoggund RM, Chan XHS, Cheah PY, Tarning J. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. *PLoS Med.* 2020 Sep;17(9):e1003252.
2075. Wiseman DM. Possible synergistic effects of hydroxychloroquine and steroids in COVID-19, time for a nuanced approach. Comment on Arshad et al. Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.* 2020. p. 344–5.
2076. Wiwanitkit V. Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19. Vol. 9, *Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). China;* 2020. p. 374.
2077. Won J-H, Lee H. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. *Int J Mol Sci.* 2020 Dec;21(24).
2078. Wong A. COVID-19 and toxicity from potential treatments: Panacea or poison. *Emerg Med Australas.* 2020 Aug;32(4):697–9.
2079. Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. *Blood Adv.* 2020 Dec;4(23):5966–75.
2080. Wright JK, Tan DHS, Walmsley SL, Hulme J, O’Connor E, Snider C, et al. Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. Vol. 21, *Trials.* 2020. p. 647.
2081. Wu J. Tackle the free radicals damage in COVID-19. Nitric oxide *Biol Chem.* 2020 Sep;102:39–41.
2082. Wu L, O’Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. *Biochem Pharmacol.* 2020 Aug;178:114114.
2083. Wu TC, Sacilotto L, Darrieux FC da C, Pisani CF, Melo SL de, Hachul DT, et al. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19. *Arq Bras Cardiol.* 2020 Jun;114(6):1061–6.
2084. Xia T, Wang Y. Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome. Vol. 20, *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.* 2020. p. 2630–1.
2085. Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, et al. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. *Front Immunol.* 2020;11:586572.

2086. Xie W, Wang Y, Zhang Z. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? *Ann rheum dis* [Internet]. 2020 Jan;80(1):e6. Available from: <https://dx.doi.org/10.1136/annrheumdis-2020-217556>
2087. Xu C-Y, Lu S-D, Ye X, Cao M-Y, Xu G-D, Yu Q, et al. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report. *QJM*. 2020 Aug;113(8):569–72.
2088. Xu T-M, Lin B, Chen C, Liu L-G, Xue Y. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report. *Virologia*. 2020 Jun;17(1):80.
2089. Xu X, Ong YK, Wang DY. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. *Mil Med Res*. 2020 May;7(1):22.
2090. Xue H, Liu Y, Luo P, Liu X, Qiu L, Liu D, et al. Hydroxychloroquine treatment in COVID-19: A descriptive observational analysis of 30 cases from a single center in Wuhan, China. *J Med Virol*. 2020 Nov;92(11):2523–7.
2091. Yahya AS, Khawaja S, Chukwuma J. The Use of “Novel Pharmacology” in the Treatment of COVID-19 and Potential Psychiatric Risks. *Prim care companion CNS Disord*. 2020 May;22(3).
2092. Yakoub-Agha I. Hydroxychloroquine in Covid-19: Does the end justify the means? Vol. 68, *Current research in translational medicine*. 2020. p. 81–2.
2093. Yamamoto V, Bolanos JF, Fiallos J, Strand SE, Morris K, Shahrokhinia S, et al. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. *J Alzheimers Dis*. 2020;77(2):459–504.
2094. Yamoah P, Alalbila TM, Bangalee V, Oosthuizen F. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. Vol. 54, *Therapeutic innovation & regulatory science*. 2020. p. 1359–62.
2095. Yang A, Yang C, Yang B. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19. Vol. 144, *Medical hypotheses*. 2020. p. 109802.
2096. Yang C-W, Peng T-T, Hsu H-Y, Lee Y-Z, Wu S-H, Lin W-H, et al. Repurposing old drugs as antiviral agents for coronaviruses. *Biomed J*. 2020 Aug;43(4):368–74.
2097. Yao X, Hou Z, Cui C, Zhang M, Tu S, Li H, et al. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. *Curr Drug Metab*. 2020;21(7):534–40.
2098. Yazdany J, Kim AHJ. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Vol. 172, *Annals of internal medicine*. 2020. p. 754–5.
2099. Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. *Ann Rheum Dis*. 2020 Aug;79(8):1007–13.
2100. Yekedüz E, Dursun B, Aydın GÇ, Yazgan SC, Öztürk HH, Azap A, et al. Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab. *J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract*. 2020 Jul;26(5):1289–94.
2101. Yi SG, Rogers AW, Saharia A, Aoun M, Faour R, Abdelrahim M, et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. *Transplantation*. 2020 Nov;104(11):2208–14.

2102. Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaee M, Eslami M. A global treatments for coronaviruses including COVID-19. *J Cell Physiol*. 2020 Dec;235(12):9133–42.
2103. Yousefzadegan S, Rezaei N. Case Report: Death due to COVID-19 in Three Brothers. *Am J Trop Med Hyg*. 2020 Jun;102(6):1203–4.
2104. Yu B, Li C, Chen P, Zhou N, Wang L, Li J, et al. Erratum to: Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. *Sci China Life Sci* [Internet]. 2020 Oct;63(10):1617–8. Available from: <https://dx.doi.org/10.1007/s11427-020-1751-3>
2105. Yuan S, Chan CC-Y, Chik KK-H, Tsang JO-L, Liang R, Cao J, et al. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). *Viruses*. 2020 Jun;12(6).
2106. Yuan S, Chan JFW, Chik KKH, Chan CCY, Tsang JOL, Liang R, et al. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. *Pharmacol Res*. 2020 Sep;159:104960.
2107. Zaidel EJ, Wyss Quintana FS, Sosa Liprandi Á, Mendoza I, Márquez MF, Nuñez E, et al. [Cardiac adverse effects of hydroxychloroquine and the need for tests]. Vol. 80 Suppl 3, *Medicina*. Argentina; 2020. p. 91–2.
2108. Zaidel EJ, Wyss Quintana FS, Sosa Liprandi Á, Mendoza I, Márquez MF, Nuñez E, et al. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. *Medicina (B Aires)*. 2020;80(3):271–4.
2109. Zampieri FG. Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs. Vol. 17, *Annals of the American Thoracic Society*. 2020. p. 937–8.
2110. Zeitlinger M, Koch BCP, Bruggemann R, De Cock P, Felton T, Hites M, et al. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. *Clin Pharmacokinet*. 2020 Oct;59(10):1195–216.
2111. Zekarias A, Watson S, Vidlin SH, Grundmark B. Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports. *Drug Saf*. 2020 Dec;43(12):1309–14.
2112. Zervos M, Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, et al. A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19. Vol. 99, *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*. 2020. p. 138–9.
2113. Zhai MZ, Lye CT, Kesselheim AS. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies. *JAMA Intern Med*. 2020 Sep;180(9):1145–6.
2114. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. *Int J Antimicrob Agents*. 2020 May;55(5):105955.
2115. Zhang C, Huang S, Zheng F, Dai Y. Controversial treatments: An updated understanding of the coronavirus disease 2019. *J Med Virol*. 2020 Sep;92(9):1441–8.
2116. Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. *Brain Behav Immun*. 2020 Jul;87:59–73.

2117. Zhang Q, Wang Y, Qi C, Shen L, Li J. Clinical trial analysis of 2019-nCoV therapy registered in China. *J Med Virol*. 2020 Jun;92(6):540–5.
2118. Zhang W-C, Zheng K, Geng D-C. Tocilizumab: do not be the next chloroquine! Vol. 24, *European review for medical and pharmacological sciences*. Italy; 2020. p. 7579.
2119. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. *Clin Immunol*. 2020 May;214:108393.
2120. Zhang X-L, Li Z-M, Ye J-T, Lu J, Ye LL, Zhang C-X, et al. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. *Acta Pharmacol Sin*. 2020 Nov;41(11):1377–86.
2121. Zhang X-Y, Huang H-J, Zhuang D-L, Nasser MI, Yang M-H, Zhu P, et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. *Infect Dis poverty*. 2020 Jul;9(1):99.
2122. Zhang Z-R, Zhang Y-N, Li X-D, Zhang H-Q, Xiao S-Q, Deng F, et al. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Vol. 5, *Signal transduction and targeted therapy*. 2020. p. 218.
2123. Zhao M, Zhang J, Li H, Luo Z, Ye J, Xu Y, et al. Recent progress of antiviral therapy for coronavirus disease 2019. *Eur J Pharmacol* [Internet]. 2020 Jan;890:173646. Available from: <https://dx.doi.org/10.1016/j.ejphar.2020.173646>
2124. Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. *Int J Antimicrob Agents*. 2020 Jun;55(6):105982.
2125. Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol*. 2020 Jul;39(7):1209–20.
2126. Zheng L, Zhang L, Huang J, Nandakumar KS, Liu S, Cheng K. Potential treatment methods targeting 2019-nCoV infection. *Eur J Med Chem*. 2020 Nov;205:112687.
2127. Zhong H, Wang Y, Zhang Z-L, Liu Y-X, Le K-J, Cui M, et al. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. *Pharmacol Res*. 2020 Jul;157:104872.
2128. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. *J Antimicrob Chemother*. 2020 Jul;75(7):1667–70.
2129. Zhu H, Lu H. The development of a quarantine strategy is an important path to a normalized response to COVID-19. Vol. 14, *Bioscience trends*. Japan; 2020. p. 396–8.
2130. Zhu Y, Chen Y, Gong Y, Pan A, Ding H, Fang J, et al. Long-term application of hydroxychloroquine could not prevent the infection of COVID-19. *J Infect Dev Ctries*. 2020 Dec;14(12):1368–73.
2131. Zou L, Dai L, Zhang X, Zhang Z, Zhang Z. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. *Arch Pharm Res*. 2020 Aug;43(8):765–72.
2132. Zubiaur P, Koller D, Saiz-Rodríguez M, Navares-Gómez M, Abad-Santos F. Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). *Clin Transl Sci*. 2020 Nov;13(6):1023–33.

2133. Zuchelkowski BE, Wang L, Gingras S, Xu Q, Yang M, Triulzi D, et al. Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a “humanized” G6PD A- mouse model. *PLoS One*. 2020;15(10):e0240266.
2134. Zurita MF, Iglesias Arreaga A, Luzuriaga Chavez AA, Zurita L. SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. *Am J Case Rep*. 2020 Sep;21:e927304.
2135. Reis Neto ET dos, Kakehasi AM, Pinheiro M de M, Ferreira GA, Marques CDL, Mota LMH da, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. *Adv Rheumatol* [Internet]. 2020 Jun;60(1):32. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&
2136. Falavigna M, Colpani V, Stein C, Azevedo LCP, Bagattini AM, Brito GV de, et al. Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. *Rev Bras Ter intensiva*. 2020 Jun;32(2):166–96.
2137. Nigri KK. A repercussão pública da guerra discursiva na pandemia da Covid-19 TT - Les répercussions publiques de la guerre discursive dans la pandémie de Covid-19 TT - A public repercussion of the discursive war in the covid-19 pandemic. *aSEPHallus* [Internet]. 2019;15(29):47–70. Available from: <http://www.isepol.com/asephallus/pdf/04>
2138. Nascimento MMG do, Santos SR, Rezende C de P, Araújo RLB de. Administration of chloroquine or hydroxychloroquine through feeding tubes: new challenges in times of coronavirus pandemic. *Rev ciênc farm básica apl* [Internet]. 2019;40:[3]-[3]. Available from: <http://rcfba.fcfar.unesp.br/index.php/ojs/article/view/640/625>
2139. Lucchetta RC, Mastroianni P de C. Rational use of chloroquine and hydroxychloroquine in times of COVID-19. *Rev ciênc farm básica apl* [Internet]. 2019;40. Available from: <http://rcfba.fcfar.unesp.br/index.php/ojs/article/view/653/623>
2140. NCT04428268. Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia. <https://clinicaltrials.gov/show/NCT04428268> [Internet]. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02118787/full>
2141. NCT04359953. Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19. <https://clinicaltrials.gov/show/NCT04359953> [Internet]. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02103403/full>
2142. NCT04356495. Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19). <https://clinicaltrials.gov/show/NCT04356495> [Internet]. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02093696/full>
2143. NCT04351724. Austrian CoronaVirus Adaptive Clinical Trial. <https://clinicaltrials.gov/show/NCT04351724> [Internet]. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089854/full>
2144. NCT04328012. Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic Adaptive randomized Clinical Trial During the COVID-19 Pandemic (COVID MED Trial). <https://clinicaltrials.gov/show/NCT04328012> [Internet]. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089488/full>
2145. NCT04322123. Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus. <https://clinicaltrials.gov/show/NCT04322123> [Internet]. Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02089408/full>

2146. IRCT20190831044653N5. ?The effect of Atorvastatin therapy in COVID-19.
<http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20190831044653N5> [Internet].
Available from: <https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02187608/full>
2147. EUCTR2020-001303-16-FR. Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : a Randomized, Multi-Centre, Adaptive, Blinded Study. <http://www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001303-16-FR> [Internet]. Available from:
<https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02169643/full>

ClinicalTrials.gov Search Results 02/07/2021

	Title	Status	Study Results	Conditions	Interventions
1	Effectiveness of Hydroxychloroquine in Covid-19 Patients	Not yet recruiting	No Results Available	• COVID19	• Drug: Hydroxychloroquine 200 Mg Oral Tablet • Drug: Azithromycin 500Mg Oral Tablet • Dietary Supplement: Glucose tablets
2	Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial	Withdrawn	No Results Available	• SARS-CoV-2 Pneumonia • COVID-19	• Drug: Hydroxychloroquine
3	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	No Results Available	• COVID	• Drug: Camostat Mesilate • Drug: Placebo • Drug: Hydroxychloroquine
4	Favipiravir vs Hydroxychloroquine in COVID -19	Recruiting	No Results Available	• SARS-CoV 2 • COVID-19	• Drug: Hydroxychloroquine • Drug: Favipiravir • Other: Routine care for COVID-19 patients
5	Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)	Withdrawn	No Results Available	• COVID-19 • SARS-CoV-2	• Drug: Hydroxychloroquine • Drug: Placebo
6	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Completed	No Results Available	• Covid-19	• Drug: HCQ • Drug: HCQ+AZT • Drug: Placebo
7	The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine plus standard preventive measures • Drug: Placebo plus standard preventive measures
8	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	Recruiting	No Results Available	• Covid-19	• Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
9	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19	Active, not recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
10	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
11	Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial	Withdrawn	No Results Available	• COVID19	• Drug: Hydroxychloroquine and azithromycin treatment • Other: conventional management of patients
12	Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Combination Product: Hydroxychloroquine plus Nitazoxanide • Other: Standard care

13	High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
----	--	------------	----------------------	------------	----------------------------

	Title	Status	Study Results	Conditions	Interventions
14	ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
15	Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease	Active, not recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
16	A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
17	Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
18	Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients	Withdrawn	No Results Available	• Covid-19	• Drug: Hydroxychloroquine and Azithromycin • Dietary Supplement: Azinc
19	#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Mannitol
20	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Terminated	No Results Available	• COVID-19	• Drug: Lopinavir/ritonavir • Drug: Hydroxychloroquine sulfate
21	Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
22	Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine + Metabolic cofactor supplementation • Drug: Hydroxychloroquine + Sorbitol
23	Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19	Active, not recruiting	No Results Available	• Covid19 • Hydroxychloroquine Adverse Reaction	• Drug: inhalable hydroxychloroquine (HCQ) • Drug: supportive and symptomatic treatment
24	Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
25	Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19	Recruiting	No Results Available	• Covid19	• Drug: Hydroxychloroquine • Drug: Azithromycin • Other: Placebo Tablet • Other: Placebo capsules

	Title	Status	Study Results	Conditions	Interventions
26	Hydroxychloroquine for COVID-19	Recruiting	No Results Available	• COVID-19, Hydroxychloroquine Sulfate	• Drug: Hydroxychloroquine Sulfate • Drug: Placebo
27	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19	Recruiting	No Results Available	• SARS-CoV-2 • COVID-19	• Combination Product: Hydroxychloroquine Sulfate + Azithromycin • Drug: Hydroxychloroquine Sulfate
28	Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebos
29	Trial of Hydroxychloroquine In Covid-19 Kinetics	Terminated	No Results Available	• Covid 19 • Corona Virus Infection	• Drug: Hydroxychloroquine • Other: Placebo
30	Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection	Active, not recruiting	No Results Available	• COVID-19 • SARS-CoV 2	• Drug: Hydroxychloroquine • Dietary Supplement: Vitamin D
31	Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients	Not yet recruiting	No Results Available	• COVID-19 Patients	• Drug: HCQ & AZ vs HCQ+SIR
32	Hydroxychloroquine, Azithromycin in the Treatment of Covid-19	Not yet recruiting	No Results Available	• SARS-CoV-2 Pneumonia • COVID-19	• Drug: Hydroxychloroquine 200 Mg Oral Tablet • Drug: Azithromycin 250 MG
33	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19	Suspended	No Results Available	• Covid-19	• Drug: Hydroxychloroquine Sulfate • Drug: Azithromycin Tablets
34	Hydroxychloroquine in COVID-19 Patients	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
35	Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19	Recruiting	No Results Available	• COVID 19	• Drug: Hydroxychloroquine Sulfate 200 MG • Other: Placebo
36	Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)	Active, not recruiting	No Results Available	• COVID-19 • Severe Acute Respiratory Syndrome	• Drug: Hydroxychloroquine • Drug: Placebo oral tablet
37	Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19	Recruiting	No Results Available	• COVID-19 Infection	• Drug: Hydroxychloroquine • Drug: Azithromycin • Drug: Telmisartan
38	Preventing COVID-19 in Healthcare Workers With HCQ: A RCT	Withdrawn	No Results Available	• Covid-19	• Drug: Hydroxychloroquine • Other: Vitamin C

	Title	Status	Study Results	Conditions	Interventions
39	Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19	Not yet recruiting	No Results Available	• COVID	• Drug: Hydroxychloroquine • Drug: Placebo oral tablet
40	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients Admitted With Moderate to Severe COVID-19	Terminated	No Results Available	• COVID-19	• Drug: Chloroquine Sulfate • Drug: Hydroxychloroquine • Other: Standard supportive care
41	Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients	Terminated	No Results Available	• Sars-CoV2	• Drug: Hydroxychloroquine (HCQ)
42	Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19	Terminated	Has Results	• COVID-19	• Drug: Hydroxychloroquine
43	Treating COVID-19 With Hydroxychloroquine (TEACH)	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine (HCQ) • Other: Placebo: Calcium citrate
44	Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Ivermectin • Drug: Placebo
45	Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Other: The control group will not receive hydroxychloroquine
46	Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin • Drug: Zinc Sulfate • Drug: Doxycycline
47	COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
48	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine Sulfate • Drug: Azithromycin Tablets
49	Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine Sulfate
50	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	Terminated	Has Results	• COVID-19	• Drug: Hydroxychloroquine Sulfate 400 mg twice a day • Drug: Hydroxychloroquine Sulfate 600 mg twice a day • Drug: Hydroxychloroquine Sulfate 600 mg once a day • Drug: Placebo oral tablet

	Title	Status	Study Results	Conditions	Interventions
51	Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycin in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID19 • Hematologic Malignancy 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil] • Drug: Azithromycin 250 MG Oral Capsule • Drug: Placebo oral tablet • Drug: Placebo oral capsule
52	Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID - 19 	<ul style="list-style-type: none"> • Drug: hydroxychloroquine in combination with camostat mesylate • Drug: Hydroxychloroquine in combination of Azithromycin
53	A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 • COVID19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Hydroxychloroquine (placebo) • Drug: Zinc • Drug: Zinc (Placebo)
54	PROphylaxis for paTiEnts at Risk of COVID-19 infecTion	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine Sulfate 200 MG
55	Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO	Suspended	No Results Available	<ul style="list-style-type: none"> • COVID19 • SARS-CoV-2 Infection 	<ul style="list-style-type: none"> • Drug: Sarilumab • Drug: Azithromycin • Drug: Hydroxychloroquine
56	Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Coronavirus Disease 2019 (COVID-19) • Post-Exposure Prophylaxis 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
57	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • COVID-19 • SARS-CoV 2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine (HCQ) • Drug: Azithromycin (Azithro) • Drug: Placebo for Hydroxychloroquine • Drug: Placebo for Azithromycin
58	Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Mucodentol • Device: Personal protective equipment

	Title	Status	Study Results	Conditions	Interventions
59	Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum	Recruiting	No Results Available	<ul style="list-style-type: none"> •Pregnancy Related • COVID • Covid-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo
60	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Tocilizumab • Drug: Hydroxychloroquine • Drug: Azithromycin
61	EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Sars-CoV-2, Community-Acquired Pneumonia, COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine and azithromycin treatment arm. • Drug: Hydroxychloroquine • Drug: Control arm
62	Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Coronavirus Infection 	<ul style="list-style-type: none"> • Drug: Chloroquine or Hydroxychloroquine
63	Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Corona Virus Infection 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet
64	Double Therapy With IFN-beta 1b and Hydroxychloroquine	Completed	No Results Available	<ul style="list-style-type: none"> • COVID 	<ul style="list-style-type: none"> • Drug: Interferon Beta-1B • Drug: Hydroxychloroquine
65	Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • CoVID-19 	<ul style="list-style-type: none"> • Drug: HCQ • Other: Standard therapy
66	Favipiravir and HydroxyChloroquine Combination Therapy	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID19 	<ul style="list-style-type: none"> • Combination Product: Favipiravir and Hydroxychloroquine
67	Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Contact Person From COVID-19 Confirmed Patient 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine as post exposure prophylaxis • Other: Others(No intervention)

	Title	Status	Study Results	Conditions	Interventions
68	Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • Pneumonia, Pneumocystis • Coronavirus • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
69	Hydroxychloroquine to Prevent SARS-CoV-2 Infection	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
70	A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Cancer 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Other: Placebo • Radiation: Radiation therapy
71	Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Severe Acute Respiratory Syndrome 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet
72	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • Respiratory Distress Syndrome, Adult • COVID-19 	<ul style="list-style-type: none"> • Drug: Dexamethasone and Hydroxychloroquine • Drug: Hydroxychloroquine
73	Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 Pneumonia 	
74	Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients	Recruiting	No Results Available	<ul style="list-style-type: none"> • Cancer & COVID 19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
75	Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID 19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
76	Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 • COVID-19 	<ul style="list-style-type: none"> • Drug: Favipiravir (3200 mg + 1200 mg) • Drug: Favipiravir (3600 mg + 1600 mg) • Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine • Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin • Drug: Hydroxychloroquine • Drug: Hydroxychloroquine combined with Azithromycin
77	Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection	Terminated	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 	<ul style="list-style-type: none"> • Other: Standard of care • Drug: Hydroxychloroquine • Drug: Azithromycin

	Title	Status	Study Results	Conditions	Interventions
78	Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients	Enrolling by invitation	No Results Available	• Covid19	• Combination Product: Hydroxychloroquine/ Azithromycine • Combination Product: Quinquina-Stevia/ Azythromycin • Combination Product: 4Plants/ Azythromycin
79	Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients	Not yet recruiting	No Results Available	• COVID-19	• Drug: HCQ & AZ
80	Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers	Active, not recruiting	No Results Available	• COVID19	• Drug: Hydroxychloroquine Sulfate (HCQ)
81	Test and Treat COVID 65plus+	Withdrawn	No Results Available	• SARS-CoV 2 • COVID-19	• Drug: Hydroxychloroquine • Other: Placebo
82	Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore	Withdrawn	No Results Available	• COVID • Coronavirus • COVID-19	• Drug: Hydroxychloroquine
83	A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh	Completed	No Results Available	• Ivermectin • Hydroxychloroquine • COVID19	• Drug: Ivermectin + Doxycycline • Drug: Hydroxychloroquine + Azithromycin
84	Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19	Completed	No Results Available	• COVID-19	
85	Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19	Withdrawn	No Results Available	• Covid-19 • HIV	• Drug: Chloroquine or hydroxychloroquine
86	Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19	Not yet recruiting	No Results Available	• Sars-CoV2	• Other: Standard of care (SOC) • Drug: Hydroxychloroquine • Drug: Association of diltiazem and niclosamide
87	Azithromycin in Hospitalized COVID-19 Patients	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
88	Asymptomatic COVID-19 Trial	Withdrawn	No Results Available	• SARS-CoV-2 Infection	• Drug: Hydroxychloroquine sulfate & Azithromycin • Drug: Placebo
89	Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection	Recruiting	No Results Available	• Asymptomatic Infections • SARS-CoV2 Infection	• Drug: Ivermectin Pill • Drug: Combined ART/hydroxychloroquine
90	Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir • Drug: Standard of care treatment

	Title	Status	Study Results	Conditions	Interventions
91	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID19 • Coronavirus • Acute Respiratory Illnesses 	<ul style="list-style-type: none"> • Drug: Chloroquine or Hydroxychloroquine • Drug: Placebo
92	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo of Hydroxychloroquine • Drug: Lopinavir and ritonavir • Drug: Placebo of LPV/r Tablets
93	Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
94	Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Covid19 • SARS (Severe Acute Respiratory Syndrome) 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Dietary Supplement: Vitamins and Minerals • Drug: Azithromycin
95	Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID-19 • SARS-CoV-2 • Pregnant Women • Hydroxychloroquine 	<ul style="list-style-type: none"> • Drug: hydroxychloroquine sulfate 200 MG • Drug: Placebo oral tablet
96	PROLIFIC Chemoprophylaxis Trial (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine - Daily dosing • Drug: Hydroxychloroquine - Weekly Dosing • Other: Matched Placebo Hydroxychloroquine
97	Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 • Healthcare Workers 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet

	Title	Status	Study Results	Conditions	Interventions
98	Will Hydroxychloroquine Impede or Prevent COVID-19	Terminated	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Coronavirus • Coronavirus Infections • SARS-CoV 2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine - Daily Dosing • Drug: Hydroxychloroquine - Weekly Dosing • Other: Placebo oral tablet • Diagnostic Test: Monitoring Visit - Baseline • Diagnostic Test: Monitoring Visit - Week 4 • Diagnostic Test: Monitoring Visit - Week 8 • Other: Weekly Assessment
99	HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine and Azithromycin
100	Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Indomethacin • Drug: Zithromax Oral Product

170 additional studies not shown

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

ClinicalTrials.gov Search Results 02/07/2021

	Title	Status	Study Results	Conditions	Interventions
1	Effectiveness of Hydroxychloroquine in Covid-19 Patients	Not yet recruiting	No Results Available	• COVID19	• Drug: Hydroxychloroquine 200 Mg Oral Tablet • Drug: Azithromycin 500Mg Oral Tablet • Dietary Supplement: Glucose tablets
2	Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial	Withdrawn	No Results Available	• SARS-CoV-2 Pneumonia • COVID-19	• Drug: Hydroxychloroquine
3	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	No Results Available	• COVID	• Drug: Camostat Mesilate • Drug: Placebo • Drug: Hydroxychloroquine
4	Favipiravir vs Hydroxychloroquine in COVID -19	Recruiting	No Results Available	• SARS-CoV 2 • COVID-19	• Drug: Hydroxychloroquine • Drug: Favipiravir • Other: Routine care for COVID-19 patients
5	Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)	Withdrawn	No Results Available	• COVID-19 • SARS-CoV-2	• Drug: Hydroxychloroquine • Drug: Placebo
6	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Completed	No Results Available	• Covid-19	• Drug: HCQ • Drug: HCQ+AZT • Drug: Placebo
7	The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine plus standard preventive measures • Drug: Placebo plus standard preventive measures
8	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	Recruiting	No Results Available	• Covid-19	• Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
9	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19	Active, not recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
10	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
11	Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial	Withdrawn	No Results Available	• COVID19	• Drug: Hydroxychloroquine and azithromycin treatment • Other: conventional management of patients
12	Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Combination Product: Hydroxychloroquine plus Nitazoxanide • Other: Standard care
13	High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine

	Title	Status	Study Results	Conditions	Interventions
14	ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
15	Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease	Active, not recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
16	A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
17	Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
18	Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients	Withdrawn	No Results Available	• Covid-19	• Drug: Hydroxychloroquine and Azithromycin • Dietary Supplement: Azinc
19	#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Mannitol
20	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Terminated	No Results Available	• COVID-19	• Drug: Lopinavir/ritonavir • Drug: Hydroxychloroquine sulfate
21	Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
22	Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine + Metabolic cofactor supplementation • Drug: Hydroxychloroquine + Sorbitol
23	Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19	Active, not recruiting	No Results Available	• Covid19 • Hydroxychloroquine Adverse Reaction	• Drug: inhalable hydroxychloroquine (HCQ) • Drug: supportive and symptomatic treatment
24	Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
25	Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19	Recruiting	No Results Available	• Covid19	• Drug: Hydroxychloroquine • Drug: Azithromycin • Other: Placebo Tablet • Other: Placebo capsules

	Title	Status	Study Results	Conditions	Interventions
26	Hydroxychloroquine for COVID-19	Recruiting	No Results Available	• COVID-19, Hydroxychloroquine Sulfate	• Drug: Hydroxychloroquine Sulfate • Drug: Placebo
27	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19	Recruiting	No Results Available	• SARS-CoV-2 • COVID-19	• Combination Product: Hydroxychloroquine Sulfate + Azithromycin • Drug: Hydroxychloroquine Sulfate
28	Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebos
29	Trial of Hydroxychloroquine In Covid-19 Kinetics	Terminated	No Results Available	• Covid 19 • Corona Virus Infection	• Drug: Hydroxychloroquine • Other: Placebo
30	Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection	Active, not recruiting	No Results Available	• COVID-19 • SARS-CoV 2	• Drug: Hydroxychloroquine • Dietary Supplement: Vitamin D
31	Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients	Not yet recruiting	No Results Available	• COVID-19 Patients	• Drug: HCQ & AZ vs HCQ+SIR
32	Hydroxychloroquine, Azithromycin in the Treatment of Covid-19	Not yet recruiting	No Results Available	• SARS-CoV-2 Pneumonia • COVID-19	• Drug: Hydroxychloroquine 200 Mg Oral Tablet • Drug: Azithromycin 250 MG
33	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19	Suspended	No Results Available	• Covid-19	• Drug: Hydroxychloroquine Sulfate • Drug: Azithromycin Tablets
34	Hydroxychloroquine in COVID-19 Patients	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
35	Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19	Recruiting	No Results Available	• COVID 19	• Drug: Hydroxychloroquine Sulfate 200 MG • Other: Placebo
36	Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)	Active, not recruiting	No Results Available	• COVID-19 • Severe Acute Respiratory Syndrome	• Drug: Hydroxychloroquine • Drug: Placebo oral tablet
37	Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19	Recruiting	No Results Available	• COVID-19 Infection	• Drug: Hydroxychloroquine • Drug: Azithromycin • Drug: Telmisartan
38	Preventing COVID-19 in Healthcare Workers With HCQ: A RCT	Withdrawn	No Results Available	• Covid-19	• Drug: Hydroxychloroquine • Other: Vitamin C

	Title	Status	Study Results	Conditions	Interventions
39	Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19	Not yet recruiting	No Results Available	• COVID	• Drug: Hydroxychloroquine • Drug: Placebo oral tablet
40	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients Admitted With Moderate to Severe COVID-19	Terminated	No Results Available	• COVID-19	• Drug: Chloroquine Sulfate • Drug: Hydroxychloroquine • Other: Standard supportive care
41	Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients	Terminated	No Results Available	• Sars-CoV2	• Drug: Hydroxychloroquine (HCQ)
42	Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19	Terminated	Has Results	• COVID-19	• Drug: Hydroxychloroquine
43	Treating COVID-19 With Hydroxychloroquine (TEACH)	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine (HCQ) • Other: Placebo: Calcium citrate
44	Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Ivermectin • Drug: Placebo
45	Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Other: The control group will not receive hydroxychloroquine
46	Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin • Drug: Zinc Sulfate • Drug: Doxycycline
47	COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
48	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine Sulfate • Drug: Azithromycin Tablets
49	Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine Sulfate
50	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	Terminated	Has Results	• COVID-19	• Drug: Hydroxychloroquine Sulfate 400 mg twice a day • Drug: Hydroxychloroquine Sulfate 600 mg twice a day • Drug: Hydroxychloroquine Sulfate 600 mg once a day • Drug: Placebo oral tablet

	Title	Status	Study Results	Conditions	Interventions
51	Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycin in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID19 • Hematologic Malignancy 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil] • Drug: Azithromycin 250 MG Oral Capsule • Drug: Placebo oral tablet • Drug: Placebo oral capsule
52	Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID - 19 	<ul style="list-style-type: none"> • Drug: hydroxychloroquine in combination with camostat mesylate • Drug: Hydroxychloroquine in combination of Azithromycin
53	A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 • COVID19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Hydroxychloroquine (placebo) • Drug: Zinc • Drug: Zinc (Placebo)
54	PROphylaxis for paTiEnts at Risk of COVID-19 infecTion	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine Sulfate 200 MG
55	Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO	Suspended	No Results Available	<ul style="list-style-type: none"> • COVID19 • SARS-CoV-2 Infection 	<ul style="list-style-type: none"> • Drug: Sarilumab • Drug: Azithromycin • Drug: Hydroxychloroquine
56	Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Coronavirus Disease 2019 (COVID-19) • Post-Exposure Prophylaxis 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
57	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • COVID-19 • SARS-CoV 2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine (HCQ) • Drug: Azithromycin (Azithro) • Drug: Placebo for Hydroxychloroquine • Drug: Placebo for Azithromycin
58	Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Mucodentol • Device: Personal protective equipment

	Title	Status	Study Results	Conditions	Interventions
59	Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum	Recruiting	No Results Available	<ul style="list-style-type: none"> •Pregnancy Related • COVID • Covid-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo
60	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Tocilizumab • Drug: Hydroxychloroquine • Drug: Azithromycin
61	EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Sars-CoV-2, Community-Acquired Pneumonia, COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine and azithromycin treatment arm. • Drug: Hydroxychloroquine • Drug: Control arm
62	Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Coronavirus Infection 	<ul style="list-style-type: none"> • Drug: Chloroquine or Hydroxychloroquine
63	Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Corona Virus Infection 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet
64	Double Therapy With IFN-beta 1b and Hydroxychloroquine	Completed	No Results Available	<ul style="list-style-type: none"> • COVID 	<ul style="list-style-type: none"> • Drug: Interferon Beta-1B • Drug: Hydroxychloroquine
65	Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • CoVID-19 	<ul style="list-style-type: none"> • Drug: HCQ • Other: Standard therapy
66	Favipiravir and HydroxyChloroquine Combination Therapy	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID19 	<ul style="list-style-type: none"> • Combination Product: Favipiravir and Hydroxychloroquine
67	Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Contact Person From COVID-19 Confirmed Patient 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine as post exposure prophylaxis • Other: Others(No intervention)

	Title	Status	Study Results	Conditions	Interventions
68	Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • Pneumonia, Pneumocystis • Coronavirus • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
69	Hydroxychloroquine to Prevent SARS-CoV-2 Infection	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
70	A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Cancer 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Other: Placebo • Radiation: Radiation therapy
71	Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Severe Acute Respiratory Syndrome 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet
72	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • Respiratory Distress Syndrome, Adult • COVID-19 	<ul style="list-style-type: none"> • Drug: Dexamethasone and Hydroxychloroquine • Drug: Hydroxychloroquine
73	Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 Pneumonia 	
74	Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients	Recruiting	No Results Available	<ul style="list-style-type: none"> • Cancer & COVID 19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
75	Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID 19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
76	Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 • COVID-19 	<ul style="list-style-type: none"> • Drug: Favipiravir (3200 mg + 1200 mg) • Drug: Favipiravir (3600 mg + 1600 mg) • Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine • Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin • Drug: Hydroxychloroquine • Drug: Hydroxychloroquine combined with Azithromycin
77	Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection	Terminated	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 	<ul style="list-style-type: none"> • Other: Standard of care • Drug: Hydroxychloroquine • Drug: Azithromycin

	Title	Status	Study Results	Conditions	Interventions
78	Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients	Enrolling by invitation	No Results Available	• Covid19	<ul style="list-style-type: none"> • Combination Product: Hydroxychloroquine/ Azithromycine • Combination Product: Quinquina-Stevia/ Azythromycin • Combination Product: 4Plants/ Azythromycin
79	Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients	Not yet recruiting	No Results Available	• COVID-19	• Drug: HCQ & AZ
80	Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers	Active, not recruiting	No Results Available	• COVID19	• Drug: Hydroxychloroquine Sulfate (HCQ)
81	Test and Treat COVID 65plus+	Withdrawn	No Results Available	<ul style="list-style-type: none"> • SARS-CoV 2 • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Other: Placebo
82	Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID • Coronavirus • COVID-19 	• Drug: Hydroxychloroquine
83	A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh	Completed	No Results Available	<ul style="list-style-type: none"> • Ivermectin • Hydroxychloroquine • COVID19 	<ul style="list-style-type: none"> • Drug: Ivermectin + Doxycycline • Drug: Hydroxychloroquine + Azithromycin
84	Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19	Completed	No Results Available	• COVID-19	
85	Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Covid-19 • HIV 	• Drug: Chloroquine or hydroxychloroquine
86	Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19	Not yet recruiting	No Results Available	• Sars-CoV2	<ul style="list-style-type: none"> • Other: Standard of care (SOC) • Drug: Hydroxychloroquine • Drug: Association of diltiazem and niclosamide
87	Azithromycin in Hospitalized COVID-19 Patients	Not yet recruiting	No Results Available	• COVID-19	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
88	Asymptomatic COVID-19 Trial	Withdrawn	No Results Available	• SARS-CoV-2 Infection	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine sulfate & Azithromycin • Drug: Placebo
89	Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection	Recruiting	No Results Available	<ul style="list-style-type: none"> • Asymptomatic Infections • SARS-CoV2 Infection 	<ul style="list-style-type: none"> • Drug: Ivermectin Pill • Drug: Combined ART/hydroxychloroquine
90	Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19	Not yet recruiting	No Results Available	• COVID-19	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir • Drug: Standard of care treatment

	Title	Status	Study Results	Conditions	Interventions
91	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID19 • Coronavirus • Acute Respiratory Illnesses 	<ul style="list-style-type: none"> • Drug: Chloroquine or Hydroxychloroquine • Drug: Placebo
92	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo of Hydroxychloroquine • Drug: Lopinavir and ritonavir • Drug: Placebo of LPV/r Tablets
93	Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
94	Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Covid19 • SARS (Severe Acute Respiratory Syndrome) 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Dietary Supplement: Vitamins and Minerals • Drug: Azithromycin
95	Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID-19 • SARS-CoV-2 • Pregnant Women • Hydroxychloroquine 	<ul style="list-style-type: none"> • Drug: hydroxychloroquine sulfate 200 MG • Drug: Placebo oral tablet
96	PROLIFIC Chemoprophylaxis Trial (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine - Daily dosing • Drug: Hydroxychloroquine - Weekly Dosing • Other: Matched Placebo Hydroxychloroquine
97	Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 • Healthcare Workers 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet

	Title	Status	Study Results	Conditions	Interventions
98	Will Hydroxychloroquine Impede or Prevent COVID-19	Terminated	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Coronavirus • Coronavirus Infections • SARS-CoV 2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine - Daily Dosing • Drug: Hydroxychloroquine - Weekly Dosing • Other: Placebo oral tablet • Diagnostic Test: Monitoring Visit - Baseline • Diagnostic Test: Monitoring Visit - Week 4 • Diagnostic Test: Monitoring Visit - Week 8 • Other: Weekly Assessment
99	HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine and Azithromycin
100	Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Indomethacin • Drug: Zithromax Oral Product

170 additional studies not shown

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services

ClinicalTrials.gov Search Results 02/07/2021

	Title	Status	Study Results	Conditions	Interventions
1	Effectiveness of Hydroxychloroquine in Covid-19 Patients	Not yet recruiting	No Results Available	• COVID19	• Drug: Hydroxychloroquine 200 Mg Oral Tablet • Drug: Azithromycin 500Mg Oral Tablet • Dietary Supplement: Glucose tablets
2	Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial	Withdrawn	No Results Available	• SARS-CoV-2 Pneumonia • COVID-19	• Drug: Hydroxychloroquine
3	Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19	Withdrawn	No Results Available	• COVID	• Drug: Camostat Mesilate • Drug: Placebo • Drug: Hydroxychloroquine
4	Favipiravir vs Hydroxychloroquine in COVID -19	Recruiting	No Results Available	• SARS-CoV 2 • COVID-19	• Drug: Hydroxychloroquine • Drug: Favipiravir • Other: Routine care for COVID-19 patients
5	Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)	Withdrawn	No Results Available	• COVID-19 • SARS-CoV-2	• Drug: Hydroxychloroquine • Drug: Placebo
6	Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease	Completed	No Results Available	• Covid-19	• Drug: HCQ • Drug: HCQ+AZT • Drug: Placebo
7	The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine plus standard preventive measures • Drug: Placebo plus standard preventive measures
8	Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia	Recruiting	No Results Available	• Covid-19	• Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet
9	Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19	Active, not recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
10	Hydroxychloroquine for the Treatment of Mild COVID-19 Disease	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
11	Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial	Withdrawn	No Results Available	• COVID19	• Drug: Hydroxychloroquine and azithromycin treatment • Other: conventional management of patients
12	Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Combination Product: Hydroxychloroquine plus Nitazoxanide • Other: Standard care
13	High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine

	Title	Status	Study Results	Conditions	Interventions
14	ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
15	Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease	Active, not recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
16	A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients	Terminated	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
17	Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19)	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
18	Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients	Withdrawn	No Results Available	• Covid-19	• Drug: Hydroxychloroquine and Azithromycin • Dietary Supplement: Azinc
19	#StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Mannitol
20	Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)	Terminated	No Results Available	• COVID-19	• Drug: Lopinavir/ritonavir • Drug: Hydroxychloroquine sulfate
21	Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
22	Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine + Metabolic cofactor supplementation • Drug: Hydroxychloroquine + Sorbitol
23	Development and Validation of "Ready-to-Use" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19	Active, not recruiting	No Results Available	• Covid19 • Hydroxychloroquine Adverse Reaction	• Drug: inhalable hydroxychloroquine (HCQ) • Drug: supportive and symptomatic treatment
24	Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
25	Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19	Recruiting	No Results Available	• Covid19	• Drug: Hydroxychloroquine • Drug: Azithromycin • Other: Placebo Tablet • Other: Placebo capsules

	Title	Status	Study Results	Conditions	Interventions
26	Hydroxychloroquine for COVID-19	Recruiting	No Results Available	• COVID-19, Hydroxychloroquine Sulfate	• Drug: Hydroxychloroquine Sulfate • Drug: Placebo
27	Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19	Recruiting	No Results Available	• SARS-CoV-2 • COVID-19	• Combination Product: Hydroxychloroquine Sulfate + Azithromycin • Drug: Hydroxychloroquine Sulfate
28	Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebos
29	Trial of Hydroxychloroquine In Covid-19 Kinetics	Terminated	No Results Available	• Covid 19 • Corona Virus Infection	• Drug: Hydroxychloroquine • Other: Placebo
30	Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection	Active, not recruiting	No Results Available	• COVID-19 • SARS-CoV 2	• Drug: Hydroxychloroquine • Dietary Supplement: Vitamin D
31	Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients	Not yet recruiting	No Results Available	• COVID-19 Patients	• Drug: HCQ & AZ vs HCQ+SIR
32	Hydroxychloroquine, Azithromycin in the Treatment of Covid-19	Not yet recruiting	No Results Available	• SARS-CoV-2 Pneumonia • COVID-19	• Drug: Hydroxychloroquine 200 Mg Oral Tablet • Drug: Azithromycin 250 MG
33	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19	Suspended	No Results Available	• Covid-19	• Drug: Hydroxychloroquine Sulfate • Drug: Azithromycin Tablets
34	Hydroxychloroquine in COVID-19 Patients	Recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine
35	Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19	Recruiting	No Results Available	• COVID 19	• Drug: Hydroxychloroquine Sulfate 200 MG • Other: Placebo
36	Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)	Active, not recruiting	No Results Available	• COVID-19 • Severe Acute Respiratory Syndrome	• Drug: Hydroxychloroquine • Drug: Placebo oral tablet
37	Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19	Recruiting	No Results Available	• COVID-19 Infection	• Drug: Hydroxychloroquine • Drug: Azithromycin • Drug: Telmisartan
38	Preventing COVID-19 in Healthcare Workers With HCQ: A RCT	Withdrawn	No Results Available	• Covid-19	• Drug: Hydroxychloroquine • Other: Vitamin C

	Title	Status	Study Results	Conditions	Interventions
39	Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19	Not yet recruiting	No Results Available	• COVID	• Drug: Hydroxychloroquine • Drug: Placebo oral tablet
40	Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients Admitted With Moderate to Severe COVID-19	Terminated	No Results Available	• COVID-19	• Drug: Chloroquine Sulfate • Drug: Hydroxychloroquine • Other: Standard supportive care
41	Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients	Terminated	No Results Available	• Sars-CoV2	• Drug: Hydroxychloroquine (HCQ)
42	Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19	Terminated	Has Results	• COVID-19	• Drug: Hydroxychloroquine
43	Treating COVID-19 With Hydroxychloroquine (TEACH)	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine (HCQ) • Other: Placebo: Calcium citrate
44	Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Ivermectin • Drug: Placebo
45	Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Other: The control group will not receive hydroxychloroquine
46	Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting	Completed	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin • Drug: Zinc Sulfate • Drug: Doxycycline
47	COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Placebo
48	Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19	Suspended	No Results Available	• COVID-19	• Drug: Hydroxychloroquine Sulfate • Drug: Azithromycin Tablets
49	Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk	Withdrawn	No Results Available	• COVID-19	• Drug: Hydroxychloroquine Sulfate
50	The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)	Terminated	Has Results	• COVID-19	• Drug: Hydroxychloroquine Sulfate 400 mg twice a day • Drug: Hydroxychloroquine Sulfate 600 mg twice a day • Drug: Hydroxychloroquine Sulfate 600 mg once a day • Drug: Placebo oral tablet

	Title	Status	Study Results	Conditions	Interventions
51	Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycin in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID19 • Hematologic Malignancy 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil] • Drug: Azithromycin 250 MG Oral Capsule • Drug: Placebo oral tablet • Drug: Placebo oral capsule
52	Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID - 19 	<ul style="list-style-type: none"> • Drug: hydroxychloroquine in combination with camostat mesylate • Drug: Hydroxychloroquine in combination of Azithromycin
53	A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 • COVID19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Hydroxychloroquine (placebo) • Drug: Zinc • Drug: Zinc (Placebo)
54	PROphylaxis for paTiEnts at Risk of COVID-19 infecTion	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine Sulfate 200 MG
55	Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO	Suspended	No Results Available	<ul style="list-style-type: none"> • COVID19 • SARS-CoV-2 Infection 	<ul style="list-style-type: none"> • Drug: Sarilumab • Drug: Azithromycin • Drug: Hydroxychloroquine
56	Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Coronavirus Disease 2019 (COVID-19) • Post-Exposure Prophylaxis 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
57	Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • COVID-19 • SARS-CoV 2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine (HCQ) • Drug: Azithromycin (Azithro) • Drug: Placebo for Hydroxychloroquine • Drug: Placebo for Azithromycin
58	Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Mucodentol • Device: Personal protective equipment

	Title	Status	Study Results	Conditions	Interventions
59	Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum	Recruiting	No Results Available	<ul style="list-style-type: none"> •Pregnancy Related • COVID • Covid-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo
60	Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Tocilizumab • Drug: Hydroxychloroquine • Drug: Azithromycin
61	EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Sars-CoV-2, Community-Acquired Pneumonia, COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine and azithromycin treatment arm. • Drug: Hydroxychloroquine • Drug: Control arm
62	Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Coronavirus Infection 	<ul style="list-style-type: none"> • Drug: Chloroquine or Hydroxychloroquine
63	Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Corona Virus Infection 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet
64	Double Therapy With IFN-beta 1b and Hydroxychloroquine	Completed	No Results Available	<ul style="list-style-type: none"> • COVID 	<ul style="list-style-type: none"> • Drug: Interferon Beta-1B • Drug: Hydroxychloroquine
65	Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • CoVID-19 	<ul style="list-style-type: none"> • Drug: HCQ • Other: Standard therapy
66	Favipiravir and HydroxyChloroquine Combination Therapy	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID19 	<ul style="list-style-type: none"> • Combination Product: Favipiravir and Hydroxychloroquine
67	Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Contact Person From COVID-19 Confirmed Patient 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine as post exposure prophylaxis • Other: Others(No intervention)

	Title	Status	Study Results	Conditions	Interventions
68	Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19	Completed	No Results Available	<ul style="list-style-type: none"> • Pneumonia, Pneumocystis • Coronavirus • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
69	Hydroxychloroquine to Prevent SARS-CoV-2 Infection	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
70	A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Cancer 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Other: Placebo • Radiation: Radiation therapy
71	Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Severe Acute Respiratory Syndrome 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet
72	Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • Respiratory Distress Syndrome, Adult • COVID-19 	<ul style="list-style-type: none"> • Drug: Dexamethasone and Hydroxychloroquine • Drug: Hydroxychloroquine
73	Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 Pneumonia 	
74	Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients	Recruiting	No Results Available	<ul style="list-style-type: none"> • Cancer & COVID 19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
75	Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • COVID 19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine
76	Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 • COVID-19 	<ul style="list-style-type: none"> • Drug: Favipiravir (3200 mg + 1200 mg) • Drug: Favipiravir (3600 mg + 1600 mg) • Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine • Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin • Drug: Hydroxychloroquine • Drug: Hydroxychloroquine combined with Azithromycin
77	Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection	Terminated	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 	<ul style="list-style-type: none"> • Other: Standard of care • Drug: Hydroxychloroquine • Drug: Azithromycin

	Title	Status	Study Results	Conditions	Interventions
78	Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients	Enrolling by invitation	No Results Available	• Covid19	• Combination Product: Hydroxychloroquine/ Azithromycine • Combination Product: Quinquina-Stevia/ Azythromycin • Combination Product: 4Plants/ Azythromycin
79	Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients	Not yet recruiting	No Results Available	• COVID-19	• Drug: HCQ & AZ
80	Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers	Active, not recruiting	No Results Available	• COVID19	• Drug: Hydroxychloroquine Sulfate (HCQ)
81	Test and Treat COVID 65plus+	Withdrawn	No Results Available	• SARS-CoV 2 • COVID-19	• Drug: Hydroxychloroquine • Other: Placebo
82	Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore	Withdrawn	No Results Available	• COVID • Coronavirus • COVID-19	• Drug: Hydroxychloroquine
83	A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh	Completed	No Results Available	• Ivermectin • Hydroxychloroquine • COVID19	• Drug: Ivermectin + Doxycycline • Drug: Hydroxychloroquine + Azithromycin
84	Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19	Completed	No Results Available	• COVID-19	
85	Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19	Withdrawn	No Results Available	• Covid-19 • HIV	• Drug: Chloroquine or hydroxychloroquine
86	Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19	Not yet recruiting	No Results Available	• Sars-CoV2	• Other: Standard of care (SOC) • Drug: Hydroxychloroquine • Drug: Association of diltiazem and niclosamide
87	Azithromycin in Hospitalized COVID-19 Patients	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine • Drug: Azithromycin
88	Asymptomatic COVID-19 Trial	Withdrawn	No Results Available	• SARS-CoV-2 Infection	• Drug: Hydroxychloroquine sulfate & Azithromycin • Drug: Placebo
89	Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection	Recruiting	No Results Available	• Asymptomatic Infections • SARS-CoV2 Infection	• Drug: Ivermectin Pill • Drug: Combined ART/hydroxychloroquine
90	Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19	Not yet recruiting	No Results Available	• COVID-19	• Drug: Hydroxychloroquine , Sofosbuvir, daclatasvir • Drug: Standard of care treatment

	Title	Status	Study Results	Conditions	Interventions
91	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID19 • Coronavirus • Acute Respiratory Illnesses 	<ul style="list-style-type: none"> • Drug: Chloroquine or Hydroxychloroquine • Drug: Placebo
92	Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo of Hydroxychloroquine • Drug: Lopinavir and ritonavir • Drug: Placebo of LPV/r Tablets
93	Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Azithromycin
94	Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • Covid19 • SARS (Severe Acute Respiratory Syndrome) 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Dietary Supplement: Vitamins and Minerals • Drug: Azithromycin
95	Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women	Withdrawn	No Results Available	<ul style="list-style-type: none"> • COVID-19 • SARS-CoV-2 • Pregnant Women • Hydroxychloroquine 	<ul style="list-style-type: none"> • Drug: hydroxychloroquine sulfate 200 MG • Drug: Placebo oral tablet
96	PROLIFIC Chemoprophylaxis Trial (COVID-19)	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine - Daily dosing • Drug: Hydroxychloroquine - Weekly Dosing • Other: Matched Placebo Hydroxychloroquine
97	Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.	Not yet recruiting	No Results Available	<ul style="list-style-type: none"> • SARS-CoV-2 • Healthcare Workers 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Placebo oral tablet

	Title	Status	Study Results	Conditions	Interventions
98	Will Hydroxychloroquine Impede or Prevent COVID-19	Terminated	No Results Available	<ul style="list-style-type: none"> • COVID-19 • Coronavirus • Coronavirus Infections • SARS-CoV 2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine - Daily Dosing • Drug: Hydroxychloroquine - Weekly Dosing • Other: Placebo oral tablet • Diagnostic Test: Monitoring Visit - Baseline • Diagnostic Test: Monitoring Visit - Week 4 • Diagnostic Test: Monitoring Visit - Week 8 • Other: Weekly Assessment
99	HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19	Withdrawn	No Results Available	<ul style="list-style-type: none"> • Sars-CoV2 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine and Azithromycin
100	Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19	Recruiting	No Results Available	<ul style="list-style-type: none"> • COVID-19 	<ul style="list-style-type: none"> • Drug: Hydroxychloroquine • Drug: Indomethacin • Drug: Zithromax Oral Product

170 additional studies not shown

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services